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Abstract 
 
Increased urinary albumin excretion, known as microalbuminuria, is an established clinical 
risk factor for renal disease in patients with diabetes. There is growing evidence that 
increasing urinary albumin even within the normal range, is a risk factor for cardiovascular 
disease (CVD) in subjects with and without diabetes.  
Microvascular dysfunction has been proposed as the common process in the 
pathophysiology of both diabetic renal disease and cardiovascular disease, resulting in 
increased urinary albumin excretion. This is further supported by evidence that urinary 
albumin excretion is associated with other microvascular complications of diabetes, such as 
retinopathy and neuropathy.  
It is important to investigate these relationships further as it could improve our ability to 
identify those at risk of CVD, and complications of diabetes at an earlier stage. This would 
result in significant improvement in the quality of lives of patients with diabetes and save 
the health service resources in managing the complications of diabetes.  
Studies that have investigated the relationship between albumin excretion and 
microvascular dysfunction are limited by the use of clinical assays, which cannot quantify 
low concentrations of urinary albumin. 
In this thesis an assay is validated to quantify low concentrations of urinary albumin. An 
accurate and reproducible method is developed to investigate low levels of urinary albumin 
excretion. This method was developed through two clinical studies and several laboratory 
experiments that investigated; a) the optimal method of collecting urine samples and 
reporting the results, b) the influence of exercise on urinary albumin excretion and c) the 
stability of urinary albumin in stored samples. 
Patients were selected from a prospective clinical study (SUMMIT) to investigate the 
relationship between low levels of urinary albumin excretion and in-vivo measures of 
microvascular function and microvascular complications of diabetes for the first time. This is 
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the first longitudinal study to report the change in these measures of microvascular function 
over three years and the influence of diabetes and CVD.   
This thesis provides novel evidence that increasing urinary albumin excretion, including 
within the normal range, is linked to generalised microvascular dysfunction. Furthermore, 
impaired microvascular autoregulation may play a role in the pathogenesis and is not 
influenced by diabetes. This is also supported by the association of urinary albumin 
excretion with background (early) changes in diabetic retinopathy. 
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Chapter 1 Introduction 
 
Albumin is the most abundant plasma protein in humans. It has a negative charge and a 
molecular weight of 66,500 Da (Peters, 1996). Due to the large size and charge of albumin it 
is not freely filtered by the kidneys and has a very low glomerular sieving coefficient 
(Haraldsson and Tanner, 2014). The majority of albumin that passes across the glomerular 
barrier is reabsorbed in the proximal tubule, the loop of Henle and distal tubule. However, a 
small amount of albumin is excreted in urine in healthy individuals and current clinical 
guidelines have termed this as normoalbuminuria. Moderately increased urinary albumin 
excretion, above the normoalbuminuria range, is termed microalbuminuria. 
Microalbuminuria is a predominant marker for early kidney damage in individuals with 
diabetes (Mogensen, 1985). Microalbuminuria is also recognised as an indicator of increased 
cardiovascular risk and a predictor of early mortality, regardless of whether an individual 
has diabetes or not (Yuyun et al., 2004, Hillege et al., 2002). Further urinary albumin 
excretion, above microalbuminuria, is termed macroalbuminuria, which is associated with 
significant kidney damage. 
The relationship between urinary albumin excretion and risk of cardiovascular disease is a 
continuous relationship and there is increasing evidence that this relationship commences 
within the ‘normal’, normoalbuminuria range (Hillege et al., 2002, Dwyer et al., 2012). This 
is supported by observations that vascular dysfunction is associated with increasing urinary 
albumin excretion even within the normoalbuminuria range (Strain et al., 2005a, Kweon et 
al., 2012, Keech et al., 2005). 
The overall aim of this thesis is to examine the relationship between urinary albumin 
excretion within the normoalbuminuria range and microvascular function in individuals with 
and without type 2 diabetes. The first stage of this research was to identify and validate a 
highly sensitive assay that is capable of reproducibly measuring low levels of urinary 
albumin. The next stage was to investigate different ways of reporting urinary albumin 
excretion, which led to investigating the reproducibility of different measurements in 
26 
 
samples collected by different methods. The next stage of this research was to determine if 
urinary albumin excretion was influenced by different intensities of exercise. The stability of 
urinary albumin during prolonged frozen storage was also investigated. The results from all 
this research was then used to guide the examination of the relationship between urinary 
albumin excretion within the normoalbuminuria range and microvascular function in a large 
cohort of patients with varying cardiovascular risk with and without diabetes. 
In this introduction I will begin by describing how different levels of urinary albumin 
excretion are clinically reported, which will inform a review of previous studies that have 
investigated the relationship of urinary albumin excretion with renal and cardiovascular 
disease (CVD).  
 
 
1.1 Reporting urinary albumin excretion 
 
There are two ways of collecting urine to assess urinary albumin excretion. Timed 
collections use the duration and sample volume to calculate an albumin excretion rate 
(AER). Whereas, untimed (spot) collections can only provide an albumin concentration. As 
urinary albumin concentration is influenced by factors such as hydration, the result is 
traditionally normalised by reporting it as a ratio to creatinine, the albumin to creatinine 
ratio (ACR). Creatinine is endogenously produced at a relatively constant rate and freely 
passes into the urine, as a result it is used to correct for variation in urine concentration. 
Spot collections are clinically preferred as patients can find timed collections cumbersome 
and are prone to making mistakes, which can lead to inaccurate results. The clinical 
albuminuria ranges are characterised by both AER and ACR in Table 1.  
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As an ACR comes from an untimed sample, an AER cannot be calculated. The ACR tells us 
how much albumin there is to creatinine. However, if the daily excretion of creatinine is 
known, then the two can be multiplied together to provide an estimate of the daily albumin 
excretion. This is what the ACR attempts to do, however it uses an assumption that 1g of 
creatinine is excreted a day, and that is why it shares the same clinical ranges (in different 
units) as a 24-hour collection (Table 1). 
The actual amount of urinary creatinine excretion is highly variable between individuals. 
Creatinine is a breakdown product from muscle metabolism, therefore, under normal 
circumstances its concentration in the blood (and urine) will be influenced by muscle mass. 
Men typically have a  higher muscle mass than women and this is an important 
consideration when reporting the ACR. As a result, the National Kidney Foundation; Kidney 
Disease Outcomes quality Initiative (NKF KDOQI) guidelines also recommend the use of 
gender specific ranges (Table 2). ACR from spot samples are routinely reported and 
interpreted using gender specific ranges.  
 
 
 
Category 
Spot (ACR) 
(U.K. units) 
 mg/mmol 
Spot (ACR)  
(U.S.A. units) 
mg/g 
24-Hour 
collection  
AER  mg/day 
Timed 
Collection  
AER µg/min 
Normoalbuminuria <3.4 <30 <30 <20 
Microalbuminuria 3.4-34 30-300 30-300 20-200 
Macroalbuminuria >34 >300 >300 >200 
Table 1 Definitions of albuminuria. Recommendations from The National Kidney 
Foundation; Kidney Disease Outcomes quality Initiative (NKF KDOQI) guidelines (National 
Kidney Foundation, 2007). 
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1.1.2 Terminology 
 
Since the name ‘microalbuminuria’ was coined in 1982 (Viberti et al., 1982) there has been 
some uncertainty on its context. By definition microalbuminuria should reflect the presence 
of small albumin molecules in urine, not the small increase in urinary albumin excretion. 
This issue is further complicated by studies that claim to have identified different forms of 
urinary albumin, including small albumin fragments (Comper et al., 2004b). Given this 
uncertainty and the fluctuating recommendations for clinical cut off values, especially with 
cardiovascular risk present in the normoalbuminuria range, some researchers have called 
for the term ‘microalbuminuria’ to be abolished (Ruggenenti and Remuzzi, 2006).     
The UK’s National Institute for Health and Care Excellence (NICE), which provides guidelines 
for diagnosing and monitoring diabetic kidney disease, now refer to microalbuminuria as 
‘moderately increased’ with the term ‘normoalbuminuria’ replaced by ‘normal to mildly 
increased’ and ‘macroalbuminuria’ by ‘severely increased’ (NICE, 2007).  
This thesis will use the classical terminology (microalbuminuria, etc.) as these have been 
used in the vast majority of research that has been carried out in this field.  
 
Category Spot (ACR)  
 Men Women 
 mg/g mg/mmol mg/g mg/mmol 
Normoalbuminuria <17 <1.9 <25 <2.8 
Microalbuminuria 17-250 1.9-28.2 25-355 2.8-40.1 
Macroalbuminuria >250 >28.2 >355 >40.1 
Table 2 Gender specific ACR reference ranges. Recommendations from the NKF KDOQI 
guidelines (National Kidney Foundation, 2002). Values obtained from a single study (Warram 
et al., 1996).  
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1.2 Diabetic Kidney Disease 
 
1.2.1 Epidemiology 
 
Diabetic Kidney Disease (DKD), also referred to as Diabetic Nephropathy, is a common 
complication of diabetes. In 2014, 3.9 million people in the UK had been diagnosed with 
diabetes and it is estimated that over 25% will develop DKD (Diabetes UK, 2014). A 
progressive loss of kidney function over months or years is known as chronic kidney disease 
(CKD) which can lead to end stage renal disease (ESRD). Patients with ESRD will most likely 
require dialysis or a renal transplant.  
DKD is a major cause of morbidity and mortality and is the most common cause of ESRD in 
Europe and the U.S. (American Diabetes Association, 2004). Data from the U.S Renal Data 
System (USRDS) 2012 Annual Report (Collins et al., 2013, Stanton, 2014, USRDS, 2015a) has 
been used in Figure 1 to show the incidence and prevalence of the primary causes of ESRD 
in the U.S. from 1982 to 2010.  
Since the early 1990s diabetes has become the leading cause of all prevalent cases and new 
incidents of ESRD in the U.S. Interestingly, the incidence rates increased up until 2002 where 
it has since remained fairly constant, but the overall prevalence has continued to rise due to 
the rising number of people with diabetes. This may be related to the decline in overall 
mortality rates among ESRD patients. From 1993 to 2002 the death rate dropped by 9% and 
from 2003 to 2012 it had dropped by 26 % (USRDS, 2015b). On this basis, if ESRD patients 
live longer, then the overall prevalence will continue to rise even with stabilising incidence 
rates. 
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One important factor that compromises the integrity of DKD epidemiology data is the ability 
to accurately diagnose DKD. Additional processes, such as hypertension, might be present in 
diabetic patients and could cause kidney disease but are commonly ‘mislabelled’ as DKD. 
Hypertension is the second most common cause of ESRD, which often co-exists with 
microalbuminuria (Figure 1 A and B). The ‘gold standard’ method of classifying kidney 
disease, which can differentiate between DKD and hypertensive kidney disease, requires 
biopsy sampling. This is not routinely adopted as it is invasive and patient management is 
often the same for DKD and hypertensive kidney disease. However, this undertaking would 
be beneficial for research purposes and improve the accuracy of DKD epidemiology data 
(Stanton, 2014). There are other renal pathologies that may be incorrectly diagnosed as DKD 
as demonstrated in a study by Sessa et al. in 1998. They analysed 66 kidney biopsies from 
patients with diabetes who had been diagnosed with DKD. In ten biopsies (15%) they 
A 
 
Figure 1 A. Incidence counts and rates of the primary causes of ESRD in the U.S. 
Diabetes has turned into the leading cause of new ESRD cases  B. Prevalence counts and 
rate of the primary causes of ESRD in the U.S. Diabetes has turned into the leading cause 
of all prevalent ESRD cases (Collins et al., 2013) 
 
 
A 
 
B 
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discovered heavy immunoglobulin-A (IgA) deposits, consistent with IgA nephropathy and 
not DKD (Sessa et al., 1998). 
To diagnose and classify an individual with CKD, regardless of the cause, both urinary 
albumin excretion and kidney function need to be measured. The NICE classification 
guidelines for CKD  are provided in Figure 2 (NICE, 2007). This has been adapted from the 
NKF KDIGO 2012 report (Inker et al., 2014) , which uses the newer term ‘moderately 
increased’ to describe microalbuminuria.  
Clinically, it is common practice to estimate kidney function, which might inherently be 
inaccurate, despite the availability of several methods to measure functionality. Moreover, 
there are also several equations that can be used, each with their own limitations. Variation 
in the equations that are selected by the centres engaged in epidemiological studies could 
also result in divergent datasets. 
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Figure 2: Classification of CKD using Glomerular Filtration Rate (GFR) and ACR categories 
in the UK.The risk of adverse outcomes increases with a rise in ACR and a reduction in GFR. A 
GFR of 60-89 ml/min/1.73m2 (G2) suggests a mild reduction in kidney function in young 
adults. In older individuals the GFR typically declines, so it is important to consider of factors, 
such as age, when classifying CKD (NICE, 2007). 
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1.2.2 Measuring kidney function  
 
Measuring kidney function and urinary albumin excretion is an integral part of diagnosing, 
assessing prognosis and monitoring treatment of CKD. The glomerular filtration rate (GFR) is 
accepted as the best overall index of kidney function and can be directly measured (mGFR) 
or estimated (eGFR).  ‘Gold standard’ methods to determine kidney function measure the 
clearance of an exogenous marker, for example inulin, iothalamate or iohexol. However, this 
direct measurement of GFR is not routinely adopted clinically due to the invasive nature of 
an intravenous infusion to deliver an exogenous marker and the complex analytical methods 
involved. 
Importantly, the urinary clearance of endogenous markers, commonly creatinine, can be 
measured. Nonetheless, this also requires a timed urine collection from patients, which is 
cumbersome and prone to errors. The Cockcroft-Gault equation was established in 1976 to 
circumvent this by estimating creatinine clearance from a serum creatinine concentration 
(Cockcroft and Gault, 1976). The equation incorporates age, weight and gender, as they are 
associated with muscle mass; the main determinant of creatinine generation. Using 
creatinine as an endogenous marker has its limitations, especially as it is not only filtered at 
the glomerulus but is also secreted from the blood into the urine by renal proximal tubular 
cells. As a consequence urinary creatinine clearance can overestimate the GFR (Michels et 
al., 2010).    
In 1999, a six-variable equation from the Modification of Diet in Renal Disease (MDRD) study 
was developed which reports the eGFR from serum creatinine. This equation showed less 
bias and greater precision when predicting the GFR compared to directly measuring 
creatinine clearance and estimating it using the Cockcroft-Gault equation (Levey et al., 
1999). A shortened four-variable equation was later released by the same group (Levey et 
al., 2000), which doesn’t require weight as a variable as it normalises the GFR for a standard 
body surface area of 1.73m2. As a result clinical laboratories can incorporate information 
that is already available, age, gender and ethnicity, enabling the eGFR to be calculated from 
just measuring serum creatinine, revolutionising how renal function can be routinely 
reported.   
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Since serum creatinine has become the most prominent marker of renal function, efforts 
have been made to standardise the analytical methods that are used amongst clinical 
laboratories (Myers et al., 2006b). This has enabled more rigorous evaluations to be carried 
out on different GFR predicting equations. In evaluation studies, the MDRD equation 
exhibits a positive bias in the higher GFR range (>60 ml/min per 1.73 m2), which is attributed 
to the equation being developed in a CKD population (Stevens et al., 2007). As a result, the 
CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) group decided in 2009 to pool 
studies of different populations, patients with and without CKD, to sample a wider range of 
GFRs. With a total of 5,504 subjects they developed the new CKD-EPI equation and validated 
it with large pooled data sets, demonstrating higher accuracy than the MDRD  (Levey et al., 
2009). 
Studies that have attempted to compare GFR predicting equations often present conflicting 
conclusions; a result of inconsistent reference GFR methods, different study populations 
and different creatinine assay calibrations between studies. To overcome this an evaluation 
of the most commonly used equations (Cockcroft-Gault, MDRD and CKD-EPI) was performed 
using the iothalamate mGFR as a ‘gold standard’ reference method (Michels et al., 2010). 
The cross-sectional study included 271 individuals, excluding children, with a mean mGFR 
±SD of 78.2 ± 33.4 ml/min. The results showed that the MDRD equation had the overall 
lowest mean bias, whereas the CKD-EPI was the most accurate. In the highest GFR range 
(>90 ml/min) the CKD-EPI provided the most accurate GFR estimate, whereas the MDRD 
performed better in the lowest range (15-29 ml/min). Interestingly, from the subgroup 
analysis, the Cockcroft-Gault equation was the most accurate in individuals with a low body 
weight or low body mass index (BMI) (Michels et al., 2010). The mean absolute difference 
between the equations and the mGFR ranged from 12.3 to 15.3 mL/min/1.73m2, with age, 
level of GFR, weight and BMI impacting on the equations in different ways. The inherent 
lack of agreement among the equations needs to be considered in research studies, 
especially when interpreting epidemiological data utilising the eGFR. 
It is understood that an eGFR, regardless of equation selection, lacks accuracy but it is 
deemed suitable for conventional clinical decision making. However, there is increasing 
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demand for measuring the GFR when an inaccurate eGFR may result in adverse 
consequences (Stevens and Levey, 2009). The use of the mGFR is already being 
implemented to assess kidney donors in renal units across the UK. 
Clinical microalbuminuria usually precedes a reduction in the GFR; accordingly the majority 
of data presented in this thesis are expected to be in the high GFR range. Consequently, 
when the eGFR is reported or referred to in this thesis, it is calculated using the CKD-EPI 
equation, described below. 
GFR = 141 × min(Scr/κ, 1)
α × max(Scr/κ, 1)
-1.209 × 0.993Age × 1.018 [if female] × 1.159 [if black] 
where: 
Scr is serum creatinine in mg/dL, 
κ is 0.7 for females and 0.9 for males, 
α is -0.329 for females and -0.411 for males, 
min indicates the minimum of Scr/κ or 1, and 
max indicates the maximum of Scr/κ or 1 
1.2.3 Progression of diabetic kidney disease  
 
Proteinuria has been associated with kidney disease and CVD for a long time, and is a widely 
used screening test and therapeutic target for all types of patients. Microalbuminuria 
precedes proteinuria, usually presenting before any loss in GFR, hence microalbuminuria is a 
risk factor for renal disease which enables intervention to start earlier than if screening 
using proteinuria. However, microalbuminuria is only used for screening in patients with 
diabetes. It is unlikely that microalbuminuria and proteinuria arise from different 
pathological processes, but rather that microalbuminuria, due to the physical properties of 
albumin, presents before other proteins that amount to proteinuria (Mogensen, 2003). 
However, some authors argue that microalbuminuria arises from proximal tubular 
dysfunction, and not increased glomerular permeability to albumin (Comper, 2008). 
The progression of DKD is characterised by an increasing AER and is categorised into five 
clinical stages (American Diabetes Association, 2004), with proteinuria occurring in stage 3 
onwards. These are displayed in Figure 3 and show how the GFR deteriorates in the later 
stages as the disease progresses from the onset of diabetes (DM). This is a generalised 
illustration showing the natural progression of DKD, however, in a clinical setting the course 
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of DKD becomes convoluted as patients are being treated to achieve optimal glycaemic 
(Perkins  et al., 2003) and blood pressure control (Parving and Hovind, 2002). Individuals 
with microalbuminuria are at a higher risk of progressing to the more severe stages of DKD 
and reaching ESRD. However, they may not progress and may even stay in the 
microalbuminuria range or even regress to normoalbuminuria (Gonzalez Suarez et al., 
2013). Individuals who do progress to ESRD will require dialysis or a kidney transplant to 
live. This is why it is so important to identify individuals who are at risk of developing ESRD 
at an early stage, and this is better achieved when screening for microalbuminuria instead of 
proteinuria. 
 
Figure 3 Schematic representation of progression of diabetic kidney disease from the onset 
of diabetes. This generalised overview demonstrates the clinical cut off points; the red 
dashed lines represent the clinical range for microalbuminuria, the blue dashed lines 
represent the clinical range for GFR and the black vertical dashed lines represent the 5 stages 
of DKD: 1= normoalbuminuria (AER <20µg/min). 2= microalbuminuria (AER 20-200 µg/min). 
3= Macroalbuminuria (AER >200 µg/min). 4= Progressive nephropathy (GFR <90ml/min). 5= 
ESRD (GFR <15ml/min). 
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Interestingly, in the early stages of DKD the GFR can be raised, known as hyperfiltration. This 
transpires from glomerular changes that occur due to the pathological development of DKD, 
which is discussed later in detail (section 1.3). This demonstrates that physiological changes 
are already occurring in stage 1, within the normoalbuminuria range, before the first clinical 
signs of microalbuminuria present in stage 2. These early physiological changes may be 
reflected by small increases of urinary albumin excretion within the normoalbuminuria 
range, but the ability to investigate this relationship is restricted by routine assays being 
incapable of measuring these low concentrations of urinary albumin.  
To identify DKD, the current guidelines recommend annual screening for microalbuminuria 
and reduced GFR in patients with DM.  The NKF KDOQI guidelines recommend that 
screening commences five years after diagnosis in type 1 diabetes (T1DM) and from the 
time of diagnosis in type 2 diabetes (T2DM) (National Kidney Foundation, 2007). The 
rationale is that microalbuminuria at the time of T1DM diagnosis is usually transient and 
attributed to acute metabolic stress, usually reverting to normoalbuminuria with improved 
glycaemic control. The majority of longitudinal studies reflect this and demonstrate that 
microalbuminuria usually presents five years after T1DM diagnosis (National Kidney 
Foundation, 2007). However, one cross-sectional study reported a significant 
microalbuminuria prevalence of 16%, one to five years after T1DM diagnosis (Stephenson 
and Fuller, 1994). It is important to consider the patient’s age at diagnosis when deciding 
the appropriate time to commence DKD screening. Increasing duration of prepubertal T1DM 
has been reported as an independent risk factor for microalbuminuria (Schultz et al., 1999), 
indicating that screening should commence earlier after diagnosis if diabetes was diagnosed 
at younger ages. In the case of T2DM, the inability to accurately determine the onset of 
diabetes means screening for DKD at the time of diagnosis is imperative (Gross et al., 2005). 
In 2003, the United Kingdom Prospective Diabetes Study (UKPDS) reported the incidence of 
the different stages of DKD among 5,097 T2DM patients. At the time of T2DM diagnosis, 333 
(6.5%) presented with microalbuminuria and 37 (0.7%) with macroalbuminuria. After a 
median follow up time of 10.4 years, a further 867 subjects had developed 
microalbuminuria, 264 macroalbuminuria, 71 had reduced renal function and 14 required 
renal replacement therapy (Adler et al., 2003). Annual death rates raised with the increasing 
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stages of DKD, with CVD the most common cause of death across all DKD stages. 
Cardiovascular death included deaths from stroke, myocardial infarction, sudden death and 
peripheral vascular disease (Adler et al., 2003). The calculated annual transition rates 
between the DKD stages reported in 2003 are summarised in Figure 4, reflecting the 
progression of the disease and the increased risk of mortality with increasing AER (Adler et 
al., 2003). 
 One weakness of the UKPDS report by Adler et al. is that a urinary albumin concentration 
(UAC) from a single spot urine sample was used to assess urinary albumin excretion, as 
opposed to the accepted ACR, thus reducing the usefulness of the report. In addition, a 
lower limit of 50mg/L to classify microalbuminuria appears high. A recent systematic review 
evaluating the diagnostic performance of UAC and ACR identified nine studies that used 
UAC to identify microalbuminuria (Wu et al., 2014). Although Wu et al found no significant 
difference in sensitivity (p = 0.70) or specificity (p =0 .63) between the UAC and ACR to 
Figure 4 Annual transition rates with 96% confidence intervals through the stages of 
nephropathy and to death of any cause. The report is obtained from assessing 5,0974 patients 
with type 2 diabetes, with a median follow up period of 10.4 years (Adler et al., 2003). 
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identify microalbuminuria, they reported that the range of lower cut off values for UAC 
across the nine studies was from 16.1 to 33.6 mg/L. Alder et al. used a cut off value of 
50mg/L in the UKPDS report which is evidently too high, resulting in an underestimation of 
the already prominent prevalence of microalbuminuria across the DKD stages. A further 
underestimation of microalbuminuria frequency may also be apparent as urine samples 
were stored at -20oC prior to analysis, which is understood to result in the loss of albumin 
(Elving et al., 1989, Brinkman et al., 2007a, Schultz et al., 2000). The impact of various 
storage conditions on urinary albumin concentration are investigated later on in Chapter 5. 
Although Adler et al. used UAC to assess urinary albumin excretion, the UKPDS report does 
demonstrate the clinical application of urinary albumin excretion in a large cohort of 
patients with type 2 diabetes. The UKPDS report revealed that 17% of their T2DM patients 
progressed from normoalbuminuria to microalbuminuria over 10 years; other studies have 
reported a greater proportion making this transition in a shorter follow up period. In a 
Danish population, 20% progressed in less than six years (Gall et al., 1997) and 35% in eight 
years in an Israeli population (Ravid et al., 1998). The differences in transition rates between 
studies can be attributed to the different cut off values used to identify microalbuminuria 
with variable follow up periods.   
Although these reports are historical now, and the transition rates might be lower now due 
to improved treatment of blood pressure and tighter glycaemic targets, they not only 
demonstrate the importance of screening for microalbuminuria at the time of T2DM 
diagnosis, but also confirm that microalbuminuria is a predictor of renal disease and CVD 
(see section 1.5), and that increasing AER reflects an increased risk of morbidity and 
mortality. 
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1.3 Pathophysiology of albuminuria 
 
The presence of albumin in urine is considered to be the result of the balance between 
glomerular filtration and tubular reabsorption. To understand the pathophysiology of 
albuminuria, it is important to first understand the properties of albumin and how it 
interacts with the different structures of the kidney and then explore the physiological 
changes that occur during DKD. 
 
1.3.1 Structure of Albumin 
 
Human serum albumin (HSA) is the most abundant plasma protein; it has many physiological 
functions with extensive clinical importance. HSA is synthesised in the liver and exists as a 
single polypeptide chain, composed of 585 amino acids with a molecular weight of 66,500 
Da and a diameter of 3.6nm and has a negative charge (Peters, 1996, Anguizola et al., 2013).  
It is arranged in a series of α-helices, folded by 17 disulphide bonds forming three 
homologous domains (Peters, 1996, He and Carter, 1992). These domains have a variety of 
ligand binding sites which enable HSA to transport a range of endogenous and exogenous 
substances around the circulatory system.  
 
1.3.2 Function of albumin 
 
Although HSA has a negative charge, its strongest interactions are with hydrophobic anions 
such as long chain fatty acids, bilirubin and haematin (Peters, 1996). Other molecules such 
as steroids, amino acids, hormones, toxins and pharmaceuticals also bind to HSA (He and 
Carter, 1992). Further to being transported by HSA, specific ligands can undergo metabolic 
modifications and some potential toxins can be rendered harmless  (Fasano et al., 2005). 
HSA also bind metal ions, for example; copper and iron, which suppresses their ability to 
form reactive oxygen species which induce oxidative stress and damage, associated with a 
range of pathological conditions (Roche et al., 2008). A further antioxidant action of HSA is 
to directly scavenge free radicals and reactive oxygen and nitrogen species. This is achieved 
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by HSA’s only free cysteine residue (Cys34) which provides a redox active thiol (sulphydryl 
group) (Roche et al., 2008, Peters, 1996). 
HSA also binds nitric oxide (NO), a well-established molecule for inducing vasodilation and 
reducing platelet aggregation (Loscalzo, 2001).  Through HSA’s ability of binding NO it has 
been associated with anti-thrombotic function, as it slows the rate of NO inactivation, 
therefore extending its anti-aggregatory effects on platelets (Evans, 2002). Further anti-
coagulant effects of HSA have also been proposed (Jørgensen and Stoffersen, 1980).    
HSA is a relatively stable protein, with a considerable half-life of approximately 20 days, 
which can be attributed to its 17 disulphide bonds. Due to the half-life of HSA and its 
capacity for glycosylation, there is increasing research on its clinical application as an 
intermediate glycation index for monitoring glycaemic control in diabetes (Roohk and Zaidi, 
2008). Along with its abundance and affinity for pharmaceuticals, HSA significantly 
influences the pharmacokinetics of many drugs, impacting their rate of delivery and efficacy 
(Fasano et al., 2005). The binding capability of HSA is also considered in other applications 
such as with contrast agents when developing cardiovascular magnetic resonance imaging 
methods (Fasano et al., 2005).  
HSA contributes up to 80% of the total oncotic pressure, retaining water in the circulatory 
system (Weil et al., 1979, Caironi and Gattinoni, 2009). This is attributed to its abundance, 
molecular weight and negative charge. Albumin synthesis is principally regulated by the 
oncotic pressure of the extravascular hepatic space, but it is also influenced by hormones 
such as insulin, cortisol and thyroxine (Evans, 2002). Approximately 12-25g of HSA is 
produced a day in healthy young adults. The majority is released directly into the blood 
circulation, of which approximately 60% travels into the extravascular interstitial 
compartment (Rozga et al., 2013). The HSA reference range in blood is 35-50g/L, outside 
these ranges can indicate various pathological conditions. Hypoalbuminaemia can be 
attributed to several mechanisms; a decrease in HSA synthesis, increased degradation, 
disrupted compartmental distribution and external losses. The most common cause of 
hypoalbuminaemia is via malnutrition (Rozga et al., 2013). 
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HSA degradation is not so well understood, but it appears to primarily occur in the skin and 
muscle (40-60%) and in the liver (<15%) (Peters, 1996, Gatta et al., 2012, Nicholson et al., 
2000). HSA has a low glomerular sieving coefficient of 0.00062, resulting in approximately 
3.3g of albumin filtered daily by the kidneys (Tojo and Kinugasa, 2012) . The majority of 
albumin which passes through the glomerular barrier is reabsorbed in the proximal tubule 
(71%), the loop of Henle and distal tubule (23%), and collecting duct (3%) (Tojo and 
Kinugasa, 2012). Approximately 10% of HSA is degraded by proteases within proximal 
tubular cells. (Haraldsson and Tanner, 2014). 
In healthy individuals a small amount of albumin is excreted in urine. In DKD there are 
higher levels of albuminuria and to understand the pathological processes causing this, an 
overview of the structure and function of the kidney is required, accompanied by the 
normal renal handling of albumin. 
 
1.3.3 Overview of the kidney 
 
The kidney performs a large number of essential functions which it achieves through the 
excretion of waste products such as creatinine, urea, uric acid and other substances. In 
addition, the kidney manages water and electrolyte homeostasis, the acid-base balance and 
regulates systemic and renal haemodynamics through the production of hormones. The 
kidneys secrete renin, which contributes to systemic blood pressure regulation through the 
renin-angiotensin-aldosterone system. They also secrete calcitriol which regulates the 
availability of calcium and phosphates, required for bone metabolism. Erythropoietin, which 
increases the synthesis of red blood cells, is also secreted by the kidneys. The kidneys also 
facilitate gluconeogenesis which helps prevent hypoglycaemia during fasting, and they also 
contribute to the degradation of some hormones, such as insulin. Finally, the kidneys are 
also a site to activate vitamin D via hydroxylation (Reilly and Perazella, 2014).    
To carry out all of these vital functions, the kidneys incorporate a range of specialised cells 
which enable the filtering, reabsorption and secretion of a variety of molecules. This is 
performed in a very precise manner through integrated regulation of renal haemodynamics 
and tubular handling of water and solutes. Disruption to these processes can lead to life 
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threatening situations. Although this chapter focuses on the mechanisms causing 
albuminuria, it will also be discussed how albuminuria itself can impact some of these 
functions of the kidney.  
The kidneys are at the back of the abdominal cavity and lie outside the peritoneum. 
Nephrons are the functional units of the kidneys and there are approximately 400,000 – 
800,000 in each one. A nephron consists of the glomerulus and associated tubules which 
lead to the collecting duct (Figure 5). The outer zone of the kidney is known as the cortex 
and the inner zone is the medulla. The cortex contains the glomeruli and the medulla 
contains the loop of Henle and the final portions of the collecting duct. Nephrons are 
surrounded by specialised (fenestrated) capillaries which enable the kidney to carry out its 
vital functions (O'Callaghan, 2009).  
 
Figure 5 Microvascular organisation of a nephron. The afferent arteriole from the renal 
artery enters the glomerulus, which branches out into fenestrated capillaries. The efferent 
arteriole leads out of the glomerulus and branches into the peritubular capillaries 
(fenestrated) which surround the proximal tubules and the loop of Henle (vasa recta), which 
all lead to the renal vein (Reece and Campbell, 2010). 
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Blood enters the kidneys via the renal artery, which receives around 20% of cardiac output. 
The afferent arteriole transports blood into the glomerular capillaries, the site of filtration, 
which then leaves via the efferent arteriole. It is rare for arterioles to become capillaries and 
then become arterioles again, but this structure assists in maintaining intra-glomerular 
pressure. From the efferent arteriole blood flows to peritubular capillaries which surround 
the proximal and distal tubules. Peritubular capillaries are fenestrated and enable 
reabsorption and secretion between blood and the inner lumen of the nephron. The 
capillaries which surround the loop of Henle are known as vasa recta. From the capillaries 
blood is returned to the heart via the renal vein which leads to the inferior vena cava. The 
renal pelvis collects the urine from all the collecting ducts and leads to the ureter which 
carries the urine to the bladder, which is finally excreted out of the body via the urethra 
(Reece and Campbell, 2010). 
There are two processes to consider when examining how albumin leaves the blood and is 
excreted in the urine; firstly how albumin passes through the glomerular barrier and 
secondly how it is processed as it moves through the proximal and distal tubules and the 
loop of Henle (Figure 6). 
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Figure 6 Renal handling of albumin. A: cross-section through three capillaries in the 
glomerulus demonstrating the movement of albumin from the blood into the urinary space 
and through the proximal tubule; B: the glomerular barrier; C: reabsorption and degradation 
of albumin by proximal tubular cells. In healthy individuals a small amount of albumin passes 
through the basement membrane and into the urinary space, the majority of which is taken 
up by proximal tubule cells where it is digested by lysosomes. Amino acids are reabsorbed 
into the peritubular capillaries and the left over albumin fragments are secreted back to the 
urine (Jefferson et al., 2008). 
The next section in this chapter describes the different components of the kidney in greater 
detail, and then focuses on the aetiology of DKD and how these renal components are 
affected, demonstrating how HSA is excreted in urine and how renal function deteriorates 
as DKD progresses.  
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1.3.4 The glomerulus 
1.3.4.1 Glomerular capillaries 
 
The diagram in Figure 6 shows a cross-section through three capillaries in the glomerulus 
(a), and demonstrates how albumin must pass through the glomerular barrier to enter the 
primary urine (b). The glomerular barrier consists of two types of cells; endothelial cells and 
podocytes, between them is a specialised extracellular matrix called the glomerular 
basement membrane (GBM). The glomerular capillaries are fenestrated which means the 
endothelium has intracellular perforations (pores) called fenestrae (Figure 7 b). 
Approximately 20-50% of the endothelium is fenestrated (perforated) (Bulger et al., 1983). 
This high density of fenestrae enables water and solutes to pass through the endothelial 
cell. The fenestrae have a diameter of around 60-80 nm (Satchell and Braet, 2009), so under 
normal conditions it cannot be the size of the fenestrae which prevents albumin  passing 
through the glomerular barrier, as albumin has a diameter of 3.6 nm.    
 
 
Figure 7: Scanning electron micrograph of a mouse glomerulus. A: Loop of capillaries 
encased by podocytes and their foot processes. B: A view of the inside the lumen of a 
fenestrated capillary showing the endothelial fenestrae, and the podocyte foot processes 
that surrounds the outside. Scale bars: A = 10 µm, B = 1 µm (Haraldsson et al., 2008). 
Endothelial fenestrae             Podocyte foot 
processess 
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Although structurally albumin may be able to pass through endothelial fenestrae, the low 
glomerular sieving coefficient is most likely attributed to the biochemical properties of the 
glycocalyx which restricts its passage (Figure 8). The glycocalyx is present on the luminal side 
of the capillaries and is plasma membrane bound with a more loosely associated area 
extending towards the lumen (Haraldsson et al., 2008). The glycocalyx is composed of 
negatively charged glycoproteins, glycosaminoglycan and membrane associated 
proteoglycans. This thick, negatively charged structure most likely contributes to the high 
permselectivity of the glomerular barrier.  
As albumin carries a negative charge it will not be able to pass freely through the glycocalyx 
and only a small amount leaves the capillary through the fenestrae, in fact some albumin is 
adsorbed in the glycocalyx, contributing to its negative charge. The loss of glycocalyx results 
in increased urinary albumin excretion in rat models (Salmon et al., 2012) 
Although albumin has a low glomerular sieving coefficient, given the abundance of albumin 
in the blood some does pass through the glomerular barrier. The majority of albumin which 
passes through the glomerular barrier is reabsorbed in the proximal tubule, the loop of 
Henle and distal tubule (section 1.3.4.5)  
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Figure 8 The glomerular barrier. A: The schematic diagram on left represents the glomerular 
barrier, demonstrating the endothelial surface layer (ESL) lining a fenestrated capillary at the 
top of the image. At the bottom of the diagram; podocyte foot processes and slit 
diaphragms form the lower part of the glomerular barrier. Filtration by endothelial cells and 
podocytes is an integrated process, demonstrated by the production of angiotensin-1 and 
vascular endothelial growth factor at the foot processes that act on the endothelial cells to 
regulate their function. The glomerular basement membrane is a specialised extracellular 
matrix that lies between the endothelial cell and podocyte foot processes. B: The glycocalyx 
is demonstrated in more detail on the schematic on the right. The glycocalyx is composed of 
membrane bound proteoglycans such as syndecan and glypican, which carry chondroitin 
sulphate and/or heparan sulphate side chains. The outer region of the ESL is composed of 
secreted proteoglycans (e.g. perlecan and versican) and secreted glycosaminoglycans (e.g. 
hyaluronan) along with adsorbed plasma proteins, such as albumin. (Haraldsson et al., 
2008). 
 
1.3.4.2 Glomerular basement membrane 
 
Albumin that does pass through the glycocalyx and through the fenestrae enters the GBM. 
The GBM is composed of type IV collagen, laminin, nidogen and heparan sulphate, which 
A B 
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are common to all basement membranes. However, the GBM is unique as it is much thicker 
(240 – 370 nm) than basement membranes in other vascular beds (e.g. 40 – 80 nm in skin, 
respiratory and gastrointestinal vascular beds) (Haraldsson et al., 2008, Miner, 2011). This 
has been attributed to GBM formation during glomerulogenesis where two distinct 
basement membranes, the endothelial and visceral epithelial basement membranes, fuse 
together (Abrahamson, 1985). The role of the GBM in glomerular filtration is unclear, it 
contains proteoglycans with heparan sulphate chains attached which may contribute to 
charge selectivity (Hassell et al., 1980). 
Traditionally the GBM has been thought of as having the principal role in renal filtration 
(Batsford et al., 1987). However, in vitro studies suggest additional components are required 
to establish glomerular permselectivity. Bolton et al. compared the sieving coefficient of an 
inert probe and its negatively charged counter-part in in-vitro studies using rat GBMs and 
found no difference across the GBM (Bolton et al., 1998). This suggests that the majority of 
charge selectivity occurs elsewhere in the glomerular barrier, most likely the endothelial or 
epithelial cell layers. However, the GBM is still an important component of the glomerular 
barrier as its fibrous network restricts fluid flux  (Haraldsson et al., 2008). 
 
1.3.4.3 Podocytes 
 
Podocytes are specialised epithelial cells which encapsulate the glomerular capillaries 
(Figure 7). Their large cell body protrudes into the urinary space, with long primary 
processes that expand to glomerular capillaries, affixing themselves by numerous foot 
processes (Figure 8). Foot processes from adjacent podocytes regularly interdigitate, 
forming filtration slits that are bridged by an extracellular structure, known as the slit 
diaphragm (Pavenstädt et al., 2003). The width between slit diaphragms is approximately 30 
– 40nm (Furukawa et al., 1991, Rodewald and Karnovsky, 1974), large enough to let albumin 
pass through. The basal membrane is where the sole of the foot processes attach to the 
GBM, the luminal membrane is in contact with the primary urine, the slit diaphragm acts as 
a border between them (Figure 8). The luminal membrane and slit diaphragm are coated in 
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a glycocalyx, similar to that in the ESL, however it is rich in sialoglycoprotiens (e.g. 
podocalyxin and podoendin) (Huang and Langlois, 1985, Sawada et al., 1986). This provides 
the podocytes with a strong negative charge, contributing to the charge selectivity of the 
glomerular barrier. In addition, this anionic charge also helps to maintain a distance 
between parietal and visceral cells, helping to maintain glomerular structure and function 
(Kerjaschki, 1994).   
 
1.3.4.4 Mesangial Cells 
 
Mesangial cells are not part of the glomerular barrier; however they maintain the structure 
in which it functions. Although the glomerular mesangium is unlikely to directly contribute 
to permselectivity, they do have contractile properties (like smooth muscle cells) which 
influence filtration (Kreisberg et al., 1985, Schlondorff, 1987). The mesangial cells also 
produce collagens, laminin, fibronectin and proteoglycans, which make up the mesangial 
matrix (Mene et al., 1989). This matrix provides the support for the glomerular capillaries 
(Haraldsson et al., 2008).   
Mesangial cells and associated matrix have been shown to play a pivotal role in glomerular 
injury (Schlöndorff, 1996). It has been demonstrated that macromolecules such as 
lipoproteins, advanced glycated proteins, IgG and IgA can be taken up by mesangial cells 
(Skolnik et al., 1991, Schlondorff, 1993, Gómez-Guerrero et al., 1994, Santiago et al., 1991). 
These macromolecules are either degraded by mesangial cells as a protective mechanism or  
they have a proinflammatory action which stimulate them to produce and release 
mediators of inflammation, causing glomerular injury (Schlöndorff, 1996). The actions of 
mesangial cells are influenced by adverse environments like hyperglycaemia (Schlöndorff, 
1996).  Mesangial cell hypertrophy/proliferation and matrix expansion is another 
mechanism of glomerular injury which can also lead to glomerulosclerosis (Haraldsson et al., 
2008). It is understood that this pathological process occurs during the early stages of DKD 
(section 1.3.6). The glomerular capillaries are tethered to the mesangial cells, and capillary 
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hypertension can pull the cells creating strain and generate more fibrosis and thus 
mesangial expansion and glomerulosclerosis (Alsaad and Herzenberg, 2007). 
1.3.5 Albumin reabsorption 
 
Although albumin has a low glomerular sieving coefficient of 0.00062, the abundance of 
albumin in blood results in approximately 3.3g of albumin being filtered daily by the kidneys 
in healthy individuals (Tojo and Kinugasa, 2012). However, the majority of albumin which 
passes through the glomerular barrier is reabsorbed in the proximal tubule (71%), the loop 
of Henle and distal tubule (23%), and collecting duct (3%) (Tojo and Kinugasa, 2012).  
The reabsorption of albumin is driven by receptor mediated endocytosis. The endocytic 
receptors are megalin and cubulin which coat the luminal side of the proximal tubule, the 
loop of Henle and distal tubule (Birn and Christensen, 2006). Albumin-receptor complexes 
become internalised and are transported to lysosomes, where receptors are recycled and 
albumin is digested and its amino acids are reabsorbed into the peritubular capillaries and 
the left over albumin fragments are secreted back to the urine (Jefferson et al., 2008).  
Reabsorption of albumin is a normal process, with the presence of albumin in urine 
considered to be the result of the balance between glomerular filtration and tubular 
reabsorption. Although the majority of evidence suggests albuminuria arises from increased 
glomerular permeability, some authors propose that a defective tubular retrieval system 
independently causes albuminuria in the early stages of DKD (Russo et al., 2007) (section 
1.3.10). It is likely that in the earliest stages of DKD, increased glomerular filtration is 
compensated for by increased tubular reabsorption, and when the retrieval mechanism is 
overwhelmed, increased albuminuria occurs (Phillips and Steadman, 2002). Structural and 
functional changes in renal biopsies from 66 patients with T1DM demonstrates that 
saturating the albumin retrieval mechanism directly causes tubular damage which leads to a 
loss in renal function as the disease progresses (Mauer et al., 1984) (section 1.3.6). 
Alterations to the cells and structures in and around the glomerulus initiate and drive the 
development of DKD. These changes arise from the interactions of two pathways; metabolic 
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and haemodynamic. How these pathways are influenced by diabetes and their effect on the 
structures of the kidney are explored next.    
1.3.6 Hyperglycaemia and the pathophysiology of diabetic kidney disease 
 
Chronic hyperglycaemia, as a result of DM, is an important initiator and promoter of DKD 
(Macisaac et al., 2014).  This was demonstrated in the Diabetes Control and Complications 
Trial (DCCT, 1993) on T1DM, and in the UK Prospective Diabetes Study (UKPDS) (UKPDS, 
1998) on T2DM. These studies investigated the incidence of microalbuminuria and 
macroalbuminuria in participants who were randomly assigned to either intensive or 
conventional glycaemic control. In the DCCT study; 711 participants with T1DM underwent 
intensive therapy (glycaemic target was HbA1c < 6.05%, within the normal range) and 730 
participants with T1DM received conventional glycaemic control (using insulin injections 
twice a day to avoid hypoglycaemia) and they were all followed up for 6.5 years. The 
intensive therapy group had a significantly lower incidence of microalbuminuria (10.2% vs 
17.7%, P < 0.01) or macroalbuminuria compared to the conventional glycaemic control 
group (1.4% vs 3.2%, P < 0.05) (DCCT, 1993). The UKPDS study had a longer follow up period 
of 10 years and recruited 2,408 participants with newly diagnosed T2DM to receive 
intensive therapy and 994 participants with T2DM to receive conventional glycaemic 
control. The target of the intensive therapy was fasting blood glucose less than 6 mmol/L 
using a sulphonylurea or with insulin. The aim of the conventional group was the best 
achievable fasting blood glucose with diet alone, drugs were added if there were 
hyperglycaemic symptoms or blood glucose greater than 15 mmol/L (UKPDS, 1998). They 
reported a significant reduction in incidences of microalbuminuria (19% vs 25%, P < 0.001) 
or macroalbuminuria (4.4% vs 6.5%, P = 0.026) in the intensive therapy group (UKPDS, 
1998).  
A meta-analysis evaluating 7 trials on 28,065 adults with T2DM who were monitored for 2 to 
15 years, also demonstrated that intensive glucose control reduced the risk of 
microalbuminuria (risk ratio, 0.86 [95% CI, 0.76-0.96]) and macroalbuminuria (0.74 [0.65-
0.85]). However, there was no reduced risk for the doubling of the serum creatinine level 
(1.06 [0.92-1.22]) or death from renal disease (0.99 [0.55-1.79]) (Coca et al., 2012). This 
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evidence suggests interventions that improve glycaemia can reduce the incidence of 
microalbuminuria, an early marker of DKD, and the intervention prior to microalbuminuria 
prevents any GFR decline. However, a follow up period between 2 and 15 years maybe 
insufficient to show changes to mortality or a decline in renal function. In addition, for a 
cohort of patients with T2DM, there may be different causes of renal disease, which are not 
related to diabetes which were not factored into the meta-analysis. 
In DM, hyperglycaemia surrounds all the cells of every tissue. Many cells can efficiently 
regulate their intake of glucose, maintaining normal intracellular glucose levels. However, 
some cells cannot achieve this which damages the cells. Examples of cell types which are 
susceptible to the damage caused by hyperglycaemia are; endothelial cells in the retina 
(diabetic retinopathy), neurons and Schwann cells in peripheral nerves (diabetic 
neuropathy) and the specialised cells of the kidney (DKD) (Brownlee, 2005).However, the 
damage from hyperglycaemia is not isolated to these cells and is widespread through the 
body. 
A number of metabolic and haemodynamic factors contribute to DKD. Figure 9 presents a 
schematic overview of the  influence of hyperglycaemia on metabolic pathways within cells 
(left) and impact on haemodynamic pathways (right) (Muskiet et al., 2014).  
The early stages of DKD (Figure 3) are often asymptomatic although physiological changes 
are occurring. Individuals often present with hyperfiltration (identified by a raised GFR) but 
this is not a clinically recognised manifestation of DKD, possibly due to the challenge of 
accurately estimating high GFR and its biological variation. Increased intra-glomerular 
pressure could be the cause of hyperfiltration. Figure 9 demonstrates that raised intra-
glomerular pressure occurs through two mechanisms. 
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Figure 9 Pathogenesis of diabetic kidney disease. Hyperglycaemia and obesity alter 
vasoactive regulators of the afferent and efferent arterioles, which increases intra-
glomerular pressure resulting in hyperfiltration and hyperperfusion. This also stretches the 
mesangial cells which are attached to the capillaries and make them produce more collagen, 
contributing to mesangial expansion and glomerulosclerosis. The haemodynamic changes 
(blue boxes) occur early in DKD, often in combination with systemic hypertension, a failure of 
autoregulation, which is important in the development and progression of DKD in T2DM. In 
addition, hyperglycaemia and dyslipidaemia increase mitochondrial reactive oxygen species 
production which activates several metabolic pathways (yellow boxes) which also lead to the 
development and progression of DKD. These factors of the diabetic milieu lead to glomerular 
damage which is characterised by glomerular basement membrane thickening, mesangial 
cell/matrix expansion and podocytopathy. “Abbreviations: AGE, advanced glycation end 
products; Ang II, angiotensin-2; ANP, atrial natriuretic peptide; COX, cyclooxygenase; ET-1, 
endothelin-1; GBM, glomerular basement membrane; IL, interleukin; NO, nitric oxide; PGC, 
glomerular capillary hydraulic pressure; ROS, reactive oxygen species; TGF, transforming 
growth factor; TNF, tumour necrosis factor; VEGF, vascular endothelial growth factor A.” 
(Muskiet et al., 2014). 
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The “vascular theory” suggests that there is an altered resistance ratio between the afferent 
and efferent arterioles, either increased efferent vasoconstriction and/or reduced afferent 
vasoconstriction. This is caused by unbalanced vasoactive factors and over activation of the 
sympathetic nervous system, which leads to increased glomerular pressure and stretching of 
mesangial cells (O'Callaghan, 2009). 
The “tubular theory” arises from increased reabsorption of glucose and sodium at the 
proximal tubule. This reduces salt delivery to the macula densa which in response releases 
renin, activating the renin-angiotensin-aldosterone system (RAAS). The macula densa are 
specialised cells which detect changes in sodium chloride levels in primary urine, and form 
part of renal autoregulation and systemic blood pressure regulation. Activation of RAAS 
increases GFR through reduced resistance in the afferent arteriole that increase blood flow 
to the glomerular capillaries (Muskiet et al., 2014). Both the “tubular” and “vascular” 
theories are linked to changing the resistance ratio in the glomerulus. 
The tubule-glomerular feedback plays a pivotal role in renal autoregulation. Activation of 
RAAS (especially elevated angiotensin II) is known to cause glomerular vascular dysfunction, 
resulting in hyperfiltration, but has also been shown to induce inflammation as well as 
mesangial and tubular hypertrophy which reduces albumin reabsorption by the tubules 
(Chawla et al., 2010). Further to this, angiotensin II has been shown to promote the 
production of the prosclerotic cytokine transforming growth factor-beta (TGF-β) which 
affects the normal operation of the glomerular cells causing glomerular sclerosis which 
impairs kidney function, however this will most likely occur at the later stages of DKD (Wolf 
et al., 1993).  
Figure 9 also demonstrates how hyperglycaemia increases flux through the polyol and 
hexosamine pathways, activates protein kinase C and forms AGEs. All these mechanisms 
inflict damage to the kidney, and at the root of it all is an increased production of 
mitochondrial superoxide causing oxidative stress (Du et al., 2000). Oxidative stress 
increases the production of proinflammatory cytokines, growth factors and vascular growth 
factors. This inflammatory response accompanied by crosslinking of AGEs and mesangial 
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matrix proteins with increased profibrotic growth factors, causes structural and function 
damage to the kidney (Muskiet et al., 2014, Navarro-Gonzalez et al., 2011).  
 
1.3.7 Morphological changes in diabetic kidney disease 
 
The earliest changes during DKD occur in the glomerulus. Glomerular hypertrophy and GBM 
thickening are common and do not usually affect the performance of the kidneys (Fioretto 
and Mauer, 2007). There may be other aspects occurring in the early stages of DKD, but 
there is limited research as human kidneys are not biopsied in early disease. Mesangial 
expansion and altered mesangial cell function causes glomerulosclerosis, which does lead to 
a loss in renal function as DKD progresses (Qian et al., 2008). 
Early mesangial expansion often occurs with hyperfiltration and is the result of increased 
extracellular matrix deposition and mesangial cell hypertrophy. Hyperglycaemia causes 
mesangial cells to become arrested in the G1-phase of the cell cycle and also causes them to 
produce more TGF-β. The arresting of mesangial cells in the G1-phase causes hypertrophy 
and is mediated by p27Kip1, an inhibitor of cyclin-dependent kinases (Wolf et al., 2001). The 
increase in mesangial cell TGF-β production plays a pivotal role in extracellular matrix 
deposition (Mason and Wahab, 2003).  
Increased matrix synthesis and reduced degradation, which have in part been attributed to 
the increased TGF-β activity, also contribute to the thickening of the GBM (Ziyadeh et al., 
2000). Biochemical changes occur in the GBM during DKD which includes increased 
deposition of type IV collagen and loss of proteoglycans with heparan sulphate side chains 
(Tsilibary, 2003). It is likely that the loss of these negatively charged proteoglycans 
contribute to the loss of charge selectivity within the GBM (Raats et al., 2000). However, the 
contribution of GBM heparan sulphate loss to microalbuminuria has been questioned. One 
study demonstrated that the complete loss of GBM heparan sulphate in rats showed no 
increase in urinary albumin excretion (Wijnhoven et al., 2007). This contradicts the findings 
that the loss of glycocalyx results in increased urinary albumin excretion in rat models 
(Salmon et al., 2012). However, in humans staining for heparan sulphate in renal biopsies 
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revealed no differences between control subjects and subject with T1DM and 
microalbuminuria (van den Born et al., 2006). These studies have focused on the loss of 
heparan sulphate in the glomerular basement membrane and have not considered heparan 
sulphate surrounding podocyte foot processes. 
These findings suggest that the clinical manifestation of albuminuria does not arise from the 
loss of heparan sulphate in the GBM alone, and most likely involves a combination of 
heparan sulphate loss with podocyte injury, endothelial dysfunction and disturbances in 
protein handling by tubular cells (Ziyadeh et al., 2000). 
There is increasing evidence that podocyte injury plays a role in DKD. In T1DM, increased 
foot process width (Bjorn et al., 1995) and reduced podocyte numbers (Steffes et al., 2001) 
have been associated with proteinuria. These findings have also been reported in T2DM 
(Pagtalunan et al., 1997, Meyer et al., 1999, Dalla Vestra et al., 2003). The luminal 
membrane and slit diaphragms of podocytes are coated in a glycocalyx, and similar to the 
GBM, heparan sulphate is lost and reduces the charge selectivity properties of the 
glomerular barrier (Ziyadeh et al., 2000).  
 
1.3.8 Endothelial dysfunction 
 
As well as an early marker for DKD, microalbuminuria is also a risk factor for CVD in both 
general and diabetic populations (Zoccali, 2006). The steno hypothesis was the first to claim 
a common link between mechanisms involved in diabetic nephropathy and CVD. The Steno 
hypothesis is that urinary albumin excretion is a marker of overall vascular dysfunction with 
increased urinary excretion in the kidney presenting itself from increased glomerular 
permeability and also representing increased vascular permeability elsewhere increasing CV 
risk (de Zeeuw et al., 2006). It is suggested the kidney was acting as a window to enable us 
to examine the “state” of the vasculature. 
In 1989, the ‘Steno Hypothesis’ was proposed which suggests that the common process is 
the dysregulation of enzymes involved in the metabolism of extracellular matrix (Deckert et 
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al., 1989). More specifically, this theory implicates enzymes (e.g. heparanase and 
hyaluronidase II) which are involved in the degradation of heparan sulphate proteoglycan, 
which is found in basement membranes, plasma membranes and extracellular matrix 
throughout the body.  Polymorphisms of these enzymes, which are sensitive to 
hyperglycaemia, have been attributed to the variable susceptibility of patients with DM to 
develop DKD (Deckert et al., 1989). More recent work has shown than that the genetic 
deletion of heparanase in mice prevents development of DKD (Gil et al., 2012)   Further 
evidence over the past 20 years supports the ‘Steno hypothesis’, confirming a disturbance in 
endothelial glycocalyx is a common process causing urinary albumin excretion and 
generalised endothelial dysfunction (Satchell and Tooke, 2008). However, it is unlikely to be 
the only factor involved.    
Reactive oxygen species and oxidative stress play a pivotal role in the mechanism of 
albuminuria by influencing several metabolic pathways and having direct cellular effects, 
including the disruption of the glycocalyx (Satchell and Tooke, 2008). Figure 9 demonstrates 
the range of growth factors, inflammatory mediators and angiogenic factors involved in DKD 
which ultimately increases the permeability of the glomerular barrier. However, renal 
damage during DKD is not limited to the glomerular barrier.    
 
1.3.9 Tubulointerstitial damage 
 
In the early stages of DKD, glomerular hypertrophy and GBM thickening occurs along with 
mesangial expansion and mesangial cell dysfunction. This leads to glomerulosclerosis, the 
first cause of reduced GFR. Similarly, the proximal tubules are subjected to hypertrophy and 
basement membrane alterations which precede tubulointerstitial fibrosis, causing a 
progressive loss in renal function (Phillips and Steadman, 2002). As DKD progresses more 
albumin and other proteins pass through the glomerular barrier. These ultra-filtered 
proteins are reabsorbed by endocytosis via megalin and cubulin (endocytic receptors), as 
part of their normal regulatory function (Birn and Christensen, 2006). The excessive uptake 
of albumin by the proximal tubules induces the secretion of a range of proinflammatory 
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markers and profibrogenic cytokines (Ziyadeh and Wolf, 2008). This leads to a reduced 
capacity to reabsorb albumin, and fibrosis causes progressive loss of renal function which is 
associated with the higher levels of urinary protein excretion (macroalbuminuria). 
 
1.3.10 The albumin retrieval hypothesis 
 
A defective proximal tubule retrieval system is an alternative hypothesis for urinary albumin 
excretion arising during the early stages of DKD (Russo et al., 2007). This theory is based on 
observations in rats with hyperglycaemia that suggests the glomerular barrier is intact and 
normally filters nephrotic levels of protein which is bound and retrieved by the proximal 
tubule cells, and only the dysfunction of this retrieval pathway leads to urinary albumin 
excretion (Russo et al., 2007, Russo et al., 2009). In addition, the same research group have 
concluded that albumin fragments are present in urine which are immuno-nonreactive and 
only detectable using high pressure liquid chromatography (HPLC) (Osicka and Comper, 
2004). They hypothesised that immunoassays are incapable of measuring these fragments 
and underestimate total urinary albumin concentration (Comper et al., 2004a).  They also 
demonstrated that in the urine of patients with diabetes with normoalbuminuria and low 
GFR there is a high prevalence of immune-nonreactive albumin, which is in accordance with 
the defective albumin retrieval hypothesis, and that HPLC analysis provides a better 
indication of kidney dysfunction over conventional immunoassays (Comper et al., 2003).   
However, other authors have demonstrated that immunoassays do not underestimate 
albumin concentration and that the co-elution of other proteins in HPLC analysis is 
responsible for the higher concentrations discovered (Sviridov et al., 2006). Methods of 
quantifying urinary albumin are discussed in detail in the next chapter.  
As previously discussed, during the progression of DKD the increase in albumin crossing the 
glomerular barrier causes increased reabsorption by proximal tubule cells which leads to 
tubulointerstitial damage. However, the defective albumin retrieval hypothesis would 
suggest less albumin was being reabsorbed, attenuating tubular activation of 
proinflammatory and profibrogenic cytokines. Although this theory states the glomerular 
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barrier is intact, the albumin sieving coefficient in their study was two to three orders of 
magnitude higher than other estimates (Haraldsson et al., 2008). The albumin retrieval 
hypothesis has not been widely accepted, which is no surprise considering the paucity of 
experimental support and the hypothesis considers the morphological changes in the 
glomerulus to be coincidental and of no pathophysiological significance in DKD (Haraldsson 
et al., 2008).  
 
1.4 Microalbuminuria; predictor of diabetic kidney disease 
 
Urinary albumin excretion was first studied in 1964 by Harry Keen (Keen and Chlouverakis, 
1964), which laid the foundations to develop prospective studies. The same group, in 
collaboration with G.C Viberti, later published the first study that demonstrated increasing 
urinary albumin excretion could predict persistent proteinuria (more than 0.5 g protein/24) 
in patients with T1DM, and coined it microalbuminuria (Viberti et al., 1982). In the following 
years, two more studies also reported that microalbuminuria could predict persistent 
proteinuria (Mathiesen et al., 1984, Mogensen and Christensen, 1984). The three studies all 
applied a different discrimination value at the bottom of the microalbuminuria range; these 
values and a summary of the studies are outlined in Table 3. The disparity in discrimination 
values are most likely the result of different urine collection procedures, analytical methods 
and follow up durations. Interestingly, several studies have shown AER to be 30-50% higher 
over a 24 hour period when compared to overnight in patients with DM (Mogensen et al., 
1995a) and without DM (Fagerstrom et al., 2015) , which may explain why the highest 
discrimination value (70 µg/min) was found when using a 24 hour collection.  
A few years after these three key studies were complete, the authors collaborated and 
released an article in which they reviewed their results (Mogensen, 1987). A discussion on 
the clinical application of microalbuminuria was led by C.E. Mogensen, and it was proposed 
that microalbuminuria be defined between the range 20-200µg/min, and collecting urine 
overnight or during a short-term at hospital was the preferred collection method.  
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The discussion led by Mogensen in 1987 also recommended that three collections were 
required to confirm microalbuminuria, due to a coefficient of variation in urinary albumin 
excretion of approximately 45% (Mogensen, 1971, Mogensen, 1987). In addition, multiple 
collections help exclude other interfering factors, such a sexual intercourse (Sadri-Ardekani 
et al., 2009), exercise (Climie et al., 2015, Heathcote et al., 2009, Koh et al., 2011), fever, 
urinary tract infections and poor glycaemic control, which have all been shown to falsely 
elevate AER (Mogensen et al., 1995b). The variability of different collection methods and 
the influence of interfering factors are investigated and discussed in later chapters. 
Although Mogensen stated AER from a timed overnight or short-term hospital collection 
was the preferred method to assess urinary albumin excretion, he also commented that 
other timed collections and spot (untimed) samples, when adjusting for creatinine, were 
also acceptable (Mogensen, 1987). Given the unreliable nature of timed collections, it is 
clinically preferred to collect spot samples and current guidelines now recommend their use 
for microalbuminuria screening and if microalbuminuria is present in two of three samples, 
which are collected within a three to six month period, then a diagnosis can be made 
(American-Diabetes-Association, 2013).  
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Table 3 Summary of three predictive studies used to define microalbuminuria in 
individuals with T1DM (Mogensen, 1987). Each study (Viberti et al., 1982, Mathiesen et al., 
1984, Mogensen and Christensen, 1984) used a different discriminatory value to identify 
individuals who would go onto to develop diabetic kidney disease (clinical proteinuria).  
 
 
 
 
(Viberti et al., 
1982) 
(Mathiesen et al., 
1984) 
(Mogensen and 
Christensen, 1984) 
Number of participants 
(%male) 
63 (65%) 71 (41%) 43 (100%) 
Mean age at screening 
(years) 
40 (17-60) 30 (13-50) 25 (18-31) 
Mean duration of 
diabetes at screening 
(range) (years)  
10 (1-41) 12 (2-36) 12 (7-20) 
Follow up period (years) 14 6 10 
Proposed 
microalbuminuria 
discrimination value  
(µg/min) 
30 70 15 
Number of participants 
who developed DKD/ 
total number with values 
above discrimination 
range 
7/8 7/7 12/14 
Number of participants 
who developed DKD/ 
total number with values 
below discrimination 
range 
2/55 3/64 0/29 
Urine collection method Overnight 24 hour 
Short term at 
hospital 
Number of Urine 
Collections 
≥1 ≥3 ≥3 
Albumin measuring 
method 
Radioimmunoassay 
Radial immune 
diffusion 
Radioimmunoassay 
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1.5 Microalbuminuria; predictor of cardiovascular disease and 
mortality 
 
A systematic review which included 11 cohort studies with patients with T2DM, 
demonstrated that microalbuminuria not only predicts renal disease but also mortality, with 
an overall odds ratio for death being 2.4 (CI:1.8 – 3.1) and for cardiovascular morbidity or 
mortality, 2.0 (1.4-2.7) (Dinneen and Gerstein, 1997). Since that review, a number of studies 
have also confirmed that microalbuminuria is an independent risk factor for CVD in the 
general population, in individuals without diabetes and without hypertension (Hillege et al., 
2002, Dinneen and Gerstein, 1997, Gerstein et al., 2001, Hillege et al., 2001, Valmadrid et 
al., 2000).   
In 2011, Lambers Heerspink et al reviewed the risk of renal and cardiovascular morbidity 
with microalbuminuria across different populations from different studies (Figure 10) 
(Lambers Heerspink et al., 2011). It is evident that microalbuminuria is a risk factor, not only 
in patients with DM but also in patients with hypertension and in the general population. 
However, the clinical utilisation of microalbuminuria outside of the management of DM has 
not made it into common guidelines (de Zeeuw et al., 2006).  
The use of microalbuminuria as a risk factor in hypertension has been evaluated by other 
studies (Bigazzi et al., 1998) and confirmed in large cohort studies that it was independent 
of other risk factors, for example; age, weight, gender, and some lipid profiles (Wachtell et 
al., 2003, Jensen et al., 2000, Gerstein et al., 2001). This was also reflected in the general 
population in the Framingham study (Arnlov et al., 2005).   
The review by Lambers Heerspink et al (Figure 10) clearly demonstrates increasing risk with 
increasing urinary albumin excretion, especially when predicting cardiovascular morbidity.  
Urinary albumin excretion is a continuous risk marker with no lower limit.  Therefore small 
increases in urinary albumin excretion within the normoalbuminuria range are associated 
with an increased risk of morbidity.   
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Figure 10: Urinary albumin excretion as a predictor of renal and cardiovascular disease. A: 
Association between urinary albumin excretion and the risk of renal morbidity in different 
populations. Data show the risk for ESRD for the general population (PREVEND) (Hillege et 
al., 2002), T2DM population (Action in Diabetes and Vascular Disease: Preterax and 
Diamicron MR Controlled Evaluation [ADVANCE]) (Heller, 2009), and individuals with 
hypertensive nephrosclerosis (African American Study of Kidney Disease and Hypertension 
[AASK]) (Wright et al., 2002). The centers of the squares are placed on the average urinary 
albumin excretion level in each population. B: Association between urinary albumin 
excretion level and the risk for cardiovascular outcomes in different populations. Data 
show the risk for cardiovascular event in the general population (PREVEND), T2DM 
population (ADVANCE) and hypertensive population (Losartan Intervention For Endpoint 
Reduction in Hypertension study [LIFE]) (Ibsen et al., 2006). The centres of the squares are 
placed on the average urinary albumin excretion level in each population. Shaded regions 
illustrated the microalbuminuria range. (Lambers Heerspink et al., 2011) 
Microalbuminuria 
range 
Microalbuminuria 
range 
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1.6 Urinary albumin excretion within the normal range associated 
with renal and cardiovascular morbidity 
 
There is an increasing amount of evidence which demonstrates that the risk of health 
complications is present with increasing urinary albumin excretion within the 
normoalbuminuria range (Figure 10) (Hillege et al., 2002, Dwyer et al., 2012). This has been 
observed in both patients with DM (Wachtell et al., 2003) and without DM (Rachmani et al., 
2000), with urinary albumin excretion in the upper normoalbuminuria range found to 
predict both renal (Wachtell et al., 2003) and cardiovascular morbidity (Rachmani et al., 
2000, Gerstein et al., 2001).   
In a population based cohort from the Framingham study, 1,568 non-hypertensive subjects 
without diabetes who had no history of CVD with an ACR below the macroalbuminuria 
range were followed up after a 6 year period to assess the relationship between baseline 
urinary albumin excretion with incidence of CVD events and death (Arnlov et al., 2005). They 
reported that the group with ACR values at or above the sex-specific median (≥3.9 mg/g for 
men and ≥7.5 mg/g for women) was associated with a 3-fold risk for developing CVD 
compared with the group with ACR below the median values. These results support findings 
that the current threshold for microalbuminuria (30 mg/g) is above the cut-off point where 
increased vascular risk begins (Arnlov et al., 2005). Receiver operating characteristic (ROC) 
analysis revealed that using 4.4 mg/g in men and 9.1 mg/g in women as the discrimination 
value to predict CVD yielded the most optimal performance (diagnostic sensitivity, 0.74; 
specificity, 0.57). However, the authors comment that overall the area under the curve 
(AUC) was <0.70, indicating suboptimal performance of ACR to correctly identify CVD 
(Arnlov et al., 2005).  
In a higher risk population, the Heart Outcomes Prevention Evaluation (HOPE) study, 
measured CVD outcomes after a median follow-up of 4.5 years in individuals with a history 
of CVD (n=5,545) or with DM and at least 1 CVD risk factor (e.g. smoking) ( n=3,498) 
(Gerstein et al., 2001). In all patients, when comparing to the lowest ACR quartile (<1.95 
mg/g), the relative risk (RR) of myocardial infarction, stroke or cardiovascular related death 
in the second quartile (1.95-5.04 mg/g) was 1.11 (95% CI, 0.95-1.30); in the third quartile 
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(5.05- 14.33 mg/g) the RR was 1.38 (1.19-1.60) and in the fourth quartile (>14.33 mg/g) it 
was 1.97 (1.73-2.25), where across the quartiles the P for trend was <0.001, even when 
excluding patients with microalbuminuria. Gerstein et al. also reported that for every 3.5 
mg/g increase in ACR, the adjusted hazard of cardiovascular events increased by 5.9% (95% 
CI, 4.9%-7.0%) (Gerstein et al., 2001). Although the data are not separated by gender, which 
is preferable when reporting the ACR (as done in the Framingham study), the results do 
reiterate the fact that the risk of cardiovascular morbidity and mortality with urinary 
albumin excretion is continuous, and that risk commences below the current 
microalbuminuria threshold (30mg/g).  A limitation to this data is that only one ACR 
measurement was taken, at least 2 collections should be performed due to the high 
variability in urinary albumin excretion. 
Urinary albumin excretion in the normal range has also shown  to be a risk factor for the 
progression to hypertension, a prominent risk factor itself for CVD (Wang et al., 2005, 
Forman et al., 2008, Jessani et al., 2012). With  the increasing evidence that the risk of 
health complications is occurring in the normoalbuminuria range, some authors have 
proposed abandoning the concept of microalbuminuria as a diagnostic category and to treat 
urinary albumin excretion as a continuous variable and to follow patients longitudinally (Ritz 
et al., 2010, Ruggenenti and Remuzzi, 2006). Other authors propose reducing the lower limit 
of microalbuminuria to 5 μg/min, as it is strongly predictive of coronary heart disease and 
death in the general population (Klausen et al., 2004) and in hypertensive individuals 
(Klausen et al., 2005). However, the use of urinary albumin excretion (in the normal or 
microalbuminuria range) has not been adopted by clinical guidelines in relation to CVD. It is 
still only used in identification and management of DKD.  
 
1.7 Calculating risk of cardiovascular disease 
 
There is a wealth of evidence that demonstrates increasing urinary albumin excretion is a 
risk factor, even in the normoalbuminuria range, for renal and cardiovascular disease. 
urinary albumin excretion is a readily available marker which is already well established in 
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routine laboratory analysis, however current models which are used to evaluate an 
individual’s risk of CVD do not utilise urinary albumin excretion. This is partly due to the 
inability of routine assays to measure low levels concentrations of albumin, and urinary 
albumin excretion is not assessed in subjects without diabetes.  CVD risk models are 
valuable clinical tools for risk stratification of asymptomatic patients, determining prognosis 
and treatment strategies, including commencing statin therapy (Stone et al., 2014).  
In the UK, the NICE guidelines recommend the QRISK2 model should be used when 
determining an individual’s risk of developing CVD over ten years in subjects without 
diabetes (NICE, 2014). The QRISK2 model was developed using 1.28 million patients in the 
UK, aged 35-74 years without DM or any existing CVD (Hippisley-Cox et al., 2007). 
Traditionally the Framingham model , which was developed in an American population, was 
adopted, but after extensive validation work the QRISK model showed better predictive 
ability and was better calibrated to the UK population (Collins and Altman, 2012). 
The risk factors inputted into QRISK2 the algorithm are “age, sex, smoking status, systolic 
blood pressure, ratio of total serum cholesterol to high density lipoprotein, body mass 
index, family history of coronary heart disease in first degree relatives aged less than 60, 
area measure of deprivation, and existing treatment with antihypertensive agent” 
(Hippisley-Cox et al., 2007). Although GFR and urinary albumin excretion are not inputted 
into the equations, the NICE guidelines recommend not using QRISK if the eGFR is < 60 
ml/min/1.73 m2 and/or if macroalbuminuria is present (NICE, 2014) as it recognises these 
individuals are already at increased risk of CVD and NICE provide separate advice on 
treatment with statins in CKD (NICE, 2007). 
However, from the overwhelming evidence previously discussed, it is clear there is an 
increased risk of CVD with small increases in urinary albumin excretion, which are below the 
current clinical threshold for microalbuminuria and before impaired renal function, yet 
these risk factors are not included in these prediction models. Perhaps the exclusion of 
urinary albumin excretion arises from the lack of available data when developing the 
models. The models were developed retrospectively using data gathered from 
asymptomatic patients that did not include patients with DM, therefore ACR testing would 
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not be performed as it is only used for annual monitoring of patients with DM and in the 
management of CKD and not for ‘healthy’ patients. It is therefore a considerable challenge 
to truly evaluate the benefit of adding urinary albumin excretion to risk prediction models, 
as measuring ACR is not routinely requested when gathering baseline data, and to 
determine if models are improved, a large number of patients would be required with a long 
follow up period.  
 
1.8 Microvascular dysfunction precedes clinical complications of 
cardiovascular disease  
 
Microvascular dysfunction precedes the development of atherosclerosis and is thought to 
occur in response to CVD risk factors (smoking, obesity and dyslipidaemia) (Shimokawa, 
1999, Holowatz et al., 2008). Microvascular dysfunction precedes clinical complications of 
CVD and is associated with other risk factors of CVD (discussed in detail in Chapter 7) 
(Widmer and Lerman, 2014, Anderson et al., 2011, Levy et al., 2001, Jonk et al., 2007, Strain 
et al., 2005a). The increased risk of CVD with microvascular dysfunction has been 
demonstrated in healthy individuals (Anderson et al., 2011), in diabetes (Sokolnicki et al., 
2007), renal disease (Stewart et al., 2004) and hypertension (Carberry et al., 1992). 
Microvascular dysfunction has been proposed as the common process in the 
pathophysiology of diabetic kidney disease, and cardiovascular disease, resulting in 
increased urinary albumin excretion (Deckert et al., 1989). This is further supported by 
evidence that urinary albumin excretion is associated with other microvascular 
complications of diabetes, such as retinopathy and neuropathy (Newman et al., 2005).   
It is important to investigate these relationships further because it could improve our ability 
to identify those at risk of CVD and microvascular complications of diabetes at an earlier 
stage. This important area forms a major part of this thesis and is discussed in greater detail 
in Chapter 7. 
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1.9 The SUMMIT study 
 
The SUMMIT study (Surrogate markers for micro- and macro-vascular hard endpoints for 
innovative diabetes tools) is a European consortium which aims at identifying markers that 
predict the risk of developing diabetes related vascular complications, in particular DKD, 
CVD, and diabetic retinopathy (DR). One of the objectives of SUMMIT was to identify non-
invasive surrogate markers for the early identification and monitoring of atherosclerosis and 
microvascular complications of diabetes. The University of Exeter participated in the 
SUMMIT consortium. As part of its involvement, participants (described below) were 
comprehensively characterised, with both clinical and vascular parameters measured over 
time. Four participant groups in Exeter were recruited:  
• Group 1: 150 individuals with T2DM with known heart disease 
• Group 2: 150 individuals with T2DM without heart disease 
• Group 3: 75 individuals without diabetes but with known heart disease 
• Group 4: 75 individuals without diabetes or heart disease 
 
Structural and functional measurements of the micro and macrovascular system were 
carried out on all participants, along with standard clinical assessments (e.g. blood pressure) 
including blood and urine analysis. Diabetic neuropathy was tested for by sensory testing, 
accompanied by recording their medical history. An additional group of 450 participants, all 
of whom had a previous diagnosis of T2DM, had retinopathy assessed by traditional eye 
examinations (retinal photographs) and by optical coherence tomography. A spot urine 
sample was collected and ACR measured, they did not have functional vascular 
measurements carried out. All participants were invited back after three years to repeat all 
the assessments. Details of the vascular and clinical assessments are described in Chapter 7.  
In this thesis the results from my early studies investigating different urine sample collection 
methods, the impact of exercise on urinary albumin excretion and optimal sample storage 
conditions are used to guide the procedures used in the SUMMIT study. The identified, 
validated highly sensitive assay is used to quantify urinary albumin in the SUMMIT samples, 
enabling the relationship between urinary albumin excretion within the normoalbuminuria 
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range and microvascular function in individuals with and without T2DM to be examined. The 
relationship of urinary albumin excretion in the subclinical levels to predict vascular function 
and back ground changes in diabetes related vascular complications has never been 
instigated before, and the results are presented for the first time in this thesis. 
 
 
 
1.10 Aims and objectives 
 
 
 
1.10.1 Aims 
 
 
The principle aim of this thesis is to develop a method to investigate low levels of urinary 
albumin excretion (Objectives A), and then to apply these findings to the SUMMIT study to 
investigate the relationship between urinary albumin excretion in the normoalbuminuria 
range with microvascular function and with diabetes related vascular complications 
(Objectives B).  
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1.10.2 Objectives 
 
 
A:  To develop a method to investigate the normoalbuminuria range 
 
Specific objectives: 
1. To identify and validate a reproducible assay to accurately measure low 
concentrations of urinary albumin, concentrations below those assessed by currently 
adopted methods. 
2. To investigate different methods of reporting urinary albumin excretion. 
3. To identify the optimal collection method to assess normoalbuminuria. 
4. To investigate the stability of low levels of urinary albumin and creatinine during 
prolonged frozen storage.  
5. To assess the effects of exercise on urinary albumin and creatinine excretion in 
healthy individuals. 
 
 
B:  To investigate the relationship between urinary albumin excretion with 
microvascular function and diabetes related vascular complications 
 
Specific objectives:  
1. To assess the relationship between urinary albumin excretion and microvascular 
function in individuals with and without T2DM, and CVD across the SUMMIT cohort 
and within the normoalbuminuria range. 
2. To investigate the relationship between changes in urinary albumin excretion over 
three years with change in microvascular function in the SUMMIT cohort and within 
the normoalbuminuria range. 
3. To investigate the relationship between urinary albumin excretion and the early 
stages of diabetic retinopathy and neuropathy. 
4. To investigate the relationship between urinary albumin excretion and 
progression/development of diabetic retinopathy and neuropathy over three years.    
5. To determine if an increase in urinary albumin excretion over three years is related 
to a progression/development of diabetic retinopathy and neuropathy. 
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Chapter 2 Quantifying Urinary Albumin 
 
2.1 Introduction 
 
At baseline, only 46% of participants in the SUMMIT study (who were recruited in Exeter) 
provided urine samples which had measurable concentrations of albumin when using the 
routine laboratory assay. The remainder had an albumin concentration below the limit of 
quantification (LOQ) of the routine assay (3mg/L). These findings are supported by an 
epidemiologic study carried out by Dyer and colleagues in 2004. A 24-hour urine collection 
was undertaken by 4,678 participants, however, only 41% of samples had a measurable 
concentration of albumin, above the lower limit of LOQ of their assay (Dyer et al., 2004).   
This chapter focuses on identifying and validating an analytical method which can accurately 
and reproducibly measure low urinary albumin concentrations.  
 
 
2.1.1 Analytical techniques 
 
Urinary albumin can be quantified by a variety of methods; immunoassays (Liu et al., 2011), 
high pressure liquid chromatography (HPLC) (Comper et al., 2003), microfluidics (Lin et al., 
2010), electrophoresis (Maachi et al., 2004) and liquid chromatography – tandem mass 
spectrometry (Seegmiller et al., 2009a). The most frequently adopted method for diagnostic 
analysis is immunoassays as they are feasible for high throughput analysers in clinical 
laboratories. Antibody based assays incorporate a range of different techniques to quantify 
urinary albumin such as: immunoturbidimetry, immunonephelometry, radioimmunoassay, 
enzyme linked immunosorbent assay (ELISA) and chemiluminescence (Liu et al., 2011). 
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Over the past decade immunoturbidimetric and nephelometric assays have become the 
most common. Both methods use antibodies to bind albumin forming immune complexes 
that precipitate, the higher the concentration of albumin the increased turbidity of the 
sample. Turbidimetry measures the absorbance of light when passed through the sample 
whereas nephelometry measures how much light is scattered. Traditionally nephelometry 
has been primarily used as it has a higher sensitivity, but due to an increasing number of 
samples to be needed to be analysed in clinical practice, turbidimetry has now become the 
leading method as it is easier to incorporate in routine diagnostic analysers which are rapid 
and inexpensive. The majority of high throughput platforms do not have expensive 
photodetectors required for nephlometry, instead turbimetric assays are used which 
incorporate inline detectors which are already used for every colorimetric method.  
Sensitivity and other performance characteristics can be improved in immunoturbidimetric 
assays by binding latex particles to the antibodies, which increases article size per complex, 
increasing light absorbance (Thakkar et al., 1991).   
External quality assurance (EQA) scheme data also demonstrates that turbidimetry is the 
most common method for quantifying urinary albumin in clinical laboratories (Table 4). To 
ensure the quality of results, it is mandatory for clinical laboratories to participate in 
national EQA schemes. These schemes distribute reference material every month to all the 
participating laboratories to assess their accuracy. EQA is a retrospective assessment of the 
whole analytical process and the blind EQA samples are run as patient samples. This allows 
identification of analytical problems and bench marks analytical platform against reference 
method and other users. Table 4 describes data from the Randox International Quality 
Assessment Scheme (RIQAS) (cycle 43, 2014) that The Royal Devon & Exeter NHS (RD&E) 
Blood Sciences Department participates in and also presents data from another scheme; 
United Kingdom National External Quality Assessment Service (UK-NEQAS) (May, 2014). 
RIQAS data indicates higher inter-laboratory variation at lower urinary albumin 
concentrations. This is also reflected in UK-NEQAS data which evaluated spiked human urine 
reference material; at 4.5mg/L the inter-laboratory coefficient of variation (CV) was 31.1%, 
whereas at 340.5mg/L the CV was 6.4%.  
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These data not only demonstrate the variability between laboratories and methods, it 
shows how the variation is higher at lower concentrations. With the current clinical 
reference ranges for microalbuminuria, this high variation at low concentrations may not be 
considered important and deemed acceptable. However, when investigating below these 
current clinical limits, in the normoalbuminuria range, it is fundamental to evaluate the 
reproducibility of these methods at the lower concentrations.  
 
  RIQAS   UK-NEQAS 
Total number of laboratories 
evaluated 
302 
 
212 
Number using Nephelometry  9 (3%)  8 (4%) 
Number using Turbidimetry 287 (95%)  196 (92%) 
Reference Material* 
Mean albumin 
concentration  
mg/L 
Inter-
laboratory 
CV % 
 Mean albumin 
concentration  
mg/L 
Inter-
laboratory 
CV % 
1* 29.2 10.7  4.5 31.1 
2* 52.9 7.4  22.1 11.4 
3* 381.7 6.1   340.5 6.4 
Table 4 External quality assurance scheme data. Data obtained from the Randox 
International Quality Assessment Scheme (RIQAS) and United Kingdom National External 
Quality Assessment Service (UK-NEQAS).Top: Frequency of nephelometric and turbidimetric 
methods assessed by different external quality schemes, presented as absolute numbers and 
proportion of total number (%). Bottom: Mean laboratory results for different reference 
materials and inter-laboratory variation assessed by different external quality schemes. 
*different reference material was used by RIQAS and UK-NEQAS 
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A consideration when interpreting EQA data is the validity of the control material used. The 
term “commutability” of a control material refers to its ability to have inter-assay properties 
comparable to the properties of clinical samples when measured by more than one 
analytical method (Vesper et al., 2007). EQA material is often prepared by adding purified 
albumin to pooled urine which is more homogenous than that normally present in urine. 
This is how the control material used by RIQAS and UK-NEQAS is prepared. Various additives 
may also be used to stabilise and simplify the urine matrix (composition). Simplifying the 
urine matrix and adding purified albumin reduces the commutability of the reference 
material as different assays are impacted in different ways by urine constituents and 
detection may be influenced by albumin homogeneity (Miller et al., 2009). The variability of 
results between laboratories and commutability of reference materials are considerable 
factors when attempting to standardise results, especially when assessing the use of a 
universal clinical range rather than locally derived reference ranges. 
 
2.1.2 The working group for standardisation of albumin in urine 
 
Harmonisation of clinical laboratory results means that results are comparable irrespective 
of the measurement procedure used and where or when a measurement was made (Miller 
et al., 2014). To achieve harmonisation, there are several key analytical considerations; 
calibration traceability to a reference system (Figure 11), commutability of reference 
materials used in a traceability scheme (section 2.1.3), and specificity of the measurement 
of the biomolecule of interest (section 2.1.4) (Miller et al., 2014).  
In 2007, a joint working group for the standardisation of albumin in urine (WG-SAU) was 
formed by the National Kidney Disease Education Program (NKDEP) and the International 
Federation of Clinical Chemistry and Laboratory Medicine (IFCC). Their aim was to improve 
the standardisation of sample collection, measurement and reporting for urine albumin 
concentration (Miller et al., 2009). With regards to the measurement of urinary albumin, the 
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WG-SAU conducted surveys on EQA scheme data across several countries and concluded 
that to improve standardisation a reference system needs to be established.  
A reference system requires primary and secondary reference material and a primary 
reference measurement procedure, through which the assigned value of a reference 
material can be accurately transferred to a patient sample through the hierarchies of a 
traceability chain (Figure 11) (Miller et al., 2009). At the time of the formation of the WG-
SAU there were no high order reference materials or a reference measurement procedure, 
however progress has been made in recent years.  
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Figure 11: Reference system showing traceability of results to higher order reference 
system. Based on international standardisation for organisation (ISO) standard 17511:2003 
(Miller et al., 2014). 
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2.1.3 Reference material 
 
Reference material intended for calibration of routine methods should be commutable with 
native urine for all methods. Immunoassays are primarily used for routine analysis (Table 4), 
therefore immunochemical reactivity towards albumin in reference material should be the 
same in native urine samples.  However, given the high variability of urine composition, 
commutability of reference materials is a challenge. Although purified albumin may not 
reflect the various molecular forms in urine, it might be the most practical approach to 
achieve standardised calibration of routine measurement (Miller et al., 2009). 
The majority of calibrators used by routine immunoassays for measuring urinary albumin 
are traceable to the serum protein reference material ERM-DA470 and its replacement lot 
ERM-DA470/IFCC (Zegers et al., 2010). The albumin concentration of ERM-DA470 is 37.2g/L, 
suitable for the concentration of albumin in serum, but requires considerable dilution for 
the microalbuminuria clinical range. A secondary reference material specific for urinary 
albumin which considers the heterogeneity property of urine, cRM-UA, has recently been 
developed (Itoh et al., 2012). It is a buffer based reference material requiring less dilution 
and is traceable to ERM-DA470. The same group who developed the new reference material 
have also reported reduced variation between immunoassays when recalibrating with cRM-
UA (Itoh et al., 2012). cRM-UA is not currently available but incorporating a reference 
material specific for urinary albumin in the future will certainly aid standardising laboratory 
procedures and assist with comparability studies between methods.  
 
2.1.4 Reference measurement procedure 
 
It is fundamental for a reference measurement procedure to specifically measure albumin in 
urine. Due to the heterogeneity of urinary albumin, immunological assays are not suitable as 
a reference method because antibodies in different procedures may react with different 
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epitopes on the albumin molecule or molecular fragments (Miller et al., 2009). A candidate 
reference measurement procedure has been developed by the Mayo Clinic and is currently 
undergoing external validation by National Institutes of Standards and Technology (NIST) 
(Lieske et al., 2013). The method requires urine samples to undergo trypsin digestion which 
is followed by liquid chromatography coupled with tandem mass spectrometry. HPLC 
separates the components of a sample (including the albumin peptides from the trypsin 
digest), and then the separated metabolites can be further identified and quantified using 
the mass spectrometer. The mass spectrometer ionises the metabolites, which are 
separated and identified by their mass/charge ratio. Using tandem mass spectroscopy 
improves the sensitivity of the method and provides more structural information (Grebe 
and Singh, 2011).  
 
2.1.5 High pressure liquid chromatography and immunoassays to quantify 
urinary albumin 
 
Albumin is a heterogeneous protein and is susceptible to modifications. These modifications 
include glycation (Cha et al., 1991), oxidation (Musante et al., 2007) and C-terminal 
truncation (Bar-Or et al., 2006). These modifications and albumin’s ability to bind a range of 
ligands can result in conformational changes (Hortin and Sviridov, 2008). This diversity of 
urinary albumin has led to a debate on the ability of different methodologies to quantify it.  
In 2004, Comper et al developed an assay to measure urinary albumin by HPLC (Comper et 
al., 2004a). When compared to routine immunoassays, HPLC produced substantially higher 
results, an average of 67% higher within the microalbuminuria range. It was hypothesised 
that  “non-immunogenic” forms of urinary albumin were present which immunoassays were 
unable to detect (Osicka and Comper, 2004).  Other studies have also reported similar 
differences in urinary albumin concentration by HPLC compared to immunoassays (Comper 
et al., 2003, Brinkman et al., 2004, Owen and Roberts, 2005).  
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However, in 2006, Sviridov et al used mass spectrometry to show that this difference could 
be attributed to the co-elution of other proteins detected by HPLC, suggesting HPLC over 
estimates albumin concentration rather than immunoassays unable to detect all forms of 
urinary albumin (Sviridov et al., 2006). Furthermore, in 2008, Sviridov et al. investigated the 
reactivity of two urinary albumin assays with modified and fragmented albumin (Sviridov et 
al., 2008). They demonstrated modified albumin had little effect on the reactivity of the 
polyclonal assay whereas the reactivity of the monoclonal assay (Immulite) was 
considerably reduced. Both assays were comparable when quantifying fragmented albumin. 
Therefore the use of polyclonal antibodies, which recognise multiple epitopes, is preferable 
when using immunoassays to quantify urinary albumin. (Miller et al., 2009, Speeckaert et 
al., 2011).  A limitation of these studies is that they have investigated the microalbuminuria 
range, and the immunoreactivity of urinary albumin at the lowest concentrations has not 
been studied. 
 
2.1.6 Comparing immunoassays to the candidate reference method 
 
All routine laboratory methods to measure urinary albumin are immunoassays (Table 4). 
These immunoassays are robust, reproducible methods which are applied to high 
throughput analysers. Three of these routine methods have been compared to the 
candidate reference (LC-MS/MS) method which showed good overall agreement (Seegmiller 
et al., 2009b). The two polyclonal immunoturbidimetric methods displayed a slight negative 
bias in the 0-200mg/L range (y = 0.91x  (CI: 0.86-0.96), and y = 0.97x (0.92-1.02), where Y=1x 
represents no difference between assays. The monoclonal immunoassay (Immulite) showed 
a positive bias (y = 1.15x (1.09-1.20).   
As described above, Sirvidov and colleagues showed Immulite was more affected by 
modified albumin than polyclonal assays. Therefore, it would be expected that the 
monoclonal assay would have a negative bias when compared to LC-MS/MS, but this was 
not the case. It is probable that the difference can be attributed to the variability of 
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calibrator materials used between assays and different influences of urinary composition. 
This reinforces the need for standardisation among urinary albumin assays. However, the 
polyclonal immunoassays showed strong agreement with the LC-MS/MS method and are a 
suitable method to be used in sensitive assays to investigate low levels of urinary albumin. 
 
2.1.7 Enzyme Linked Immunosorbent Assays (ELISAs) 
 
ELISAs are a feasible option to quantify low concentrations of albumin below the LOQ of 
routine clinical assays.  ELISAs are carried out in microwells, of which there are usually 96 
wells per plate. ELISAs use antibodies and colour change to identify and quantify specific 
substances in a sample. ELISAs use standards (samples with a known concentration of the 
analyte), for which the absorbance of light through the standard is measured and plotted in 
a graph at the end of the assay. The graph is known as the standard curve. This enables the 
concentration of the analyte to be determined in test samples by comparing the absorbance 
of light to the standard curve. ELISAs can work in several different ways; here “sandwich” 
and “competitive” methods are described (Figure 12).   
There are various advantages and limitations of using different methods of ELISA. Sandwich 
ELISAs use two antibodies, so are highly specific however this is more expensive. 
Competitive ELISAs only require one antibody, which is not only cheaper and quicker, but it 
enables them to quantify small analytes which can’t permit binding of both a capture and 
detection antibody.     
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Figure 12 Different methods of enzyme linked immunosorbent assays to detect albumin. 
Sandwich ELISAs have a capture antibody, which is sensitised to HSA, bound to the bottom 
of a microwell. When the sample is added, urinary albumin will bind to these capture 
antibodies. The rest of the sample is washed away and then detection antibodies which cross 
react to a second site on the albumin protein are added and bind to the captured albumin. 
These detection antibodies have a conjugated enzyme which, when substrate is added, 
results in colour development. The light intensity is measured by a spectrophotometer and is 
proportional to the concentration of analyte in the sample. Competitive ELISAs have albumin 
bound to microwells. The sample is added first, followed by the detection antibodies. These 
antibodies bind to both the albumin bound to the microwells and in the sample. The lower 
the concentration of albumin in the sample, the more antibodies that will bind to the HSA 
bound to the micro well. So when the well is washed, and the appropriate substrate is 
added, there will be a high intensity of light when compared to a sample with a higher 
albumin concentration. Therefore, in competitive ELISAs, the concentration of albumin is 
inversely proportional to light intensity. 
 
The original studies that identified microalbuminuria as a risk factor utilised immunoassays 
(Parving et al., 1982, Viberti et al., 1982, Mathiesen et al., 1984, Mogensen and Christensen, 
1984).  Although some authors claim assays using antibodies are incapable of measuring 
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“non-immunogenic”  albumin (Osicka and Comper, 2004), immunoassays have shown good 
overall agreement with a candidate reference method (Seegmiller et al., 2009b). Antibody 
based methods are applied to all routine diagnostic analysers and can reproducibly quantify 
urinary albumin in the microalbuminuria range, but cannot at lower concentrations in the 
normoalbuminuria range (Table 4). From EQA data and comparative studies it is evident that 
the majority of these diagnostic methods have a LOQ between 3 and 12mg/L (Bachmann et 
al., 2014). The routine assay used by the biochemistry department at the RD&E hospital has 
a LOQ of 3mg/L (the “COBAS” method). Sandwich and competitive ELISAs are suitable 
methods to measure below 3 mg/L, where the use of polyclonal antibodies is preferable. 
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2.2 Aim  
 
Identify a robust assay to accurately and reproducibly quantify low levels of urinary albumin.  
 
2.2.1 Specific objectives  
 
1. To identify commercially available ELISA kits which can quantify urinary albumin 
below 3mg/L. 
 
2. To select assays that meet initial requirements for preliminary validation studies.   
 
3. To select the most robust, sensitive, accurate and reproducible urine albumin assay 
for more extensive validation testing to ensure its suitability for use in clinical 
studies. 
 
 
2.3 Methods 
 
2.3.1 Search for commercially available ELISAs 
 
An extensive search for commercially available ELISAs was carried out primarily by internet 
searches targeting laboratory diagnostics manufacturers and distributors and contacting 
sales managers for further information. 
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2.3.2 Inclusion criteria for assay to be considered for preliminary validation  
 
The following criteria were used to identify potential assays, from which assays would be 
selected to undergo preliminary validation: 
1) Ability to measure human albumin in urine 
2) Ability to quantify at concentrations less than 3mg/L 
3) The clonality of the antibodies are known 
4) Assay performance characteristics are reported by the manufacturer 
 
2.3.3 Inclusion criteria for assay to undergo preliminary validation studies 
 
The following criteria were used to prioritise and select assays to undergo preliminary 
validation: 
1) Antibodies are polyclonal 
2) Manufacturer reported intra-assay variability (coefficient of variation) is < 10% 
throughout the assay range. 
3) Cost per test is less than £10.00 (test samples run in duplicate)  
 
2.3.4 Parameters of preliminary validation testing and inclusion criteria to 
undergo extensive validation 
 
Assays which meet the criteria for the following parameters were selected to undergo 
further more extensive validation testing. Details of the methods used for each assay to 
determine these parameters follow this section. 
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 Reproducibility/precision; this tests the closeness of agreement (degree of scatter) 
between a series of measurements obtained by multiple testing of the same sample. 
Only intra-assay variation was tested in the preliminary validation studies. A CV less 
than 20% was an inclusion criteria to undergo further more extensive validation 
testing. An intra-assay variation of 20% was an arbitrary cut-off value which is 
generally used to exclude an assay, as >20% suggests it is not appropriate for clinical 
use. However, to comprehensively determine an assay’s suitability for clinical use, 
the reproducibility must be considered in conjunction with the biological variation of 
the analyte being measured. This is investigated in Chapter 4.  
 
 Accuracy; this tests the closeness of test results to the true value. In these 
preliminary validation experiments the COBAS method was the reference method 
that the tested ELISA was compared to. All test samples were analysed in duplicate 
and mean of the two results is reported. If the difference between the two results is 
greater than 20% of the mean value then the test is repeated in duplicate again. 
Accuracy of the ELISA is tested by the following methods: 
o The correlation of the test ELISA results with the COBAS method was 
determined and the difference between them assessed using Bland Altman 
analysis (discussed in statistical analysis, Section 2.3.9). Samples within the 
COBAS detection range were selected and then appropriately diluted to be 
measured across the range of each ELISA. 
o Linearity of dilution; shows the accuracy of an assay to measure samples 
tested at different dilutions in duplicate (dilutions made with provided assay 
diluent). Linearity of dilution test determines the extent to which the dose-
response of the analyte is linear in a particular diluent. Linearity is 
determined by diluting a sample and calculating the closeness of the result to 
the expected concentration when taking the dilution factor into account. The 
acceptable recovery limit is 80-120%.  
ELISA analyses were carried out using an automated platform, a ‘Dynex DS2’ (Dynex 
Technologies, VA, USA). Automating analysis improves the reproducibility of an assay, 
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reduces the risk of human error and enables a higher throughput of samples when 
compared to carrying out analysis manually. 
The urine samples used in this validation work were from patients at the RD&E hospital, 
who have provided consent for research analysis to be carried out on their samples. After 
routine analysis the samples were stored for a maximum of four days at 4oC. Within that 
time they were used in this validation work and then disposed of in accordance with local 
policy and procedures.   
 
2.3.5 Preliminary validation study method; Genway assay (Genway Biotech Inc. San 
Diego, CA, USA) (assay range: 0.004 - 3 mg/L) 
 
Intra-assay reproducibility was tested on six urine samples and two certified reference 
materials (CRM1 & CRM2). CRM 1 was diluted 1:4000, CRM 2 was diluted 1:1000, and urine 
samples were diluted 1:100. All dilutions were made using a 1% bovine serum albumin 
solution as suggested by the manufacturer. Each sample was measured 10 times on the 
same assay run.  
To assess accuracy, 20 urine samples were measured by the COBAS method, then diluted 
1:100 in 1% bovine serum albumin solution and measured by the Genway ELISA in duplicate, 
with the average being reported.  
Dilution linearity testing was carried out on two urine samples, diluting them in 1% bovine 
serum albumin solution. Sample 1 was analysed after diluting at 1:2, 1:4 and 1:8. Sample 2 
was analysed after diluting at 1:1.25, 1:1.6 and 1:1.95. These dilutions were chosen to 
ensure the full range of the assay is being tested. 
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2.3.6 Preliminary validation study method; Bethyl E88-129 assay (Bethyl 
Laboratories Inc. Montgomery, TX, USA) (assay range: 0.00069 – 0.5 mg/L) 
 
Intra-assay reproducibility was tested on two urine samples and two CRMs. Each sample 
was measured 10 times on the same assay run. CRM 1 was diluted 1:15000, CRM 2 was 
diluted 1:1800, and both urine samples were diluted 1:100. All dilutions were made using 
sample diluent provided by the manufacturer.  
To assess accuracy, 20 urine samples were measured by the COBAS method, and then 
diluted 1:100 in sample diluent provided by the manufacturer and then measured by the 
Bethyl ELISA. 
Dilution linearity testing was carried out on two urine samples, diluting them in sample 
diluent provided by the manufacturer. Sample 1 was analysed after diluting at 1:2, 1:4, 1:8 
and 1:16. Sample 2 was analysed after diluting at 1:1.25, 1:1.6, 1:1.95 and 1:2.44.  
 
2.3.7 Preliminary validation study method; Fitzgerald assay (Fitzgerald Industries 
International, North Acton, MA, USA) (assay range: 0.15 - 400 mg/L) 
Intra-assay reproducibility was tested on three urine samples and two CRMs. Each sample 
was measured 10 times on the same assay run. Both CRMs were diluted 1:10 using sample 
diluent provided by the manufacturer and urine samples were tested undiluted.  
To assess accuracy, 21 urine samples were measured by the COBAS method, then measured 
undiluted by the Fitzgerald ELISA. 
Dilution linearity testing was carried out on two urine samples, diluting them in sample 
diluent provided by the manufacturer. Sample 1 was analysed after diluting at 1:3.3, 1:9.1, 
1:27, 1:83, 1:250 and 1:1000. Sample 2 was analysed after diluting at 1:2, 1:4, 1:8, 1:16, 
1:32, 1:64 and 1:128. 
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2.3.8 Parameters and method of extensive validation study 
 
The most robust, sensitive, accurate and reproducible urine albumin assay was selected to 
undergo more extensive validation testing. The following parameters and criteria were 
tested to ensure its suitability for use in clinical studies.  
 Inter-assay variation between analytical runs was determined by repeat measures of 
2 quality control materials provided by the manufacturer and 2 urine samples on 16 
different ELISA kits, where new standards and reagents were used for each kit. 
Samples were not diluted prior to analysis. An inter-assay CV of <20% was deemed 
acceptable for an ELISA to be used for research sample analysis. 
 
 Accuracy was tested by measuring two routinely used certified reference material 
(CRM). The CRMs have a known value and the closeness of the result from the test 
ELISA can be calculated, where less than 10% error is generally acceptable. 
 
 Accuracy is further tested by analysing 44 samples by the COBAS (the reference 
method) and the tested ELISA. The correlation between the two methods is 
examined by Passing-Bablok regression and Bland Altman analysis (discussed in 
section 2.3.9)  
 
 Limit of detection (LOD); this is the lowest concentration of a substance that can be 
distinguished from the absence of that substance (a blank sample). LOD is estimated 
by taking ten repeat measurements of a blank sample, calculating the mean and 
adding three multiples of standard deviation (SD). This provides a 1% error margin 
(the probability of a false positive, i.e. detecting albumin in a sample when there is 
not). The acceptable cut off value for LOD will be assessed by the frequency of urine 
samples which are not measurable by the assay, where an assay with a lower 
LOD/LOQ may be required. 
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 Limit of quantification (LOQ); The LOQ is often defined by adding the multiple of the 
SD ten times to the mean of repeat blank measurements, reducing the chance of a 
false negative result. However, in this validation work the reproducibility (intra-assay 
CV%) is also determined at the LOQ, to ensure the assay can robustly measure at 
that concentration. This is determined by diluting a standard and measuring it five 
times to determine the intra-assay variation at that known concentration. The LOQ 
was determined as 10 multiples of the SD added to the mean of repeat blank 
measurements, at this concentration the CV must be less than 20% to be within the 
limit of quantification. In addition to this the percent recovery in linearity of dilution 
tests at this concentration must also be between 80% and 100%. 
 
 
2.3.9 Statistical analysis 
 
 To determine the reproducibility of an assay, the CV is calculated from repeat 
measurements of the same sample. The CV is presented as a percentage and is 
calculated using the following equation: 
CV% = Standard Deviation       x 100 
        Mean 
 
 When evaluating the agreement between two analytical methods, a Passing-Bablok 
regression was carried out to assess the correlation. Passing-Bablok regression is a 
statistical method to test the equality of measurements from two different analytical 
methods (Passing and Bablok, 1983). The Passing-Bablok method fits the parameters 
“a” and “b” of the linear equation “y = ax + b ” using non parametric methods. The 
slope coefficient “a” measures the proportional difference between the two 
methods. If one is included in the confidence interval around “a” then the 
proportional difference between the two methods is equal to one. The y-axis interval 
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value “b” measures the systematic differences between the methods. If zero is inside 
the confidence interval around “b”, then the systematic different between the two 
methods is zero. So if and “a” = 1 and “b”=0, it can be concluded that there are no 
systematic and no proportional differences between the two methods, which can be 
supported by a regression plot. The regression results will be presented in the legend 
of correlation graphs in the following format: 
[y = a (CI)x  + b (CI)]    
 
 If there was a systematic difference between two analytical methods then a Bland 
Altman difference plot was used to investigate the difference and determine if a 
consistent bias existed. The difference between the two methods for each sample 
was plotted over the value obtained by the reference method (COBAS). If the two 
assays produced the exact same value for each sample, there would be no difference 
and each sample would be plotted along the line of identity (y=0). 
 
 To assess the accuracy of an assay, the percentage error of a result was calculated 
using the following equation: (the “actual value” is determined by the COBAS 
method) 
% error = (Test value – actual value)   x 100 
     Actual value 
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2.4 Results 
 
2.4.1 Commercially available ELISA kits 
A list of commercially available ELISA kits which met the inclusion criteria (Section 2.3.2) to 
be considered for preliminary validation is collated in Figure 13. From this table of available 
assays, the ‘Genway’, ‘Bethyl E88-129’ and ‘Fitzgerald’ kits met the criteria to undergo 
preliminary validation (Section 2.3.3). Each assay uses polyclonal antibodies, the highest 
reported intra-assay CV was <10% and the cost per test was < £10 (Table 5).
 
Figure 13 Detection ranges of commercially available ELISA kits to measure human 
albumin. Assays which use polyclonal antibodies are in blue and assays which use 
monoclonal are in red. The Genway, Bethyl (E88-129) and Fitzgerald assays were selected for 
preliminary validation. 
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 Genway Bethyl Fitzgerald 
Clonality Polyclonal Polyclonal Polyclonal 
Highest reported CV across 
the analytical range (%) 
4.3 9.7 5.3 
Cost per test (£) 0.96 9.70 2.90 
Table 5 Criteria for selected assays to undergo preliminary validation. Each assay met the 
criteria required to undergo preliminary validation. 
 
2.4.1.1 Genway ELISA kit information (Genway Biotech Inc. San Diego, CA, USA) 
The only components provided as part of the Genway assay are the capture and detection 
antibodies and a stock calibrator solution (30mg/L), therefore the plates must be coated 
prior to analysis. However, they provide enough materials to test 10 plates, making it a 
feasible option for testing a large number of samples. The manufacturer states the range of 
the assay is 0.004 to 3 mg/L, measuring up to the LOQ of the COBAS method. The protocol 
for this sandwich ELISA and other required materials for the assay are described by the 
manufacturer (appendix 1). The antibodies used in the Genway assay are immunoglobulins Y 
(IgY), the major antibodies produced by chickens (Warr et al., 1995). 
 
2.4.1.2 Bethyl E88-129 ELISA kit information (Bethyl Laboratories Inc. Montgomery, 
TX, USA)  
 
The Bethyl ELISA kit consists of a pre-coated 96-well strip plate with all the necessary 
components to carry out this sandwich ELISA. The manufacturer states the range of the 
assay is 0.00069 to 0.5 mg/L, the most sensitive ELISA to be selected for validation. Although 
this assay has the lowest LOQ, its analytical range does not overlap or meet the COBAS 
range, which is a disadvantage. The capture and detection antibodies are polyclonal 
antibodies raised in goats. The protocol for the assay is described by the manufacturer 
(appendix 2). 
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2.4.1.3 Fitzgerald ELISA information (Fitzgerald Industries International, North 
Acton, MA, USA) 
 
The Fitzgerald kit is a competitive ELISA and all the necessary components are provided. The 
manufacturer states the assay has an analytical range of 0.15 to 400 mg/L. The Fitzgerald 
ELISA has the largest range, overlapping with the COBAS method. This ELISA uses polyclonal 
antibodies from rabbit serum. The protocol for the assay is described by the manufacturer 
(appendix 3). 
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2.4.2 Preliminary validation results 
 
2.4.2.1 Genway ELISA (Genway Biotech Inc. San Diego, CA, USA) 
 
Intra-assay reproducibility was tested on six urine samples and two CRMs (Table 6).  The 
correlation between the COBAS and Genway methods is presented in Figure 14. A Bland 
Altman plot is used to describe the difference between the two methods (Figure 15). The 
results from the dilution linearity tests carried out on two samples are presented in Table 7. 
 
Sample 
Mean albumin  
(µg/L) 
St Dev 
(µg/L) 
CV% 
CRM1 5.5 0.3 4.5 
CRM2 146.9 29.0 19.7 
Urine 1 6.5 0.4 6.0 
Urine 2 39.6 10.1 25.5 
Urine 3 58.3 4.4 7.5 
Urine 4 63.1 13.7 21.7 
Urine 5 155.6 29.1 18.7 
Urine 6 209.4 22.8 10.9 
Table 6 Intra-assay variation of the Genway ELISA to measure albumin in urine samples 
and certified reference material.  Each sample was measured 10 times on the same assay 
run to determine reproducibility. CRM 1 was diluted 1:4000, CRM 2 was diluted 1:1000, and 
urine samples were diluted 1:100. All dilutions were made using a 1% bovine serum albumin 
solution as suggested by the manufacturer. For all samples, the calculated mean and 
standard deviation (n = 10) do not account for dilution. 
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Figure 14 Correlation between albumin measurements quantified using both the Genway 
ELISA and COBAS method. Urinary albumin was quantified in 20 urine samples by the COBAS 
method and by the Genway ELISA. Samples were analysed undiluted by the COBAS method, 
and were diluted 1:100 when measured by the Genway ELISA. Results have been adjusted for 
dilution. The dashed line represents the line of identify, which represents where the results 
would lie if there was no difference between the two methods. [y =  0.23 (0.16 – 0.31) x  -
2.46 (-3.83 – 5.61) ]  
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Figure 15 Bland Altman difference plot for albumin concentration in samples quantified 
using both the Genway and COBAS methods. The line of identity represents no difference in 
measuring urinary albumin between the two methods. The mean difference (-14.3 mg/L) is 
shown in green, with the 95% confidence intervals in red.  
Dilution Factor Mean Albumin (µg/L) % Recovery 
Sample 1 107 
 1:2 98 183 
1:4 40 150 
1:8 18 132 
Sample 2 148 
 1:1.25 201 169 
1:1.60 98 104 
1:1.95 66 87 
Table 7 Linearity of dilution results for Genway ELISA. At each concentration of a sample, 
the mean of two results is reported. Recovery indicates the closeness of the result to the 
expected concentration when taking the dilution factor into account. The acceptable 
recovery limit is 80-120%.  
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2.4.2.2 Bethyl ELISA (Bethyl Laboratories Inc. Montgomery, TX, USA)  
 
Intra-assay reproducibility was tested on two urine samples and two CRMs (Table 8).  The 
correlation between the COBAS and Bethyl assays is presented in Figure 16, and a Bland 
Altman plot is used to describe the difference between the two assays (Figure 17). The 
results from the dilution linearity tests carried out on two samples are presented in Table 9. 
 
Sample Mean Albumin 
(µg/L) 
St Dev 
(µg/L) 
CV% 
CRM1 2.7 0.4 16.3 
CRM2 158.9 47.4 29.8 
Urine 1 68.7 12.3 18.0 
Urine 2 65.4 9.1 13.9 
Table 8 Intra-assay variation of the Bethyl ELISA to measure albumin in urine samples and 
certified reference material. Each sample was measured 10 times on the same assay run to 
determine reproducibility. CRM 1 was diluted 1:15000, CRM 2 was diluted 1:1800, and urine 
samples were diluted 1:100. All dilutions were made using sample diluent provided by the 
manufacturer.  
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Figure 16 Correlation between albumin samples quantified using the Bethyl ELISA and 
COBAS methods. Albumin was quantified in 20 urine samples by the COBAS method and by 
the Bethyl ELISA. Samples were analysed undiluted by the COBAS method, and were diluted 
1:100 when measured by the Bethyl ELISA. Results are adjusted for dilution. Five samples 
(38-47 mg/L when measured by COBAS method) were above the analytical range of the 
Bethyl ELISA and not included in this analysis. The dashed line represents the line of identify. 
[y = 1.66 (1.04 – 2.40) x  -2.23 (-10.89 – 4.81)]    
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Figure 17 Bland Altman difference plot for albumin samples quantified by both Bethyl and 
COBAS methods. The line of identity (black line) represents no difference in measuring 
urinary albumin between the two methods. The mean difference (4.4 mg/L) is shown in 
green, with the 95% confidence intervals in red.  
Dilution Factor Mean Albumin 
µg/L 
% Recovery 
Sample 1 335  
1:2 196 117 
1:4 119 142 
1:8 92 219 
1:16 50 239 
Sample 2 322  
1:1.25 288 112 
1:1.60 274 133 
1:1.95 231 140 
1:2.44 192 145 
Table 9 Linearity of dilution results for Bethyl ELISA. At each concentration of a sample, the 
mean of two results is reported. Recovery indicates the closeness of the result to the 
expected concentration when taking the dilution factor into account. The acceptable 
recovery limit is 80-120%. 
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2.4.2.3 Fitzgerald ELISA (Fitzgerald Industries International, North Acton, MA, 
USA) 
 
Intra-assay reproducibility was tested on three urine samples and two CRMs (Table 10).  The 
correlation between samples quantified using both the COBAS and Fitzgerald methods is 
presented in Figure 18, and a Bland Altman plot is used to describe the difference between 
the two methods (Figure 19). The results from the dilution linearity tests carried out on two 
samples are presented in Table 11. 
 
Sample Mean albumin 
(mg/L) 
St Dev 
(mg/L) 
CV% 
CRM1 37.2 1.30 3.50 
CRM2 3.1 0.21 6.82 
Urine 1 6.1 0.33 5.49 
Urine 2 3.2 0.37 11.75 
Urine 3 2.2 0.15 6.84 
Table 10 Intra-assay reproducibility of the Fitzgerald assay tested on three urine samples 
and two CRMs. Each sample was measured 10 times on the same assay run. Both CRMs 
were diluted 1:10 using sample diluent provided by the manufacturer and urine samples 
were tested undiluted.  
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Figure 18 Correlation between albumin samples quantified using both the Fitzgerald ELISA 
and COBAS methods. Albumin was quantified in 21 urine samples by the COBAS method and 
by the Fitzgerald ELISA. The dashed line represents the line of identify. [y = +  0.84 (0.80 – 
1.00) x + 4.78 (2.61 – 6.30) ]    
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Figure 19 Bland Altman difference plot for albumin samples quantified using both the 
Fitzgerald and COBAS methods. The line of identity (black line) represents no difference in 
measuring urinary albumin between the two methods. The mean difference (-4.1 mg/L) is 
shown in green, with the 95% confidence intervals in red. 
Dilution Factor Mean albumin 
(mg/L) 
% Recovery 
Sample 1 335.35 
 
1:3.3 95.12 85 
1:9.1 35.62 96 
1:27 10.82 87 
1:83 4.34 105 
1:250 1.51 109 
1:1000 0.57 124 
Sample 2 44.91  
1:2 21.17 94 
1:4 11.08 99 
1:8 5.03 90 
1:16 2.63 94 
1:32 1.18 84 
1:64 0.78 111 
1:128 0.52 148 
Table 11 Linearity of dilution results for Fitzgerald ELISA in two urine samples. The dilution 
linearity tests show that the Fitzgerald can measure in a linear response to dilution, from 
335.35 mg/L to 0.78 mg/L. Samples were diluted by diluent provided by the manufacturer. 
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2.4.2.4 Comparison of the three assays that underwent preliminary validation 
 
The reproducibility of the three assays is compared in Table 12. The correlation of results for 
each assay with the reference method (COBAS) is summarised in Table 13. Dilution linearity 
results among the assays is described in Table 14. 
 
1) Reproducibility 
 
 Genway Bethyl Fitzgerald 
 Mean 
albumin 
concentration 
(µg/L) 
Intra 
assay CV 
(%) 
Mean albumin 
concentration 
(µg/L) 
Intra 
assay CV 
(%) 
Mean albumin 
concentration 
(mg/L)* 
Intra  
assay CV  
(%) 
CRM1 5.5 ± 0.3 4.5 2.7 ± 0.4 16.3 3.1 ± 0.2 6.8 
CRM2 146.9 ± 29.0 19.7 158.9 ± 47.4 29.8 37.2 ± 1.3 3.5 
Urine A 6.5 ±  0.4 6.0 65.4 ± 9.1 13.9 2.2 ± 0.2 6.8 
Urine B 39.6 ± 10.1 25.5 68.7 ±12.3 18.0 3.2 ± 0.4 11.8 
Table 12 Intra-assay variation of three ELISAs to quantify urinary albumin. CRMs were 
diluted at different ratios to ensure they could be measured within the different analytical 
ranges. Urine A corresponds to the urine sample with the lowest concentration of albumin 
tested. Urine B corresponds to the urine sample with the highest concentration. Each sample 
was measured 10 times on the same assay run. * Note samples tested on the Fitzgerald 
assay did not require dilution to fit into analytical range, hence different units compared to 
the Genway and Bethyl assays.  
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2) Correlation with reference method (COBAS) 
  Genway Bethyl Fitzgerald 
Passing Bablock 
[y = ax + b] 
a (CI) 0.23 (0.16 – 0.31) 1.66 (1.04 – 2.40) 0.84 (0.80 – 1.00) 
b (CI) -2.46 (-3.83 – 5.61) -2.23 (-10.89 – 4.81) 4.78 (2.61 – 6.30) 
Table 13 Correlation between albumin measured by the three test ELISAs with the 
reference (COBAS) method. Passing-Bablok regression is used to assess the correlation 
between the test ELISAs and the COBAS method. The slope coefficient “a” measures the 
proportional difference between the two methods. If one is included in the confidence 
interval around “a” then the proportional difference between the two methods is equal to 
one. The y-axis interval value “b” measures the systematic differences between the methods. 
If zero is inside the confidence interval around “b”, then the systematic different between the 
two methods is zero.  
 
3) Dilution linearity 
Dilution 
Factor 
Genway Bethyl Fitzgerald 
Albumin 
Concentration 
(µg/L) 
% 
Recovery 
Albumin 
Concentration 
(µg/L) 
% 
Recovery 
Albumin 
Concentration 
(mg/L) 
% 
Recovery 
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335 
 
44.91 
 
1:2 98 183 196 117 21.17 94 
1:4 40 150 119 142 11.08 99 
1:8 18 132 92 219 5.03 90 
1:16 - - 50 239 2.63 94 
1:32 - - - - 1.18 84 
1:64 - - - - 0.78 111 
1:128 - - - - 0.52 148 
Table 14 Dilution linearity results for three test ELISAs undergoing preliminary validation 
testing. For ease of comparison, only samples which had serial dilution of 1:2 during the 
validation testing are included in this table. Different samples were used between the assays. 
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Recovery indicates the closeness of the result to the expected concentration when taking 
the dilution factor into account. Recovery must be between 80-120% for an assay to 
undergo further more extensive validation testing.  
When assessing reproducibility and dilution linearity, only the Fitzgerald assay meets the 
criteria to progress to further more extensive validation testing. When investigating the 
relationship between the Fitzgerald assay and COBAS method, there is a strong correlation 
at the lower concentrations of albumin, however above 40 mg/L the results become 
divergent. This is not a concern for the Fitzgerald assay as it is to be used to test samples 
with low concentrations, therefore the Fitzgerald assay underwent further validation work, 
focusing on samples with an albumin concentration below 40mg/L. 
 
 
 
2.4.3 Extensive validation of the Fitzgerald assay  
 
Inter-assay reproducibility was tested on two quality controls (QCs) and two urine samples 
(Table 15). To investigate the accuracy of the Fitzgerald assay, the percentage error was 
calculated when measuring two CRMs, each with a known albumin concentration (Table 16). 
The correlation between the COBAS and Fitzgerald methods, when quantifying samples with 
an albumin concentration less than 40 mg/L is presented in Figure 20, and a Bland Altman 
plot is used to describe the difference between the two methods (Figure 21).  
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1) Inter-assay reproducibility 
Sample 
Mean albumin 
(mg/L) 
St Dev 
(mg/L) 
CV% 
QC1 5.4 0.6 11.51 
QC2 55.5 3.6 6.44 
Urine 1 3.4 0.6 18.42 
Urine 2 12.4 1.6 13.18 
Table 15 Inter-assay variation of albumin measurements using the Fitzgerald ELISA.  Inter-
assay variation between analytical runs was determined by repeat measures of 2 quality 
control materials provided by the manufacturer and 2 urine samples on 16 different ELISA 
kits, where new standards and reagents were used for each kit.  
 
2) Accuracy (percent error) 
Sample 
Expected albumin 
mg/L 
Measured albumin 
mg/L 
% Error 
CRM1 37.60 37.22 -1.0 
CRM2 2.93 3.09 5.5 
Table 16 Percentage error of CRM measurements using the Fitzgerald ELISA. CRMs have a 
known value and the closeness of the result from the Fitzgerald ELISA was calculated. Each 
CRM was measured in duplicated, with the average reported. 
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3) Accuracy (agreement with reference method) 
 
 
Figure 20 Correlation between Fitzgerald ELISA and COBAS method in 44 samples with an 
albumin concentration less than 40mg/L. Dashed lights represents the line of identity. 
[y = 0.98 (0.90 – 1.08) x + 3.66 (2.69 – 4.50)]    
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Figure 21 Bland Altman difference plot for Fitzgerald and COBAS methods in samples with 
an albumin concentration less than 40mg/L The line of identity (black line) represents no 
difference in measuring urinary albumin between the two methods. The mean difference is 
3.55 mg/L (SD 2.13mg/L) which is shown in green, with the 95% confidence intervals in red. 
Difference calculated as Fitzgerald result minus Cobas result. 
 
4) Limit of detection & limit of quantification 
 
To determine what the lowest concentration of albumin that can be reproducibly measured 
by the Fitzgerald assay, the LOD and LOQ were determined. A blank sample was measured 
10 times and produced a mean albumin concentration of 0.24mg/L (SD = 0.05), therefore 
the LOD (mean + 3 SD) is 0.39mg/L.  
Traditionally the LOQ is calculated as (mean +10 SD of the blank sample), so it would 
therefore be 0.74mg/L. However, the dilution linearity test showed the assay can measure 
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in a linear response to 0.78mg/L. To determine if the Fitzgerald assay can measure 
reproducibility at these low albumin concentrations, a urine sample underwent several 
dilutions and was measured five times to determine the intra-assay CV at each 
concentration (Table 17). The assay can reproducibility measure to 0.44mg/L, however to 
include the traditional LOQ definition and to have a %recovery within 80-120% from the 
dilution linearity tests; this work shows that LOQ of the Fitzgerald ELISA is 0.78mg/L. 
Dilution linearity results from preliminary validation studies demonstrate the Fitzgerald 
assay can measure in a linear response to dilution, from 40 mg/L to 0.78 mg/L (Table 11) 
 
Mean Albumin 
mg/L 
St Dev  
(mg/L) 
Intra-assay 
CV% 
1.12 0.06 5.28 
0.63 0.08 13.22 
0.44 0.05 10.60 
Table 17 Reproducibility of the Fitzgerald ELISA to measure low urinary albumin 
concentrations. A urine sample was diluted using assay diluent provided by the 
manufacturer. At each dilution the sample was measured 5 times to determine the intra-
assay CV. 
 
2.5 Discussion 
 
The aims of this chapter were achieved, and a validated assay that fulfils predefined 
objectives, can be used to quantify low concentrations of urinary albumin. 
The work of the joint working group for the standardisation of albumin in urine (WG-SAU) 
demonstrates the complexity of measuring albumin in urine (Miller et al., 2009). The results 
from the WG-SAU and from EQA scheme data reflect the high variability between methods 
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to quantifying urinary albumin, especially at low concentrations and the need to improve 
standardisation by establishing a reference system (Miller et al., 2009). 
Routine assays are unable to measure low urinary albumin concentrations, however 
immunoassays using polyclonal antibodies are a suitable alternative. An extensive search of 
the internet identified thirteen ELISAs (Figure 13) which met the criteria outlined in section 
2.3.2. These assays were selected due to their ability to measure urinary albumin, their 
analytical ranges and performance characteristics.  From these assays, three met the criteria 
(Section 2.3.4) to undergo preliminary validation; the Genway (Genway Biotech Inc. San 
Diego, CA, USA), the Bethyl (Bethyl Laboratories Inc. Montgomery, TX, USA) and the 
Fitzgerald (Fitzgerald Industries International, North Acton, MA, USA) ELISAs. Each assay 
uses polyclonal antibodies, with good reproducibility at low concentrations and each test 
costs under £10 (Table 5). 
 
2.5.1 Genway preliminary validation (Genway Biotech Inc. San Diego, CA, USA) 
 
Intra-assay CV ranged from 6% to 26% in urine samples, failing to meet the <20% criteria 
(Table 6). This assay only provided the antibodies and a standard solution at high 
concentrations. Although this is economically attractive, it requires all assay solutions to be 
prepared at a working concentration prior to analysis, which is prone to error if not 
automated. Although inter-assay variation between days was not tested for this assay, with 
an intra-assay CV of up to 26% and the intricacy of assay solution preparation, it is  unlikely 
to be very reproducible and fulfil the <20%  criteria.  
The correlation of Genway results with the COBAS method were poor (Figure 14), and the 
Bland Altman plot (Figure 15) reveals the Genway produces very similar results to the 
COBAS method up to 15mg/L. It appears that the Genway ELISA doesn’t detect any further 
increase in albumin concentration above 15mg/L as the difference in results grows with 
increasing albumin concentration. The results from the dilution linearity test (Table 7) also 
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reflected inaccuracies at the higher detection range of the ELISA with percent recovery 
outside the acceptable range (80-120%).  
 
2.5.2 Bethyl validation (Bethyl Laboratories Inc. Montgomery, TX, USA)  
 
The Bethyl ELISA showed poor intra-assay reproducibility with a high CV ranging from 13.9% 
to 29.8% for both urine samples and CRMs (Table 8). The regression plot (Figure 16) and 
Bland Altman plot (Figure 17) shows that the Bethyl ELISA produces higher results than the 
reference method (mean difference of 4.4mg/L), except for two samples which were 21.3 
and 31.8 mg/L lower. Dilution linearity tests also confirmed the Bethyl ELISA has poor 
accuracy, with recovery far greater than 120% (Table 9).   
 
2.5.3 Fitzgerald preliminary validation (Fitzgerald Industries International, North 
Acton, MA, USA) 
 
The Fitzgerald assay had the best intra-assay reproducibility among all the assays which 
underwent preliminary validation. The highest CV for a urine sample was 11.8% 
(concentration: 3.2mg/L) and 6.8% for CRM (3.9 mg/L) (Table 10). However, the correlation 
with the COBAS method (Figure 18) showed that the assay was producing higher results 
[y = +  0.84 (0.80 – 1.00) x + 4.78 (2.61 – 6.30) ]   where the “y intercept” value of 4.78 mg/L 
shows a positive systematic difference. This was confirmed by the Bland Altman plot, which 
also demonstrated that above 40mg/L the results were discordant (Figure 19).  Although the 
assay lacks accuracy at the higher concentrations, the dilution linearity results demonstrate 
that it does measures in a dose dependent response in the sample diluent provided (Table 
11). 
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2.5.4 Comparison of the three candidate ELISAs 
 
The performance characteristics of the Fitzgerald ELISA meet the criteria required for an 
assay to accurately and reproducibly measure low concentrations of urinary albumin. The 
Fitzgerald ELISA was the only assay to have an intra-assay CV < 20% across its analytical 
range (Table 12). Only the Fitzgerald assay showed a strong correlation with the routine 
(COBAS) method, although it lacks accuracy at higher concentrations (Table 13). The dilution 
linearity results demonstrate that it is only the Fitzgerald assay that has suitable recovery 
when diluting samples (Table 14). Therefore it is the Fitzgerald assay that underwent further 
validation.  
 
2.5.5 Fitzgerald extensive validation (Fitzgerald Industries International, North 
Acton, MA, USA) 
 
Inter-assay variation was also below 20%, with the highest CV being 18% for a urine sample 
(concentration: 3.4mg/L) (Table 15). The Fitzgerald assay also demonstrated good accuracy 
with a maximum percentage error of 5.5% (Table 16) 
Although the performance of the assay is suboptimal at the higher albumin concentrations, 
it is not where this research is focused. This research investigates the normoalbuminuria 
range, and therefore the agreement of the assay with the COBAS method was more 
extensively investigated using 44 samples with an albumin concentration below 40mg/L. 
The correlation was improved [y = 0.98 (0.90 – 1.08) x + 3.66 (2.69 – 4.50)] with lower 
confidence intervals around the “y intercept” which again suggested a systematic 
difference, and the slope coefficient was 0.98 (0.90-1.08), demonstrating that the difference 
is systematic and not proportional to the concentration of albumin (Figure 20). The Bland 
Altman plot confirms this and finds a consistent positive bias of 3.55 mg/L (SD 2.13mg/L) 
(Figure 21).  
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The LOD was found to be 0.24 ± 0.05 mg/L. The LOQ for the Fitzgerald assay was found to be 
0.78mg/L. LOQ was determined by combining the results of the dilution linearity tests, 
adding 10 SDs to the mean of 10 repeat measurements of a blank sample and the results of 
intra-assay reproducibly at low albumin concentrations (Table 17).  
 
2.6 Conclusion 
 
The Fitzgerald ELISA will be taken forward to quantify urinary albumin in the studies and 
experiments carried out in this thesis. The validated measurable range is 0.78 – 40 mg/L, 
values above this are diluted in the assay diluent provided by the manufacturer. The 
validation results demonstrated that the Fitzgerald ELISA has a consistent positive bias of 
3.55 mg/L over the COBAS method. If the Fitzgerald ELISA was going to replace the COBAS 
or if the results of a study have been determined by the different methods, then they would 
need to be adjusted to make them comparable, and the bias is used to achieve this. 
However, in this thesis, only the Fitzgerald ELISA will be used to measure urinary albumin, 
but the bias must be considered when interpreting the results in relation to clinical 
reference ranges for albuminuria. 
 
  
115 
 
Chapter 3 Investigating Methods to Adjust Urinary Albumin 
Concentration in Untimed Samples to Account for Variable 
Urinary Concentration 
 
3.1 Introduction 
 
Timed overnight collections are the “gold standard” method to collect urine to investigate 
microalbuminuria; however spot samples are clinically preferred. In untimed spot samples, 
the concentration of albumin is directly influenced by the overall concentration of urine, 
reflecting the hydration status of the individual. Creatinine is endogenously produced at a 
relatively constant rate and freely passes into the urine. Normalising the albumin result to 
the urinary creatinine concentration by reporting as albumin to creatinine ratio (ACR) is the 
standard clinical method to account for this variation in urine concentration. When 
reporting the ACR it is therefore important to ensure an accurate and robust method is used 
to quantify creatinine, especially when measuring low albumin concentrations.  
The ACR calculation assumes that creatinine excretion is at the same rate for all individuals, 
however, the actual amount of creatinine excretion varies between people. Creatinine 
excretion is dependent on muscle mass, which is variable between individuals. This is 
acknowledged by gender specific cut off values for microalbuminuria when using ACRs. 
Three equations have been published that estimate creatinine excretion using clinical 
characteristics. These equations can be used to estimate albumin excretion when measuring 
an ACR. This chapter will explore if these equations can be used to improve the relationship 
of an ACR to the “gold standard” overnight AER.  
Urine specific gravity (USG) is another measure of urinary concentration. USG can be 
measured by refractometry and in this chapter a digital refractometer undergoes validation, 
determining its ability to measure urinary concentration. If the validation of the USG 
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refractometer is successful, the use of USG to normalise albumin concentration, instead of 
creatinine, will be tested in future studies.   
When using untimed spot samples it is equally important to evaluate the method for 
adjusting for urine concentration as it is for measuring albumin levels. Therefore, this 
chapter aims to: 
1. Compare two methods of quantifying urinary creatinine 
 
2. Evaluate different methods of estimating albumin excretion rate from untimed 
samples by estimating creatinine excretion 
 
3. Evaluate the reproducibility of a urine specific gravity refractometer and compare 
test results to creatinine concentration 
 
 
 
3.2 Quantifying urinary creatinine 
 
3.2.1 Introduction 
 
When reporting the ACR it is important to consider the performance characteristics of the 
creatinine assay, especially when it is used in conjunction with very low albumin 
concentrations. Consider the following example to demonstrate the clinical impact the 
variability of a urinary creatinine assay can have when interpreting an ACR.  
A male patient provides a spot sample which has an albumin concentration of 10mg/L and a 
creatinine concentration of 5 mmol/L, resulting in an ACR of 2 mg/mmol (within the 
normoalbuminuria range). If the creatinine assay has high variability, of 20% for example, 
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then the creatinine measured on a different day in the same sample could be 4mmol/L, 
resulting in an ACR of 2.5, in the microalbuminuria range. This issue is magnified when also 
considering the impact the reproducibility of the albumin assay contributes to the variability 
of an ACR. As we are investigating the low levels of urinary albumin excretion in the 
normoalbuminuria range, the impact of assay variability is amplified, especially when 
investigating change over time. 
The Jaffe reaction is the most common routine clinical method for measuring creatinine in 
serum and urine samples. The Jaffe reaction is a colorimetric method which adds picric acid 
to an alkaline solution with the resultant colour change being directly proportional to the 
concentration of creatinine (Jaffe, 1886). However, the Jaffe reaction is susceptible to 
interference by endogenous (e.g. pseudocreatinines, bilirubin, glucose) and exogenous (e.g. 
cephalosporins) substances (Allegaert et al., 2014). The presence of interfering substances 
in serum can lead to the overestimation of serum creatinine by as much as 15%–25%, falsely 
lowering eGFR. Interferences from glucose and acetoacetate are particularly important 
because  people with diabetes are a high-risk population to develop CKD (Myers et al., 
2006a). The Jaffe reaction has since been modified, often by optimising kinetic assays 
(where measurements are taken multiples times over a fixed interval), which have improved 
specificity and minimises interference. Creatinine is routinely quantified in serum and urine 
using a modified form of the Jaffe method due to the quick reaction time, adaptability to 
high throughput analysers and cost effectiveness.  
Enzymatic methods are also available to measure creatinine and are considered to be less 
susceptible to interference and to be more precise than the Jaffe method (Apple et al., 
1986). However, there are still some substances which have been shown to interfere with 
enzymatic assays (e.g. bilirubin and dopamine), however glucose does not which is 
important when assessing a diabetic population (Apple et al., 1986, Myers et al., 2006a).  
Studies which have investigated the agreement between enzymatic assays and the Jaffe 
method have focused on quantifying serum creatinine. A study on 27 subjects, 10 with renal 
impairment and 17 healthy controls, demonstrated that serum creatinine was 3 to 4mg/L 
higher when measured by the Jaffe method (p<0.05), regardless of GFR (Apple et al., 1986). 
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A larger study using paired results from 529 routine clinical samples, demonstrated a mean  
bias of 0.0 mg/dL (95% CI: -1.32 to 1.33) and showed no significant difference between the 
Jaffe and enzymatic methods (Schmidt et al., 2015). The regression slope between the 
assays was 1.006 (95% CI: 0.998 to 1.103) and the intercept was -0.005 (95% CI: -0.015 to 
0.006).  When investigating the impact on eGFR and classification of CKD, the risk of 
misclassification due to bias is much less than the risk of misclassification due to biological 
variation (Schmidt et al., 2015). 
Enzymatic methods might be more accurate than the Jaffe method to quantify serum 
creatinine, but they are far more expensive. The clinical impact of misclassification due to 
loss in assay specificity is less than that of biological variation, therefore a simple cost 
benefit analysis demonstrates that the Enzymatic method is not viable for routine analysis, 
even though it is more accurate (Myers et al., 2006a).  
These studies that have compared enzymatic methods with modified Jaffe methods to 
quantify creatinine have been limited to serum samples, and have not evaluated their 
application to analyse urine samples across a diverse population. As demonstrated by the 
earlier example, the impact of assay variation on the ACR can impact clinical decisions; 
therefore assay comparison studies are required on urine samples.  
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3.2.2 Aim 
 
To evaluate the performance of the routinely used modified Jaffe method and an enzymatic 
method to quantify urinary creatinine. 
  
 
3.1.2.1 Objectives 
 
1. Determine intra-assay reproducibility of both assays 
 
2. Determine inter-assay reproducibility of both assays 
 
3. Evaluate the agreement between both assays 
 
 
 
3.2.3 Method  
 
3.2.3.1 The Jaffe method 
  
The ‘Roche Creatinine Jaffé Gen.2’ (Roche Diagnostics Ltd., Burgess Hill, UK), hereafter 
referred to as the ‘Jaffe method’ was selected to undergo comparative testing. 
 
This is the routine assay used by the RD&E Blood Science laboratory. When quantifying 
serum creatinine the assay uses “rate-blanking” to minimize interference by bilirubin. To 
correct for non-specific reaction caused by serum/plasma pseudo-creatinine chromogens, 
including proteins and ketones, the results for serum or plasma are corrected by -26 μmol/L 
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(-0.3 mg/dL) (Roche-Cobas, 2010).  When quantifying urinary creatinine, no correction is 
applied.  
 
The assay uses a 2 point calibration with an analytical range of 0.36 to 57.5 mmol/L. The 
assay is traceable to ID-MS, with two quality controls tested twice every day (Roche-Cobas, 
2010). Urine samples were not centrifuged prior to analysis, and were diluted (1:20) in the 
analyser with deionized water. Analysis was performed on the routine high throughput 
‘Roche COBAS 8000 modular analysers’ (Roche Diagnostics Ltd., Burgess Hill, UK). Data was 
extracted using the application ‘Modulab’ (Systelab Technologies, S.A, Llica d’Moot, Spain). 
 
3.2.3.2 The enzymatic method 
 
The ‘Roche Creatinine plus Ver.2’ (Roche Diagnostics Ltd., Burgess Hill, UK), hereafter 
referred to as the ‘enzymatic method’ was selected to undergo comparative testing.  
This enzymatic method is based on the conversion of creatinine with the aid of creatininase, 
creatinase, and sarcosine oxidase to glycine, formaldehyde and hydrogen peroxide. 
Catalyzed by peroxidase the liberated hydrogen peroxide reacts with 4-aminophenazone 
and HTIB (Koser’s reagent) to form a quinone imine chromogen. The colour intensity of the 
quinone imine chromogen formed is directly proportional to the creatinine concentration in 
the reaction mixture. (Roche-Cobas, 2011) 
The assay uses a 2 point calibration with an analytical range of 0.30 to 60.0 mmol/L. The 
assay is traceable to ID-MS, with two quality controls tested twice every day (Roche-Cobas, 
2011). Urine samples were not centrifuged prior to analysis, and were diluted (1:10) in the 
analyser with deionized water. Analysis was performed on the routine high throughput 
‘Roche COBAS 8000 modular analysers ’(Roche Diagnostics Ltd., Burgess Hill, UK). Data was 
extracted using the application ‘Modulab’ (Systelab Technologies, S.A, Llica d’Moot, Spain). 
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Urine samples used in the evaluation work were patient samples that had been sent to the 
laboratory for routine ACR measurement. Samples were not stored prior to analysis, with 
the test complete within 24 hours of sample collection. 
 
3.2.3.3 Objective 1: Intra-assay reproducibility 
 
Intra-assay reproducibility for each method was tested by analysing seven urine samples 
and two quality control materials 20 times on the same run on the same day. The CV was 
calculated as previously described at Chapter 2.3.9. 
 
3.2.3.4 Objective 2: Inter-assay reproducibility   
 
Inter-assay reproducibility for each method was determined by analysing one quality control 
material on nine different days. The CV was then calculated from data collected using each 
method. The quality control material was prepared according to the routine laboratory 
standard operating procedures, with aliquots being stored at -20oC after preparation. A 
sample was defrosted and thoroughly mixed on rollers and allowed to return to room 
temperature prior to analysis 
 
3.2.3.5 Objective 3:  Agreement between the methods 
 
804 urine samples were assessed at RD&E Biochemistry for routine ACR analysis, where 
creatinine was quantified by both methods (only the routine Jaffe method result was 
clinically reported). Passing-Bablok regression was carried out to evaluate the relationship 
between the two methods. The significance and interpretation of the Passing-Bablok are 
discussed in Section 2.3.9. To summarise the slope coefficient measures the proportional 
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difference between the two methods and the y-axis interval value measures the systematic 
differences between the methods.  
A Bland Altman plot was carried out, as described in Chapter 2.3.9, to evaluate the 
difference between the two methods. The proportion of that difference (percentage) was 
also plotted against the mean value of the two assays to indicate the proportionality of any 
bias between the methods. 
 
 
 
3.2.4 Results 
 
Intra-assay reproducibility ranged from 0.86 to 4.17% and from 0.88 to 2.08% with the Jaffe 
and enzymatic methods, respectively (Table 18). Inter-assay reproducibility was 2.35% and 
2.14% with the Jaffe and enzymatic methods respectively (Table 19). Results from both 
methods for quantifying creatinine were strongly correlated, see Figure 22. A Bland Altman 
plot is used to describe a mean difference of 0.12 ± 0.26 mmol/L between the two methods 
(Figure 23 and Figure 24).  
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3.2.4.1 Objective 1: Intra-assay reproducibility 
 
Table 18 Intra-assay reproducibility of two assays to measure urinary creatinine in quality 
control materials and urine samples.  All samples were measured 20 times in the same run. 
The mean creatinine concentration is the mean from both assays, where the value from each 
assay is the mean of the 20 repeats. The mean (SD) of the CV for the Jaffe method was 1.67 
±1.04 %, and 1.10 ±0.39 % for the enzymatic method.  
3.2.4.2 Objective 2: Inter-assay reproducibility   
 
Jaffe 
Method 
Enzymatic 
Method 
Mean creatinine 
concentration (mmol/L) 
6.78 6.93 
Standard Deviation (mmol/L) 0.16 0.15 
CV% 2.35 2.14 
Table 19 Inter-assay reproducibility of two assays to measure urinary creatinine. Inter-
assay variation between analytical runs was determined by repeat measures of one quality 
control material on 9 different days. 
Sample 
Mean 
creatinine 
concentration 
mmol/L 
Jaffe  
Method 
CV% 
Enzymatic 
Method 
CV% 
Difference in 
CV% 
QC 1 6.95 1.49 0.88 -0.61 
QC 2 16.93 0.86 0.89 0.03 
Urine 1 1.61 4.17 2.08 -2.09 
Urine 2 5.01 1.76 0.83 -0.93 
Urine 3 8.41 1.33 1.06 -0.27 
Urine 4 10.32 1.07 0.99 -0.09 
Urine 5 14.73 1.00 0.90 -0.10 
Urine 6 19.24 2.30 1.25 -1.06 
Urine 7 21.79 1.08 1.03 -0.05 
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3.2.4.3 Objective 3:  Agreement between the methods 
 
Figure 22 Correlation between enzymatic and Jaffe methods to measure urinary 
creatinine. Urinary creatinine was quantified in 804 urine samples by the Jaffe and 
enzymatic methods. The dashed line represents the line of identify, which indicates where 
the results would lie if there was no difference between the two methods. Passing-Bablok 
regression was carried out to show the agreement between the two methods: y = 1.03 (1.03 
to 1.04) x -0.15 (-0.17 to -0.13)  
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Figure 23 Bland Altman difference plot for Jaffe and enzymatic methods to quantify 
urinary creatinine. The line of identity illustrates where results would be positioned if there 
was no difference in measuring urinary creatinine between the two methods (black line) 
(n=804). The enzymatic method has a mean bias (±SD) of 0.12 ± 0.26 mmol/L as shown by 
the green line with 95% confidence intervals in red.  
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Figure 24 Bland Altman percent difference plot for Jaffe and enzymatic methods to 
quantify urinary creatinine. Percentage difference plot demonstrates if the bias between 
two methods is proportional to the concentration of creatinine being quantified (n=804). The 
enzymatic method has a mean bias (±SD) of 0.52 ± 3.08 %. 
 
3.2.5 Discussion 
3.2.5.1 Reproducibility 
 
Intra-assay reproducibility for quantifying creatinine is similar for both methods, when 
measuring quality control materials and urine samples (Table 18). The highest CV was 4.17% 
and 2.08% for the Jaffe and enzymatic methods respectively, when analysing the sample 
with the lowest creatinine concentration (1.61 mmol/L). These results are higher than the 
manufacturer (Roche Diagnostics Ltd., Burgess Hill, UK) reported results; 2.1% at 1.1mmol/L 
using the Jaffe method and 0.8% at 2.12mmol/L using the enzymatic method, determined 
from measuring urine samples 21 times on the same run. In our validation work the mean 
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(SD) of the CV for the Jaffe method was 1.67 ±1.04 %, and 1.10 ±0.39 % for the enzymatic 
method.  
Inter-assay reproducibility was also very similar for both methods, with a CV of 2.35% and 
2.14% for the Jaffe and enzymatic methods respectively. The reproducibility results suggest 
that the enzymatic assay has a slightly lower variation, but both assays are very robust and 
both are suitable for routine clinical analysis. 
The example (section 3.2.1) used to show the impact of assay reproducibility could have on 
clinical decisions, demonstrated that an inter-assay CV of 20% could reclassify a result from 
normoalbuminuria to microalbuminuria. The results presented here indicate that the 
enzymatic method is marginally more precise, but with a mean intra-assay CV of 1.67 
±1.04%, and an inter-assay CV of 2.35%, the variability of the Jaffe method will have minimal 
impact on an ACR, certainly less than biological variation of urinary creatinine (Investigated 
further in Chapter 4).  
 
3.2.5.1 Agreement between methods 
 
The correlation between the two methods was very strong with a Passing-Bablok regression 
of: y = 1.03 (1.03 to 1.04) x -0.15 (-0.17 to -0.13) (Figure 22). The y-axis intercept at less than 
zero indicates there is a systematic difference between the assays and with a slope 
coefficient greater than one it can be concluded that that the difference is proportional to 
the concentration of creatinine being measured. To explore this relationship further, the 
Bland Altman graph (Figure 23) reveals that overall the enzymatic method has a positive 
bias (0.12 ± 0.26 mmol/L) over the Jaffe method.  
The largest difference between the methods is 1.4mmol/L at a creatinine concentration of 
24 mmol/L. At such high concentrations a difference of 1.5mmol/L has minimal impact on 
an ACR. This is reflected by the proportionality of the bias, identified by plotting the percent 
difference in the Bland Altman graph (0.52 ± 3.08 %) (Figure 24). 
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There is disagreement between studies which have compared the same two methods for 
quantifying serum creatinine, one reporting reported a positive bias (3 to 4mg/L) when 
using the Jaffe method (p<0.05) (Apple et al., 1986), another demonstrated a mean  bias of 
0.0 mg/dL (95% CI: -1.32 to 1.33) and showed no significant difference between the 
methods (Schmidt et al., 2015). In our evaluation testing, the Jaffe method had a slight 
negative bias (-0.52 ± 3.08 %). This suggests that the interferences the Jaffe method suffers 
from, causing a loss in analytical specificity, are not present or have minimal impact in urine 
samples.   
  
3.2.5.1 Summary 
 
The Jaffe and enzymatic methods have very similar performance characteristics; the 
enzymatic method is slightly more precise. The precision of the Jaffe method is acceptable 
to report ACR, this is taken into consideration with the biological variation of urinary 
albumin excretion in Chapter 4. 
Although substances that may interfere with the methods were not directly investigated in 
this experiment, previous work shows that both assays are susceptible from some 
interferences (Apple et al., 1986, Myers et al., 2006a). The results from this validation 
suggest many of the interfering chromogens are not present in the urine samples tested. 
Routine samples were used in this evaluation work, so a diverse population was tested. 
There is no reported information from the manufacturer, that a cohort of individuals with 
diabetes would provide samples with properties (e.g. glycosuria) that would interfere with 
the Jaffe (Roche-Cobas, 2010) or Enzymatic methods (Roche-Cobas, 2011). Therefore, either 
method would be appropriate to test the SUMMIT cohort. 
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3.2.6 Conclusion 
The Jaffe method is a very precise assay, with a strong agreement with the enzymatic 
method, and its low cost makes it a feasible option to use in future studies, without 
jeopardising clinical interpretation of an ACR. Therefore, the Jaffe method will be used to 
quantify urinary creatinine in samples from the SUMMIT cohort.  
 
3.3 Estimating personalised creatinine excretion rate 
 
3.3.1 Introduction 
 
The ACR is reported from untimed spot samples, instead of albumin concentration alone, to 
account for differences in urinary concentration. Creatinine is endogenously produced at a 
relatively constant rate and freely passes into the urine, as a result it is used to correct for 
variation in urine concentration. The ACR relies on the assumption that creatinine excretion 
rate (CER) is the same in every subject. This is evident from the clinical reference range to 
identify microalbuminuria (Chapter 1, Table 1); from a 24 hour collection the albumin 
excretion rate needs to be between 30 and 300 mg/24 hrs, and for an ACR it is 30 to 300 
mg/g, therefore it is assumed that CER is 1g/day. 
The actual amount of urinary creatinine excretion is variable between individuals (variability 
of CER is investigated further in Chapter 4). Creatinine excretion was studied in eight healthy 
males who collected 54 to 97 24-hour urine specimens (Greenblatt et al., 1976). Daily 
creatinine excretion varied within individuals who underwent normal activity, the standard 
deviations were from 10.5 to 14.4 per cent of the mean (Greenblatt et al., 1976).  
Creatinine is a breakdown product from muscle metabolism, therefore, under normal 
circumstances its concentration in the blood (and urine) will be influenced by muscle mass. 
Men typically have a  higher muscle mass than women (Kyle et al., 2001) and this is an 
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important consideration when reporting the ACR. As a result, the National Kidney 
Foundation; Kidney Disease Outcomes quality Initiative (NKF KDOQI) guidelines recommend 
the use of gender specific ranges (Chapter 1, Table 2). ACR from spot samples are routinely 
reported and interpreted using gender specific ranges.  
Gender specific reference ranges acknowledge that a limitation of using creatinine to adjust 
urinary albumin  concetration is that creatinine excretion varies. Gender specific ranges may 
be sufficient to account for this limitation when clinically interpretting ACR results, but there 
are alternative methods to calculate personalised cretainine excretion, which may provide a 
more accurate assessment of an individuals urinary albumin excretion. The ACR tells us how 
much albumin there is to creatinine. If the daily excretion of creatinine is known, then the 
two can be multiplied together to provide an estimate of the daily albumin excretion.   
Two recent studies by Fotheringham et al. and Abdelmalek et al. have investigated the 
variation of creatinine excretion, and both studies have formulated equations to determine 
personalised estimates of creatinine excretion rate (eCER) using prediction equations 
(Fotheringham et al., 2014, Abdelmalek et al., 2014). These eCER equations acknowledge 
that CER is not 1g/day for everyone, and provide a personalised estimate of CER considering 
a combination of clinical characteristics; the individuals gender, age, ethnicity and weight 
(all relating to muscle mass). These estimates of CER can be multiplied with an ACR to 
provide an estimated albumin excretion rate (eAER).  
Gender specific ranges may be suitable to account for variation in creatinine excretion when 
clinically identifying microalbuminuria, but when investigating the low levels of urinary 
albumin excretion using ACRs from spot samples and also change over time, estimating 
albumin excretion using these eCER equations may improve the accuracy of an ACR and 
provide a better assessment of urinary albumin excretion. 
Two recent studies have detailed three equations which estimate creatinine excretion.  The 
equation in the MDRD study population is hereafter referred to as the eCER_MDRD 
equation (Fotheringham et al., 2014). The equation developed from a pooled data set of 
several CKD populations is hereafter referred to as the eCER_CKD-EPI (Abdelmalek et al., 
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2014). The equation developed and used in a clinical practice is referred to as eCER_WALSER  
(Walser, 1987). Below are the equations: 
 
 
eCER_MDRD (mg/day): 
Male/black:   1413.9 + (23.2 x age) - (0.3 x age
2
) 
Female/black:  1148.6 + (15.6 x age) - (0.3  x age
2
) 
Male/non-black: 1307.3 + (23.1 x age) - (0.3 x age
2
) 
Female/non-black:  1051.3 + (5.3 3 age) - (0.1 x age
2
) 
 
eCER_WALSER (mg/day): 
Male: (28.2 - 0.172 x age)  x weight (kg) 
Female: (21.9 - 0.115 x age) x weight (kg) 
 
eCER_CKD-EPI (mg/day): 
879.89 + (12.51 x weight) – (6.19 x age) 
+ 34.51 (if black) – 379.42 (if female) 
 
The two studies have evaluated the equations in various populations by assessing three 
factors; bias which identifies any systematic difference between eAER with measured AER 
(mAER); precision which shows the spread of the differences; and accuracy which refers to a 
combination of bias and precision. Overall, eCER improves the accuracy of ACR (when 
assuming CER = 1g/day), but the accuracy of the equations are very variable, especially 
between different populations. From the data tested, there is no equation that is superior, 
although CKD and Walser consider weight which may provide a more accurate estimating of 
muscle mass. Equation selection may be dependent on the study population.  
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Although these studies have evaluated the accuracy of eAER to predict mAER, they have not 
investigated if eAER improves the diagnostic accuracy of an ACR to identify individuals with 
microalbuminuria.  
 
3.3.2 Aim 
 
To investigate if estimating AER from an ACR by using a personalised creatinine excretion 
rate rather than an assumed creatinine excretion rate of 1g/day, improves an ACR’s ability 
to identify an individual with microalbuminuria. 
 
 
3.3.2.1 Objectives 
 
1. To investigate the relationship of estimating AER from an ACR by using a 
personalised creatinine excretion rate and by assuming creatinine excretion rate of 
1g/day, with measured AER. 
 
2. To determine if estimating AER using a personalised creatinine excretion rate 
improves diagnostic accuracy of an ACR to identify individuals with 
microalbuminuria.  
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3.3.3 Method 
 
3.3.3.1 Study inclusion criteria 
 
Participants from the SUMMIT study were selected for this investigation. The inclusion 
criteria are; an overnight urine collection had been received, anthropometric measurements 
had been taken and routine pathology tests on blood and urine had been performed. There 
were no exclusion criteria.  
3.3.3.2 Sample analysis 
 
Blood and urine samples had been sent to the RD&E Blood Science laboratory for routine 
analysis of albumin and creatinine on the day of completion. Urine volume and collection 
duration of the overnight urine collections were recorded. Albumin was measured by the 
routine COBAS method and creatinine was quantified using the routine Jaffe method. Only 
samples with measurable albumin (>2.9 mg/L) were included in the analysis. 
The laboratory reports creatinine concentration as mmol/L and the ACR as mg/mmol. The 
eCER equations result is in g/day. Therefore, to convert the ACR into mg/g,  a conversion 
factor of; 1mg/g =  0.113mg/mmol is used which makes the ACR compatible with the eCER 
equations and the calculated estimated AER (eAER) result will be in mg/day.  
From each overnight collection the AER was measured, mAER, this is the reference method 
that the eAERs are compared to. From the same overnight collection, the ACR was also 
determined. The ACR uses the assumption that creatinine excretion rate (CER) is the same in 
every subject, at 1 g/day. Therefore AER can be estimated from the ACR using the 
assumption that creatinine excretion is set at 1g/day for all subjects, this measure is termed 
‘eAER’ throughout the analysis. As creatinine excretion varies between subjects, 
personalised creatinine excretion rates are used to estimate AER from the ACR. The three 
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eCER equations (Section 3.3.1) are used to generate three estimates of AER; termed 
eAER_MDRD, eAER_CKD-EPI and eAER_WALSER.  Figure 25 outlines this process. 
 
Figure 25 Calculating albumin excretion rate using different creatinine excretion rate 
estimations from an overnight urine collection. Measured AER (reference method) and ACR 
were determined from each timed overnight collection. AER was estimated from the ACR by 
assuming creatinine excretion was constant at 1g/day (eAER) and by using personalised 
estimates of creatinine excretion (eAER_MDRD, eAER_CKD-EPI and eAER_WALSER). 
 
3.2.3.2 Statistics 
 
Normality of the data was tested using the Shapiro-Wilk test. Normally distributed data are 
presented as mean (±SD) and non-normally distributed data as the median [IQR].  
Associations with non-normally distributed data were examined using the Spearman’s rank 
correlation test.  
To enable the relationship with eAER to be comprehensively investigated the results have 
been log transformed in scatter graphs and Bland Altman plots due to the skewness of the 
data. The use of Bland Altman plots has been previously described in Chapter 2.3.3. 
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To determine the diagnostic accuracy of ACR and eAERs to identify individuals with 
microalbuminuria, the sensitivity and specificity of each test was calculated. Individuals with 
mAER between 30 and 300 mg/day were classified with microalbuminuria. 
Sensitivity measures the proportion of individuals with microalbuminuria that are correctly 
identified. Specificity measures the proportion of individuals without microalbuminuria that 
are correctly identified as such. Sensitivity and specificity are calculated as follows: 
 
Sensitivity =                     true positives                   X 100 
               true positives + false negatives 
 
Specificity =                     true negatives                   X 100 
              true negatives + false positives 
 
Receiver operator characteristic (ROC) curve analysis was performed which examines the 
performance of each test to identify microalbuminuria as the discrimination threshold is 
varied. The curve is created by plotting the true positive rate (sensitivity) against the false 
positive rate (which is calculated as 1 – specificity). The total area under the curve (AUC) is 
equal to the probability that the test will rank a randomly chosen positive result higher than 
a randomly chosen negative one. The ROC AUC therefore represents the overall accuracy of 
a test to correctly identity microalbuminuria, where the closer the result is to one, the more 
accurate the test is.  
Individuals with mAER between 30 and 300 mg/day were classified with microalbuminuria. 
The same reference range was used when testing the eAER equations. When reporting ACR; 
microalbuminuria was defined as >2.5 mg/mmol in males and > 3.5mg/mmol in females. 
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3.3.4 Results 
 
3.3.4.1 Participant characteristics 
 
245 participants from the SUMMIT study (Table 20) met the inclusion criteria to be included 
in this investigation (Section 3.3.3.1). Participant characteristics are summarised in Table 20.  
 
 
Characteristic  
Age (years) 68 ± 10 
Gender  75% Male 
Weight (kg) 85.7 [78.0 to 96.5] 
HbA1c (mmol/mol) 50 [41 to 62] 
Serum creatinine (µmol/L) 84 [72 to 97] 
eGFR (CKD-EPI) (ml/min/1.73m2) 77.6 [66.1 to 87.7] 
Table 20 Participant characteristics of 245 participants from the SUMMIT study utilised to 
examine the impact of estimating personalised creatinine excretion rate when reporting 
an ACR. Normally distributed results are presented as mean (±SD) and non-normally 
distributed results as the median [IQR]. These participants met the inclusion criteria; an 
overnight urine collection had been received, anthropometric measurements had been taken 
and routine pathology tests on blood and urine had been performed.  
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3.3.4.2 The relationship of estimating AER from an ACR with measured AER. 
 
Estimated AERs from an ACR using a personalised creatinine excretion rate and by assuming 
creatinine excretion rate of 1g/day, and measured AER, are reported in Table 21. The 
difference between the different estimates of AER with the reference method; measured 
AER are also described in Table 21 . 
 
 
  
mAER eAER 
eAER 
MDRD 
eAER 
WALSER 
eAER 
CKD-EPI 
Median AER 
mg/day 
11.9 
[6.2 to 23.0] 
8.2  
[4.2 to 16.5] 
10.2  
[5.6 to 21.0] 
10.9  
[6.1 to 22.5] 
11.5  
[6.2 to 23.8] 
Median difference with mAER 
mg/day 
-2.8  
[-8.4 to -0.9] 
-0.6  
[-3.7 to 0.7] 
-0.6  
[-3.2 to 1.1] 
-0.1  
[-1.9 to 1.6] 
Mean difference with mAER 
mg/day 
-12.6 ± 38.7 -6.9 ± 32.8 -4.7 ± 25.7 -3.5 ± 27.2 
Median % difference  
with mAER 
 
-32.2  
[-44.0 to -11.4] 
-7.2  
[-23.1 to 10.5] 
-6.2  
[-19.6 to 14.6] 
-1.9  
[-13.3 to 16.3] 
Mean % difference 
with mAER  
 
-23.1 ± 35.8 -3.2  ± 34.1 1.6 ± 35.6 5.6 ± 34.7 
Table 21 Measured and estimated albumin excretion rates. The mean (SD) and median 
[IQR] actual difference and percentage difference of estimated AER with measured AER from 
245 participants from the SUMMIT cohort are displayed. 
 
The correlation of estimating AER from an ACR by using a personalised creatinine excretion 
rate and by assuming creatinine excretion rate of 1g/day, with measured AER are presented 
below (Figure 26 to Figure 29, and Table 22). 
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Figure 26 Correlation of measured AER with estimated AER assuming creatinine 
concentration is 1g/day. Logarithmic scales are used to spread the data from 245 subjects 
of the SUMMIT cohort. The dashed black line represents the line of identity (y=x). The red 
line is the line of best fit through the data. Rs = 0.915, Rs2 = 0.836, p <0.0001. 
 
Figure 27 Correlation of measured AER with eAER_MDRD. Logarithmic scales are used to 
spread the data from 245 subjects of the SUMMIT cohort. The dashed black line represents 
the line of identity (y=x). The red line is the line of best fit through the data. Rs = 0.952, Rs2 = 
0.907, p <0.0001.  
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Figure 28 Correlation of measured AER with eAER_WALSER. Logarithmic scales are used to 
spread the data from 245 subjects of the SUMMIT cohort. The dashed black line represents 
the line of identity (y=x). The red line is the line of best fit through the data. Rs = 0.951, Rs2 = 
0.903, p <0.0001.  
 
Figure 29 Correlation of measured AER with eAER_CKD-EPI. Logarithmic scales are used to 
spread the data from 245 subjects of the SUMMIT cohort. The dashed black line represents 
the line of identity (y=x). The red line is the line of best fit through the data. Rs = 0.957, Rs2 = 
0.915, p <0.0001.   
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Table 22 Correlation of estimates of AER with measured AER. Significance of the spearman 
rank correlation (Rs) is represented by the p value. 
Bland Altman plots are used to describe the difference between the two methods (Figure 
30). These demonstrated that AER_CKD-EPI has the smallest bias (-0.1mg/day) compared to 
measured AER.  
 
 
Figure 30 Bland Altman difference plots for the individual estimates of AER with measured 
AER. A: eAER, B: eAER_MDRD, C: eAER_WALSER, D: eAER_CKD-EPI. The black line represents 
the line of identity (if there was no difference between the methods). The green line is the 
mean difference (bias), and the red lines are the 95% confidence intervals around the mean. 
 Rs Rs
2 p 
eAER 0.915 0.836 <0.0001 
eAER_MDRD 0.952 0.907 <0.0001 
eAER_WALSER 0.951 0.903 <0.0001 
eAER_CKD-EPI 0.957 0.915 <0.0001 
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3.3.4.3 Diagnostic accuracy 
 
43/184 male participants were identified in the microalbuminuria range, defined as an 
albumin excretion of 30-300 mg/day using measured AER (Figure 31).  Six females were 
found to be in the microalbuminuria range, but as the ACR uses gender specific ranges ROC 
curves were only plotted for the male participants as they had the most cases (Figure 31). 
 
 
Figure 31 ROC curve of ACR and eAERs to identify male individuals with microalbuminuria. 
Microalbuminuria was defined from measured AER (30 to 300 mg/day). 43/184 male 
participants were identified in the microalbuminuria range (defined using mAER). ACR uses 
gender specific ranges, therefore ROC curves were only plotted for the gender with the most 
cases. Only six females were found to be in the microalbuminuria range.  
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A summary of the results from the ROC curve analysis are presented in Table 23. Overall 
accuracy, the AUC, was similar with all eAERs, though percent correctly diagnosed varied 
from 92.5% with eAER to 96.7% with eAER_CKD_EPI.   
 Sensitivity Specificity AUC 
% correctly 
identified 
ACR 
80.4% 
(66.1 to 90.6) 
99.5% 
(97.2 to 99.9) 
0.99  
(0.98 to 1.00) 
95.9 
eAER 
63.0% 
(47.6 to 76.8) 
99.5% 
(97.2 to 99.9) 
0.99 
(0.97 to 1.00) 
92.5 
eAER_MDRD 
84.8% 
(71.1 to 93.6) 
98.5% 
(95.6 to 99.7) 
0.99 
(0.98 to 1.00) 
95.9 
eAER_WALSER 
84.8% 
(71.1 to 93.6) 
99.0% 
(96.3 to 99.8) 
0.99 
(0.98 to 1.00) 
96.3 
eAER_CKD-EPI 
89.1% 
(76.4 to 96.3) 
98.5% 
(95.6 to 99.6) 
0.99 
(0.99 to 1.00) 
96.7 
Table 23 Diagnostic accuracy of ACR and estimates of AER to identify male individuals 
with microalbuminuria. 43/184 male participants were identified in the microalbuminuria 
range, defined using mAER from an overnight urine collection). 
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3.3.5 Discussion 
 
245 participants from the SUMMIT study (Table 20) met the inclusion criteria to be included 
in this investigation (Section 3.3.3.1). It is a male dominant cohort (75% males) with a mean 
(SD) age of 68 ±10 years. A median eGFR of 77.6 ml/min/1.73m2 is typical for this group of 
subjects of this age. 20% had microalbuminuria based on a timed overnight AER.  
All methods of reporting urinary albumin excretion had a significant correlation (p<0.001) 
with measured AER. Whether estimating AER from an ACR by using a personalised 
creatinine excretion rate or by assuming a creatinine excretion rate of 1g/day, there is a 
negative bias compared to measured AER. This is demonstrable through the difference 
between methods detailed in Table 21, and visualised in the Bland Altman plots in Figure 30. 
eAER_CKD-EPI has the smallest bias (-0.1mg/day). The difference in eAER across all the 
Bland Altman plots is greater at higher concentrations, this is most likely due to be a 
proportional bias, relative to the rate of urinary albumin excretion being measured (Figure 
30).  
Our findings are very similar to the work of Abdelmalek et al. who reported median 
difference of: -2.3, -0.9, -0.8 and -1.0 mg/day when reporting ACR, eAER_MDRD, 
eAER_Walser and eAER_CKD-EPI respectively, when compared to measured 24 hour urinary 
albumin excretion (Abdelmalek et al., 2014). The study by Abdelmalek et al. included 2,711 
community-living individuals from the general population of the Netherlands participating in 
the PREVEND (Prevention of Renal and Vascular Endstage Disease) Study. They 
demonstrated that there is no superior equation, although CKD and Walser which include 
weight may provide a more accurate approximation of muscle mass (Abdelmalek et al., 
2014, Fotheringham et al., 2014).  
Estimating creatinine excretion using the CKD-EPI equation has the smallest bias and 
strongest correlation among the estimating equations with measured AER, but the margin 
of improvement is small. Assessing diagnostic accuracy using the different equation also 
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demonstrates there is no superior equation, supporting the conclusions of others studies 
(Abdelmalek et al., 2014, Fotheringham et al., 2014).   
Estimating AER using the assumption that CER is 1g/day yielded the lowest diagnostic 
sensitivity (63%) to identify microalbuminuria (Table 23). Clinically, it is recognised that 
there is a difference in muscle mass between genders; therefore gender specific ranges are 
used to identify microalbuminuria when reporting the ACR. There is no difference in AUC 
from the ROC curve whether reporting the ACR or estimating AER from an ACR by using a 
personalised creatinine excretion rate or by assuming creatinine excretion rate of 1g/day 
(Table 23). Diagnostic sensitivity is improved when estimating AER using the personalised 
creatinine excretion rates, but with no overall improvement on diagnostic accuracy, its 
application in routine diagnostics is unlikely.  
The use of estimating creatinine excretion equations that require weight (CKD-EPI and 
WALSER) are limited in clinical practice, as that information is not readily available in 
pathology laboratories where the results are generated.   
The gold standard collection method to assess microalbuminuria is an overnight collection. 
Clinically, microalbuminuria needs to be confirmed in at least two collections to make a 
diagnosis. A limitation to this study is that only one overnight collection was used to classify 
individuals with microalbuminuria. In addition, the ACR was reported from an overnight 
collection, when clinically it would only be reported from untimed spot samples.  
 
3.3.6 Conclusion 
This work demonstrates that estimating AER using personalised creatinine excretion rates 
does not meaningfully improve diagnostic accuracy of an ACR to identify individuals with 
microalbuminuria.  
Chapter 4 investigates if estimating albumin excretion from a spot sample improves the 
accuracy of an ACR to identify individuals with microalbuminuria, classified by measuring 
AER from an overnight urine collection.  
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3.4 Validation of a urine specific gravity refractometer 
 
3.4.1 Introduction 
 
A limitation of using creatinine to account for urine concentration is that the amount of 
creatinine excreted is variable between individuals. The purpose of estimating an 
individual’s creatinine excretion is to overcome this limitation. Urine specific gravity (USG) is 
another measure of urinary concentration which can be used to adjust the concentration of 
albumin to account for urine concentration. USG is determined by the concentration of 
excreted molecules for example inorganic ions such as sodium, potassium, chloride, 
magnesium, calcium, ammonium, sulphates, and phosphates. USG is measured as the ratio 
of urine density compared with water density, where in adults the normal USG range is from 
1.003 to 1.030 (Fischblach, 2004).  
Using USG to normalise urinary albumin concentration is not a novel approach, and previous 
studies have evaluated USG’s clinical application (Parikh et al., 2002, Moore et al., 1997, 
Newman et al., 2000).  USG has shown a positive correlation with urinary creatinine 
concentration in  both the general population (n=50)  (r = 0.79, P <0.001) (Moore et al., 
1997)  and in individuals with diabetes (n = 34) (r = 0.83, p < 0.001) (Parikh et al., 2002). In 
1997, Moore and colleagues investigated the use of USG on diagnostic accuracy to identify 
individuals with microalbuminuria in a diabetic population. When using the routine 
laboratory method to measure albumin, the sensitivity and specificity when reporting ACR 
was 89% and 93% respectively, and when using USG instead of creatinine it was 88% and 
93% (Moore et al., 1997). They also reported USG in conjunction with an albumin result 
from a urine dipstick test (Micral-Test by Roche). The Micral-Test is a cheap alternative to an 
ACR and results are determined a lot quicker. An increase in diagnostic sensitivity from 63% 
to 69% was reported when accounting for USG, however there was a loss in specificity (from 
100% to 80%) (Moore et al., 1997). Although USG and urinary creatinine concentration have 
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shown good correlation, USG does not improve on what is currently achieved reporting 
urinary creatinine, therefore it hasn’t been taken forward clinically.  
The studies which have investigated the clinical application of USG have done so in the 
clinical ranges of microalbuminuria and macroalbuminuria. One of the aims of this thesis is 
to establish an accurate and robust method of reporting albuminuria within the normal 
range of urinary albumin excretion. Before evaluating the use of USG to normalise low 
urinary albumin concentrations, the device measuring USG must undergo validation to 
ensure the results are accurate and reproducible. USG is the ratio of urine density to water 
which can be determined using refractometry. The higher the urine concentration, the 
higher urine density and therefore light is refracted more. Digital urine specific gravity 
refractometers are available and in this work the commercially available USG-α (ATAGO) 
refractometer (ATAGO Ltd., Tokyo, Japan) undergoes validation.  
Upon satisfactory validation results, the digital refractometer can be utilised in future work 
investigating its ability to adjust albumin to account for urinary concentration. 
 
3.4.2 Aim 
 
Validate the USG-α refractometer as a measure of USG to reflect urine concentration.  
 
3.4.2.1 Objectives 
 
1. Determine intra-assay reproducibility of USG-α refractometer. 
 
2. Determine inter-assay reproducibility of USG-α refractometer. 
 
3. Determine the correlation of USG with urine creatinine concentration as assessed by 
the Jaffe method. 
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3.4.3 Method 
 
Objective 1:  
Intra-assay reproducibility was determined by 10 repeat measurements of four urine 
samples, all analysed on the same day. The CV was calculated as previously described at 
Chapter 2.3.3.  
 
Objective 2:  
Inter-assay reproducibility was determined by analysing four urine samples on seven 
consecutive days by the same operator. Samples were stored in a fridge at 4oC throughout 
the testing period. Samples returned to room temperature prior to analysis 
 
Objective 3:  
33 clinical samples were selected to assess the correlation between USG measured by USG-
α refractometer with urine creatinine concentration.  
USG was measured by the USG-α refractometer (ATAGO Ltd., Tokyo, Japan) and urinary 
creatinine quantified by the routine ‘Roche Creatinine Jaffé Gen.2’ method (Roche 
Diagnostics Ltd., Burgess Hill, UK).  
 
3.4.3.1 Statistics 
 
Normality of the data was tested using the Shapiro-Wilk test. Associations with non-
normally distributed data are examined using the Spearman’s rank correlation test.  
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3.4.3.2 Sample analysis 
 
Urine samples used in the validation experiments were patient samples sent to the RD&E 
Blood Science laboratory for routine ACR measurement. Samples were not stored prior to 
analysis, with the test usually complete within 24 hours of sample collection. The samples 
were selected depending on their creatinine concentration to ensure a wide range was 
tested. Samples underwent four hand inversions prior to creatinine and USG analysis, 
measured by the USG- α refractometer.  
To evaluate the relationship between the USG- α results and creatinine, scatter plots were 
created with spearman’s rank correlation (Rs) reported along with the significance (p) of the 
correlation.   
 
3.4.4 Results 
 
Intra-assay reproducibility determined on four urine samples by analysing them 10 times in 
the same day ranged from 0.25 to 3.03% (Table 24). Inter-assay reproducibility for USG-α 
ranged from 2.05 to 14.37% (Table 25). USG measured by the USG-α refractometer and 
urinary creatinine were significantly associated (Rs= 0.95, p=<0.001) (Figure 32).  
 
Sample 
Mean USG 
[refraction ratio] 
St Dev CV% 
Urine 1 1.0022 0.00006 3.03 
Urine 2 1.0088 0.00009 1.04 
Urine 3 1.0235 0.00016 0.67 
Urine 4 1.0284 0.00007 0.25 
Table 24 Intra-assay reproducibility of USG-α to measure USG in four urine samples.  All 
samples were measure ten times in the same assay by the same operator. 
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Sample 
Mean USG 
[refraction ratio] 
St Dev CV% 
Urine 1 1.0026 0.00040 14.37 
Urine 2 1.0094 0.00048 5.57 
Urine 3 1.0241 0.00044 2.05 
Urine 4 1.0287 0.00059 2.34 
Table 25 Inter-assay reproducibility of USG-α. USG was measured by USG-α refractometer 
in four urine samples. All samples were measured once a day, over seven days by the same 
operator.  
 
Figure 32 Correlation between USG measured by USG-α refractometer and urinary 
creatinine. 33 samples had USG determined by USG-α refractometer and urinary creatinine 
quantified by the routine ‘Roche Creatinine Jaffé Gen.2’ method. The solid line represents the 
line of best fit through the data. (Rs= 0.95, p=<0.001) 
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3.4.5 Discussion 
 
Previous studies have demonstrated a strong relationship between USG and urinary 
creatinine concentration in the general population (n=50, r = 0.79, P <0.001) (Moore et al., 
1997) and in the individuals with diabetes (n = 34, r = 0.83, p < 0.001) (Parikh et al., 2002). In 
the SUMMIT cohort a stronger correlation between USG and creatinine was determined 
(Rs= 0.95, p=<0.001). This may be attributed to the differences between cohorts, where 
diversity in the general population may influence this relationship. 
There has been no previous evidence that diagnostic accuracy is improved when using USG 
to adjust urinary albumin concentration in untimed spot samples to identify individuals with 
microalbuminuria or macroalbuminuria (Moore et al., 1997). The results from the SUMMIT 
cohort support this, however, ACR was not measured in spot samples, but rather from an 
overnight collection.  
The aim of this work was to validate the USG-α refractometer (ATAGO Ltd., Tokyo, Japan) to 
measure USG. Upon successful validation, the device can then be used in future studies 
which evaluate its application for adjusting low levels of urinary albumin excretion in 
untimed spot samples. 
The USG-α refractometer results were very reproducible, but offered no improvement over 
using the Jaffe method to measure creatinine. The highest intra-assay CV reporting USG was 
3.03% when repeat measuring four urine samples ten times on the same day (Table 24). The 
mean (SD) of the CV for the Jaffe method was 1.67 ±1.04 % (Section 3.2).  
When measuring USG, the highest intra-assay CV was identified when measuring the sample 
with the lowest USG (1.0022 refraction ratio). The inter-assay CV of the same sample was 
14.37%. However, in samples with a higher USG the typically day to day variation was less 
than 6% (Table 25). The higher inter-assay variability can most likely be attributed to the 
test being carried out manually. This is a limitation of USG testing using a manual method, 
whereas quantifying creatinine using a high throughput analyser yielded lower inter-assay 
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variation (maximum CV of 2.35%, creatinine concentration 6.78mmol/L) when measured by 
the routine Jaffe method (Table 19). 
USG-α is strongly associated with urinary creatinine concentration (n=33, Rs= 0.95, 
p=<0.001), confirming that both are markers of urinary concentration. There is less 
agreement in the results with very low creatinine concentration where USG 
disproportionately increases with an increase in creatinine concentration. At the highest 
creatinine concentration it appears USG-α has reached its measurable limit as USG does not 
increase with increasing creatinine concentration and with so few samples at this high 
concentration further investigation is warranted. The manufacturer advises that USG-α can 
accurately measure up to 1.0600, so further validation would be required if this was to be 
used on clinical samples. This demonstrates the importance of carrying out in house 
validation. 
The USG-α refractometer is an acceptable method to measure USG as a marker of urinary 
concentration. However, it is less precise and may be less accurate in samples with the 
lowest and highest USG. In this validation work, USG has been compared to urinary 
creatinine concentration as an indicator of how concentrated the urine is. As CER varies 
between people, it is not the ideal reference method but it is the clinical standard. USG is a 
measure of the concentration of excreted molecules and just like creatinine it may be highly 
variable between individuals. 
In this work USG and creatinine were quantified on fresh samples. This is consistent with 
routine clinical analysis; however, research studies often freeze samples prior to analysis. A 
limitation of this study was that the impact of freezing on USG prior to analysis was not 
investigated. The impact of storage and freezing on urinary albumin and urinary creatinine 
are evaluated in Chapter 5.  
The work in the present chapter shows that USG-α (ATAGO Ltd., Tokyo, Japan) has a strong 
agreement with urinary creatinine concentration, and can be taken forward in other studies 
(Chapter 4) to evaluate if an albumin to USG ratio can improve the relationship of a spot 
sample (when reporting ACR) with the ‘gold standard’ overnight AER.   
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3.5 Summary and conclusions 
 
This chapter has investigated different methods of accounting for the variation in urinary 
concentration, which affects the concentration of albumin in untimed samples. 
Traditionally, the ACR is used to report albuminuria in spot samples. The first study 
compared two methods of measuring urinary creatinine to ensure the most accurate and 
reproducible method is used in future studies. There was a very strong agreement between 
the two methods and they were both highly reproducible. The enzymatic assay had a 
slightly lower CV%, and had a small proportional bias (0.52 ± 3.08 %) compared to the Jaffe 
method. Overall, there is little improvement when using the more expensive enzymatic 
assay over the routinely used Jaffe method and therefore the Jaffe method will be used in 
future studies in this thesis.  
The second investigation validated equations that estimate creatinine excretion. These 
equations consider the limitation that creatinine excretion is highly variable between 
individuals, which impacts on the ability of ACR to normalise albumin concentration in 
untimed samples. The results showed a high correlation with mAER, but offered no 
improvement on diagnostic accuracy compared to reporting ACR alone. Further work is 
required to determine if estimating AER in random spot samples improves the relationship 
of an ACR with timed collections and if diagnostic accuracy is improved. 
USG is another measure of urinary concentration and it can be tested by refractometry. The 
USG-α refractometer (ATAGO Ltd., Tokyo, Japan) had a strong correlation with urinary 
creatinine concentration and was reproducible. USG-α can be used in other studies as a 
measure of urinary concentration and its use will be evaluated when investigating different 
methods of reporting albumin excretion in the low albuminuria range. 
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Chapter 4 Urine Collection Methods to Assess the Excretion of 
Albumin in the Normal Range 
 
An AER from an overnight urine collection is considered the “gold standard” for assessing 
albuminuria (Mogensen et al., 1985, Mogensen, 2003).  However, timed collections are 
burdensome for patients, who can be prone to making mistakes, which can lead to 
inaccurate results. It is clinically preferred to use untimed spot urine samples to measure 
the ACR (National Kidney Foundation, 2002). 
The aim of this chapter is to identify what time is best to collect a spot sample which 
provides an appropriate surrogate for a timed overnight collection. To achieve this; 
reproducibility (biological variability) of albumin excretion is determined in different urine 
collection methods, and the correlations of spot samples with the ‘gold standard’ method 
are evaluated. 
In using the validated Fitzgerald ELISA to quantify urinary albumin (described in Chapter 2), 
the extended normal albumin excretion range can be fully investigated, and the biological 
variation of albumin excretion in healthy individuals can be determined.  
Estimating albumin excretion from an ACR in spot samples by using a personalised 
creatinine excretion rate was discussed in Chapter 3.3. The relationship of estimating AER 
from an ACR from a spot sample with an overnight AER is also investigated in this chapter, 
along with its diagnostic accuracy to identify individuals with microalbuminuria.   
To fully investigate the relationships between spot samples and timed overnight collections, 
this chapter consists of two different studies, the results of the first study instigating the 
aims of the second study. 
Investigation 1: The Optimal Urine Collection Method to Assess the Excretion of 
Albumin in the normal range 
Investigation 2: The relationship of estimating AER from an untimed spot using a 
personalised creatinine excretion rate with an overnight AER 
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The Optimal Urine Collection Method to Assess the Excretion of 
Albumin in the normal range 
 
4.1 Introduction 
 
4.1.1 The “gold standard” collection method to diagnose microalbuminuria 
 
When microalbuminuria was first defined it was recommended that three timed overnight 
or short-term at hospital samples, collected within a few months of each other, were 
required to diagnose microalbuminuria (Mogensen, 1987). However, the majority of studies 
which have investigated urine collection methods have utilised a 24 hour collection as the 
“gold standard” collection. 
A 24 hour collection has been the long standing “gold standard” to assess proteinuria, and 
therefore it may be assumed to be the “gold standard” to assess albuminuria. It has been 
proposed that albumin excretion follows a circadian rhythm (Mogensen et al., 1985, Hansen 
et al., 2002, Capani et al., 1988), therefore 24 hour collections may be desirable as they 
incorporate diurnal variations. Several studies have shown AER to be 30-50% higher over a  
24 hour period compared to overnight in patients with diabetes (Mogensen et al., 1995a), 
but these studies are limited to the higher clinical levels of albumin excretion. 
The reason for lower AER overnight is most likely the result of decreased activity/exercise 
(Climie et al., 2015, Heathcote et al., 2009, Koh et al., 2011), lower blood pressure and GFR 
(Mogensen et al., 1995a, Miller et al., 2003) and a recumbent posture (Montagna et al., 
1983). Because these factors that raise AER have less impact during the night, it is 
conceivable that the overnight collection is more reproducible than a 24 hour collection. 
When the discrimination value for microalbuminuria was determined, three studies were 
evaluated, each using a different collection method. The proposed discrimination values 
when using timed overnight (Viberti et al., 1982), short term at hospital (Mogensen and 
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Christensen, 1984) and 24 hour collections (Mathiesen et al., 1984) were 30µg/min, 
15µg/min and 70µg/min respectively (table 1.3). The higher discrimination value for 
microalbuminuria found using 24 hour collections is most likely the result of higher AER 
during the day. However, the microalbuminuria threshold was set at 20µg/min, determined 
from the values proposed using timed overnight and short term in hospital collections; 
these collections were also appointed the “gold standard” methods to collect urine 
(Mogensen, 1987).  Therefore, this study will use a timed overnight collection as the “gold 
standard” method to assess albumin excretion. 
In order to diagnose microalbuminuria, urine collections need to be repeated to reduce the 
influence of intra-individual biological variation and to exclude any other interfering factors, 
such as sexual intercourse (Sadri-Ardekani et al., 2009), exercise (Climie et al., 2015, 
Heathcote et al., 2009, Koh et al., 2011), fever, urinary tract infections and poor glycaemic 
control, which have all been shown to falsely elevate AER (Mogensen et al., 1995b). It is 
important to be aware of these interfering factors so they can be limited when designing a 
study that evaluates the variation of different collection methods. 
 
4.1.2 Using spot samples to assess albumin excretion 
 
Timed collections are burdensome for patients, who can be prone to making mistakes, 
which can lead to inaccurate results. This is reflected in several studies that have reported 
that up to 31% of non-hospitalised timed samples are incomplete (Garde et al., 2004, 
Sampaio and Delfino, 2008). Therefore, it is clinically preferred to use untimed spot urine 
samples to measure the ACR (National Kidney Foundation, 2002). There are three main 
types of untimed spot samples, each characterised by the time of the collection; first 
morning void (FMV), second morning void (SMV) and random.  
Current guidelines now recommend the use of spot samples for microalbuminuria 
screening. If microalbuminuria is present in two of three samples, which are collected within 
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a three to six month period, then a diagnosis can be made (American-Diabetes-Association, 
2013).  
A survey of 2,178 general practitioner (GP) surgeries across eight European countries was 
carried out in 2006 (Aakre et al., 2008). The survey revealed that the majority (>70%) of 
them used spot samples (unspecified) to initially screen for microalbuminuria, although 
when repeat testing, they saw an increase in the use of timed collections. This suggests that 
GPs consider timed collections to be more accurate than spot samples, which is 
questionable given the increased risk of errors arising from the timed collection procedure. 
One surprising finding from the survey was that 55% of GPs in the Netherlands only used 
one result to diagnose microalbuminuria, which not only reflects the discordance with 
international guidelines but also the need for education in this area. 
To investigate which collection method is more reproducible for monitoring albuminuria 
over time, a coefficient of variation (CV) can be calculated from repeat collections. A study 
of 241 participants from the PREVEND cohort (predominately without DM), carried out 
three 24 hour, FMV and random collections over three weeks (Witte et al., 2009). The CV of 
the collections were 19.0%, 19.1% and 35.8% respectively, revealing that only the FMV CV 
did not significantly differ from the 24 hour AER (p=0.64). The study also assessed the 
accuracy of the FMV and random samples with the 24 hour collection, reporting that when 
using the FMV ACR, 81.8% of participants were classified in the same category as when 
using the 24 hour AER. This fell to 72.1% when using the random sample ACR. The 
correlation (r2) of FMV and random samples to the 24 hour collection were 0.87 and 0.83 
respectively. This indicates that ACR from a FMV would be preferable over an ACR in a 
random sample to assess albuminuria.  
It is logical that a FMV is more reproducible and accurate than a random sample, as factors 
which may affect albumin excretion are at their least influential overnight. Another 
potential contributor to explain the better reproducibility observed  with  FMVs compared 
to random samples is that the low levels of water intake overnight usually results in more 
concentrated urine, which allows easier detection of albumin by traditional assays. Other 
spot collections later in the day (e.g. SMV) have not been readily investigated as they are 
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often more dilute than FMV samples and traditional assays are unable to measure at the 
lower albumin concentrations. Using a more sensitive assay, alternative samples like SMV, 
can now be investigated.  
Although more dilute, it is well reported that spot urine samples collected throughout the 
day provide higher ACR values than the FMV (Witte et al., 2009, Mogensen et al., 1995b, 
Howey et al., 1987). This has been attributed to diurnal variations in AER, which may be 
related to changes in posture or exercise (Hortin, 2013). A cross-sectional study of 5,247 
participants in the U.S., investigated the difference between paired random and FMV 
samples (Saydah et al., 2013). At the microalbuminuria threshold (an ACR of 30mg/g) they 
reported that ACR from random samples were 50% higher than ACR from FMVs. The 95th 
percentile in FMV samples was 28.2 mg/g compared to 46.5mg/g in the random samples. 
When reviewing this study, another author, Hortin, commented that there were differences 
in the shipping and handling of the different samples, which may have contributed to a 
slight lowering in albumin concentration in FMV samples. Random samples were analysed 
on the day of collection, whereas the FMV samples were posted, although albumin and 
creatinine are considered stable for a week under those conditions (Hortin, 2013). 
However, high ACR values in random samples may be clinically preferred over FMV samples 
for microalbuminuria screening, as random samples have a higher diagnostic sensitivity 
(fewer false negative results). Random samples are also more practical, as patients can 
produce a sample whilst at their GP and are not required to make a repeat visit. The lower 
diagnostic specificity can be resolved by confirming microalbuminuria through repeat 
testing the ACR in FMV samples, which is necessary to make a diagnosis due to the 
variability of albumin excretion. Measuring an ACR in a random sample to screen for 
microalbuminuria and using an ACR in several FMV samples for confirmation is now 
reflected in the international ‘Kidney Disease Improving Global Outcomes’ guidelines 
(KDIGO, 2013).  
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4.1.3 Reporting albuminuria in spot samples 
 
There are several different methods of reporting albumin excretion in spot samples, 
including as urinary albumin concentration (UAC) and adjusting for hydration levels using 
creatinine concentration (albumin to creatinine ratio)  (ACR), or using personalised 
estimated creatinine excretion (eAER)  or urine specific gravity (A/USG).  
Some authors argue that UAC should be measured alone, as reporting the ACR in untimed 
samples introduces a second biological factor (creatinine) which increases variability 
(Townsend, 1986b). A study in 2011 reported that FMV ACR correlated better with a 24 
hour AER compared to a random ACR (r: 0.80 vs 0.62 respectively). Interestingly, in both the 
FMV and random samples, the correlation improved when the results were reported as  
UAC ( r= 0.94 and 0.92 respectively) (Chavan et al., 2011). The authors, therefore, suggested 
that screening for microalbuminuria should be carried out using UAC in FMV samples. 
However, this study was carried out on 104 T2DM patients who had a median 24 hour AER 
of 328 mg/24 hours, which is suggestive of macroalbuminuria. In fact, the lowest AER in the 
study was 90 mg/24 hours, which is three times higher than the lower microalbuminuria 
threshold. This invalidates their conclusion that UAC should be used for microalbuminuria 
screening, as the lower microalbuminuria threshold was not investigated, although it may 
be applicable to identify macroalbuminuria.  
Furthermore, an epidemiologic study of 4,678 participants across four countries (Dyer et al., 
2004), found slightly lower mean intra-individual CVs using UAC compared to ACR  in men 
(59.6% vs 62.0% respectively) and women (57.7% vs 60.8% respectively). The variation of 24 
hour AER was 61.7% and 60.2% in men and women respectively. However, there are factors 
in their methodology that may contribute to this high variability. Firstly, samples were 
stored at -20oC for approximately three years before analysis. There is increasing evidence 
that long term storage at -20oC results in falsely low UAC (Elving et al., 1989, Brinkman et al., 
2005, Erman et al., 1988, Schultz et al., 2000).  It appears that the loss of UAC may not be 
universal, with one study reporting only 28% of their samples were impacted (Kania et al., 
2010), which could have ramifications on the variability of UAC in repeat collections when 
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samples have been stored at -200C. Another considerable limitation of this epidemiologic 
study was that only two 24 hour samples were collected and no spot samples, so they used 
the 24 hour samples to determine 24 hour AER, ACR and UAC. Therefore no conclusion 
should be made regarding the variation of ACR or UAC in a spot sample as no additional spot 
samples were collected. (Gansevoort et al., 2006). Importantly, it is inaccurate to calculate a 
SD from just two repeat measurements and therefore the CV is unreliable which may 
explain why their results were so high. 
From this it can be concluded that for studies examining the variation of collection methods, 
it is important to repeat collections at least three times within a short time period, and if 
urine samples can’t be analysed when they are fresh, then storage at -80oC is preferable 
(storage conditions are discussed and investigated in Chapter 5).  
Gender specific reference ranges to identify microalbuminuria acknowledge that a limitation 
of using creatinine to adjust urinary albumin  concentration is that creatinine excretion 
varies. Gender specific range may be sufficient to account for this limitation when clinically 
interpreting ACR results, but there are alternative methods to calculate personalised 
creatinine excretion, which may provide a more accurate assessment of an individual’s 
urinary albumin excretion. This will be explored in this chapter at the extended lower 
albumin excretion range. 
Another measure of urinary concentration is urine specific gravity. Therefore UAC can be 
adjusted for dilution using USG (A/USG), which is another method of reporting albuminuria. 
There are very few studies which have looked at using A/USG (Newman et al., 2000, 
Fagerstrom et al., 2015, Moore et al., 1997), and there are none that have investigated its 
use in different spot samples when comparing to an overnight AER.  
My study will therefore, not only investigate which spot sample (FMV, SMV or random) is 
best suited to replace a timed overnight collection, it also determines the best method of 
reporting albuminuria within those spot samples: UAC, ACR, eAER or A/USG.  
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4.2 Aim 
 
To identify which spot sample (FMV, SMV or random) and which method of reporting 
albumin excretion (UAC, ACR, A/USG or eAER) is the best surrogate marker of a timed 
overnight urine collection, when investigating the extended normal albumin excretion 
range. 
 
 
4.2.1 Objectives 
 
1. To determine albumin excretion levels by different collection methods and by 
different methods of reporting albumin excretion. In healthy individuals using an 
ELISA to quantify urinary albumin with a validated measurable range of 0.78 – 40 
mg/L. 
 
2. To assess the intra-participant reproducibility of different collection methods and 
different methods of reporting albumin excretion. 
 
3. To assess the inter-individual variation of different collection methods and different 
measures of albumin excretion. 
 
4. To assess which spot collection method and method of reporting albumin excretion 
(UAC, ACR and A/USG) correlates best to an overnight albumin excretion rate. 
 
5. To investigate if the correlation of a spot sample with an overnight albumin 
excretion rate can be improved by estimating AER. 
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4.3 Method 
 
4.3.1 Study design 
 
4.3.1.1 Participant recruitment 
 
17 healthy adults (aged 21-50 years old) were recruited from the Exeter 10,000 bio-resource 
of individuals interested in hearing about research, held by the NIHR Exeter Clinical 
Research Facility.  
The exclusion criteria for the study was; an eGFR < 60ml/min/1.73m2 an ACR above the 
normoalbuminuria range, diagnosed with diabetes, cardiovascular disease, hypertension or 
were on antihypertensive medication. 
 
4.3.1.2 Study protocol 
 
The study protocol was reviewed and approved by the South West Regional Ethics 
Committee (REC Reference: 14SW0049). Written informed consent was obtained from all 
participants, who then attended a screening visit, where anthropometric measurements 
(height and weight) were taken along with collecting a blood and random urine sample. 
Participants were not fasted, and had a normal breakfast prior to providing samples. The 
blood sample was used to measure serum creatinine; to determine if eGFR meets the 
inclusion criteria for the study (Section 4.3.1.1). ACR was reported from the urine sample to 
ensure the participant met the study criteria to have a normal albumin excretion rate 
(Section 4.3.1.1). 
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Blood and Blood pressure was measured five times in the non-dominant arm using a digital 
blood pressure monitor; with the mean of the last three measurements representing 
brachial blood pressure.  
 
4.3.1.3 Study method 
 
Each participant collected their urine over a 36 hour period on three separate occasions. 
During recruitment and screening, all participants received detailed written, drawn and oral 
instructions about the procedure for collecting the urine samples. The patient information 
sheet that set out these details is provided at appendix 4 and is outlined in Table 26. In 
summary, each participant received five numbered containers. 
 
Firstly, they would provide a mid-stream FMV sample into container one (C1). Then they 
started a timed day collection where they would collect every pass of urine throughout the 
day and evening, up to and including the final void before going to bed, into container two 
(C2). Then the timed overnight collection began, in which they passed all urine into 
container three (C3), including the first pass of urine in the morning recording the times of 
the start and finish of the collection on the bottle. Then they would collect a mid-stream 
sample in container four (C4) the next time they voided urine (SMV). Finally, they were free 
to provide a random mid-stream sample in container five (C5) whenever they desired (as 
long as it was before 17:00 that day).  
 
Samples were stored in a refrigerator or kept in a cool place until bringing them into the 
research centre on the same day the collection was completed. Each participant carried out 
the collection procedure three times, with an aim to complete all the collections within a 
month.  
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Container Number Sample Type Measures of Albuminuria 
C1 FMV UAC, ACR, A/USG & eAER 
C2 Timed Day AER } combined for 24 Hr AER 
C3 Timed Night AER 
C4 SMV UAC, ACR, A/USG & eAER 
C5 RDM UAC, ACR, A/USG & eAER 
Table 26 The containers used to collect different urine samples. Different measures of 
albumin excretion for each sample type are presented. An AER is calculated for each timed 
collection. A sample from both timed collections are combined together to represent a 24 
hour collection. The volume of the samples added are proportional to the volumes of the 
two timed collections. Each participant collected samples according to this procedure three 
times. AER: albumin excretion rate, UAC: urinary albumin, ACR: albumin to creatinine ratio, 
A/USG: Albumin to specific gravity ratio, eAER: estimated albumin excretion rate. 
 
Participants were asked to avoid exercise and sexual intercourse, which can affect albumin 
excretion, the evening before and during the collection period. All participants were advised 
not to collect if they were ill for any reason and women were advised to avoiding collecting 
whilst menstruating. When samples were received, participants were questioned about 
their activities prior to and during the collection, to determine compliance with the 
protocol. 2/51 collections were repeated due to exercise undertaken and one collection was 
repeated due to an incomplete timed overnight sample.  
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4.3.2 Sample Processing 
 
Timed collections were weighed to determine volume and the durations were recorded. All 
samples underwent dipstick analysis (COBAS Combur-Test strips87) (Roche Diagnostics Ltd., 
Burgess Hill, UK) and were then aliquoted into several microtubes and immediately stored 
at -80oC.  
 
An AER is calculated for each timed collection. A sample from both timed collections are 
combined together to represent a 24 hour collection. The volume of the samples added is 
proportional to the volumes of the two timed collections. From this combined sample a 24 
hour AER can be determined. 
 
Sample analysis was carried out after all collections were complete. Prior to analysis, the 
samples were left to return to room temperature and then underwent five hand inversions 
to gently mix the contents. Urinary and blood creatinine was measured using the COBAS 
Jaffe method (Roche Diagnostics Ltd., Burgess Hill, UK). USG was determined using a digital 
refractometer (ATAGO Ltd., Tokyo, Japan). Urinary albumin was quantified by the Fitzgerald 
ELISA (Fitzgerald Industries International, North Acton, MA, USA). For each participant, all 
the urine samples (from all three collections) were analysed on the same ELISA plate, to 
eliminate the impact of inter-plate variation on intra-individual reproducibility results.  
ELISA analyses were carried out using an automated platform, a ‘Dynex DS2’ (Dynex 
Technologies, VA, USA). 
 
 
 
 
 
 
165 
 
4.3.3 Statistical analysis 
 
Sample size: 
 
From the literature review, the reported correlations between ACR and 24 hour AER have an 
r value > 0.7 (Witte et al., 2009, Chavan et al., 2011). To detect a correlation of r=>0.7, a 
sample size of n=17 will give 90% power at p=0.05. (Machin et al., 2009). 
 
Normality of data was tested using the Shapiro-Wilkes test. If data were not normally 
distributed, associations were examined using the Spearman’s rank correlation test. 
Normally distributed data are presented as mean (±SD) and non-normally distributed data 
as the median [IQR].  
Wilcoxon signed-rank test is used to test if the difference in albumin excretion is 
significantly different in different collections and by different methods of reporting albumin 
excretion. 
For each spot collection the correlation of UAC, ACR and A/USG with overnight AER is 
reported using Spearman’s rank correlation test.  
Estimating AER was carried out using the MDRD, CKD and WALSER equations. eAERs and 
A/USG were calculated as previously described (Chapter 3 Section 3.3).  
The coefficient of variation, diagnostic sensitivity and specificity were also calculated as 
previously described (Chapter 2 Section 2.3.9). For each collection method, each 
participant’s CV was calculated from three repeated collections and then the median values 
among participants are used to summarise intra-participant variability.  
Inter-individual variability was demonstrated by calculating the CV for each collection 
method between all the participants.  
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4.4 Results 
 
Seventeen participants met the inclusion criteria (Section 4.3.1.1) and completed the three 
study visits. The characteristics of this cohort are summarised in Table 27.  
4.4.1 Participant characteristics:  
 
Characteristic n=17 
Age (years) 34 [22-47] 
% male 47% 
Weight  (kg) 75.1 (15.9) 
BMI (kg/m2) 24.3 [23.0 - 25.3] 
Blood Creatinine (mmol/L) 76.94 (16.5) 
eGFR (ml/min) 101.3 (15.6) 
Systolic BP (mmHg) 116 (12) 
Diastolic BP (mmHg) 72 (9) 
Table 27 Characteristics of the study participants. Data presented as mean (SD) or median 
[IQR] depending on normality of data. Seventeen participants met the inclusion criteria 
(Section 4.3.1.1) and completed the three study visits. 
4.4.2 Objective 1: To determine albumin excretion levels by different collection 
methods and by different methods of reporting 
Albumin excretion by different collection methods are summarised in  Table 28. The unit of 
AER for the 24 hour collection is µg/min, enabling an easier comparison to be made with the 
other timed collections. AER is significantly lower overnight than during the day (p=0.0005). 
This is also demonstrated by the spot samples, where ACR from a FMV is lower than ACR 
from the SMV (p=0.005) and a random spot sample (p=0.005) collected later in the day. 
Consequently, when estimating AER in spot samples, an eAER from a FMV is more 
representative of an overnight AER and an eAER from a random sample is more comparable 
to a timed day or 24 hour AER.  
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Table 28 Median albumin excretion levels by different urine collection methods. The median values [IQR] among 17 healthy individuals are 
reported. For each participant the mean of three collections was calculated. . AER is significantly lower overnight than during the day (p<0.001). 
There is no significant difference in UAC between FMV and SMV samples (p=0.650), FMV and random samples (p=0.068), and SMV and 
random samples (p=0.076). When taking urinary concentration into account; FMV ACR is significantly lower than ACR from the SMV (p=0.005) 
and a random spot sample (p=0.005) collected later in the day.  AER: albumin excretion rate, ACR: albumin to creatinine ratio, eAER: estimated 
albumin excretion rate, UAC: urinary albumin concentration.
Collection Method AER  µg/min 
Timed: 
 
24 Hour 4.11 [2.48 - 5.76] 
Timed Overnight 3.23 [1.20 - 3.96] 
Timed Day 4.51 [2.74 - 6.92] 
Spot: 
UAC                   
mg/L 
ACR                 
mg/g 
eAER MDRD 
µg/min 
eAER CKD  
µg/min 
eAER WALSER  
µg/min 
First Morning 4.17 [1.97 – 7.99] 3.10 [2.30 - 4.51] 3.02 [2.01 – 5.22] 2.97 [2.25 – 5.08] 3.25 [3.36  - 5.88] 
Second Morning 3.84 [1.81 – 8.13] 4.78 [2.83 - 6.55] 4.12 [3.22 – 6.01] 5.47 [3.08 – 6.74] 5.63 [3.24 – 7.37] 
Random 1.92 [1.18 – 3.99] 4.78 [2.83 - 7.17] 5.35 [2.97 – 8.29] 4.67[3.34 – 7.34] 5.06 [3.77 – 7.11] 
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4.4.3 Objective 2: To assess the intra-participant reproducibility of different 
collection methods and different methods of reporting albumin excretion. 
 
17 healthy participants collected their urine by different methods, three times. The mean 
period (±SD) to complete all three collections was 26.8 days (±12.3). To determine intra-
individual reproducibility, the CV was calculated for each collection method and for the 
different methods of reporting albuminuria (Table 29 and Figure 33).  
 
Collection Method 
Method of reporting 
albumin excretion  
Median 
CV% 
Min  
CV% 
Max 
CV% 
24 Hour  AER 14.4 [8-30] 5.2 53.5 
Overnight  AER 15.4 [9-44] 2.4 58.9 
Timed Day  AER 17.8 [14-34] 1.5 73.6 
First Morning  UAC 26.8 [23-50] 2.9 162.3 
Second morning  UAC 42.1 [27-75] 15.2 128.5 
Random  UAC 60.8 [42-74] 8.0 163.5 
First Morning  ACR 15.9 [12-22] 2.7 157.9 
Second morning  ACR 22.1 [6-39] 2.1 126.8 
Random  ACR 22.6 [16-39] 4.2 167.4 
First Morning  A/USG 22.7 [18 - 28] 7.9 160.0 
Second morning  A/USG 28.2 [16 - 53] 3.0 126.2 
Random  A/USG 26.0 [16 - 50] 11.4 168.7 
Table 29 The median intra-individual reproducibility of different urine collection methods 
to assess albuminuria. The coefficient of variation was calculated from repeating the 
collections three times by 17 participants. The median CV [IQR] is reported. Among the spot 
collections; CV was only significantly improved when reporting UAC from FMV compared to 
reporting UAC from random spot samples (p=0.02). AER: albumin excretion rate, ACR: 
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albumin to creatinine ratio, UAC: urinary albumin concentration, A/USG: albumin to urine 
specific gravity ratio. 
As this study is examining variation, all results were included in this analysis. Among the 
spot samples, the FMV ACR has the lowest median CV, although one participant had the 
maximum CV of 157.9%. Interestingly, dipstick analysis revealed that there was 
haemoglobin in one of the FMV samples from this individual, which may have interfered 
with the albumin assay, causing a falsely high result. Reproducibility is poorer (CV is higher) 
when reporting UAC or A/USG in spot samples compared to the ACR.   
The box and whisker plot in Figure 33 also presents intra-individual variation for the 
different collection methods (only spot sample ACR CV is presented). The intra-individual CV 
of UAC, ACR and A/USG in the different spot samples are presented in Figure 34.  
When investigating the largest outliers across the spot collections, blood in a FMV sample 
has already been identified as a potential cause of analytical error. In the SMV sample which 
had the highest CV, the abnormality might have been the result of the urine being very 
concentrated (creatinine = 21.6 mmol/L) subsequently causing a very high albumin 
concentration of 189 mg/L.  
Dipstick analysis in the highest outlying random sample indicated the presence of 
leucocytes, which could suggest that the participant was experiencing an inflammatory 
challenge, resulting in increased albumin excretion. These potential causes for the outlying 
results are common issues when collecting samples to assess albumin excretion. 
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Figure 33 Box and whisker plots of intra-individual reproducibility of different collection 
methods. The coefficient of variation was calculated from repeating the collections three 
times by 17 participants. The horizontal line inside the box represents the median, the edges 
of the box are the upper and lower interquartile and the whiskers represent the minimum 
and maximum values, with outlying (●) results individually plotted. AER: albumin excretion 
rate,  ACR: albumin to creatinine ratio, FMV: first morning void, SMV; second morning void, 
RND: random spot sample. 
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Figure 34 The intra-individual reproducibility of different methods of reporting albumin 
excretion in spot samples. The coefficient of variation was calculated from repeating the 
collections three times by 17 participants. Among the spot collections; CV was only 
significantly improved when reporting UAC from FMV compared to reporting UAC from 
random spot samples (p=0.02).The horizontal line inside the box represents the median, the 
edges of the box are the upper and lower interquartile and the whiskers represent the 
minimum and maximum values, with outlying (●) results individually plotted. UAC: urinary 
albumin concentration, ACR: albumin to creatinine ratio, A/USG: albumin to urine specific 
gravity ratio, FMV: first morning void, SMV; second morning void, CV coefficient of variation. 
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4.4.4 Objective 3: To assess the inter-individual variation of different collection 
methods and different measures of albumin excretion. 
 
Inter-individual variation was investigated by taking the result from each participant’s first 
collection, so the CV between participants could be calculated. The reason for taking just 
the first collection result is that it reflects what would be carried out clinically, when 
screening for microalbuminuria. The variation between people is less in a timed overnight 
collection compared to a timed day collection, which is to be expected as during the day 
there are a lot more factors (activity, fluid intake etc.) that influence AER. This is also 
reflected by the spot samples, where the variation in UAC, ACR and A/USG increases 
throughout the day. 
  Inter-individual CV (%) 
24 Hour AER 123 
Overnight AER 55 
Timed Day AER 140 
First Morning UAC 90 
Second morning UAC 131 
Random UAC 302 
First Morning ACR 69 
Second morning ACR 79 
Random ACR 114 
First Morning A/USG 70 
Second morning A/USG 67 
Random A/USG 156 
Table 30 Inter-individual variability of different urine collection methods and different 
ways of reporting albumin excretion in 17 healthy participants. Albumin excretion was 
determined in the samples from the first collections of 17 healthy participants.  UAC, ACR 
and A/USG are reported in the spot samples. AER: albumin excretion rate, ACR: albumin to 
creatinine ratio, UAC: urinary albumin concentration, A/USG: albumin to urine specific 
gravity ratio, CV coefficient of variation. 
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4.4.5 Objective 4: To assess which spot collection method and method of 
reporting albumin excretion correlates best to an overnight albumin excretion 
rate. 
 
The correlation of spot samples to the “gold standard” overnight AER was determined in the 
first collection from 17 healthy participants (Table 31). The FMV sample always 
demonstrated the strongest correlation with overnight AER. The correlation of ACR was 
generally higher than UAC and A/USG. Graphs of the correlation between spot sample ACR 
and overnight AER are presented in Figure 35, Figure 36 and Figure 37 (ACR is reported as 
mg/g to enable easier comparison with estimating eAER graphs in Section 4.4.6). 
 
 
 
Correlation with overnight AER 
 
Rs p 
First Morning UAC 0.84 <0.001 
Second Morning UAC 0.48 0.054 
Random UAC 0.45 0.073 
First Morning ACR 0.88 <0.001 
Second Morning ACR 0.54 0.025 
Random ACR 0.59 0.012 
First Morning A/USG 0.87 <0.001 
Second Morning A/USG 0.46 0.062 
Random A/USG 0.60 0.012 
Table 31 Correlation between spot urine collections and methods of reporting with 
overnight AER to assess albumin excretion. For each spot collection the correlation of UAC, 
ACR and A/USG with overnight AER is reported using Spearman’s rank correlation test. 
Albumin excretion was determined in the samples from the first collections of 17 healthy 
participants. AER: albumin excretion rate, ACR: albumin to creatinine ratio, UAC: urinary 
albumin concentration, A/USG: albumin to urine specific gravity ratio. 
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Figure 35 Correlation of FMV ACR with overnight AER, from the first collection of 17 
healthy participants. (Rs = 0.88, p<0.001). AER: albumin excretion rate, ACR: albumin to 
creatinine ratio, FMV: first morning void. 
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Figure 36 Correlation of SMV ACR with overnight AER, from the first collection of 17 
healthy participants. (Rs = 0.54, p=0.025). AER: albumin excretion rate, ACR: albumin to 
creatinine ratio, SMV: second morning void. 
  
Figure 37 Correlation of random spot samples with overnight AER, from the first collection 
of 17 healthy participants. (Rs = 0.59, p=0.012). AER: albumin excretion rate, ACR: albumin 
to creatinine ratio. 
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4.4.6 Objective 5: To investigate if the correlation of spot samples with overnight 
albumin excretion rate can be improved by estimating AER. 
 
Correlations of ACR and estimates of AER from untimed spot samples with overnight AER 
are displayed in Table 32. eAER in FMV samples marginally improved the correlation with 
overnight AER, whereas in SMV and random samples there is an increase in correlation. 
eAERMDRD improves the correlation of a random sample from 0.59 to 0.78 (Figure 38). 
 
 
 
 
 
 
 
 
 
 
 
Table 32 Correlation of different urine spot collections and methods of reporting albumin 
excretion with the “gold standard” overnight AER to assess albumin excretion. Estimating 
creatinine excretion equations are applied to the spot collections to determine if the 
correlation is improved by estimating albumin excretion in each untimed samples. Albumin 
excretion was determined in the samples from the first collections of 17 healthy participants. 
AER: albumin excretion rate, ACR: albumin to creatinine ratio, eAER: estimated albumin 
excretion rate, Rs: Spearman’s rank correlation. 
 
Correlation with 
overnight AER 
 
Rs p 
First Morning ACR 0.88 <0.001 
eAERMDRD 0.89 <0.001 
eAERCKD 0.89 <0.001 
eAERWALSER 0.88 <0.001 
Second Morning ACR 0.54 0.025 
eAERMDRD 0.67 0.003 
eAERCKD 0.71 0.001 
eAERWALSER 0.71 0.001 
Random ACR 0.59 0.012 
eAERMDRD 0.78 <0.001 
eAERCKD 0.76 <0.001 
eAERWALSER 0.74 <0.001 
177 
 
 
Figure 38 Correlation of ACR and estimated AER from a random spot sample with 
overnight AER. Albumin excretion was determined in the samples from the first collections 
of 17 healthy participants. eAER was calculated using the MDRD equation (Section 4.3.3) 
Correlation with overnight AER when reporting; ACR: Rs = 0.59, p=0.012, and when reporting 
eAERMDRD:  Rs = 0.78, p<0.001. AER: albumin excretion rate, ACR: albumin to creatinine ratio, 
eAER: estimated albumin excretion rate, Rs: Spearman’s rank correlation. 
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The relationship of estimating AER from an untimed spot using a 
personalised creatinine excretion rate with an overnight AER 
 
4.5 Introduction  
 
The previous results (Section 4.4) suggest that an ACR in a FMV sample would be the best 
spot sample as a surrogate for a timed overnight collection, when assessing the extended 
lower albumin excretion range. However, when screening for microalbuminuria, random 
samples are clinically more desirable as patients can provide a sample when visiting their 
GP, instead of carrying out the FMV collection at home. Interestingly, when estimating AER 
using the MDRD equation there is an increase in the correlation (Rs from 0.59 to 0.78) when 
reporting the ACR in random spot samples with an overnight AER (Table 32, Figure 38). A 
limitation of these results is the small number of healthy participants (n-17). To investigate 
this further another study was carried out to test a larger and more diverse population, 
more representative of the targeted patient groups.  
In the SUMMIT study (described in more detail in Chapter 7), participants provided two 
overnight urine collections and a random spot sample, collected at the same time as one of 
the overnight samples. Therefore, it can be examined whether estimating AER improves the 
correlation of an ACR in a random sample with an overnight AER. In addition, two overnight 
samples were collected, therefore individuals with persistent microalbuminuria can be 
identified and the diagnostic accuracy of ACR and eAER in random samples can be tested.  
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4.6 Aim  
 
To investigate the relationships of reporting ACR and reporting an estimate of AER (using a 
personalised creatinine excretion) from random untimed spot samples with albumin 
excretion from an overnight urine collection.  
 
4.6.1 Objectives 
 
Objective 1: To determine if estimating AER improves the correlation of an ACR from a 
random spot collection with a timed overnight AER in a large group of healthy individuals 
and people with T2DM.  
 
Objective 2: To determine if estimating AER improves the diagnostic accuracy of random 
spot samples to identify individuals with persistent microalbuminuria. 
 
 
4.7 Method 
 
4.7.1 Participants 
 
Participant results were selected from the SUMMIT study cohort. The only inclusion criteria 
was that they had urine samples stored from a timed overnight collection and a random 
spot sample, which were both completed on the same day. This cohort consisted of 
participants with and without T2DM, some with reported cardiovascular disease. 
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4.7.2 Sample collection 
 
Participants completed an overnight urine collection on the morning of their visit to the 
research centre. During the course of the visit a random urine sample was collected.  
Anthropometric measurements and blood pressure were also assessed. Blood pressure was 
measured five times in the left arm using an automated device, with the mean of the last 
three measurements taken as representative of the patients brachial blood pressure. 
Participants collected a second overnight sample, usually a week later. The second sample 
was only used to confirm if persistent microalbuminuria was present. 
 
4.7.3 Sample analysis 
 
Creatinine in blood and urine was measured using the COBAS Jaffe method (Roche 
Diagnostics Ltd., Burgess Hill, UK) on the day of collection. Urine samples were aliquoted 
and stored at -80 oC on the day that they were collected. Urinary albumin was later 
quantified by Fitzgerald ELISA (Fitzgerald Industries International, North Acton, MA, USA). 
Samples were defrosted and mixed by four hand inversions prior to analysis. 
HbA1c was measured using the routine HPLC method (TOSOH-G7, Tosoh Bioscience, Inc., 
San Francisco, CA, USA). 
 
4.7.4 Data analysis: 
 
Estimating AER was carried out using the MDRD, CKD and WALSER equations. eAERs and 
A/USG were calculated as previously described (Chapter 3 Section 3.3). 
Normality of data was tested using the Shapiro-Wilkes test. If data were not normally 
distributed, associations were examined using the Spearman’s rank correlation test. 
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Normally distributed data are presented in the text as mean (±SD) and non-normally 
distributed data as the median [IQR].  
Subjects with persistent microalbuminuria were identified from two timed overnight 
collections, both with AER between 20µg/min and 200µg/min.  
To determine the diagnostic accuracy of ACR and eAERs in random spot samples, the 
sensitivity and specificity to identify individuals with microalbuminuria was calculated as 
previously described (Chapter 3, Section 3.2.3.2) The area under the curve (AUC) from a 
receiver operator characteristic (ROC) analysis and the percent of individuals correctly 
identified was also calculated (Chapter 3, Section 3.2.3.2). 
 
4.8 Results 
 
4.8.1 Participant characteristics:  
194 participants met the inclusion criteria (Section 4.7.1). The characteristics of this cohort 
are summarised in Table 33. 
Characteristic n=194 
Age (years) 70 (±8) 
% Male 64% 
% T2DM  58% 
Weight (Kg) 81.2 [71.8 - 91.9] 
BMI (kg/m2) 27.6 [ 24.7 - 31.7] 
Hba1c (mmol/mol) 47 [41 - 59] 
Blood Creatinine (µmol/L) 84 [73 - 95] 
eGFR (ml/min/1.73m2) 78.6 [65.7 - 86.9] 
Systolic BP (mmHg) 133 (±16) 
Diastolic BP (mmHg) 71 (±8) 
Table 33 Characteristics of SUMMIT participants included in the study. 194 participants 
met the inclusion criteria (Section 4.7.1). Data presented as means (±SD) medians [IQR] 
depending on normality of data (n = 194). BMI: body mass index, T2DM; type 2 diabetes, 
eGFR: estimate glomerular filtration rate, BP: blood pressure. 
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The median levels of albuminuria in overnight and random collections are reported in Table 
34. Although the eAER median values are similar to overnight AER, the interquartile ranges 
suggest that estimating AER provides higher results, although they are not significantly 
different (p>0.10). The correlations of ACR and eAER with overnight AER are reported in 
Table 35. 
Overnight Collection 
 
AER µg/min 7.20 [4.5 - 13.1] 
Random Collection 
 
ACR, mg/g 8.80 [5.8 - 17.2] 
eAERMDRD, µg/min 7.49 [5.1 – 14.8] 
eAERCKD, µg/min 7.57 [5.5 – 17.0] 
eAERWALSER, µg/min 7.18 [5.1 – 15.0] 
Table 34 Albumin excretion from overnight and random collections in participants with 
and without type 2 diabetes. The median values [IQR] among 194 participants are reported. 
AER: albumin excretion rate, ACR: albumin to creatinine ratio, eAER: estimate albumin 
excretion rate. 
 
4.8.2 Objective 1: To determine if estimating AER improves the correlation of an 
ACR from a random spot collection with a timed overnight AER. 
n=194 
Correlation with Timed 
Overnight AER 
  rs p 
ACR 0.60 <0.001 
eAERMDRD 0.67 <0.001 
eAERCKD 0.69 <0.001 
eAERWALSER 0.67 <0.001 
Table 35 Association of ACR and estimates of AER from a single spot random sample with 
timed overnight urine collection. Spearman’s rank correlation is reported from the 194 
participant samples. AER: albumin excretion rate, ACR: albumin to creatinine ratio, eAER: 
estimate albumin excretion rate. 
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4.8.3 Objective 2: To determine if estimating AER improves the diagnostic 
accuracy of random spot samples to identify individuals with persistent 
microalbuminuria. 
 
27/194 participants had persistent microalbuminuria, which was identified from two timed 
overnight collections. The ability to correctly identify individuals with microalbuminuria 
when reporting either ACR or eAER in a random sample is displayed in Table 36. 
 
 Sensitivity % (CI) Specificity % (CI) AUC (CI) % Correctly 
Identified 
ACR 85.2 (66.3 – 95.8) 92.8 (87.8 – 96.2) 0.97 (0.95 – 0.99) 91.75 
eAERCKD 96.3 (81.0 – 99.9) 89.8 (84.2 – 94.0) 0.98 (0.96 – 1.00) 90.72 
eAERMDRD 88.9 (70.8 – 97.7) 92.2 (87.1 – 95.8) 0.98 (0.96 – 1.00) 91.75 
eAERWALSER 92.6 (75.7 – 99.1) 89.8 (84.2 – 94.0) 0.98 (0.96 – 1.00) 90.21 
Table 36 Diagnostic accuracy of ACR and estimates of AER in a random sample to identify 
individuals with microalbuminuria. Microalbuminuria was identified from two timed 
overnight collections, 27/194 participants were identified as having persistent 
microalbuminuria. Sensitivity, specificity and AUC from ROC analysis with the accompanying 
95% confidence intervals are reported. The percent of correctly identified individuals (with 
and without microalbuminuria) are reported. 
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4.9 Chapter Discussion 
 
A timed overnight urine collection is the “gold standard” for assessing albumin excretion. 
However, timed collections are burdensome for patients, who can be prone to making 
mistakes, which can lead to inaccurate results. The overall aim of this study was to 
investigate which untimed spot collection and which method of reporting albumin excretion 
is the best surrogate of timed overnight collections.  
The risk of cardiovascular disease with albumin excretion is continuous, starting within the 
normal levels of albumin excretion. We can utilise the validated ELISA (Fitzgerald Industries 
International, North Acton, MA, USA) to quantify the lowest concentrations of urinary 
albumin enabling us to investigate the biological variation of albumin excretion at the 
lowest levels in healthy individuals.  
To fully investigate the relationships between spot samples and timed overnight collections, 
this chapter consists of two different studies, the results of the first study instigating the 
aims of the second study. 
 
Investigation 1: The optimal urine collection method to assess the excretion of albumin 
in the normal range in healthy individuals 
Investigation 2: The relationship of estimating AER from an untimed spot using a 
personalised creatinine excretion rate with an overnight AER in individuals with and 
without T2DM. 
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Investigation 1: The Optimal Urine Collection Method to Assess the 
Excretion of Albumin in the normal range 
 
The results from this study indicate that a FMV is the most appropriate surrogate for an 
overnight urine collection, and that ACR should be reported, as they provide the lowest 
median intra-individual reproducibility (CV = 15.9%, Table 29) and have the highest 
correlation with overnight AER (Rs = 0.88, Table 31).  
This agrees with and extends the findings of other studies, including those from the 
PREVEND cohort, who reported an intra-reproducibility of 19.0% for a FMV sample 
reporting the ACR, supporting their conclusion that a FMV sample is more reliable than a 
random sample (Witte et al., 2009). The PREVEND study is unable to investigate these lower 
levels of albumin excretion and has a much more diverse population, closer associated with 
the tested cohort in the second study (Section 4.8.1) (discussed further in Section 4.9.4)    
Our study has used healthy individuals, and by using the validated ELISA (Chapter 2) 
(Fitzgerald Industries International, North Acton, MA, USA) the biological variation of 
albumin excretion at the lowest levels was investigated for the first time.  
 
4.9.1 Albumin excretion levels by different collection methods and by different 
methods of reporting albumin excretion. 
 
Albumin excretion levels by different collection methods are summarised in Table 28. AER in 
timed day collections was 4.5 µg/min [2.7 – 6.9] compared to an overnight AER of 3.2 
µg/min [1.2 – 4.0] (p=0.0005) (Table 28). AER is significantly lower overnight than during the 
day. This is also demonstrated by the spot samples, where ACR from a FMV is lower than 
ACR from the SMV (p=0.005) and a random spot sample (p=0.005) collected later in the day. 
Consequently, when estimating AER in spot samples, an eAER from a FMV is more 
representative of an overnight AER and an eAER from a random sample is more comparable 
to a timed day or 24 hour AER.  
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AER has been reported as 30-50% lower overnight compared to during the day in other 
studies (Mogensen et al., 1995b, Witte et al., 2009, Howey et al., 1987). A recent study of 
145 healthy participants, similar to our cohort, reported a mean 24 hour AER of 5.25 µg/min 
and an overnight AER of 4.10 µg/min (Fagerstrom et al., 2015). The reported albumin 
excretion is very similar to our results; however, these studies have not been able to 
quantify the lowest levels of urinary albumin excretion. Presumably they have reported the 
limit of quantification for samples which are unmeasurable by their assay.  
The majority of authors do not report if samples which have an albumin concentration 
below the measurable range of their assay are included in the analysis. All the samples 
tested in our study had an albumin concentration within the measurable range of the 
validated Fitzgerald ELISA (Fitzgerald Industries International, North Acton, MA, USA).  
In the PREVEND study of 241 participants (predominately without diabetes), the reported 
mean AER [IQR] from three 24 hour collections was 7.99 µg/min [5.00 to 12.36], 
considerably higher than our reported 24 hr AER of 4.11 µg/min [2.48 to 5.76]  (Witte et al., 
2009).  
The higher reported AER in the PREVEND study is most likely attributed to the more diverse 
and older population they tested. The mean age of the PREVEND cohort was 58.7 ± 11.3 
years, the median age [IQR] of participants in our study was 34 [22-47]  . However 
differences between the assays used may contribute to the disparity and it is likely that they 
have reported the limit of quantification for samples which are unmeasurable by their assay. 
The assay used to quantify urinary albumin was the Behring BN II analyser (Dade Behring, 
Marburg, Germany) which has a lower limit of detection was 2.40 mg/L (Witte et al., 2009). 
The reason for reduced AER overnight, compared to during the day is most likely the result 
of low levels of physical activity and a low, steady blood pressure overnight, as reflected in 
the FMV sample. During the day, the influence of these factors will not only increase but 
vary considerably day to day, within people as well as between individuals, resulting in an 
increase in the variability of albumin excretion and the amount of albumin excretion.  
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4.9.2 Variability of albumin excretion in different urine collection methods 
 
The intra-individual reproducibility of albumin excretion declined as the day progressed, 
which was demonstrated by an increasing CV in spot samples that were collected later in 
the day, with FMV, SMV and random ACRs having a CV of 15.9%, 22.1% and 22.6 % 
respectively (Table 29). CV significantly improved when reporting UAC from a FMV (26.8% 
[23-50]) compared to reporting UAC from a random spot sample (60.8% [42-74]) p= 0.02.  
The PREVEND study of 241 participants carried out three 24 hour, FMV and random 
collections over three weeks (Witte et al., 2009). The CV of the collections were 19.0%, 
19.1% and 35.8% respectively, revealing that only the FMV CV did not significantly differ 
from the 24 hour AER (p=0.64). In the PREVEND study, 24 hour AER was selected as the 
reference method. Our investigation of the literature states that an overnight AER is the 
gold standard method to assess albumin excretion. This is supported by our findings that 
albumin excretion is more reproducible when taken over night or as a spot from a first 
morning void. In our study the CV when reporting an ACR from a FMV had no significant 
difference with overnight AER (p=0.723). There were also no significant differences between 
the CV of ACR when reporting from a SMV (p=0.407) and random spot sample (p=0.163) 
with overnight AER.   
The inter-individual variability in albumin excretion also increased throughout the day. This 
was expected, as the impact of factors that influence albumin excretion differs between 
people as the day progresses, but overnight the variability of these factors is less (Table 30). 
This is demonstrated by FMV ACRs in the first collection having an inter-individual CV of 
69%, compared to random sample ACRs collected later in the day with a CV of 114%. The CV 
increased further when only reporting UAC; with a CV of 90% and 302% in the FMV and 
random samples respectively. The CV was 70% and 156% for FMV and random samples 
when reporting A/USG, which is lower than reporting UAC alone, but no improvement on 
the ACR. This reflects the influence of hydration status when reporting albuminuria and the 
need to account for it. 
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When considering intra-individual reproducibility, the CV of spot samples was highest when 
reporting UAC alone; 26.8%, 42.1% and 40.8% in FMV, SMV and random samples 
respectively. When adjusting UAC by urine specific gravity (A/USG), the CV was reduced 
(22.7%, 28.2% and 26.0%), but the least variability was seen when reporting ACR (15.9%, 
22.1% and 22.6 %, Table 29).  
Reporting the ACR from a FMV is the most reproducible method of investigating the urinary 
albumin excretion in spot samples. This is in accordance with other studies which have 
investigated at a higher albumin excretion than our study. Our study is the first to evaluate 
the biological variability of albumin excretion in all healthy individuals, facilitated by using a 
validated highly sensitive assay. 
For each participant, all the urine samples (from all three collections) were analysed on the 
same ELISA plate, to eliminate the impact of inter-plate variation on intra-individual 
reproducibility results. This analytical approach may contribute to the variability seen 
between participants. Assessing inter-individual variability was one of the study objectives, 
but this limitation is accepted as intra-individual variability is a more important factor when 
identifying a spot sample to be a surrogate overnight collection. 
 
4.9.3 Reproducibility of methods of adjusting albumin concentration for variation 
in urine concentration  
 
This study finds that ACR is the most reproducible method of reporting albumin excretion in 
spot samples, which contradicts the views of some authors who argue that the ACR 
increases variability because another biological factor (creatinine) is being measured (Dyer 
et al., 2004). However, their conclusions were drawn from an epidemiological study where 
only two 24 hour samples and no spot samples were collected, with UAC being reported 
from the same 24 hour samples. In our study it is evident that the ACR should be reported in 
spot samples, as UAC not only resulted in higher variability, it had a poorer correlation with 
overnight AER (Table 31).  
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Another method instead of creatinine to adjusting for urinary concentration is urine specific 
gravity (USG), but there are major differences between them. Creatinine is a breakdown 
product of muscle metabolism, which is freely filtered by the kidneys and excreted into the 
urine at a relatively constant rate. A limitation of using creatinine is that creatinine 
production/excretion is associated with muscle mass which varies among individuals. USG is 
a marker of the density of urine, comparing the refraction of light in a sample to that of 
water, which is dependent on the concentration of particles in the sample. Therefore, an 
elevated concentration of particles, not related to low urinary flow, will increase USG. This is 
a limitation, especially when measuring albumin excretion in patients with DM, where large 
particles such as albumin and glucose may be present which refract light to a large degree, 
falsely elevating USG.   
Creatinine is a standardised and comparable measurement between laboratories, and with 
the results of this study suggesting there is no improvement when reporting A/USG 
compared to ACR, it is evident that the ACR is the preferable measure of urinary albumin 
excretion in spot samples. 
 
4.9.4 Correlation of spot samples with overnight AER 
 
The correlation of spot samples to the “gold standard” overnight AER was determined in the 
first collection from 17 healthy participants (Table 31). The FMV sample always 
demonstrated the strongest correlation with overnight AER. The correlation of ACR was 
generally higher than UAC and A/USG. Our findings are in accordance with the PREVEND 
study which reported a correlation (rs) of ACR from FMV and random samples to the 24 hour 
collection were 0.87 and 0.83 respectively (Witte et al., 2009). 
In our study correlation of ACR in FMV, SMV and random spot samples with timed overnight 
AER was 0.88, 0.54 and 0.59 respectively. Correlation of UAC in FMV, SMV and random spot 
samples with timed overnight AER was 0.84, 0.48 and 0.45 respectively. Correlation of 
A/USG in FMV, SMV and random spot samples with timed overnight AER was 0.87, 0.46 and 
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0.60 respectively. Only reporting a A/USG from a SMV and UAC from a random spot sample 
did not have a significant correlation with overnight AER (A/USG-SMV: Rs=0.46 p=0.062) 
(UAC-Random spot: Rs=0.45 p=0.073) (Table 31). Graphs of the correlation between spot 
sample ACR and overnight AER are presented in Figure 35, Figure 36 and Figure 37.  
 
Another study found that a FMV ACR correlated better than a random sample ACR to a 24 
hour AER (their reference method) (r = 0.803 versus 0.623), however they reported that the 
correlation in both samples was increased using UAC (r = 0.943 and 0.920) (Chavan et al., 
2011). In our results, the correlation of the FMV, SMV and random samples with overnight 
AER was consistently reduced when reporting UAC alone (Table 31). Regardless of reporting 
ACR, UAC or A/USG, the correlation is weaker in the SMV and random samples than in FMV 
samples and is again most likely the result of changes in the concentration of the urine and 
the influence of other factors (e.g. exercise).  
The improvement in correlation Chavan et al. found using UAC in FMV samples, maybe the 
result of the level of albumin excretion they were investigating. They reported a median 24 
hour AER of 228 µg/min, in our study it was 4.11 µg/min [2.48 - 5.76]. Perhaps at those 
higher albumin excretion levels, it is not so important to account for urinary concentration 
but it is imperative when investigating the low levels of albumin excretion, especially when 
screening for microalbuminuria or for the accurate estimation of lower levels of albumin in 
urine which may become important for the future monitoring of individuals given the 
important epidemiological evidence which suggests cardiovascular risk is increased right 
down into the normal range (Rachmani et al., 2000, Gerstein et al., 2001, Hillege et al., 
2002, Dwyer et al., 2012).  
 
 
 
191 
 
4.9.5 Estimating AER in random samples 
 
The Kidney Disease: Improving Global Outcomes (KDIGO) working group, who provide 
reccomendations for clinical guidelines, advocate screening for microalbuminuria using 
random samples, as it provides a more sensitive test (KDIGO, 2013). It is also more 
convenient for patients to provide a urine sample whilst at the GP or in clinic, rather than 
collecting a FMV at home.   
In our study the reduced albumin excretion and better reproducibility in overnight 
collections, or from the first morning void, have been attributed to low levels of physical 
activity and a low, steady blood pressure overnight. Although a random sample might be 
more variable than a FMV, it might be desired as a screening test for microalbuminuria 
because during random testing the kidney will be under more stress. Therefore, a larger 
increase in albumin excretion during the day may indicate a lack of autoregulation or 
impaired autoregulation, demonstrating early abnormal findings in the kidney, increasing 
the diagnostic sensitivity of the test. 
In our study it was demonstrated that the correlation of a random ACR (rs = 0.59, p=0.012) 
to overnight AER was improved to 0.78 (p<0.001) when estimating AER (Table 32). This 
improvement is plotted in Figure 38.  
Regardless of when a spot sample was taken, the correlation of the ACR always improved 
when estimating AER. However the largest improvements were found in samples taken later 
in the day (SMV and random), which may be related to differences in urine concentration 
and variability (Table 29).   
The eAERMDRD equation, which incorporates an additional clinical characteristic (weight) in 
its estimation of creatinine excretion, improved the correlation the most, although previous 
validation work suggested that eAERCKD-EPI was best (Chapter 3). In the previous validation 
work, no spot samples were collected, only a single overnight collection and a much larger 
(n=245) and a more diverse population was tested. Therefore, to determine if estimating 
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AER from a random sample can correlate to an overnight AER, potentially as well as a FMV 
sample, the SUMMIT cohort were tested. 
 
4.9.6 Limitations  
 
The reason for finding a spot collection method to replace timed collections is because 
timed collections are burdensome and are prone to errors which can lead to inaccurate 
results. A fundamental limitation of this study is the uncertainty that the timed collections 
were accurately completed, as is the case for every study utilising timed urine collections. 
Participants were questioned when returning samples to verify that they had completed the 
collection correctly, but 100% compliance cannot be guaranteed. The study could have been 
improved by using para-aminobenzoic acid (PABA) as a marker of 24 hour urine collection 
completeness (Bingham and Cummings, 1983). PABA is taken orally on the day of the 
collection and the recovery of PABA in the urine 24 hours after indicates completeness 
(Jakobsen et al., 2003).  
The mean period (±SD) to complete all three collections was 26.8 days (±12.3). Ideally the 
collections would have been done one after the other, however this wasn’t feasible for the 
participants. Participants were questioned to determine if they deviated from the protocol, 
2/51 collections were repeated due to exercise undertaken and one collection was repeated 
due to an incomplete overnight sample. There may have been more protocol deviations that 
participants did not report, as they were disinclined to repeat the collection.  
All outlying results were investigated by urinalysis. In some cases haemoglobin was present 
which may have interfered with the assay. In one case the presence leucocytes was 
indicated, suggestive of an infection which may influence albumin excretion. Interestingly, 
the largest outlier in the SMV samples might have been the result of it being a very 
concentrated sample (creatinine = 21.6mmol/L) with a UAC of 189 mg/L. This questions the 
suitability of creatinine to account for urinary concentration, especially at the high levels. 
However, the answer is not measuring UAC alone. USG was also measured in this study, but 
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no improvement over ACR was found. However, it may be beneficial to measure in samples 
with a high creatinine concentration. The use of USG requires further research across larger, 
more diverse populations, especially in those with reduced kidney function who would have 
impaired creatinine excretion. 
 
Investigation 2: The relationship of estimating AER from an untimed 
spot using a personalised creatinine excretion rate with an overnight 
AER 
 
194 participants from the SUMMIT study cohort met the inclusion criteria of having a stored 
sample from an overnight urine collection and a random spot sample, both collected on the 
same day (Section 4.7.1) This cohort are older (70 years old ±8) than the first study cohort 
(34 years old [22-47]), with 58% diagnosed with T2DM (Table 33).  
The median [IQR] AER for an overnight collection in this cohort was 7.20 µg/min [4.5 to 
13.1], much higher than the median AER in the cohort of the first study 3.23 µg/min [1.20 - 
3.96] (Table 28). The AER of this second cohort is closer associated with the participants of 
the PREVEND study, who reported a median AER [IQR] of 7.99 µg/min [5.00 to 12.36] (Witte 
et al., 2009). This might be attributed to SUMMIT and PREVEND cohorts testing older aged 
subjects, indicating that albumin excretion increases with age. This is supported by the low 
prevalence of diabetes in the PREVEND cohort (2%). 
In this study, of subjects from the SUMMIT study (n=194), the median values for estimating 
AER using personalised estimates of creatinine excretion, are similar to overnight AER (Table 
334). The interquartile ranges suggest that estimating AER provides higher results, although 
they are not significantly different (p>0.10).  
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4.9.6 Correlation of ACR and estimated AER in random spot samples with timed 
overnight AER in the SUMMIT study. 
 
The correlation of an ACR from a random spot sample to overnight AER was 0.60 (p<0.001) 
(Table 35), which improved to 0.67, 0.69 and 0.67 when estimating AER from the spot 
sample using the MDRD, CKD-EPI and WALSER eCER equations respectively (all p<0.001).  
These results are similar to the findings of the previous study (n=17) (Table 31). The 
previous study also showed that the correlation of random sample ACR improved from 0.59 
(p=0.012) to 0.78 (p<0.001), 0.76 (p<0.001) and 0.74 (p<0.001) when estimating AER from 
spot samples using the MDRD, CKD-EPI and WALSER eCER equations respectively.  
In the previous study (n=17) the MDRD method to estimate albumin excretion had the 
biggest improvement on correlation, whereas in this current study (n=194) the CKD-EPI 
provides the biggest improvement. This demonstrates that no single method of estimating 
an AER from a spot sample is superior, and selection of a method may be dependent of the 
cohort being tested (Chapter 3.3). 
By testing the larger, more diverse, population in the second study (n=194), which includes 
subjects with diabetes (58%), the impact of estimating AER on diagnostic accuracy to 
identify microalbuminuria could be tested. 
 
4.9.7 Diagnostic accuracy of ACR and eAER in a random spot collection and 
correlation with timed overnight AER 
 
From the 194 SUMMIT participants, 27 were identified with persistent microalbuminuria 
(identified using two overnight collections). Therefore, the diagnostic accuracy of the ACR 
and eAERs in a single random sample could be determined. Using clinically recognised 
gender specific cut-offs for microalbuminuria, the ACR in random spot samples had a 
195 
 
sensitivity of 85.2% and a specificity of 92.8%. Sensitivity increased when using the eAER 
equations (maximum of 96.3% using eAERCKD), although specificity was lost (Table 36). 
The positive bias found when comparing eAER with overnight AER may be contributing to 
the increased sensitivity as higher values are being reported (compared to the ACR), so 
more individuals with microalbuminuria are found (Table 34). This is desirable for a 
screening test but comes with a loss in specificity.  
Another method of investigating diagnostic accuracy is to calculate the AUC from a ROC 
analysis. The AUC of each test shows the probability that the test will rank a randomly 
chosen positive sample higher than a random chosen negative sample; where the closer to 1 
to better the test. The AUC and percent of individuals correctly identified (Table 36) were 
almost the same when using ACR and eAER, suggesting that there is not a considerable 
improvement in the overall diagnostic accuracy when estimating AER. However, as the 
sensitivity is increased when reporting eAER, it may be beneficial when screening for 
microalbuminuria.  
The eCERCKD equation had the largest improvement in correlation and diagnostic sensitivity. 
This was also found in our previous validation work (Chapter 3.3), but not in the previous 
study in this chapter (Section 4.4.6), which identified the MDRD equation to improve 
correlation the most between random spot samples with overnight AER in 17 healthy 
individuals.  
Among the eCER equations, the CKD-EPI equation was developed on the largest population 
with the widest range of GFRs, and the equation includes the most clinical characteristics, 
which might be why it is suited to the more diverse population of the SUMMIT cohort. 
However, it incorporates weight that is not readily available routine clinical laboratory 
request notes, limiting its clinical use. The eCERMDRD equation does not utilise weight, just 
age, gender, and ethnicity, and is therefore more clinically applicable. It also improved 
random sample correlations and diagnostic accuracy, but to a lesser degree. This work 
demonstrates the benefit of estimating AER in spot samples and confirms the need for 
further validation.  
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4.9.9 Limitations 
 
An important limitation of this study is the environment in which samples were collected. 
The participants for this study were recruited from the Exeter 10,000 bio-resource of 
individuals interested in hearing about research held by the NIHR Exeter Clinical Research 
Facility. The nature of recruiting by this method can influence study results, as subjects are 
not representative of the general population. In our study we collected a timed overnight 
collection and a random spot sample. The participants were provided with a detailed 
procedure to follow to ensure the sample was collected properly (e.g. no exercise or 
caffeine before providing a sample).  
This is a very controlled environment, and is not representative of collecting samples in 
primary care. The random spot samples were collected during a visit to the research centre, 
where some participants would have been resting in the supine position for over 2 hours 
before providing a sample. In the primary care environment a real random spot sample 
might be provided after walking 30 minutes to the GP surgery. The impact of exercise on 
albumin excretion is investigated in Chapter 6. 
 
4.10 Conclusion 
 
Albumin excretion is significantly lower overnight than during the day. A FMV is the best 
spot sample to investigate the lower levels of albumin excretion; the ACR should be 
reported as it provides the most reproducible results and has the highest correlation with 
the “gold standard” timed overnight AER. However, a random spot sample is clinically more 
desirable and the correlation to overnight AER is improved when estimating AER, although 
there is no improvement in overall diagnostic accuracy to identify individuals with 
microalbuminuria. However, diagnostic sensitivity is increased when reporting eAER, which 
may be beneficial when screening for microalbuminuria. 
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Chapter 5 Storing Urine for the Assessment of Albumin 
Excretion 
 
5.1 Introduction 
 
Studies that have investigated the stability of albumin in frozen stored urine samples have 
had mixed findings. Several studies have demonstrated insignificant changes in urinary 
albumin concentration (UAC) (Collins et al., 1993, Giampietro et al., 1993, Comper et al., 
2004b, Parekh et al., 2007), whilst others have demonstrated significant losses (Elving et al., 
1989, Osberg et al., 1990, Brinkman et al., 2007a, Hara et al., 1994, Marko et al., 2009, 
Erman et al., 1988, Schultz et al., 2000, MacNeil et al., 1991). The strongest agreement 
amongst these studies is that urinary albumin is more stable when stored at -70oC or -80oC 
when compared to -20 oC. 
The disagreement between studies which have investigated the loss of UAC during storage 
can be attributed to different storage temperatures, sample sizes, storage durations, sample 
processing, analytical techniques, study populations and the albumin excretion range 
investigated. Many studies are limited by a low sample size and short storage durations. 
When interpreting the results of storage experiments it is also important to consider the 
inter-assay variability of the assay (if the same assay was used) and also the type of assay.     
 
5.1.1 Impact of analytical method when investigating loss of albumin with 
prolonged frozen storage 
 
In 2007, Brinkman and colleagues carried out a very comprehensive study which not only 
looked at the effect on UAC when storing samples at -20 oC and -80 oC, they also investigated 
the impact of measuring urinary albumin by different methods (Brinkman et al., 2007a). 
Prior to commencing the study another research group led by W. Comper had developed a 
HPLC method for quantifying urinary albumin (Comper et al., 2004a).  Validation 
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experiments carried out by the same research group showed that HPLC produced higher 
results compared to immunoassays and they hypothesised that immune-nonreactive forms 
of urinary albumin were present which immunoassays were unable to quantify (Osicka and 
Comper, 2004).  This theory has been contested by other authors who have demonstrated 
that the co-elution of other proteins causes the higher HPLC results (Sviridov et al., 2008). 
Brinkman and colleagues tested Comper’s proposed hypothesis that albumin loses 
immunogenicity and is therefore underestimated by immunoassays. It is conceivable that 
prolonged freezing reduces immunoreactivity and therefore the loss would be greater when 
using immunoassays, compared to HPLC, to measure albumin. To test this, urine samples 
from the PREVEND study (general population) had urinary albumin quantified by 
immunonephelometry and HPLC within 5 days of being collected. The fresh samples were 
then aliquoted in to polypropylene vials for assessment after storage for 2, 4, 12 months at -
20 oC (n=295) and after 12 months at -80 oC (n=224). The results are summarised in Figure 
39.  
 
Figure 39 Percent change in urinary albumin concentration in samples stored at -20 and -
80 assessed by immunonephelometry and HPLC from the PREVEND study. Data are 
presented as mean (SD) percentage difference in urinary albumin concentration (Brinkman 
et al., 2007a). 
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The results from Brinkman’s study show that more urinary albumin is lost when stored at -
20 oC compared to -80 oC, regardless of the method used to measure it. The results also 
indicate that more albumin is lost when using the HPLC method. This contradicts Comper’s 
theory and supports the possibility that other proteins are being measured, as well as 
albumin, by the HPLC method. It is the loss of these other proteins which causes the larger 
percentage difference (Sviridov et al., 2008). These results support other studies which find 
immunoassays a suitable method to measure urinary albumin and that urine samples should 
be kept at -80 oC for prolonged storage (Seegmiller et al., 2009b, Schultz et al., 2000).    
 
5.1.2 Sample processing prior to analysis 
 
Urine samples collected in cohort studies are often kept at -20 oC for variable times before 
analysis, which could jeopardise the accuracy of results. In 2005, Brinkman and colleagues 
investigated the loss of albumin in samples stored at -20 oC for up to 24 months (Brinkman 
et al., 2005). The samples were divided into 3 groups, the first group (n=600) were not 
mixed prior to analysis, the second (n=596) underwent 3 to 4 hand inversions and the third 
group (n=689) were vortex-mixed for 5 to 10 seconds. After 3months storage, there was a 
considerably larger change in UAC in the unmixed samples than in the samples which were 
inverted or vortex mixed (mean ±SD): -34.9% (±28.6) vs -5.3% (±30.6) and -2.6 % (±27.5), 
respectively, p<0.001). The inverted and vortex mixed samples were then measured again 
after 18 months storage, and showed a significant loss in UAC (-23.7% (±26.2) and -26.1% 
(±24.7), respectively).  Post hoc analysis showed there was no difference between the two 
mixed groups and that after 8 months of storage, the difference in UAC had stabilised to 
around -25% to -30% (Brinkman et al., 2005).  
The results of this study from the PREVEND cohort suggest that the loss in albumin 
concentration is highly variable between samples, represented by a large standard deviation 
in the loss of UAC. In their analysis, the mean loss of UAC has been investigated; however, 
with such large standard deviations some samples would have lost 30% of their UAC after 8 
months storage, whereas some samples would have been stable with 0% loss in UAC. 
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Properties such as pH and bacterial contamination (discussed in Section 5.1.4) might be able 
to help explain why some samples have a decline in UAC and why some don’t. This is 
investigated further in our study. 
Brinkman and colleagues also reported that the maximum loss of UAC, -28% (±33), was seen 
in the 10-20mg/L category (categories determined from measurement with fresh samples). 
Samples in the highest category (200-500mg/L) had a significantly lower difference, -9.2% 
(±17.4), compared to the other groups. This study not only demonstrated the importance of 
mixing samples prior to analysis, they also showed that the difference in UAC over time 
varies between concentration ranges. The limitation of this study, and others, is they have 
used assays which cannot measure the low concentrations of urinary albumin, therefore the 
effect of storage in the normoalbuminuria range is not fully understood. 
In 1993, a study by Collins and colleagues reported that there was no significant difference 
in UAC after storage at 20 oC, 4 oC,  -20 oC and -40 oC for 7 days (Collins et al., 1993). It is 
important to know this, as it can take several days for samples to be analysed or stored, 
especially in epidemiological studies. The samples (n=84) were from individuals with DM, 
who had a range of albumin excretion. The authors also reported no significant difference in 
UAC between samples which were centrifuged or not prior to analysis, and that there was 
no effect of a freeze-thaw cycles on UAC. Collins and colleagues also investigated the 
change in UAC in different types of storage containers at -20 oC. 26 urine samples from 
patients with DM were aliquoted into polypropylene, polystyrene and borosilicate glass 
tubes with and without gelatine added. There was no significant difference in UAC (p>0.97) 
in any of the storage tube types when stored at -20 oC for either one week or one month. 
However, after 1 month of storage the average change in UAC was -7% which was reduced 
to -4% in the tubes which had gelatine added to reduce protein absorption. It is conceivable 
that the adsorption of albumin to storage containers could contribute to the loss of UAC 
over time at -20 oC. Since Collin’s study in 1993, storage tubes that are specifically designed 
to reduce the adsorption of proteins have become available and their ability to prevent UAC 
loss is investigated in this chapter.  
 
201 
 
 
5.1.3 Mechanisms of urinary albumin concentration decline during freezing 
 
The loss of UAC as a result of protein adsorption to storage containers is one possibility for 
the decline of UAC during freezing. However, further work is required beyond the Collins 
study due to its small sample size and short storage duration (Collins et al., 1993). The exact 
mechanism that results in the decline of UAC during freezing is still unknown as is the cause 
of variation in the loss of UAC among samples (reflected by large standard deviations of UAC 
loss), especially as some samples are unaffected. Some authors suggest that albumin is 
trapped in precipitate, the result of an alteration in pH that occurs during freezing 
(Townsend, 1986a). Other authors have suggested that bacterial contamination may cause a 
loss in UAC (Kania et al., 2010) whilst others have demonstrated that the loss of UAC is 
correlated to pH (Brinkman et al., 2007b). These are described in more detail below.  
 
5.1.4 Urinary proteases 
 
The loss of urinary albumin as a result of proteases was investigated by Kania and colleagues 
in 2010. Using sodium dodecyl sulphate (to denature proteins) and polyacrylamide gel 
electrophoresis (to separate the proteins) (SDS-PAGE), they demonstrated that albumin 
remained intact when stored for 12 months at -70oC but was degraded at -20oC (Kania et al., 
2010). This was confirmed by using mass spectrometry to analyse the fragments. The 
degradation of UAC occurred in 11/40 samples when stored at -20 oC. They also carried out 
in-vitro experiments where the pH of urine samples was lowered which induced rapid 
degradation of endogenous and exogenous albumin. The pattern of albumin fragments was 
similar to those produced by pepsin digestion and degradation was completely inhibited in 
samples with pepstatin (protease inhibitor) added. However, samples with leupeptin 
(protease inhibitor) added (as well as lowered pH) showed no inhibition from proteases and 
the albumin was degraded. This suggests the urinary proteases which degrade albumin may 
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belong to the pepstatin-sensitive protease family. Other studies have also reported 
improved protein stability with the addition of protease inhibitors when storing urine 
samples (Havanapan and Thongboonkerd, 2009, Zhou et al., 2006).  
Kania and colleagues’ results suggest that urinary proteases cleave albumin but the identity 
of these proteases has not yet been revealed. The proteases may arise from several sources:  
glomerular filtrate, urothelial secretion and bacterial contamination (Deng et al., 2001). 
Kania and colleagues demonstrated that that pepstatin can prevent degradation in-vitro, 
although, there are no studies to date which have investigated if pepstatin can prevent the 
loss of UAC in patient samples during long term storage. This is investigated in this chapter.  
Bacterial contamination is a possible source of proteases. There is a wide range of bacteria 
that can contaminate urine samples, mostly from normal skin flora. Some bacteria secrete 
proteases which acts as an exotoxin, an example of a virulence factor in bacterial 
pathogenesis (Frees et al., 2013). The quantity and type of bacteria present in urine varies 
between people and this variability could explain the difference in the samples which lose 
UAC during prolonged frozen storage. Bacterial contamination is investigated in this 
chapter, to determine if there is a link with the samples which lose UAC after storage at -20 
oC.    
 
5.1.5 Urine pH  
 
There are few studies that have investigated pH as a determinant of UAC decline associated 
with freezing. A study in 1988 reported no association (Erman et al., 1988), although this 
was only after 7 days storage at -20 oC. More recent studies have shown it takes longer than 
1 week for UAC to decline at -20 oC (Collins et al., 1993, Brinkman et al., 2005). In 2007, 
Brinkman and colleagues showed urine pH was associated with a decline of UAC in samples 
stored at -20 oC (Brinkman et al., 2007b). Urine samples from the PREVEND study (n=230, 
UAC>5 & <200mg/L) had UAC determined by immunonephelometry and had pH measured 
by dipstick analysis and were then frozen at -20 oC. UAC was measured again after 4 and 12 
months storage. Samples were thawed and mixed by hand inversions prior to analysis. The 
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results of the analysis after 12 months are shown at Figure 40. The largest decline in UAC 
occurs at the lowest pH and there was a significant trend for the magnitude of loss in 
relation to pH (p<0.001). 
 
Figure 40 Percent change in urinary albumin concentration after 12 months of storage at -
20 oC according to pH in the PREVEND study. The boxes indicated lower and upper quartiles 
and the central lines are medians. The whiskers represent 95% confidence intervals. P< 0.001 
for trend across pH levels (Brinkman et al., 2007b). 
 
An earlier study investigated neutralising the pH in 38 samples from patients with DM prior 
to storage at -20 oC for 8 weeks (Townsend et al., 1988) . Although they had low numbers 
and a short storage period, they reported no significant decrease after adjustment of pH, 
while UAC decreased significantly (p<0.05) in unadjusted samples, of which 8 samples had a 
decrease of 23% to 91% of their original concentration. It is not clear how UAC changed in 
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the remaining 30 samples, but this work also reflects the variation in UAC loss between 
samples stored unadjusted at -20 oC. 
More recently, Brinkman’s research group alkalised urine samples (n=90, from patients with 
DM) to pH>8.0 and demonstrated it prevents UAC decline during storage at -20oC after one 
year (Lambers Heerspink et al., 2009). The group speculated that the loss at low pH could be 
associated to the relatively low iso-electric point of albumin (4.7), with less aggregation at a 
higher pH resulting in less albumin being trapped in precipitate. They also suggested that 
alkalinisation prevents conformational changes that occur to albumin during freezing, 
improving antibody binding during quantitative immuno-analysis. Their final conjecture was 
that urinary albumin is being hydrolysed by bacterial proteases from contaminated samples 
and that alkalisation may inhibit the enzyme activity.  
It is beneficial to combine the methods used by the Brinkman and Kania research groups to 
provide insight into what effect alkalisation has on urinary albumin; whether it prevents 
fragmentation or if urinary pH influences the performance of the assay. The effect of pH and 
alkalising samples on UAC after frozen storage will be investigated in this chapter.  
 
5.1.6 Summary 
 
Previous studies have reported the effect of prolonged frozen storage on UAC, although 
they have not reported the effect on creatinine and the ACR. It is important to know how 
UAC changes for timed collections, but the stability of creatinine must be considered when 
storing spot samples for ACR assessment. 
Several approaches to reduce the loss of UAC when stored at -20 oC have been previously 
tested; alkalisation, protease inhibitors and using specific sample containers. Other studies 
have shown the importance of mixing prior to analysis, and have confirmed immunoassays 
are acceptable methods to quantify UAC in stored samples. All these findings are applied to 
the urine storage study carried out in this chapter. 
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Although previous studies report that UAC is stable at -80 oC, they have all used assays 
which cannot measure the low concentrations of urinary albumin. Using the validated ELISA 
described in Chapter 2, the effect of frozen storage in the extended low albumin excretion 
range can now be fully explored. Using additives to prevent a loss in UAC will also provide 
information on the mechanism of UAC decline. 
5.2 Aim 
 
To identify the optimal long-term frozen storage conditions to preserve urinary albumin and 
creatinine concentrations for the assessment of albumin excretion rate and ACR.  
 
5.2.1 Objectives 
 
1. To determine the effect of multiple freeze thaw cycles on albumin and creatinine 
concentrations and the assessment of ACR. 
 
2. To identify the optimal storage conditions to preserve urinary albumin and 
creatinine levels and the assessment of ACR over 12 months.  
 
3. To investigate the effect of storage duration on albumin and creatinine 
concentrations and the assessment of ACR in samples stored at -80oC. 
 
Each of these objectives is separated into individual investigations composed of separate 
methods, results and a discussion at the end of each investigation.  
An overall summary all the investigations is presented at the end of the chapter with a 
conclusion.  
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5.3 The effect of multiple freeze thaw cycles on albumin and 
creatinine concentrations and the assessment of ACR. 
 
 
5.3.1 Method 
 
20 patient urine samples which had been sent to the RD&E Blood Science department for 
routine ACR analysis were selected. All samples were received on the same day, and they 
were selected to enable a wide range of albumin concentrations to be tested (3-255mg/L). 
Six aliquots were taken from each sample. One aliquot remained at room temperature, and 
the others underwent a different number of freeze thaw cycles before analysis (up to 5 
cycles). Samples were frozen to -80oC on each cycle and remained frozen for 30 minutes. 
Samples were defrosted to room temperature before being frozen again (for at least 30 
minutes) if testing another freeze thaw cycle. 
Prior to analysis, samples were thoroughly defrosted and underwent 4 hand inversions to 
mix them. Albumin was measured by the routine COBAS method and creatinine was 
quantified using the routine Jaffe method, with all samples measured in the same run.   
 
5.3.1.1 Statistical analysis 
 
Data are presented as mean (±SD) and median [IQR].  Normality of the data was tested 
using the Shapiro-Wilkes test. For not normally distributed data, Wilcoxon sign-rank test 
was used to determine the difference between freeze thawed samples and fresh samples, 
p<0.05 was considered as a significant difference.  
The change of albumin/creatinine/ACR after each freeze thaw is presented as percent 
change from baseline, reporting the mean percent change and confidence intervals. 
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5.3.2 Results 
Albumin was not influenced by repeated freeze-thaw cycles (Table 37), whilst there was a 
small and significant decrease in creatinine levels with freeze-thaw cycles (Table 38) that 
had no effect on ACR (Table 39). Change from fresh sample measurements are presented in 
Figure 41.  
Number of 
freeze thaw 
cycles 
Mean Albumin 
mg/L 
Median Albumin 
mg/L 
Mean 
difference with 
fresh sample 
(%) 
Wilcoxon sign-
rank test  
(p) 
0 58.9 ± 73.5 21.0 [6.6 to 95.3]   
1 58.9 ± 74.3 21.0 [6.4 to 95.9] -0.56 ±6.0 0.21 
2 58.6 ± 74.1 19.9 [6.2 to 96.8] -2.7 ± 4.1 0.21 
3 58.6 ± 73.8 20.2 [6.5 to 96.0] -2.7 ± 3.7 0.25 
4 58.8 ± 74.1 20.3 [6.3 to 95.1] -2.1 ± 3.4 0.41 
5 59.1 ± 73.8 21.5 [6.8 to 97.2] -0.0 ± 3.6 0.97 
Table 37 Impact of repeated freeze thaw cycles on albumin concentration. *significant 
difference between freeze thawed samples and fresh samples (0 freeze thaws). 
Number of 
freeze thaw 
cycles 
Mean 
Creatinine 
mmol/L 
Median 
creatinine 
mmol/L 
Mean 
difference with 
fresh sample 
(%) 
Wilcoxon sign-
rank test (p) 
0 8.6 ± 4.2 7.8 [5.7 to 12.7]   
1 8.6 ± 4.1 7.7 [5.7 to 12.7] -0.6 ± 1.4 0.02* 
2 8.6 ± 4.2 7.7 [5.7 to 12.6] -0.2 ± 1.3 0.74 
3 8.5 ± 4.2 7.6 [5.7 to 12.8] -1.7 ± 1.6 0.001* 
4 8.5 ± 4.1 7.7 [5.6 to 12.6] -1.2 ± 1.5 0.004* 
5 8.6 ± 4.1 7.7 [5.6 to 12.9] -1.0 ± 1.5 0.02* 
Table 38 Impact of repeated freeze thaw cycles on creatinine concentration. *significant 
difference between freeze thawed samples and fresh samples (0 freeze thaws). 
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Number of 
freeze thaw 
cycles 
Mean ACR 
mg/mmol 
Median ACR 
mg/mmol 
Mean 
difference with 
fresh sample 
(%) 
Wilcoxon sign-
rank test (p) 
0 7.9 ±10.3 2.7 [1.0 to 9.7]   
1 7.9 ±10.4 2.7 [1.0 to 9.8] 0.1 ± 6.2 0.59 
2 7.9 ±10.7 2.6 [0.9 to 9.3] -2.5 ± 4.4 0.35 
3 8.0 ±10.6 2.6 [0.9 to 9.6] -1.0 ± 4.3 0.98 
4 7.9 ±10.6 2.6 [0.9 to 9.9] -0.9 ± 4.0 0.68 
5 8.0 ±10.6 2.7 [1.0 to 9.9] 1.0 ± 4.3 0.26 
Table 39 Impact of repeated freeze thaw cycles on ACR. *significant difference between 
freeze thawed samples and fresh samples (0 freeze thaws). 
 
 
Figure 41 Percentage change of albumin, creatinine and ACR by number of freeze thaw 
cycles. Error bars represent a 95% confidence interval around the mean change from 
measured fresh. 
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5.3.3 Discussion 
 
The freeze thaw experiment demonstrated that there is no significant difference in albumin 
concentration as a result of freeze thawing (Table 37), although creatinine is significantly 
reduced (Table 38). Although creatinine is lost during freeze thawing process, the actual loss 
is very small (-1.7 ± 1.6 %) and it had no effect on the ACR (Table 39). The reduction of 
creatinine was not influenced by the number of freeze thaw cycles. The small loss of 
creatinine has minimal impact on the ACR (Figure 41). 
This study was not able to assess the effect of freeze thaws at the lowest albumin 
concentration, as the routine COBAS method was used. However, there was no significant 
difference in albumin or ACR across the albumin excretion range tested in this study. 
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5.4 Optimal storage conditions to preserve urinary albumin and 
creatinine concentrations and the assessment of ACR over 12 months. 
 
 
5.4.1 Objectives 
 
 
1. To determine if there is a difference in albumin and creatinine concentrations and 
the assessment of ACR after 12 months storage at -20oC and -80 oC. 
 
2. To determine how albumin and creatinine levels and the assessment of ACR change 
over 12 months when stored at -20 oC and -80 oC. 
 
3. To investigate if additives and low protein binding tubes prevent any loss of albumin, 
creatinine and ACR after 12 months storage at -20 oC and -80 oC? 
 
5.4.2 Method 
 
20 random spot samples and 10 timed samples were collected from participants of the urine 
collection study (Chapter 4, Section 4.3.1). Each sample was divided into 5 portions. Each 
portion received a different treatment: 
1. No additives 
2. Alkalisation 
3. Boric acid 
4. Protease inhibitor 
5. Low protein binding tubes 
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5.4.2.1 Sample treatments 
 
1. No additives: 
Samples were divided into 400µl aliquots. The storage tubes used were 2ml polypropylene 
micro tubes (Sarstedt product number: 72.609.001, Sarstedt AG & Co, Nümbrecht, 
Germany). These tubes were used to store all samples from all the treatments, except for 
the low protein binding tubes used in treatment 5. 
 
2. Alkalisation: 
pH was measured by a portable pH tester (Hanna instruments product number: HI-98127, 
Hannah Instruments, Rhode Island, USA). 15µl of NaOH 1M (Sigma Aldrich product number: 
38212, Sigma Aldrich, Missouri, USA) was added to 10ml of sample. The sample was gentle 
mixed by four hand inversions and then pH was measured again to ensure pH ≥ 8.  
 
3. Boric acid: 
Samples were added to containers precoated with boric acid (Sarstedt product number: 
51.9923.820). Boric acid maintains the microbiological quality of a sample by preventing the 
overgrowth of organisms. Urine samples sent to the microbiology laboratory for routine 
analysis are transported in boric acid. The samples were gently mixed before being 
aliquoted (into the same tubes used for treatments 1, 2 and 4) and stored. An aliquot was 
also sent to the RD&E hospital microbiology laboratory for the following analysis: 
 
1) Urinalysis: An inverted microscope was used to identify and semi quantify; epithelial 
cells, casts, red blood cells and leucocytes  
 
2) Culture: Urine samples are routinely cultured on specialised mediums which 
specifically enable pathogens which cause urinary tract infections to grow. However, 
in this investigation any bacterial growth is of interest as it might be related to a loss 
of UAC during storage. Therefore the follow media was used to enable the growth of 
any organisms in the samples: 
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 Horse blood agar (grows majority of aerobic bacteria) 
 Gram + selective blood agar (prevents coliform growth which can outcompete 
other organisms) 
 Fastidious anaerobic agar +  neomycin (isolates anaerobic bacteria) 
 Dextrose agar (isolates yeasts & fungi).   
Organisms were identified using routine biochemical tests and confirmed using matrix-
assisted laser desorption/ionization time-of-flight analysis (MALDI-TOF). 
 
4. Protease inhibitor: 
Kania and colleagues demonstrated that urinary proteases which degrade albumin may 
belong to the pepstatin-sensitive protease family (Kania et al., 2010). Therefore, pepstatin 
was added to the samples in this study to prevent degradation (Sigma Aldrich product 
number: P5318, Sigma Aldrich, Missouri, USA). This is the same product and protocol used 
in the study carried out by Kania and colleagues (Kania et al., 2010). 
1mg pepstatin was dissolved in 1ml of a 10% acetic acid: 90% methanol solution (Sigma 
Aldrich product numbers: 33209 and 32213 respectively, Sigma Aldrich, Missouri, USA). A 
1:10 dilution was made using deionised water to make a working solution of 0.1mg/ml. The 
manufacturer states the effective concentration of pepstatin is 1 µg/ml. Therefore, 100 µl of 
the working solution was added to 9,900 µl of urine samples. 
5. Low protein binding tubes: 
400µl of sample was aliquoted into 1.5ml low protein binding micro tubes (Sarstedt product 
number: 72.706.600).  
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5.4.2.2 Sample processing and analysis 
 
After the samples had undergone the different treatments, 400 µl aliquots were made and 
stored at either -20 oC or -80 oC. Baseline measurement was taken from a fresh aliquot from 
the sample which underwent no treatment.  
Albumin was measured by the Fitzgerald ELISA (Fitzgerald Industries International, North 
Acton, MA, USA) and creatinine measured by the routine Jaffe method (Roche Diagnostics 
Ltd., Burgess Hill, UK). Dip stick analysis was carried out using the Cobas Combur10 Test 
(Roche Diagnostics Ltd., Burgess Hill, UK); with pH confirmed by a hand held meter (Hannah 
Instruments, Rhode Island, USA). 
The samples were removed from storage and analysed after 6, 9, 11 and 12 months. Prior to 
analysis samples were thoroughly thawed and mixed by 4 hand inversions. When 
quantifying albumin, each sample was analysed in the same microwell location on the ELISA 
plate at each time point, to reduce inter-assay variability. 
 
5.4.2.3 Statistical analysis 
 
Normality of the data was tested using the Shapiro-Wilkes test. The median [IQR] is 
reported for not normally distributed. The difference between the values from stored 
samples with baseline is reported as the mean (SD) and median [IQR], for both actual 
difference and percent difference. For not normally distributed data, Wilcoxon sign-rank 
test was used to determine the difference is significant (p<0.05).  
Box and whisker plots are used to graphical demonstrate the data. The horizontal line inside 
the box represents the median, the edges of the box are the upper and lower interquartile 
and the whiskers represent the minimum and maximum values, with outlying results 
individually plotted. 
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Two point line graphs are used to show the change of individual samples. Bland Altman 
difference plots are used to show the difference between samples measured after being 
stored with the baseline value, plotted against the original concentration. The mean 
difference is plotted (with 95% confidence intervals), and the shaded area shows the region 
of difference which can be explained by inter-assay variability. Bland Altman plots are used 
to show actual difference and percent difference. 
The Fitzgerald assay was used to quantify albumin.  It has an inter-assay variability of 18.3% 
(Chapter 2). The assay used to measure creatinine was the routine Jaffe method, which has 
an inter-assay variability of 2.35% (Chapter 3). The variability of ACR is 18.45%, and was 
calculated by combining the variability of both assays, using the following equation: 
 
Total variation CV =          (Albumin CV2 + Creatinine CV2) 
                     
 
The change of albumin/creatinine/ACR overtime is presented as a percent of baseline which 
reports the mean percent change and confidence intervals. At the 9 month time point, the 
quality control values for the albumin assay were below the acceptable limit and therefore 
have been excluded from the analysis. 
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5.4.3 Results 
 
5.4.3.1 Objective 1  
To determine if there is a difference in albumin and creatinine concentrations and the 
assessment of ACR after 12 months storage at -20oC and -80 oC. 
5.4.3.1.1 Albumin  
 
There is a significant loss of urinary albumin when stored at -20oC for 12 months (p<0.0001), 
however there is no significant difference when stored at -80 oC (p=0.06) (Figure 42, Table 
40). The mean percent difference when stored at -20oC was -36 ±33.5 % whereas at -80 oC it 
was -2.7 ±13.2% (Table 40). The change in UAC when stored at -80 oC compared to -20 oC 
can be seen when grouping the samples together in Figure 42 or individually in Figure 43. 
 
Figure 42 Box and whisker plots to show the distribution of urinary albumin concentration 
from 30 samples at baseline (measured fresh)  and after 12 months storage at -20oC and -
80 oC. The horizontal line inside the box represents the median, the edges of the box are the 
upper and lower interquartile and the whiskers represent the minimum and maximum 
values, with outlying results individually plotted. There is a significant loss of urinary albumin 
when stored at -20oC for 12 months (p<0.0001), however there is no significant difference 
when stored at -80 oC (p=0.06)
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 Baseline 
Albumin 
concentration 
 (mg/L) 
12 months 
Albumin 
concentration 
 (mg/L) 
Difference in albumin 
concentration 
Percent difference in albumin 
concentration Wilcoxon 
p 
Number of samples  
with reduced UAC   Median 
(mg/L) 
Mean 
(mg/L) 
Median 
(%) 
Mean 
(%) 
-20 
2.7 
[1.7 to 6.3] 
1.7 
[0.9 to 2.3] 
-0.92 
[-2.71 to -0.27] 
-1.86 
±2.21 
-24.8 
[-64.1 to -10.0] 
-36.9 
±33.5 
<0.001 
27/30  
(90%) 
-80 
2.7 
[1.8 to 5.4] 
-0.14 
[-0.43 to 0.09] 
-0.26  
± 0.60 
-3.5 
[-15.4 to 5.9] 
-2.7 
± 13.2 
0.060 
18/30  
(60%) 
Table 40 Baseline and repeated urinary albumin concentration for 30 samples stored at -20oC and -80oC for 12 months. The actual and percentage 
difference at each storage temperature is reported. 
 
Figure 43 Change in urinary albumin concentration in 30 individual samples after 12 months storage at A: -20oC, B: -80oC. 
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Bland Altman plots show the difference (Figure 44) and percent difference (Figure 45) in UAC after storage for 12 months at -20 oC and -80oC. 
 
                 
Figure 44 Bland Altman plots to show the difference in UAC when stored at A: -20oC, B: -80 oC, after 12 months storage. The shaded orange area 
demonstrates the inter-assay variability of the Fitzgerald assay. The green line represents the mean difference in UAC with the 95% confidence intervals 
indicated with red lines from 30 samples. Mean (±SD) difference in UAC was = -1.86 ±2.21 mg/L when stored a t -20oC (A), and -0.26 ±0.60 mg/L at -80 oC (B). 
A B 
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Figure 45 Percent different Bland Altman plots to show the proportional difference in UAC when stored at A: -20oC, B: -80 oC, after 12 months storage. The 
shaded orange area demonstrates the inter-assay variability of the Fitzgerald assay. The green line represents the mean percent difference in UAC with the 
95% confidence intervals indicated with red lines from 30 samples. Mean (±SD) percent difference in UAC was = -36.9 ±33.5 % when stored a t -20oC (A), and -
2.7± 13.2 % at -80oC (B). 
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5.4.3.1.2 Creatinine 
 
Urinary creatinine concentration was significantly different after 12 months storage at both -20 oC (p<0.0001) and -80 oC (p=0.0001) (Table 41). The mean 
percent difference for samples stored at -20 oC was -4.3 ±4.7 % and at -80 oC it was -3.5 ±4.3 %. The actual difference and percentage difference is significantly 
larger when stored at -20 oC compared to -80 oC, p=0.002 and p=0.04 respectively.  
The change in creatinine concentration when stored at -80 oC compared to -20 oC can be for each sample in Figure 46. Bland Altman plots show the difference 
(Figure 47) and percent difference (Figure 48) in creatinine concentration after storage for 12 months at -20 oC and -80oC. 
 
 
 
 
 
 
 
Table 41 Baseline and repeated urinary creatinine concentration for 30 samples stored at -20oC and -80oC for 12 months. The actual and percentage 
difference at each storage temperature is reported. 
 
Baseline 
creatinine 
concentration 
(mmol/L) 
12 months 
creatinine 
concentration 
(mmol/L) 
Difference in creatinine 
concentration 
Percent difference in 
creatinine concentration Wilcoxon 
p 
Number of 
samples with 
reduced 
creatinine  
 Median 
(mmol/L) 
Mean 
(mmol/L) 
Median 
(%) 
Mean 
(%) 
-20 
5.9 
[1.9 to 9.9] 
5.55 
[1.9 to 9.2] 
-0.41 
[-0.60 to -0.08] 
-0.42 
± 0.46 
-6.2 
[-7.6 to -2.7] 
-4.3 
± 4.7 
<0.0001 24/30 
-80 
5.7 
[2.0 to 9.3] 
-0.27 
[-0.45 to -0.02] 
-0.33 
± 0.41 
-4.0 
[-6.2 to -0.9] 
-3.5 
± 4.3 
0.0001 23/30 
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Figure 46 Change in urinary creatinine concentration in 30 individual samples after 12 months storage at A: -20oC, B: -80oC. 
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Figure 47 Bland Altman plots to show the difference in creatinine concentration when stored at A: -20oC, B: -80 oC, after 12 months storage. The shaded 
orange area demonstrates the inter-assay variability of the Jaffe method. The green line represents the mean difference in creatinine concentration with the 
95% confidence intervals indicated with red lines of 30 samples. Mean (±SD) difference in creatinine concentration was = -0.42 ± 0.46mmol/L when stored a t -
20oC (A), and -0.33 ± 0.41 mmol/L at -80 oC (B).            
A B 
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Figure 48  Bland Altman plots to show the percent difference in creatinine concentration when stored at A: -20oC, B: -80 oC, after 12 
months storage. The shaded orange area demonstrates the inter-assay variability of the Jaffe method. The green line represents the 
mean percent difference in creatinine concentration with the 95% confidence intervals indicated with red lines of 30 samples. Mean (±SD) 
percent difference in creatinine concentration was = -4.3 ± 4.7% when stored a t -20oC (A), and -3.5 ± 4.3% at -80 oC (B). 
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5.4.3.1.3 ACR 
 
There is a significant loss in ACR when stored at -20oC for 12 months (p<0.0001), although there is no significant difference when stored at -80 oC (p=0.91) 
(Table 42). The mean percentage difference when stored at -20oC was -34.3 ±34.6% whereas at -80 oC it was 1.1 ±14.6% (Table 42).  
 
The change in ACR when stored at -80 oC compared to -20 oC is visualised in Figure 49. Bland Altman plots show the difference (Figure 50) and percent 
difference (Figure 51) in ACR after storage for 12 months at -20 oC and -80oC. 
 
 
 Baseline 
ACR 
(mg/mmol) 
12 months 
ACR 
(mg/mmol) 
Difference in ACR Percent difference in ACR 
Wilcoxon 
p 
Number of 
samples with 
reduced ACR 
 Median 
(mg/mmol) 
Mean 
(mg/mmol) 
Median 
(%) 
Mean 
(%) 
-20 
0.52 
[0.45 to 0.80] 
0.38 
[0.20 to 0.63] 
-0.16 
[-0.30 to -0.06] 
-0.21 
± 0.23 
-23.9 
[-61.6 to -12.3] 
-34.3 
± 34.6 
<0.001 26/30 
-80 
0.54 
[0.42 to 0.84] 
0.001 
[-0.07 to 0.07] 
0.002 
± 0.12 
-0.21 
[-12.6 to 12.7] 
1.1 
± 14.6 
0.91 16/30 
Table 42 Baseline and repeated ACR for 30 samples stored at -20oC and -80oC for 12 months. The actual and percentage difference at each storage 
temperature is reported. 
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Figure 49 Box and whisker plots to show the distribution of ACR from 30 samples at baseline and after 12 months storage at -20oC and -80 oC. The 
horizontal line inside the box represents the median, the edges of the box are the upper and lower interquartile and the whiskers represent the minimum and 
maximum values, with outlying results individually plotted. There is a significant loss in ACR when stored at -20oC for 12 months (p<0.0001), although there is 
no significant difference when stored at -80 oC (p=0.91) 
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Figure 50 Bland Altman plots to show the difference in ACR when stored at A: -20oC, B: -80 oC, after 12 months storage. The shaded orange area 
demonstrates the inter-assay variability of the albumin and creatinine assays. The green line represents the mean difference in ACR with the 95% confidence 
intervals indicated with red lines of 30 samples. Mean (±SD) difference in ACR was = -0.21 ±0.23 mg/mmol/L when stored a t -20oC (A), and -0.002 ±0.12 
mg/mmol/L at -80oC (B). 
A B 
D 
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Figure 51 Bland Altman plots to show the percent difference in ACR when stored at A: -20oC, B: -80oC, after 12 months storage. The shaded orange area 
demonstrates the inter-assay variability of the albumin and creatinine assays. The green line represents the mean percent difference in ACR with the 95% 
confidence intervals indicated with red lines of 30 samples. Mean (±SD) percent difference in ACR was -34.3 ±34.6% when stored a t -20oC (A), and 1.1 ± 14.6% 
at -80oC (B). 
A B 
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5.4.3.2 Objective 2  
 
To determine how albumin and creatinine concentrations and the assessment of ACR 
change over 12 months when stored at -20 oC and -80 oC. 
 
5.4.3.2.1 Albumin 
 
The change in UAC over 12 months is shown as the mean percentage of baseline 
measurement in Figure 52. The decline in UAC when stored at -20 oC appears to stabilise 
after six months with around 40% of UAC lost. UAC remains stable at -80 oC over 12 months. 
 
Figure 52 Change of urinary albumin concentration in 30 samples over 12 months when 
stored at -20oC and -80oC. The left Y-axis shows the percent of baseline UAC at each time 
point, reported as the mean and 95% confidence intervals. The right Y-axis is the UAC to 
show the quality control measurements (green lines). The shaded region shows the percent 
difference which can be attributed to inter-assay variation. Data recorded at 9 months is not 
included as QC results were outside the acceptable limits. 
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5.4.3.2.2 Creatinine 
 
The change in creatinine over 12 months is shown in Figure 53. It appears that creatinine is 
increasingly lost as time increases, regardless of storage temperature, however this loss is 
very small after 12 months (Section 5.4.3.1.2). 
 
 
Figure 53 Change of urinary creatinine concentration in 30 samples over 12 months when 
stored at -20oC and -80oC. Percent of baseline creatinine at each time point is reported as 
the mean and 95% confidence intervals. The shaded region shows the percent difference 
which can be attributed to inter-assay variation.  
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5.4.3.2.3 ACR 
 
The change in ACR over 12 months is shown as the mean percentage of baseline 
measurement in Figure 54. The decline in ACR follows the pattern of urinary albumin. ACR 
loss in samples stored at -20 oC whereas ACR remains stable at -80 oC over 12 months. 
 
 
Figure 54 Change of ACR in 30 samples over 12 months when stored at -20oC and -80oC. 
Percent of baseline ACR at each time point is reported as the mean and 95% confidence 
intervals. The shaded region shows the percent difference which can be attributed to inter-
assay variation.  
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5.4.3.3 Objective 3  
 
Investigate if additives or low protein binding tubes prevent any loss of albumin, creatinine 
and ACR after 12 months storage at -20 oC and -80 oC 
5.4.3.3.1 Albumin 
 
The impact different treatments have on preventing the loss of albumin concentration is 
visualised in Figure 55. Alkalisation marginally reduced the loss in UAC in samples stored at -
20oC from -36.9 ±33.5% (with no additives) to -29.2 ±30.2%, but still it was significantly 
different to when UAC was measured fresh (p<0.001) (Table 43). Storing samples at -20oC 
with boric acid or protease inhibitor or in low protein binding tubes did not prevent the loss 
of UAC (p values <0.001). 
 
Figure 55 Difference in urinary albumin concentration in 30 samples which have 
undergone different treatments prior to being stored at -20oC and -80oC for 12 months. 
The shaded region shows the percent difference which can be attributed to inter-assay 
variation. Each of the 30 samples had five aliquots taken, each to undergo a different 
treatment. The mean UAC (95% confidence intervals) of the 30 samples for each treatment is 
reported.
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Storage 
temperature  
Baseline After storage for 12 months 
   
No additives Alkalisation Boric acid 
Protease 
inhibitor 
Low protein 
binding tube 
-20oC 
Median albumin 
concentration 
(mg/L) 
2.7 
[1.7 to 6.3] 
1.7 
 [0.9 to 2.3] 
2.5  
[1.4 to 4.0] 
1.5  
[1.0 to 2.0] 
1.5  
[1.0 to 1.8] 
1.5  
[0.8 to 2.3] 
Mean percent difference  -36.9 ±33.5 -29.2 ± 30.2 -38.6 ± 30.8 -42.9 ± 31.7 -39.9 ± 36.2 
 Wilcoxon p value <0.001* <0.001* <0.001* <0.001* <0.001* 
 Number decreased  27 (90%) 29 (97%) 28 (93%) 29 (97%) 27 (90%) 
-80 oC 
Median albumin 
concentration 
(mg/L) 
2.7  
[1.8 to 5.4] 
2.9  
[1.6 to 5.6] 
2.5  
[1.8 to 4.0] 
2.4  
[1.6 to 4.8] 
2.8  
[1.8 to 5.2] 
Mean percent difference  -2.7 ± 13.2 -4.3 ± 30.1 -9.2 ± 15.7 -14.3 ± 16.6 -2.9 ± 19.4 
 Wilcoxon p value 0.06 0.78 0.001* <0.001* 0.28 
 Number decreased 18 (60%) 13 (43%) 23 (77%) 25 (83%) 15 (50%) 
Table 43 Change in urinary albumin concentration in 30 samples which have undergone different treatments prior to being stored at -20oC 
and -80oC for 12 months. * denotes treatment groups which are significantly different from baseline values. 
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5.4.3.3.2 Creatinine 
 
Urinary creatinine concentration is reduced by freeze thawing, regardless of freezer storage 
temperature (Section 5.3.2). None of the treatments prevented the loss in creatinine (Figure 
56), with the results after storage remaining significantly different to baseline values 
(p=0.0001) (Table 44). The difference in creatinine concentration in alkalised samples stored 
at -20oC for 12 months was greatly increased (-15.6 ±24.9%) compared to untreated 
samples (-4.3 ±4.7%), although this did not occur in the alkalised samples stored at -80oC (-
4.4 ±4.1%) (Table 44). 
Figure 56 Difference in urinary creatinine concentration in 30 samples which have 
undergone different treatments prior to being stored at -20oC and -80oC for 12 months. 
The shaded region shows the percent difference which can be attributed to inter-assay 
variation. Each of the 30 samples had five aliquots taken, each to undergo a different 
treatment. The mean creatinine concentration (95% confidence intervals) of the 30 samples 
for each treatment is reported.
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Table 44 Change in urinary creatinine concentration in 30 samples which have undergone different treatments prior to being stored at -20oC 
and -80oC for 12 months. * denotes treatment groups which are significantly different from baseline values  .
Storage 
temperature  
Baseline No additives Alkalisation Boric acid 
Protease 
inhibitor 
Low protein 
binding tube 
-20 
Median creatinine 
concentration 
(mmol/L) 
 
5.9 
[1.9 to 9.9] 
5.6 
[1.9 to 9.2] 
5.6 
[1.7 to 9.1] 
5.6 
[1.8 to 9.2] 
5.5  
[1.8 to 9] 
5.6 
[1.8 to 9] 
Mean percent difference -4.3 ± 4.7 -15.6 ± 24.9 -6.2 ± 3.9 -6.5 ± 3.6 -5.1 ± 4.5 
Wilcoxon p value  <0.0001* <0.0001* <0.0001* <0.0001* <0.0001* 
 Number decreased  24/30 27/30 27/30 27/30 25/30 
-80 
Median creatinine 
concentration 
(mmol/L) 
5.7 
[2.0 to 9.3] 
5.7 
[1.8 to 9.4] 
5.7  
[1.9 to 9.2] 
5.5  
[1.9 to 9.1] 
5.7 
[1.9 to 9.5] 
Mean percent difference -3.5 ± 4.3 -4.4 ± 4.1 -5.1 ± 4.6 -5.2 ± 4.2 -3.8 ± 4.4 
Wilcoxon p value  0.0001* <0.0001* <0.0001* <0.0001* 0.0001* 
 Number decreased   23/30 27/30 24/30 25/30 24/30 
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5.4.3.3.3 ACR 
 
Alkalisation of samples prior to storage for 12 months at -20oC appears to recover ACR, with 
a difference that could almost be explained by the variability of the albumin and creatinine 
assays (Figure 57). The difference is still significant with baseline values (p=0.0004) (Table 
45) and the reduction of the difference compared to untreated samples can be attributed to 
the increased loss of urinary creatinine concentration after alkalisation (Figure 56, Table 44). 
The other treatments do not improve the loss of ACR when samples are stored at -20oC. For 
samples stored for 12 months at -80oC, the difference with baseline values becomes 
positive, again this is the result of lost creatinine due to freeze thawing. Untreated samples 
stored at -80oC have the least significant difference after storage (p=0.91). 
Figure 57 Difference in ACR in 30 samples which have undergone different treatments 
prior to being stored at -20oC and -80oC for 12 months. The shaded region shows the 
percent difference which can be attributed to inter-assay variation. Each of the 30 samples 
had five aliquots taken, each to undergo a different treatment. The mean creatinine 
concentration (95% confidence intervals) of the 30 samples for each treatment is reported. 
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Baseline No additives Alkalisation Boric acid Protease inhibitor 
Low protein 
binding tube 
-20 
Median ACR 
(mg/mmol) 
0.52 
[0.45 to 0.80] 
0.38 
[0.20 to 0.63] 
0.42 
[0.34 to 0.60] 
0.36 
[0.19 to 0.64] 
0.33 
[0.17 to 0.61] 
0.35 
[0.16 to 0.59] 
Mean percent difference -34.3 ± 34.6 -18.8 ± 22.7 -34.5 ± 33.2 -38.2 ± 33.5 -37.0 ± 38.9 
Wilcoxon p value <0.0001* 0.0004* <0.0001* <0.0001* 0.0001* 
Number decreased 26/30 23/30 27/30 26/30 24/30 
-80 
Median ACR 
(mg/mmol) 
0.54 
[0.42 to 0.84] 
0.54 
[0.42 to 0.66] 
0.55 
[0.40 to 0.78] 
0.49 
[0.39 to 0.79] 
0.56 
[0.42 to 0.80] 
Mean percent difference  1.1± 14.6 0.50 ± 33.1 -4.1 ± 17.4 -8.8 ± 18.7 1.1 ± 20.1 
Wilcoxon p value 0.91 0.67 0.13 0.008* 0.64 
Number decreased 16/30 11/30 18/30 21/30 12/30 
Table 45 Change in ACR in 30 samples which have undergone different treatments prior to being stored at -20oC and -80oC for 12 months. 
 * denotes treatment groups which are significantly different from baseline values   
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5.4.4 Discussion 
 
5.4.4.1 Objective 1 
 
Determine if there is a difference in albumin and creatinine concentrations and the 
assessment of ACR after 12 months storage at -20oC and -80 oC. 
 
5.4.4.1.1 Albumin 
 
There is significant loss of urinary albumin when stored at -20oC for 12 months (p<0.0001), 
however there is no significant difference when stored at -80 oC (p=0.06) (Figure 42, Table 
40). 
This is agreement with the findings that Brinkman and colleagues reported from the 
PREVEND study (Brinkman et al., 2007a). They reported a mean loss of UAC, -9.2% (±17.4, 
when quantifying samples with an AUC of 200-500mg/L which had been stored at -20oC for 
12 months. They also reported a mean loss of UAC, -28% (±33), when quantifying samples 
with an AUC of 10-20mg/L which was a significantly lower difference compared the group 
assessing higher concentrations of albumin (p<0.05). 
Using our validated ELISA (Chapter 2) we have now determined the same pattern continues, 
that the proportion of UAC loss increases with the lower concentration of albumin in the 
sample. We report mean percent loss of 36 ±33.5 % in samples with an albumin 
concentration <11mg/L (p=<0.0001) (Table 40). 
Brinkman and colleagues also reported the UAC was stable at -80oC for 12 months 
(Brinkman et al., 2007a). We also demonstrate that this is still valid when measuring the 
lowest levels urinary albumin excretion.  
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The Bland Altman plots (Figure 44, which show the difference (and percent different) across 
the range of UAC, demonstrate the loss of UAC is variable between samples when stored at 
-20 oC. This is reflected by the large standard deviation of the mean percent difference (36 
±33.5 %). This variability has been reported in previous study at the higher albumin 
excretion levels (Townsend, 1986a) (Kania et al., 2010, Brinkman et al., 2007b).  
To help identify why some samples are affected more by frozen storage samples underwent 
dipstick analysis then sent to microbiology for analysis prior to being stored. There was no 
correlation between organisms cultured, white cell count, epithelial cell contamination and 
sample pH, with reduced UAC.  
There was no correlation for changes in creatinine and the ACR. 30 samples were collected 
for this investigation, 20 were random spot samples and 10 were from timed overnight 
collections. There was no pattern for the loss of UAC, creatinine or ACR with the sample 
collection method.  
The Bland Altman plots demonstrate that UAC is stable across the tested range for samples 
stored at -80oC (Figure 44), with the difference attributable to inter-assay variability. If all 
the samples had a negative (or positive) difference there would be a systematic difference, 
but this is not the case.  In the low normoalbuminuria range, UAC was stable when stored at 
-80 oC for up to 12 months.  
 
 
5.4.4.1.2 Creatinine 
 
Urinary creatinine concentration was significantly different after 12 months storage at both 
-20 oC (p<0.0001) and -80 oC (p=0.0001) (Table 41). The mean percent difference for samples 
stored at -20 oC was -4.3 ±4.7 % and at -80 oC it was -3.5 ±4.3 %. The actual difference and 
percentage difference is significantly larger when stored at -20 oC compared to -80 oC, 
p=0.002 and p=0.04 respectively. When individual results from samples after storage are 
plotted against baseline values (Figure 46), it is evident that the magnitude of change is 
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relatively small, although it is still significant. The Bland Altman plots (Figure 48) show that 
the loss in creatinine is proportional to creatinine concentration and that the difference 
cannot be attributed to inter-assay variation as there is a negative bias, regardless of the 
storage temperature.  
The earlier investigation showed that freeze thawing caused a significant reduction in 
urinary creatinine concentration (Table 38). The mean difference after one freeze thaw cycle 
at -80oC was -0.6 ± 1.4 %, although in this experiment it is much larger; -3.5 ±4.3 %. The 
difference between the two methods is that samples have been stored for 12 months, 
suggesting that urinary creatinine may degrade over time. This is investigated further in the 
final investigation of this chapter (Section 5.5). 
 
5.4.4.1.3 ACR 
 
There is a significant loss in ACR when stored at -20oC for 12 months (p<0.0001), although 
there is no significant difference when stored at -80 oC (p=0.91). The mean percentage 
difference when stored at -20oC was -34.3 ±34.6% whereas at -80 oC it was 1.1 ±14.6% 
(Table 42). The stability of ACR when stored at -80 oC compared to -20 oC can be seen in 
Figure 49 when examining the repeated results with their baseline values. The Bland Altman 
plots show the difference (and percentage difference) across the range of ACR (Figure 51). 
Overall, when storing at -80 oC, the majority of the change in ACR can be explained by the 
inter-assay variability of both the albumin and creatinine assays. However, there are several 
samples which cannot be explained by assay variability and it is these samples that have 
experienced the largest decline in creatinine concentration. 
Whilst the degradation of creatinine might be relatively small, as it is being used as the 
denominator in the ACR, the effect is amplified, falsely elevating the ACR. This study has 
only investigated the change of albumin/creatinine and ACR over 12 months, if creatinine 
continues to degrade then the difference in ACR might become significantly different. 
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After 12 months storage at -80 oC, UAC is stable but creatinine is not. Although the ACR is 
not statistically significantly different, it is affected by creatinine degradation, which is 
studied in more detail in the final investigation of this chapter (Section 5.5).       
5.4.4.2 Objective 2  
 
Determine how albumin, creatinine and ACR change over 12 months when stored at -20 oC 
and -80 oC. 
 
5.4.4.2.1 Albumin 
 
The decline in UAC when stored at -20 oC appears to stabilise after six months with around 
40% of UAC lost (Figure 52). However, UAC remains stable at -80 oC with the difference 
attributed to inter-assay variation.  
Our findings are very similar to those from the PREVEND study which reported that after 18 
months storage at -20oC, there was a significant loss loss in UAC; -23.7% (±26.2) (p<0.05). 
Post hoc analysis showed that after 8 months of storage, the difference in UAC had 
stabilised to around -25% to -30% (Brinkman et al., 2005) 
 
5.4.4.2.2 Creatinine 
 
The change in creatinine over 12 months is shown in Figure 53. From earlier work (Table 38) 
a single freeze thaw caused a significant loss in urinary creatinine concentration (-0.6 ± 
1.4%, p=0.02). The impact of a freeze thaw cycle is evident at six and nine months, although 
creatinine concentration continues to decline at 11 and 12 months. This suggests that 
creatinine slowly degrades during frozen storage after 9 months, although this cannot be 
confirmed as the storage duration is limited to 12 months, and only a few time points were 
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sampled. The loss of creatinine was shown to be greater when stored at -20 oC compared to 
-80 oC (Table 41). After 11 months storage this appears to be true, the mean creatinine 
difference is greater for samples stored at -20 oC, although this is less evident at 12 months. 
The degradation of creatinine over a longer time period is investigated in the next 
investigation presented in this chapter (Section 5.5). 
  5.4.4.2.3 ACR 
 
The change in ACR over 12 months (Figure 54) follows the same pattern as UAC (Figure 52). 
However, due to the possible degradation of creatinine, the ACR may be falsely elevated. 
Due to the stability of UAC when stored at -80 oC, the ACR appears stable as well. However, 
due to the decline in UAC when stored at -20 oC, the ACR is also reduced. Each sample had 
many aliquots taken, so the change in ACR will be monitored over a longer time. 
 
5.4.3.3 Objective 3  
 
Investigate if additives or low protein binding tubes prevent any loss of albumin, creatinine 
and ACR after 12 months storage at -20 oC and -80 oC? 
 
5.4.4.3.1 Albumin 
 
 UAC is lost when stored for 12 months at -20oC and this investigation examined if it may be 
prevented by the use of additives or specialised storage tubes. This would help to develop a 
method to store samples at -20oC when freezing at -80oC is not available. The additives and 
tubes used in this study have not prevented the loss of UAC at -20 oC (Figure 55). Alkalisation 
marginally reduced the loss in UAC from -36.9 ±33.5% (with no additives) to -29.2 ±30.2%, 
but still it was significantly different (p<0.001) and more samples had decreased UAC (90% 
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vs 97% ) (Table 43). Storing samples with boric acid or protease inhibitor or in low protein 
binding tubes did not prevent the loss the UAC and all treatments provided results that 
were significantly different to baseline values (p values <0.001).   
There is no significant difference (p=0.06) in UAC in samples stored for 12 months at -80oC 
with no additives (60% of samples had reduced UAC). The number of samples that had a 
decline in UAC was reduced in those that had been alkalised, or where low protein binding 
tubes had been used; 43% and 50% respectively (Table 43), with the significance further 
reduced, p=0.78 and 0.28 respectively. Samples stored with boric acid or protease inhibitor 
had a greater difference in UAC; -9.2± 15.7% and -14.3 ±16.6% and were both significantly 
different from baseline values, p=0.001 and <0.001 respectively. It is possible that boric acid 
and the protease inhibitor interfere with the assay which might cause lower results; it is 
unlikely to be a dilution effect, as it would only account for a difference of 1% due to the 
small volumes added.  
Our results disagree with the findings of Lambers Heerspink and colleagues, who reported 
that urine alkalisation prevents the decline in UAC associated with 12 months frozen storage 
at −20°C (Lambers Heerspink et al., 2009). They reported a median change of UAC of -
13.67% in untreated samples stored for 12 months at -20oC, compared to +2.4% in alkalised 
samples. In our investigation the mean loss of UAC was -39.6% and -29.2% in treated and 
untreated samples respectively. There are differences between the methodologies which 
might explain this; only urine samples from patients with DM, which had an UAC >5.0 mg/L, 
were included in their study which resulted in a median baseline UAC of 15.5 [8.6–39.4] 
mg/l from 90 samples. In our investigation, samples were collected from healthy controls 
and the median baseline UAC was 2.7 [1.7 to 6.3] mg/L.  The difference between the studies 
could be attributed to testing in the different albuminuria ranges and on different 
populations. However, in their method they stated that they weighed every sample before 
and after the addition of sodium hydroxide to correct UAC for the added volume. We did 
not do this, 15µl of NaOH 1M was added to 10ml of every sample, which would dilute the 
sample by 0.15%, as it is such a small error it was deemed negligible and the UAC was not 
adjusted in the analysis. Their study reported the mean addition of NaOH 1M was 00.2 ± 
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0.002 ml, which is very similar to our 15µl volume. There does not appear to be an issue 
with their adjustment of samples which have been alkalised, as the change in UAC for 
samples which were treated and not treated when stored at -80oC were similar, 5.6% and 
5.4% respectively. 
This investigation does not support the findings of Kania and colleagues, which showed 
pepstatin inhibited the degradation of endogenous and exogenous albumin in in-vitro 
studies (Kania et al., 2010). To our knowledge our investigation is the first study that has 
investigated the use of pepstatin to inhibit UAC degradation in samples stored at -20 oC over 
12 months. However, there was no reduction in UAC degradation when adding pepstatin to 
samples. This may be a methodological issue; the effective concentration recommended by 
the manufacturer is designed to prevent the degradation of authophagic cargo in 
autophagosomes, a very different working environment to inhibiting the degradation of 
albumin in urine.  The same pepstatin product (Sigma Aldrich product number: P5318, 
Sigma Aldrich, Missouri, USA) was used in our study and in the in-vitro study by Kania et al. 
Both studies followed manufacturer recommendations when preparing pepstatin working 
solutions to add to samples.Further work is required to ensure an effective concentration of 
pepstatin is used in future studies investigating its use to prevent UAC degradation in urine 
samples stored at -20oC. 
There is no evidence UAC is preserved when storing samples in boric acid and there was no 
correlation between microbial growth and samples which lost UAC, suggesting bacterial 
contamination is not responsible for the loss of UAC. Low protein binding tubes did not 
inhibit the loss of UAC at -20oC, which indicates albumin is not being adsorbed to the 
storage containers.   
Our results indicate that if ACR cannot be measured on a fresh sample, then it should be 
stored at -80oC, and it is insufficient to store it at -20oC, regardless if any additives or low 
protein binding tubes are used. 
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5.4.4.3.2 Creatinine 
 
Previous studies have failed to identify and investigate the impact of additives on creatinine 
and the overall assessment of ACR during prolonged storage. Our results have identified 
that creatinine is lost due to freeze thawing, regardless of sample treatment and storage 
temperature (Figure 56). None of the treatments prevented the loss in creatinine, with the 
results after storage remaining significantly different to baseline values (p=0.0001) (Table 
44). The difference in creatinine concentration in alkalised samples stored at -20oC for 12 
months was greatly increased (-15.6 ±24.9%) compared to untreated samples (-4.3 ±4.7%), 
although this did not occur in the alkalised samples stored at -80oC (-4.4 ±4.1%). Therefore, 
alkalisation of samples either increases the degradation of creatinine when stored at -20oC, 
or it affects the creatinine assay, although this is unlikely as it did not occur in the samples 
stored at -80oC (Table 44).  
 
5.4.4.3.3 ACR 
 
Alkalisation of samples prior to storage for 12 months at -20oC appears to recover ACR, with 
a difference that could almost be explained by the variability of the albumin and creatinine 
assays (Figure 57). The difference is still significant (p=0.0004) (Table 45) and the reduction 
of the difference compared to untreated samples can be attributed to the increased loss of 
urinary creatinine concentration after alkalisation. The other treatments do not improve the 
loss of ACR when samples are stored at -20oC. For samples stored for 12 months at -80oC, 
the difference with baseline values becomes positive, again this is the result of lost 
creatinine due to freeze thawing. Untreated samples stored at -80oC have the least 
significant difference after storage (p=0.91). In light of these observations untreated 
samples would be the preferred method to store samples frozen for 12 months when 
measuring albumin, creatinine and the ACR.  
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5.5 The effect of storage duration on albumin and creatinine levels 
and the calculation of ACR in samples stored at -80oC 
 
5.5.1 Method 
 
Urine samples from 91 participants of the SUMMIT study were selected for this 
investigation. Samples were chosen to cover a wide range of urinary albumin concentrations 
and storage times. An aliquot from each sample was sent to the RD&E Blood science 
laboratory for routine analysis of albumin and creatinine on the day of collection. Albumin 
was measured by the routine COBAS method (Roche Diagnostics Ltd., Burgess Hill, UK) and 
creatinine was quantified using the routine Jaffe method (Roche Diagnostics Ltd., Burgess 
Hill, UK). Remaining aliquots were stored at -80oC on the day of collection.    
The samples were collected over three years and a stored aliquot of the selected samples 
were all analysed on the same day once the study was complete. Samples were thoroughly 
thawed and mixed by four hand inversions prior to analysis. 
The same assays were used to measure albumin and creatinine when samples were fresh 
and after storage. However, new analysers had been installed and validation work carried 
out by engineers revealed a bias between the old and new analysers. The bias for the 
urinary albumin assay is shown in Table 46 and for the urinary creatinine assay in Table 47. 
Unfortunately, in the albumin assay validation no samples with a concentration <7mg/L 
were tested.  
Urinary albumin 
concentration range 
(mg/L) 
Number of samples 
Mean bias 
(mg/L) 
Mean percent bias 
(%) 
7 to 40 9 -1.96 -14.7 
40 to 150 3 -4.90 -9.3 
Table 46 New COBAS analyser validation result for urinary albumin.  
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 Urinary creatinine 
concentration 
 range 
(mmol/L) 
Number of 
samples 
Mean bias 
(mmol/L) 
Mean Percent Bias 
(%) 
0 to 5 6 0.16 5.6 
5 to 10 16 0.28 3.8 
10 to 25 3 0.32 2.2 
Table 47 New COBAS analyser validation results for urinary creatinine.  
 
5.5.1.1 Statistical analysis 
 
To determine if there is a correlation between the difference in albumin/creatinine or ACR 
with duration of storage at -80oC, a difference plot (actual difference and percentage 
difference) over time is used. The mean difference is plotted with 95% confidence intervals.  
Normality of the data was tested using the Shapiro-Wilkes test. For non-normally 
distributed data Spearman’s rank correlation test was used to investigate the relationship 
between difference and duration of storage. The correlation is tested for both actual and 
percentage difference. For each correlation the Rs and Rs 
2 is reported along with the 
significance of the correlation (p) and the coefficient to show the rate of change over time. 
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5.5.2 Results 
 
5.5.2.1 Albumin 
 
The difference plot for actual difference in UAC against storage time indicates that UAC loss 
becomes less with time (Figure 58A) and that there is a significant correlation to reinforce 
this (RS= 0.48, p=<0.001) (Table 48). However, this is not the case. Patients in the SUMMIT 
study with CVD were recruited last, therefore the samples with the largest UAC have had 
the shortest storage duration. This is reflected by the difference plot (Figure 58B) that 
shows the proportional difference and demonstrates that there is no significant correlation 
with UAC change over time (RS= -0.19,  p= 0.07) (Table 48). 
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Figure 58 Difference in urinary albumin concentration in 91 samples stored at -80oC over 
850 days (A: actual difference, B: percent difference). The green line represents the mean 
difference in UAC with the 95% confidence intervals indicated with red lines. Mean difference 
is -2.4 ±4.4 mg/L and the mean percent difference is -11.2 ±13.2 % compared to fresh 
samples.  
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 RS RS
2 p Coefficient 
Actual difference 0.48 0.23 <0.001 0.01 
Percent difference -0.19 -0.04 0.07 -0.01 
Table 48 Correlation between change in UAC and duration of storage at -80oC in 91 
samples. 
 
 
 
5.5.2.2 Creatinine 
 
Urinary creatinine degrades over 850 days when stored at -80oC in 91 urine samples (Figure 
59). This is confirmed by a strong significant correlation for both actual difference and 
percent difference; RS = -0.95, p <0.0001 and RS = -1.00, p <0.0001, respectively (Table 49). 
Due to the difference in analysers it appears creatinine concentration is increased after 
short storage duration, however this can be attributed to the application of the new 
analyser which has a positive bias of 5.6% in the 0 to 5 mmol/L range (Table 47). 
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Figure 59 Difference of creatinine over 850 days in 91 samples stored at -80oC (A: actual 
difference, B: percent difference). The green line represents the mean difference in 
creatinine concentration with the 95% confidence intervals indicated with red lines. Mean 
difference is -0.1 ±0.3 mmol/L and the mean percent difference is -0.5 ±3.8 % compared to 
fresh samples. 
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 RS RS
2 p Coefficient 
Actual difference -0.95 -0.90 <0.0001 -0.001 
Percent difference -1.00 -0.99 <0.0001 -0.016 
Table 49 Correlation between change in creatinine and duration of storage at -80oC in 91 
samples. 
It appears urinary creatinine degrades during prolonged storage at -80oC. This was 
investigated further by testing an additional 360 urine samples from different participants in 
the SUMMIT study. The combined results of the 360 samples and 91 samples from the 
previous experiment are presented in Figure 60.   
 
Figure 60 Urinary creatinine degradation during prolonged storage at -80oC  over three 
years . The percent difference in creatinine has been adjusted to account for the bias of the 
new analyser using the validation results reported in Table 47. Linear regression was used to 
determine the rate of degradation over 541 days, the regression coefficient/gradient was -
0.024% / day (CI: -0.029 to -0.019). 
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The results seen in Figure 60 indicate that urinary creatinine degrades and then stabilises. 
Segmented regression analysis was performed to identify that at 541 days (CI: 483 to 599) 
the degradation of creatinine stabilises. Linear regression was used to determine the rate of 
degradation over 541 days, the regression coefficient/gradient was -0.024% / day (CI: -0.029 
to -0.019). 
 
 
5.5.2.3 ACR 
 
The change in ACR over 850 days when stored at -80oC (Figure 61) reflects the same pattern 
seen in the change of UAC (Figure 58). ACR distribution is also skewed as a result of 
recruiting CVD patients at the end of the study, showing a positive correlation for actual 
difference in ACR with storage duration (RS = 0.62, P<0.0001) (Table 50). However, no 
significant correlation is found for percentage difference (RS = 0.02, P = 0.87). The mean 
percentage difference is -10.7 ±13.3%, which can be explained by variability of the assays 
and the change of analyser. 
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Figure 61 ACR difference over time in samples stored at -80oC over 850 days (A: actual 
difference, B: percent difference). The green line represents the mean difference in ACR with 
the 95% confidence intervals indicated with red lines. Mean difference is -0.71 ±2.13 
mg/mmol and the mean percent difference is-10.7 ±13.3 % compared to fresh samples. 
 RS RS
2 p Coefficient 
Actual difference 0.62 0.38 <0.0001 0.004 
Percent difference 0.02 0.00 0.87 0.002 
Table 50 Correlation between change in ACR and duration of storage in 91 samples over 
850 days at -80oC. 
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5.5.3 Discussion 
 
5.5.3.1 Albumin 
 
Patients in the SUMMIT study with CVD were recruited last, therefore the samples with the 
largest UAC have had the shortest storage duration. This is reflected by the difference plot 
(Figure 58) that shows the proportional difference and demonstrates that there is no 
significant correlation with UAC change over time (RS= -0.19,  p= 0.07) (Table 12). The mean 
difference is -11.2 ± 13.2%, which can be accounted for by not only inter-assay variation but 
also the variation caused by using different analysers. The validation work showed the new 
analysers provide UAC results with a -14.7% bias in the 7 to 40mg/L range. This 
demonstrates how important it is to ensure that the same assay is used on the same 
analysers in clinical trials and long term storage studies. However, this is not always 
possible, as was the case in this study. It is therefore necessary to carry out validation work 
to account for variability. 
 
5.5.3.2 Creatinine 
 
Urinary creatinine degrades over time when stored at -80oC (Figure 59). This is supported by 
a strong significant correlation for both actual difference and percent difference; RS = -0.95, 
p <0.0001 and RS = -1.00, p <0.0001, respectively (Table 49). Due to the difference in 
analysers it appears creatinine concentration is increased after short storage duration, 
however this can be attributed to the application of the new analyser which has a positive 
bias of 5.6% in the 0 to 5 mmol/L range (Table 47). 
Degradation of urinary creatinine is an important finding and warranted further 
investigation to determine if the rate of degradation continues in stored samples over a 
longer duration. Many studies (especially epidemiological research) store samples for many 
years prior to analysis and the accuracy of results will be influenced by creatinine 
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degradation, especially when using it as a denominator in a ratio to account for urinary 
concentration. 
To investigate this further, an additional 360 urine samples were reanalysed, of which some 
had been stored for over 1000 days. The combined results of the 360 samples and 91 
samples from the previous experiment (Figure 60) demonstrate that urinary creatinine 
degrades at a rate of 0.024% / day (CI: -0.029 to -0.019) up until 541 days (CI: 483 to 599) at 
which point degradation stabilises. The results in Figure 60 were adjusted to account for 
differences caused by the new analyser (Table 47). Samples which had been measured on 
the day of collection by the new analysers were not adjusted. From the results of this 
analysis, an equation can be created (Equation 1) to correct for the loss in urinary creatinine 
in samples stored at -80oC prior to analysis. 
 
     Corrected Urinary                 =               Measured creatinine concentration        x 100 
Creatinine concentration                               (100 – (0.029 x days stored *) 
 
*input 541 for samples stored more than 541 days  
 
Equation 1 Correcting for urinary creatinine degradation after storage at -80oC. 
 
As a result of this finding, urinary creatinine results from samples stored in the SUMMIT 
study will be adjusted using this equation. This is important as it improves the accuracy of 
reporting an ACR from stored samples, which is essential when investigating the relationship 
of ACR in the normoalbuminuria range with sensitive measures of vascular function. 
5.5.3.3 ACR 
 
Although creatinine degradation occurs, the magnitude of it is not enough to cause the ACR 
result to significantly increase with storage time. However, the accuracy of an ACR to report 
urinary albumin excretion in samples stored at -80oC is impaired, and is suboptimal when 
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investigating the lowest levels of albumin excretion. Accounting for the rate of creatinine 
degradation will improve this accuracy. 
 
5.6 Chapter Summary 
 
5.6.1 Albumin  
 
Other studies have reported that the loss of UAC in samples stored at -20oC can be 
prevented by; alkalising samples, adding protease inhibitors and using specialised storage 
tubes. These findings have been incorporated into our study to help identify the optimal 
method to store urine samples to assess low levels of albumin excretion. Several authors 
have suggested that bacterial contamination is the cause of lost UAC, therefore all samples 
were cultured, but no correlation was found.  
The results from this study show that UAC is unaffected by freeze thawing (up to 5 cycles). 
However, a significant loss of UAC occurs in samples stored at -20oC. The decline in UAC 
appears to stabilise by six months with around 36% of UAC lost. This is similar to previous 
findings which have shown UAC to stabilise at around 30% loss after 8 months storage at -
20oC (Brinkman et al., 2005). None of the additives tested prevented the loss in UAC.  
UAC in the normoalbuminuria range is stable when stored for up to 12 months at -80oC, any 
difference between measurements can be explained by inter-assay variation. Using the 
COBAS method to quantify albumin in SUMMIT samples revealed that UAC is stable for up 
to 850 days at -80oC. Therefore, if timed collections cannot have UAC measured fresh, then 
they must be stored at -80oC. However, many studies use random spot samples and report 
the ACR, therefore the impact of frozen storage on creatinine was also investigated. 
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5.6.1 Creatinine 
 
There is a significant difference in urinary creatinine concentration after freeze thawing, 
which doesn’t increase with the number of cycles. However, this difference is small and 
does not affect the ACR. After 12 months storage the difference in creatinine was larger 
than a freeze thaw cycle (at both -20oC and -80oC), suggesting creatinine is degrading over 
time. This was confirmed by reanalysing SUMMIT samples, where a strong correlation of 
loss of creatinine with storage duration was found. Upon further investigation creatinine 
was found to degrade at a rate of 0.024% / day for 541 days and then it stabilises. This 
information has enabled an equation to be created which can adjust a creatinine 
measurement to account for degradation (Equation 1). However, the deterioration of 
creatinine did not significantly impact the ACR in samples stored over 12 months. 
Creatinine degradation is an important finding, as many epidemiological studies store 
samples for many years prior to analysis, and will need to account for creatinine 
degradation when using it to account for variation in urinary concentration. In the SUMMIT 
study, some baseline random spot samples have been stored for 5 years at -80oC prior to 
ACR measurement. The creatinine measurements will be adjusted using Equation 1 in these 
samples.  
 
5.6.1 ACR 
 
Although creatinine degradation occurs during prolonged frozen storage, the magnitude of 
it is not enough to cause the ACR result to significantly increase. However, the accuracy of 
an ACR to report urinary albumin excretion in samples stored at -80oC is impaired, and is 
suboptimal when investigating the lowest levels of albumin excretion. Accounting for the 
rate of creatinine degradation will improve this accuracy. 
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5.7 Conclusion 
 
Urinary albumin is stable over prolonged storage at -80 oC, however creatinine degrades at a 
rate of 0.024% / day for 541 days and then stabilises. Accounting for the rate of creatinine 
degradation will improve the accuracy of an ACR to report urinary albumin excretion in 
samples stored at -80oC. 
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Chapter 6 Impact of Exercise on Urinary Albumin Excretion 
 
Kidney disease, urinary tract disorders, fever, heart failure and exercise have all been shown 
to increase AER (Lillehoj and Poulik, 1986). Transient changes in AER after exercise has been 
documented in the clinical ranges, but the extended lower range has not been investigated. 
Not only is it important to understand the biological variation of albumin excretion at low 
levels (Chapter 4), it is important to understand how much albumin excretion can be 
influenced by additional factors, such as exercise. This needs to be understood first before 
interpreting results from studies investigating the lowest levels of albumin excretion.  
The influence of exercise on albumin excretion in healthy individuals will be investigated 
using the validated sensitive ELISA (Chapter 2), when reporting the ACR (Chapter 3) from 
samples being collected using the appropriate method (Chapter 4), which have been stored 
at -80oC (Chapter 5).  
 
 
6.1 Introduction 
 
In 1978, Viberti and colleagues investigated exercise induced macroalbuminuria by 
recruiting 16 patients with T1DM and nine healthy controls (Viberti et al., 1978). AER was 
measured before exercise and again one hour after (cycling at 98W for 20 mins, mild 
intensity exercise). The results showed that participants with T1DM had a significant 
increase in AER (p<0.01), but there was no significant difference in the control group (Figure 
62).  
The diabetic group was divided into two subgroups, group 1 had a resting AER in the same 
range as the controls (n=8) and group 2 had a higher baseline AER (n=8). By separating the 
diabetic groups, the control group can be compared to patients with T1DM who had similar 
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resting AER. The increase in diabetic group 1 is much more than the controls, indicating DM 
per se increases susceptibility to exercise induced albuminuria, potentially an earlier marker 
of renal damage, which would not be detected from an overnight collection  (Viberti et al., 
1978).   
 
 
Figure 62 Changes in urinary albumin excretion after exercise in controls and in 
participants with diabetes. Participants with diabetes were divided into two groups, 
participants with rest AER in the range of the controls are in group 1. Only participants with 
T1DM had a significant increase in AER (p<0.01) after cycling at a mild intensity for 20 
minutes (Viberti et al., 1978). 
 
6.1.1 Mechanisms of exercise induced albuminuria 
 
Identifying raised AER after exercise in individuals with DM but not in healthy controls has 
been reported in studies prior to Viberti’s work (Mogensen, 1976, Mogensen and Vittinghus, 
1975), but the mechanism of how it arises was not understood. Previous authors had 
speculated that exercise induced albuminuria was the result of increased glomerular 
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filtration pressure, decreased tubular reabsorption or changes in glomerular permeability, 
although there was nothing conclusive to support these.  
Given that 90% of albumin is reabsorbed by the proximal tubules, increased AER after 
exercise can either be from increased trans-glomerular passage and/or by reduced albumin 
reabsorption by the proximal cells. β-2-microglobuin (B2M) excretion can be measured to 
differentiate between raised AER from increased trans-glomerular passage or reduced 
proximal reabsorption. B2M is a marker of tubular function. The proximal tubules normally 
reabsorb B2M so an increased B2M urinary excretion indicates reduced tubular function. 
Therefore, increased AER with normal B2M excretion indicates increased glomerular 
passage of albumin and not decreased proximal tubular reabsorption (Peterson et al., 1969). 
Subsequently, an increase in the ratio of albumin/B2M suggests glomerular albuminuria and 
a decreased ratio is an index for tubular albuminuria.  
Viberti and colleagues also measured the excretion of B2M in their study and reported the 
change in albumin/B2M ratio after exercise (Figure 63). 
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Figure 63 Changes in urinary albumin/β2-microglobulin ratio after exercise in controls and 
in participants with diabetes (Viberti et al., 1978). 
 
The change in albumin/B2M ratio suggests that the observed increase in AER resulted from 
glomerular changes, either increased permeability to albumin or increased glomerular 
filtration pressure, and not due to reduced tubular reabsorption. Hypertension is associated 
with increased AER (Mani, 2016), although in Viberti’s study there was no correlation in the 
change of systolic blood pressure with change in albumin excretion in both the diabetic 
group and the controls. This could be due to the low sample size (n=25) tested in Viberti’s 
study. Viberti concluded that it is unlikely that the change of AER after exercise is caused by 
an ‘abnormal’ cardiovascular response  (Viberti et al., 1978). This broad conclusion might 
not be appropriate, as it does not consider that change in brachial pressure may not reflect 
changes in glomerular pressures. If autoregulation is failing in the patients with diabetes 
then glomerular pressures may be increasing more in patients with diabetes than in control 
participants, influencing filtration of albumin. Impaired autoregulation has been 
demonstrated in patients with T2DM (n=25) compared to controls matched by sex and age 
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(n=25) (Tur et al., 1991). The relationship between urinary albumin excretion and 
autoregulation is investigated in SUMMIT cohort in Chapter 7. 
The change in glomerular permeability during exercise has not been thoroughly 
investigated, probably due to the challenge of measuring glomerular permeability in-vivo. 
Increased glomerular permeability might arise from increased shedding of the glycocalyx 
(Satchell and Tooke, 2008). However, one study on 21 young, healthy men demonstrated 
that there was no significant change in serum syndecan-1 and heparan sulphate 
concentrations (markers of glycocalyx shedding) after maximal incremental cycling exercise 
until exhaustion (Majerczak et al., 2016). The links between glycocalyx shedding and urinary 
albumin excretion have been investigated in in patients with T1DM, subjects with T1DM had 
endothelial glycocalyx damage, the severity of which is increased in presence of 
microalbuminuria (Nieuwdorp et al., 2006). Glycocalyx perturbation and increased vascular 
permeability has also been demonstrated in T2DM (Broekhuizen et al., 2010). 
The majority of studies that have measured biomarkers of the glycocalyx (especially urinary 
biomarkers) have mostly been carried out in animal models, so assays to quantify glycocalyx 
markers require validation before testing human samples. Samples from this investigation 
are stored for future analysis of glycocalyx markers and also markers of proximal tubule 
function.  
6.1.2 Exercise induced albuminuria in different cohorts 
 
Increased AER after exercise has been shown in T1DM (Vittinghus and Mogensen, 1981)  
and T2DM (Climie et al., 2015). Jefferson and colleagues carried out a study on 40 children 
with T1DM and 21 controls, the mean age (range) was 12 years (8 to 16) and showed only 
children with T1DM had a significant increase in ACR after cycling for 15 minutes at a 
moderate to heavy intensity (Jefferson et al., 1985) The mean duration of diabetes (range) 
among the children with T1DM was 9.9 years (0.2 to 11.9), suggesting that increased ACR in 
response to cycling occurs early in T1DM. The geometric mean (95% CI) ACR of the control 
group (n=21) was 0.0011 (0.004 to 0.032) mg/mg before exercise, and 0.009 (0.003 to 
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0.027) mg/mg after (p>0.05). In the children with diabetes (n=40) ACR was 0.009 (0.003 to 
0.0032) mg/mg before exercise and 0.016 (0.003 to 0.089) mg/mg after (p<0.0001). Young 
patients with hypertension also have significantly increased AER after moderate exercise 
compared to age matched normotensive controls (Pedersen et al., 1981). 
In 2011, Koh and colleagues investigated the change in ACR, 1 and 2 hours after a one 
kilometre treadmill walking exercise in thirty-five participants with diabetes (three with 
T1DM and 32 with T2DM) and nine control subjects, those with diabetes had a range of pre 
exercise levels of albumin excretion across the full albuminuria range (Koh et al., 2011).  
In accordance with previous studies there was no significant difference in ACR after exercise 
in the control groups, although the female controls did exhibit a non-significant trend for an 
increase in ACR. Males with diabetes in the normoalbuminuria range did not have a 
significant increase in ACR after exercise. However, the females with diabetes did and the 
average ACR increased above the microalbuminuria threshold at 1 hour post exercise, 
returning to baseline levels by 2 hours (Figure 64). This data indicates that female patients 
with diabetes and normoalbuminuria have walking induced increased albumin excretion, 
which might represent an early nephropathy. The clinical significance of this data requires 
further study, and it is considered in conjunction with results from the SUMMIT cohort in 
Chapter 7. 
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Figure 64 Mean ACR in controls and participants with diabetes with normoalbuminuria, at 
first morning void, immediately before exercise, 1 h and 2 h after a 1km treadmill walking 
exercise. Nine controls and 10 subjects with diabetes were include in the analysis. Sex-
specific cut-off for microalbuminuria for males is a solid line and for females a dashed line.    
( ) = Control male, (  )= Control female, ( ) = Male with diabetes, ( ) = Female 
with diabetes (Koh et al., 2011). 
 
Both males and females subjects with pre-exercise ACR In the microalbuminuria and 
macroalbuminuria ranges had a significant increase in ACR after exercise. In addition, by 
taking repeat measurements over time, Koh and colleagues were able to determine that 
ACR was not significantly different to pre-exercise ACR 2 hours after exercise was 
completed.  
Contrary to the findings of previous studies, in 2009 Heathcote and colleagues showed that 
ACR was significantly increased in healthy individuals after exercise (Heathcote et al., 2009).  
14 healthy women and 16 healthy men were exercised to maximal heart rate or exhaustion 
using the Bruce Treadmill protocol. The mean baseline ACR in women was 0.5 ± 0.3 
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mg/mmol and 0.4 ± 0.1 mg/mmol in men. After high intensity exercise this increased to a 
mean of 5.6 ± 9.7 and 7.6 ± 17.1 mg/mmol in women and men respectively. Overall, 40% of 
the participants had an ACR in the microalbuminuria range after exercise and two 
participants were in the macroalbuminuria range. However, samples were collected only 15 
minutes after completing the high intensity exercise. All participants had returned to 
normoalbuminuria range within 24 hours. 
The reason other studies have not seen a change in ACR in healthy individuals is most likely 
due to the difference in exercise intensity and the type of exercise exerted. The participants 
in the study by Heathcote and colleagues were exercised to maximal heart rate of 
exhaustion using a treadmill, whereas in the earlier study by Viberti (where controls had a 
non-significant change in ACR) participants cycled at a moderate intensity for 20 minutes 
(Viberti et al., 1978). Also the subjects from the Heathcote et al study were younger (mean 
age 24 ±2 years in women and 28 ±5  years in men) than the Viberti cohort (mean age 32 
±9). Tolerance to exercise induced increase urinary albumin excretion might represent 
microvascular autoregulation, which has been proposed as a mechanism to cause increased 
urinary albumin excretion, which reflects generalised microvascular function, this is 
explored further in Chapter 7. 
Studies that have investigated the change in AER after exercise all suffer from low 
participant numbers and have used a wide range of methods to induce exercise, making it 
challenging to draw comparisons between them. It is not only important to determine at 
what intensity of exercise does AER significantly increase, and in what cohorts, but clinically 
it is important to know how long AER is increased. 
 
 
6.1.3 Duration of exercise induced albuminuria 
 
The duration of increased AER after exercise is not well defined. Due to different frequency 
of urination between participants, it is very challenging to determine how long it takes for 
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AER to return to resting levels. One study exerted 16 male participants to exhaustion by 
cycling at 30W for two minutes then increasing the intensity by 30W every minute. Urine 
samples were collected before exercise and then every hour for three hours afterwards 
(Table 51) (Poortmans et al., 1989). They reported that AER declined logarithmically after 
exercise with a half-life of 54 minutes. The characteristics of the participants in this study 
were not described. 
 
 Pre-exercise Post exercise 
  1 hours 2 hours 3 hours 
Albumin excretion rate 
(µg/min) 
15.3 ±1.3 315.6 ±30.0 136.3 ±15.8 63.6 ±12.3 
Table 51 Albumin excretion rate before and after exercise in 16 healthy male participants. 
16 male participants cycled to exhaustion by cycling at 30W for two minutes then increasing 
the intensity by 30W every minute. Urine samples were collected before exercise and then 
every hour for three hours afterwards. Data presented as mean ± standard deviation. 
(Poortmans et al., 1989). 
 
In Koh’s study of participants with DM, all participants across all the albuminuria ranges had 
ACR return to pre-exercise levels within 2 hours after finishing exercise (Koh et al., 2011). 
However, in a study on 30 healthy participants who were exercised to exhaustion or 
maximal heart rate, AER had returned to the pre-exercise values within 24 hours (Heathcote 
et al., 2009). AER could have returned to pre-exercise values sooner but they were unable to 
detect this due to sampling frequency as they only sampled at 15mins and 24 hours post 
exercise. 
The differences between these results can be attributed to the difference in sample 
collection frequency and any activity taken between collections. Studies investigating how 
long it takes for albumin excretion to return to resting levels need to consider this in their 
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design. Before the recovery of albumin excretion after exercise is determined, it must be 
ensured that all the participants undergo the same amount of exercise. 
 
6.1.4 Normalising exercise intensities 
 
Figure 62, which shows individual responses to exercise, demonstrates that regardless of 
diabetes status, the change in AER after exercise varies between people. The reason for this 
has not been investigated before. If the variation in responses is caused by physiological 
changes, then it would be beneficial to carry out a prospective study investigating the 
relationship between different responses to exercise with the risk of developing kidney and 
cardiovascular disease. Previous studies have considered exercise a suitable provocation 
test to unmask underlying glomerular abnormalities (Viberti et al., 1978). 
However, the variation in AER response to exercise may not be the result of physiological 
differences, but may arise from methodological issues. In the previously discussed studies, 
exercise has been tested using a variety of methods; cycling, running, walking and sports, 
each using a different measure of intensity and duration of the exercise (until maximal heart 
rate (HR) is reached, 80% maximal HR, exhaustion, exercise with a fixed load for 20 minutes, 
incremental loads, etc.). However, the same exercise and duration is applied to all the 
participants within each study. 
A limitation of using the same workload and durations for all participants is that it will affect 
people in different ways, depending on their age, gender and fitness. For example, an 
inactive individual cycling for 20 minutes at 60W might find it very strenuous, which could 
cause a lot of stress on the body, resulting in a large change in AER, whereas a fit individual 
who cycles to work every day would find it easy and might have a no change in AER. 
Therefore, exercise intensities need to be relative to each individual’s level of fitness, and 
personalised work rates can be calculated to ensure the same intensity of exercise is 
exerted on all the participants.  
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To determine personalised work rates, exercise physiologists evaluate an individual’s 
capacity for dynamic exercise using protocols which measure ventilator and gas exchange 
responses to exercise. Cycle ergometry is often used in these protocols as the desired work 
intensity (work rate) can be programmed and maintained automatically by adjusting 
resistance in relation to cycling rate. Work rate is calculated in watts (W) and cycle 
ergometry enables work rate to be increased in increments.  
Ramp (incremental) exercise is used in protocols to determine an individual’s capacity for 
exercise and is characterised by a linear and continuous increase in work rate (Boone and 
Bourgois, 2012). Work rate continues to increase in ramp exercise and the test is only 
complete once the individual has reached volitional exhaustion. Throughout the ramp test 
ventilatory gas exchange analysis is carried out which provides measures of the metabolic 
response to exercise. This breath by breath analysis monitors three parameters: 
1. Percent O2  
2. Percent CO2  
3. Respiratory airflow 
Knowing these three factors enables oxygen uptake (VO2) and carbon dioxide output (VCO2) 
to be calculated. To establish an individual’s capacity for exercise, there are two markers of 
aerobic function that are determined; the gas exchange threshold (GET) and the maximum 
oxygen uptake (VO2max).  
 
6.1.4.1 Gas exchange threshold 
 
The GET or anaerobic threshold was first conceptualised in 1964 and is defined as the work 
rate at which anaerobic metabolism supplements aerobic mechanisms during progressive 
exercise (Wasserman and McIlroy, 1964). Traditionally invasive methods to quantify blood 
lactate and bicarbonate concentrations were used to identify the GET (otherwise known as 
the lactate threshold). Gas exchange measurements are now widely used and provide a 
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non-invasive method to determine GET. By plotting VC02 against the VO2 during progressive 
exercise, the GET is determined by identifying the ‘breakpoint’ (deflection point) in the 
slope caused by an increase in VCO2 from bicarbonate buffering lactic acid (Figure 65). 
Identifying the GET using this method is known as the V-slope method and the level of work 
rate (exercise intensity), which corresponds to this breakpoint, is considered the GET 
(Whipp et al., 1981).  
 
Figure 65 Determining the gas exchange threshold using the V-Slope method. GET is 
determined from the breaking point in the slope of the relationship between VC02 and VO2. 
The work rate which corresponds to the breakpoint is the GET, denoted by black arrow. 
(Bergstrom et al., 2013) 
 
6.1.4.2 Maximal oxygen uptake (VO2max) 
 
VO2max is the maximum rate of oxygen consumption during incremental exercise and 
reflects the aerobic physical fitness of an individual. VO2max is reached when oxygen 
consumption remains at a steady state despite an increase in work rate. The plateau in VO2, 
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which identifies the VO2max, is not always apparent during ramp testing, as participants can 
reach exhaustion prior to this. Therefore, the peak VO2 reached can be used to represent 
the individual’s peak oxygen consumption (Kaminsky et al., 2014). 
To normalise exercise intensity between participants in exercise studies, each participant’s 
GET and VO2max (or peak) needs to be determined. Terminology of different exercise 
intensities varies between studies and in this investigation two intensities are going to be 
utilised: 1) ‘Moderate’ intensity defined as 80% of the work rate of the GET, ensuring 
participants undergo exercise which does not require anaerobic metabolism. 2) ‘Heavy’ 
exercise defined as a 40% change in work rate from the GET to the VO2 peak. This is 
summarised in Figure 66. These definitions of exercise thresholds are commonly used in  
exercise testing (Jones et al., 2012a). 
 
Figure 66 Classification of different exercise thresholds. ‘Moderate’ intensity is defined as 
the 80% of the work rate at the GET (shown in red) ‘Heavy’ exercise is defined as a 40% 
change (∆) in work rate from the GET to the VO2 peak (shown in green). The work rate at the 
GET (shown in blue) was determined by plotting VC02 against the VO2 using the same 
method used in Figure 65. 
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By defining exercise thresholds in this way, work rates will vary between participants, but 
each participant will be tested at the same intensity relative to their capacity for exercise.  
By normalising the exercise thresholds, a comprehensive investigation into the change of 
AER after exercise can be carried out. Using the validated albumin ELISA kit, small changes in 
AER can be detected and the influence of exercise in the normoalbuminuria range studied.  
 
6.1.5 Investigating exercise increased albumin excretion in the lower albumin 
excretion range 
 
This study will help increase our understanding of the mechanisms underlying the increase 
in albumin excretion after exercise, the change in albumin and creatinine were monitored 
individually, as well as the change in urine specific gravity (USG). Creatinine and USG are 
both markers of urinary concentration (Section 3.4). If only the concentration of albumin 
significantly increases after exercise then the ACR is not raised due to increased urinary 
concentration or a change in urinary flow, as creatinine and USG are not affected in the 
same way.  
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6.2 Aim 
 
To determine the impact of different exercise intensities on urinary albumin excretion in the 
normoalbuminuria range in healthy individuals and to explore the underlying mechanisms.  
 
 
6.2.1 Objectives 
 
1. To examine if ACR changes after different intensities of exercise in young, healthy 
individuals  
 
2. To determine if the change in ACR is different between exercise intensities 
 
3. To explore how long it takes for the ACR to return to resting levels after exercise 
 
4. To determine how albumin, creatinine and urine specific gravity change after 
exercise to differentiate the effect of exercise on albumin excretion from urinary 
concentration and flow.  
 
5. To investigate if the change in ACR after exercise is related to an increase in blood 
pressure and heart rate 
 
6. To explore the effect of participants activity levels before exercise and during 
recovery on exercise induced changes in albumin excretion 
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6.3 Method  
 
6.3.1 Participant recruitment and screening 
 
11 healthy adults (aged 21-50 years old) were recruited from a database of individuals 
interested in hearing about research held by the NIHR Exeter Clinical Research Facility. The 
inclusion criteria required participants to have an eGFR > 60ml/min/1.73m2 and an ACR in 
the normoalbuminuria range. Participants who had been diagnosed with diabetes, 
cardiovascular disease, hypertension or were on antihypertensive medication were 
excluded from the study.  
The study protocol was reviewed and approved by the University of Exeter Medical School 
ethics committee. Written informed consent was obtained from all participants, who then 
attended a screening visit, where anthropometric measurements were taken along with a 
blood and random urine sample for routine analysis (Section 6.3.4). Blood pressure was 
measured five times in the non-dominant arm using a digital blood pressure monitor; with 
the mean of the last three measurements representing brachial blood pressure. Participants 
then underwent a ramp test to determine their personalised threshold work rates. 
 
6.3.2 Exercise threshold analysis 
 
Ramp test: 
The ramp test was carried out using an electronically braked cycle ergometer (Lode 
Excalibur Sport, Groningen, The Netherlands) and ventilatory gas exchange  analysis was 
carried out using the ‘Ultima Cardio O2’ gas analyser and mouthpiece (MGC diagnostics, St 
Paul, Minnesota, USA). Prior to testing participants the volume transducer was calibrated 
with a 3L precision syringe.  
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The seat height of the ergometer was adjusted to a comfortable height for participants. A 
nose and mouth mask connected to the gas analyser was secured to participants and then 
they were asked to cycle at a cadence of 60-75 rpm. The initial workload was set at 20W for 
3 minutes, then it increased by 15W every 30 seconds. The test stopped at volitional 
exhaustion, or when the cadence dropped below 60 rpm and could not return to above 60 
rpm despite verbal encouragement. Throughout the test; %O2 intake, %CO2 output and 
respiratory airflow was monitored. 
Knowing these three factors enables oxygen uptake (VO2) and carbon dioxide output (VCO2) 
to be calculated. To establish an individual’s capacity for exercise, there are two markers of 
aerobic function that were determined; the gas exchange threshold (GET) and the maximum 
oxygen uptake (VO2max), as described above.  
The data from the ramp test was sent to University of Exeter Sport Science department to 
be independently analysed by Dr Daryl Wilkerson and Dr Anthony Shepherd (lecturers in 
exercise physiology) to determine the GET. From these results personalised threshold were 
calculated. 
 
Personalised exercise thresholds to test on study visits: 
Each participant was asked to carry out the study protocol four times on different days, with 
at least 2 days between visits, and all visits completed within 6 weeks. Different exercise 
intensities were carried out on each visit in a random order. The personalised intensities 
were defined as follows: 
1. Resting (sitting for 30 minutes) (control visit) 
2. Moderate exercise for 15 minutes (80% of the work rate at the GET) 
3. Moderate exercise for 30 minutes (80% of the work rate at the GET) 
4. Heavy exercise until volitional exhaustion (40% change in work rate from the GET to 
the VO2 peak) 
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Participants cycled at 20W for 3 minutes before the work rate increased according to the 
exercise intensity being tested on that visit. This did not occur when ’resting’ was being 
tested. 
6.3.3 Visit day protocol 
 
Participants were asked to avoid exercise and sexual intercourse, which may affect albumin 
excretion, the day before and during the study day. All participants were advised not to start 
the study day if they were ill for any reason and women were advised to avoid study visits 
during menstruation. During the study participants were questioned about their activities 
prior to and during the collection periods, to determine compliance with the protocol.  
On each visit day, as soon as the participant wakes up they were asked to put on a 
pedometer. Then every time they passed urine they were required to collect a spot 
(untimed) sample and record the time of collection and the pedometer reading. After each 
time the participant passed urine, they were advised to gradually drink a small bottle 
(330ml) of water until the next time they passed urine and to continue doing this 
throughout the day. Participants were allowed other liquids, this was to ensure participants 
remained hydrated and to reduce the impact of dehydration on the results. Participants 
were asked to document everything they ate throughout the day and they were asked to 
avoid consuming alcohol and creatine/protein supplements.  
Participants attended the Diabetes and Vascular Research Centre at approximately 11am on 
visit days. A spot urine sample was collected prior to cycling on the ergometer, at the 
predetermined work rate for that visit. Blood pressure was measured five times in the non-
dominant arm using a digital blood pressure monitor before exercising; with the mean of 
the last three measurements representing brachial blood pressure. Participants were 
encouraged to maintain cycling at a cadence of 60-75 rpm. 
After cycling was complete, blood pressure and heart rate were immediately measured 
three times on their non-dominant arm, with the highest value reported. Participants were 
asked to collect their entire next urine void in a large container within 60 minutes of 
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completing the exercise. After this participants collected a spot urine sample every time 
they passed urine up to and including the second pass of urine on the following day. 
The patient information sheet is provided at appendix 5, which includes diagrams that 
outlines the study protocol.  
 
Figure 67 Diagram representing example urine sample collection times on study days 
around an exercise regime. On each visit day, as soon as the participant wakes up they were 
asked to put on a pedometer. Then every time they passed urine they were required to 
collect a spot (untimed) sample and record the time of collection and the pedometer 
reading. 
 
6.3.4 Sample processing 
 
Blood and urine samples taken at the screening visit were sent to the RD&E Hospital Blood 
Science department for analysis of blood creatinine, urinary albumin and urinary creatinine. 
Albumin was measured using the routine method (COBAS, Roche Diagnostics Ltd., Burgess 
Hill, UK), and creatinine using the routine Jaffe method (Roche Diagnostics Ltd., Burgess Hill, 
UK). 
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Urine samples collected on study visit days were also aliquoted into ten microtubes and 
immediately stored at -80oC. Sample analysis was carried out after all collections from all 
participants were complete. Prior to analysis, the samples were left to return to room 
temperature and then underwent five hand inversions to gently mix the contents. USG was 
determined using the USG-α refractometer (ATAGO Ltd., Tokyo, Japan) in thawed samples 
which had returned to room temperature prior to analysis. Urinary albumin was quantified 
using Fitzgerald ELISA (Fitzgerald Industries International, North Acton, MA, USA). To reduce 
inter-assay variation, samples from the same study visit were measured on the same ELISA 
plate, preferably with the visits all from the same participant. 
 
6.3.5 Dipstick analysis for indication of leukocytes 
 
Samples from the ‘resting’ and ‘moderate intensity for 15 minutes’ exercise tests with pre-
exercise levels above the normoalbuminuria range underwent dipstick analysis  (COBAS 
Combur-Test strips87) (Roche Diagnostics Ltd., Burgess Hill, UK) to check for presence 
leukocytes or proteinuria. Statistical analysis was repeated excluding samples positive for 
the presence of leukocytes or proteinuria in the primary sample. Both results were 
reported.  
 
6.3.6 Sample Size 
 
Heathcote and colleagues examined the change in ACR after exercise on healthy 
participants (Heathcote et al., 2009). The mean baseline ACR in women was 0.5 ± 0.3 
mg/mmol and 0.4 ± 0.1 mg/mmol in men. After exercise this increased to a mean of 5.6 ± 
9.7 and 7.6 ± 17.1 mg/mmol in women and men respectively. The smallest mean increase 
was 5.1 mg/mmol in women, which was a 10.2 fold increase of the mean or an increase of 
34 standards deviations from the mean at resting. In the Heathcote et al. study, participants 
exercised to maximal heart rate or exhaustion.  
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In this study participants exercised at lower intensities, where a smaller difference in ACR 
was anticipated. In our sample size calculation we therefore accepted a 1 standard deviation 
as the minimal detectable difference from the mean at resting. Based on within-participant 
comparisons, a sample size of n=11 will enable us to detect a 1SD with 90% power at the 5% 
level. 
 
6.3.7 Statistical analysis 
 
Data are presented as mean (±SD) and median [IQR].  Due to the non-normal distribution of 
results (tested by Shapiro-Wilkes test) data was analysed using non-parametric analysis. 
Wilcoxon sign-rank test was used to determine the difference between samples collected 
before and after exercise, p<0.05 was considered as significant.  
The Friedman test was used to explore if there was a significant difference between any of 
the exercise intensity groups for absolute and percent change in ACR. The Wilcoxon sign 
rank test was carried out to determine the intensities between which the change of ACR was 
significant. Spearman’s rank correlation was used to evaluate the relationship between the 
change in ACR with blood pressure and heart rate. 
 
6.3.8 Defining how long for an ACR to return to resting levels 
 
From the Urine Collection Study (Chapter 4) the median intra-individual reproducibility of a 
random sample, when reporting the ACR, was 22.6%. Applying this variability to the pre-
exercise sample enables the time it takes for the ACR to return to resting levels after 
exercise to be determined. Using 22.6% as the CV of a random sample, a range (the 
standard deviation) can be calculated around the pre-exercise sample, and when the ACR is 
back within this range it is reported as returned to resting levels. The range has been 
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determined using the following calculations (where the mean is the value of the pre-
exercise sample), as demonstrated in Figure 68. 
CV% =    StDev  x100 
     Mean 
 
StDev  = CV% x Mean  
           100 
 
Figure 68 An example demonstrating how the time for ACR to return resting levels is 
calculated. The dashed lines represent one standard deviation (when the CV=22.6%) around 
the pre-exercise sample. One the ACR is below the upper limit, it is reported that it has 
returned to resting levels.  
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6.4 Results 
 
Eleven participants met the inclusion criteria (Section 6.3.1) and completed the initial 
screening and four study visits. All participants reached exhaustion after heavy exercise, 
which had a mean (±SD) duration of 17 (±7) minutes. The characteristics of this cohort are 
summarised in Table 27.  
 
Characteristic n=11 
Age, years 29 (±7) 
% male 55 
Weight, kg 75.9 (±13.4) 
BMI, kg/m2 24.0 [22.7 – 28.8] 
Serum Creatinine, µmol/L 78.5 (±16.8) 
eGFR (CKDEPI), ml/min/1.73m2 105.0 (±15.4) 
Systolic BP, mmHg 119.5 (±10.3) 
Diastolic BP, mmHg 75.3 (±7.2) 
Table 52 . Characteristics of the eleven participants who completed the study. Means (±SD) 
and medians (IQR) are reported. 
 
6.4.1 Objective 1 
 
To determine if ACR changes after different intensities of exercise  
When analysing all participant data, ACR was only significantly increased after moderate 
exercise for 30 minutes (p=0.006) and heavy exercise (p=0.003) (Table 53). When removing 
results which indicated the presence of leukocytes and/or proteinuria, the change in ACR 
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after resting became significant (p=0.03), however after moderate exercise for 15 minutes 
remained not significant. 
Pre and post exercise (within 1 hour post exercise) ACR values for the different exercise 
intensities are summarised in Table 53 for all participants.  
Table 53 ACR before and after different intensities of exercise. ACR was significantly 
increased after moderate exercise for 30 minutes and heavy exercise until exhaustion in 11 
healthy participants. *significant difference in ACR after exercise.  
The change in ACR after resting became significant (p=0.03) when samples which showed 
clinical symptoms of urinary tract infections (the presence of leukocytes from dipstick 
analysis) were excluded from the analysis (participants: IDL04, 05 and 11). The change in 
ACR after moderate exercise for 15 minutes remained non-significant (p=0.31) when 
samples which showed the presence of leukocytes and/or proteinuria were removed from 
the analysis (participants: IDL05, 07, 08 and 11). 
The change in ACR in individual samples after 11 healthy subjects underwent different 
intensities of exercise are shown in Figure 69, Figure 70, Figure 71 and Figure 72. Heavy 
exercise increases ACR sufficiently enough to place 64% of participants into the 
microalbuminuria range (Figure 72). 
Exercise 
intensity 
Pre-exercise 
Median ACR 
(mg/mmol) 
Post-exercise 
Median ACR 
(mg/mmol) 
Wilcoxon 
signed-
rank test p 
Number of subjects 
who’s ACR increased 
after exercise 
Resting 
0.58  
[0.46 to 0.89] 
0.64  
[0.54 to 1.17] 
0.72 7/11 (70%) 
Moderate 
(15 minutes) 
0.62  
[0.40 – 3.69] 
0.73  
[0.60 to 2.26] 
0.37 7/11 (75%) 
Moderate 
(30 minutes) 
0.69  
[0.52 to 1.05] 
1.08  
[0.68 to 1.91] 
0.006* 10/11 (91%) 
Heavy 
0.85  
[0.62 to 1.49] 
3.55  
[1.44 to 7.00] 
0.003* 11/11 (100%) 
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Figure 69 Individual participant plots showing the change in ACR after resting for 30 
minutes. Median ACR [IQR] before resting for the 11 healthy participants was 0.58 [0.46 to 
0.89] mg/mmol and 0.64 [0.54 to 1.17] mg/mmol (p=0.72) after resting period. Samples 
from participants: IDL04, 05 and 11 indicated the presence of leukocytes from dipstick 
analysis. 
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Figure 70 Individual participant plots showing the change in ACR after moderate exercise 
for 15 minutes. Median ACR [IQR] before and after moderate exercise for the 11 healthy 
participants was 0.62 [0.40 to 3.69] mg/mmol and 0.73 [0.60 to 2.26] mg/mmol, respectively 
(p=0.37). Samples from participants: IDL04, 05 and 11 indicated the presence of leukocytes 
from dipstick analysis. 
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Figure 71 Individual participant plots showing the change in ACR after moderate exercise 
for 30 minutes. Median ACR [IQR] before moderate exercise for 30 minutes for the 11 
healthy participants was 0.69 [0.52 to 1.05] mg/mmol. This increased to 1.08 [0.68 to 1.91] 
mg/mmol (p=0.006). 
 
Figure 72 Individual participant plots showing the change in ACR after heavy exercise. 
Median ACR [IQR] before heavy exercise until exhaustion for the 11 healthy participants was 
0.85 [0.62 to 1.49] mg/mmol. This increased to 3.55 [1.44 to 7.00] mg/mmol (p=0.003). 
Heavy exercise increases ACR sufficiently enough to place 64% of participants into the 
microalbuminuria range. 
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6.4.2 Objective 2 
 
To determine if the change in ACR is different between exercise intensities 
Absolute and percent change in ACR after each exercise intensity is presented in Table 
54.The Friedman test indicated there was a significant difference across the exercise 
intensity groups for actual ACR change (p=0.007) and percent change (p=0.04). The 
Wilcoxon sign rank test was carried out to determine the intensities between which the 
change in ACR was significantly different (Table 55). 
 
 
Median change in 
ACR 
(mg/mmol) 
Mean change 
in ACR 
(mg/mmol) 
Median percent 
change in ACR 
(%) 
Mean percent 
change in ACR 
(%) 
Resting 
0.04 
[-0.10 to 0.16] 
-0.21  
± 0.86 
4.5 
[-21.7 to 35.6] 
8.5  
± 36.0 
Moderate 
(15 minutes) 
0.10 
[-0.08 to 0.23] 
-0.56  
± 3.88 
23.6 
[-13.6 to 51.8] 
26.9  
± 72.7 
Moderate 
(30 minutes) 
0.22 
[0.15 to 1.13] 
0.56  
± 0.62 
34.2 
[19.0 to 128.6] 
71.46  
± 85.9 
Heavy 
2.56 
[0.66 to 5.51] 
3.95  
± 4.36 
257.0 
[90.7 to 495.2] 
446.2  
± 542.2 
Table 54 Actual and percent change of ACR after different exercise intensities. Both the 
mean (SD) and medians (IQR) are reported for actual and percent change in ACR. The data is 
non-normally distributed therefore the median is reported. There are also individual results 
with a large change which influence the mean, so the mean is also reported to demonstrate 
this. 
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Table 55 Significance levels from Wilcoxon sign rank test to determine between which two 
intensities of exercise the change in ACR is significantly different. *significant difference 
between the two exercise intensities. 
 
Only the change in ACR after heavy exercise is significantly different to the change after 
resting, which represents normal variability. Therefore, only the increase in ACR after heavy 
exercise will be investigated in the following objectives. Heavy exercise was compared to 
cycling up a steep hill, where all participants reached exhaustion after a mean (±SD) 
duration of 17 (±7) minutes. 
 
6.4.3 Objective 3 
 
To explore how long it takes for the ACR to return to normal after heavy exercise 
 
The mean (± SD) number of samples collected the same day after heavy exercise from the 
11 healthy participants was 6.7 (±2.6). The minimum number of collections was 4 and the 
maximum was 11. This illustrates the variability in the number of samples collected among 
the participants, which limits the conclusions which can be drawn from this investigation. 
Exercise intensity 
 
Resting 
Moderate 
(15 minutes) 
Moderate 
(30 minutes) 
  Actual % diff Actual % diff Actual % diff 
Moderate (15 minutes) p 0.93 0.80     
Moderate (30 minutes) p 0.09 0.13 0.25 0.33   
Heavy p 0.003* 0.003* 0.003* 0.006* 0.01* 0.01* 
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The change in ACR over 24 hours for all participants after heavy exercise is shown in Figure 
73. The time for ACR to return to resting levels, using the method defined to determine 
recovery time (Section 6.3.8), is investigated in Figure 74, and summarised in Table 56. The 
maximum time for ACR to return to pre-exercise levels is 304 minutes. 
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Figure 73 Change in ACR over 24 hours after heavy exercise in 11 healthy participants. The variable results from participant IDL04 are 
explored in objective 6 (Section 6.4.6).  
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Figure 74 Time for ACR to return to resting levels after heavy exercise. Resting levels are 
defined as: an ACR within 1 standard deviation of the value of the pre-exercise sample (at 
resting), the standard deviation is calculated using a constant that the CV=22.6% (Methods 
6.3.8).  Participants IDL04 and IDL08 have been excluded from the analysis due to high 
activity levels following exercise test and for low frequency of sample collections, 
respectively. 
 
Samples from IDL04 were excluded from the analysis due to an aberrant number of steps 
taken after exercise and IDL08 was excluded due a low frequency of sample collections (not 
shown in Figure 74). A summary of the time for ACR to return to resting levels is provided in 
Table 56. 
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 Mean  Median  Minimum Maximum 
Time to return to 
normal (minutes) 
199.3 
±84.2 
176.5  
[125 to 299] 
95 304 
Table 56 Time for ACR to return to resting levels after heavy exercise. 9 healthy individuals 
collected samples for ACR analysis after heavy exercise until exhaustion. 
 
6.4.4 Objective 4 
 
To determine how albumin, creatinine and urine specific gravity individually change after 
heavy exercise  
 
When analysing all participant data, only the change in ACR (p=0.003) and albumin (p=0.003 
were significant after heavy exercise until exhaustion (Table 57). Creatinine (p=0.21) and 
USG (p=0.053) did not significantly change after heavy exercise. Absolute and percent 
change in ACR, albumin, creatinine and USG after heavy exercise intensity are presented in 
Table 58.  
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Pre-heavy 
exercise  
 
Post-heavy 
exercise 
 
Wilcoxon 
signed-rank test 
p 
Number of 
subjects who’s 
ACR increased  
ACR (mg/mmol) 
0.85 
[0.62 to 1.49] 
3.55 
[1.44 to 7.00] 
0.003* 11/11 (100%) 
Albumin (mg/L) 
5.0 
[1.4 to 12.9] 
27.2 
[9.0 to 52.5] 
0.003* 11/11 (100%) 
Creatinine (mmol/L) 
2.8 
[1.6 to 20.8] 
4.7 
[2.5 to 23.4] 
0.21 8/11 (73%) 
USG (refraction 
compared to water) 
1.0057 
[1.0031 to 1.0232] 
1.0068 
[1.0052 to 1.0221] 
0.53 7/11 (64%) 
Table 57 ACR, albumin, creatinine and USG before and after heavy exercise in 11 healthy 
participants. Data presented as median [IQR]. * denotes significant difference after exercise. 
 
 
 
 
 
 Median 
change 
 
Mean 
change 
 
Median percent 
change 
(%) 
Mean percent 
change 
(%) 
ACR (mg/mmol) 
2.56 
[0.66 to 5.51] 
3.95  
± 4.36 
257.0 
[90.7 to 495.2] 
446.2  
± 542.2 
Albumin (mg/L) 
33.4 
[1.7 to 39.7] 
30.6 
± 26.0 
308.1 
[132.9 to 1556.6] 
840.3 
± 1143.7 
Creatinine (mmol/L) 
1.8 
[-0.4 to 3.8] 
1.1 
± 3.3 
25 
[-17.4 to 104.3] 
52.7  
± 86.6 
USG (refraction 
compared to water) 
0.0011 
[-0.0009 to 0.0024] 
0.0002 
± 0.0 
7.8 
[-17.0 to 67.7] 
27.2 
± 60.2 
Table 58 Actual and percent change of ACR, albumin, creatinine and urine specific gravity 
after heavy exercise in 11 healthy participants. Data presented as median [IQR] or mean 
(SD).  
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6.4.5 Objective 5 
 
To investigate if the change in ACR after heavy exercise is related to an increase in blood 
pressure and heart rate 
As expected, blood pressure and heart rate significantly increased with heavy exercise until 
exhaustion are (Table 59). Absolute and percent change in blood pressure and heart rate 
with heavy exercise intensity are presented in Table 59. 
 
Pre-heavy 
exercise 
Post-heavy 
exercise 
Wilcoxon signed-rank 
test (p) 
Systolic BP 
(mmHg) 
123 
[113 to 127] 
153 
[135 to 168] 
0.003* 
Diastolic BP 
(mmHg) 
74 
[67 to 76] 
78 
[74 to 84] 
0.032* 
Heart Rate 
(bpm) 
66 
[50 to 74} 
136 
[122 to 146] 
0.003* 
Table 59 Blood pressure and heart rate before and after heavy exercise in healthy 
individuals. Data presented as median [IQR]. * denotes significant difference after exercise. 
BP: blood pressure 
  
Median  
change 
Mean  
change 
Median percent 
change 
Mean percent 
change 
Systolic BP 
(mmHg) 
24.4  
[14.7 to 35.3] 
25.8  
± 12.4 
20.4  
[12.6 to 31.3] 
21.5  
± 10.6] 
Diastolic BP 
(mmHg) 
4.0  
[0.0 to 18.2] 
7.8  
± 11.9 
5.3  
[0.0 to 27.5] 
11.8  
± 17.8 
Heart Rate 
(bpm) 
111.0  
[92.1 to 172.0] 
122.9  
± 50.1 
160.7  
[121.2 to 344.0] 
219.8  
± 139.3 
Table 60 Actual and percent change of blood pressure and heart rate after heavy exercise. 
Data presented as median [IQR] or mean (SD). 
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There was no association between change in blood pressure and heart rate with 
change in ACR after heavy exercise in healthy individuals (actual change: Table 61 
and percent change: Table 62).  
 
 
Spearman’s rank correlation with 
change in ACR 
 Rs p 
Change 
Systolic BP 
0.02 0.96 
Change 
Diastolic BP 
-0.26 0.45 
Change HR 0.41 0.21 
Table 61 No association between change in blood pressure and heart rate with change in 
ACR after heavy exercise in 11 healthy individuals.  
 
Spearman’s rank correlation with 
% change in ACR 
 Rs p 
% Change 
Systolic BP 
0.09 0.79 
% Change 
Diastolic BP 
-0.33 0.32 
% Change HR 0.38 0.25 
Table 62 No association between percent change in blood pressure and heart rate with 
percent change in ACR after heavy exercise in 11 healthy individuals.  
The correlation between percent change in ACR with maximum reached systolic BP, diastolic 
BP, heart rate and percent of maximal heart rate was also investigated (Figure 74), with the 
correlation between percent of maximal heart rate reached after heavy exercise with 
percent change in ACR presented in Figure 75. 
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Spearman’s rank correlation with 
% change in ACR 
 Rs p 
max Sys BP 0.25 0.47 
max Dys BP -0.07 0.84 
max HR 0.66 0.03* 
%maximalHR 0.62 0.04* 
Table 63 Correlation between maximum blood pressure and heart rate with percent 
change in ACR after heavy exercise in 11 healthy participants. * denotes a significant 
correlation 
 
 
Figure 75 Correlation between percent of maximal heart rate and percent change in ACR 
after moderate exercise for 15 and 30 minutes and after heavy exercise in 11 healthy 
participants with. Spearman’s rank correlation across all the intensities (not resting) 
between %maximal heart rate and percent difference was 0.61( Rs) and p= 0.0004. 
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6.4.6 Objective 6 
 
To investigate the effect of participant’s activity levels before exercise and during recovery 
on exercise induced changes in albumin excretion 
 
The change in ACR after heavy exercise for each participant is displayed in Figure 73. The 
results for participant ILD04 varied from observations from other participants, with the 
change in ACR increasing later in the day compared to after heavy exercise. This was 
investigated by examining the relationship of the change of ACR with the number of steps 
taken as recorded by the pedometer (Figure 76).   
 
Figure 76 Relationship between ACR and (A) cumulative steps, (B) step rate, after heavy exercise for 
participant IDL04. Step rate is calculated from the number of steps taken since the previous time point 
(urine collection), divided by the duration. Time at 0 mins demonstrates the time point at which heavy 
exercise was complete (participant reached exhaustion). There is only one sample collected before exercise. 
The final two collections are the first and second morning voids from the following day after exercise.  
 
 
B A 
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Participant IDL04 was not compliant with the protocol and had a high step count after 
exercise;  8,105 steps in 270 mins, a step rate of 30 steps/min, which is not in accordance to 
the study protocol. However, it demonstrates that the ACR increases with an increase in 
steps taken, and the response in ACR is not immediate, but slightly delayed.  
To investigate this observation further, graphs showing the relationship of ACR with steps 
(cumulative steps and step rate) were created for all participants on all study visits 
(appendix 6). Three patterns were found; delayed change in ACR (n=1) (Figure 76), 
immediate change (n=2) (Figure 77) and no change (n=7) (Figure 78) in response to number 
of steps taken/step rate. 
 
 
Figure 77 Representative graph demonstrating ACR responding immediately to number of steps taken. 
Relationship between ACR and (A) cumulative steps, (B) step rate, after heavy exercise for participant 
IDL09. 
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Figure 78 Representative graph demonstrating  of ACR not responding to number of steps taken. 
Relationship between ACR and (A) cumulative steps, (B) step rate, after heavy exercise for participant 
IDL11. 
 
Although there were different responses to the change in ACR to the number of steps taken, 
all results (where collections were received) show an increase in ACR from the FMV to SMV 
on the second day (on heavy exercise visit). The FMV sample is more standardised than any 
other sample, as subjects were sleeping prior to its collection. Therefore, the change in ACR 
between the FMV and SMV samples are individually plotted (Figure 49). The correlation 
between steps taken between the FMV and SMV with the change in ACR following the 
heavy exercise visit was investigated (Figure 80). Though a trend was observed it wasn’t 
significant (p=0.12). 
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Figure 79 Change in ACR from first morning void to second morning void for each 
participant following the heavy exercise visit. Participants IDL07, IDL09, and IDL11 failed 
either a FMV and/or a SMV the day after the heavy exercise visit. 
 
Figure 80 Correlation between the percent change in ACR from first morning void to 
second morning void with the rate of steps taken. Percent change in ACR from first morning 
void to second morning void with step rate is shown for each participant following the heavy 
exercise visit.  Participants IDL07, IDL09, and IDL11 failed either a FMV and/or a SMV the day 
after the heavy exercise visit. Spearman’s rank correlation; Rs= 0.60 , R
2= 0.35, p=0.12.  
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6.5 Discussion  
 
6.5.1 Change in ACR after different intensities of exercise 
 
In young healthy individuals, ACR significantly increases after heavy exercise and returns to 
resting levels within 304 minutes. Heavy exercise increases ACR sufficiently enough to place 
64% of participants into the microalbuminuria range (Figure 72). 
Walking can also increase ACR although it is not clear why ACR does not increase after 
moderate exercise, perhaps duration of exercise is a contributing factor. Furthermore, ACR 
did not change after walking for all participants, indicating altered susceptibility to walking 
induced urinary albumin excretion, and further investigation is required. Next, these 
findings are discussed in relation to other studies, to provide further understanding of the 
underlying mechanisms and to demonstrate their clinical significance. 
 
6.5.2 Comparison with the Heathcote et al. study 
 
In my study the validated ELISA was used to investigate the influence on exercise in the 
lowest levels of albumin excretion in healthy individuals. Our findings agree with those from 
Heathcote and colleagues, that ACR significantly increases when healthy individuals are 
exercised to exhaustion (Heathcote et al., 2009). 14 healthy women and 16 healthy men 
were exercised to maximal heart rate or exhaustion using the Bruce Treadmill protocol in 
the Heathcote study. The mean resting ACR in women was 0.5 ± 0.3 mg/mmol and 0.4 ± 0.1 
mg/mmol in men. After high intensity exercise ACR increased to a mean of 5.6 ± 9.7 and 7.6 
± 17.1 mg/mmol in women and men respectively. The mean increase in women was 5.1 
mg/mmol, which was a 10.2 fold increase of the resting mean ACR. In my study, the median 
[IQR] ACR increased from 0.85 [0.62 to 1.49] mg/mmol to 3.55 [1.44 to 7.00] mg/mmol, this 
is a 4.1 increase in ACR after heavy exercise (p=0.003).   
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Overall, 40% of the participants in the Heathcote et al. study on healthy individuals had an 
ACR in the microalbuminuria range after exercise and two participants were in the 
macroalbuminuria range (Heathcote et al., 2009). In my study heavy exercise increases ACR 
sufficiently enough to place 64% of participants into the microalbuminuria range, with none 
reaching the macroalbuminuria range (Figure 72). Both studies had very similar baseline 
ACR. In addition to differences in exercise protocols, a reason for the bigger increase in ACR 
in the Heathcote study is that their samples were collected only 15 minutes after 
completing the high intensity. In my study samples were collected within 60 minutes of 
completing exercise, which may be enough time for exercise induced albumin excretion to 
start recovering.  
Duration of exercise and cardio outputs after exercising subjects until exhaustion on a 
treadmill in the Heathcote et al. study and on a bike in my study are compared in Table 64. 
This demonstrates that similar exercise thresholds were tested in the two studies, as they 
have a similar duration of exercise until exhaustion. The maximal hear rate is a lot lower in 
our study compared to subjects in the study by Heathcote et al. This is most likely due to 
time taken to record heart rate measurements in our study, which used a digital blood 
pressure monitor, instead of recording heart rate in real time. Heathcote et al. measured 
blood pressure at the same time after exercise as we did, and systolic blood pressure was 
very similar between the studies, reflecting similar exercise thresholds were tested. 
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  My study Heathcote et al. 
  All subjects 
(n=11) 
Women 
(n=14) 
Men 
 (n=16) 
Duration of exercise  
(minutes) 
17 (±7) 14.7 ±2.7 15.5 ±3.0 
Max. Heart rate  
(bpm) 
136 
179  ±10 180 ±12 
[122 to 146] 
Max. Systolic BP 
(mmHg) 
153 
148 ±13 168 ±23 [135 to 168] 
Table 64 Duration of exercise until exhaustion and cardio outputs in two studies. The 
results from my study and the Heathcote et al. study are presented. Data are presented as 
mean ± standard deviation, and median [IQR]. BP; blood pressure, bpm; beats per minute.  
 
6.5.3 Duration of exercise induced albumin excretion to return to resting levels 
after heavy exercise 
 
This investigation showed that ACR increases after heavy exercise and returned to resting 
levels within 304 minutes. Therefore, future studies that investigate the change of ACR as a 
result of walking would not require long study visits over several hours. This means more 
robust protocols can be established in controlled environments to ensure participants do 
not walk before and after exercise, and a more regimental urine collection procedure is 
used. The only other study to identify exercise induced urinary albumin excretion in healthy 
individuals was not been able to determine duration as they took a single sample shortly 
after exercise and 24 hours later (Heathcote et al., 2009). However, in this investigation it is 
not possible to accurately determine how long it takes for the ACR to return to normal after 
heavy exercise.  This is due to the fact that the urine samples from individuals had variable 
collection times.  
Participants were asked to remain well hydrated throughout the study and to collect all 
samples after exercising whilst not walking too much and to drink a standard amount 
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consistently over the period of interest. However, the protocol was not always adhered to 
and the results from two participants had to be excluded (1 due to low frequency of 
collection, 1 due to unexpected high step rate). Figure 74 shows how variable the time 
between sample collections is among participants. Despite the frequency of samples, the 
maximum time for ACR to return to normal after heavy exercise is 304 minutes (Table 56). 
Although it appears that the higher the ACR after exercise the longer it takes to return to 
normal, no significant correlation was found (p=0.38) , this is most likely the results of a lack 
of consistent time intervals for urine sampling. 
Future studies would benefit from the use of activity trackers to constantly record heart rate 
and number of steps taken. Although cycle ergometers are suitable for ramp testing, the use 
of treadmills is required to test the impact of walking. It would also be of value to clinically 
follow up participants, to identify which participants develop kidney disease or CVD to 
investigate if there is an association with increased ACR induced by exercise/steps. This 
would help validate exercise as a suitable provocation test to unmask underlying 
glomerular/ vascular abnormalities.  
 
6.5.4 Change in albumin, creatinine and urine specific gravity after heavy exercise  
 
To help understand the mechanisms behind the increase in ACR after heavy exercise, the 
change in albumin and creatinine were studied individually. USG was also measured as 
another marker of urinary concentration. The median percent change for albumin, 
creatinine and USG was 308% [133 to 1557], 25 % [-17 to 104] and 7.8% [-17 to 68] 
respectively (Table 58). Only the change in albumin was similar to that of the ACR (257% [91 
to 495]) and only the concentration of albumin was significantly different after heavy 
exercise (Table 57). This demonstrates that the ACR is not raised due to increased urinary 
concentration or a change in urinary flow, as creatinine and USG are not affected in the 
same way. The raised ACR is the result of increased albumin excretion.  
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Increased glomerular permeability in response to exercise might arise from increased 
shedding of the microvascular glycocalyx (Satchell and Tooke, 2008). However, one study on 
21 young, healthy men demonstrated that there was no significant change in serum 
syndecan-1 and heparan sulphate concentrations (markers of glycocalyx shedding) after 
maximal incremental cycling exercise until exhaustion (Majerczak et al., 2016). Impaired 
proximal tubular dysfunction has also been proposed as a cause of increased urinary 
albumin excretion in early stage of diabetic nephropathy (Russo et al., 2009). The response 
of proximal tubular function to exercise is not known.  
Samples have been stored for the later analysis of; a) markers of glycocalyx shedding to 
investigate the role of increased microvascular permeability, and b) markers of proximal 
tubule function, to determine if this increased albumin excretion arises from trans-
glomerular passage or reduced tubular reabsorption.  
 
6.5.5 Relationship between blood pressure and heart rate with change in ACR 
after heavy exercise 
 
There is a significant correlation between maximum heart rate achieved (Rs = 0.66, p=0.03) 
and percent change in ACR, and also between percentage of maximal heart rate (Rs = 0.66, 
p=0.03) with percentage change in ACR after heavy exercise (Table 63). It is unlikely that 
increasing heart rate is the cause of increasing AER, but rather reflecting how hard the 
individual is exercising. This is supported by the significant correlation between percent of 
maximum heart rate achieved with the percent change in ACR (Rs = 0.61, p= 0.0004) across 
all intensities (except when resting as blood pressure and heart rate were not measured) 
(Figure 75). The variable change in ACR seen between the participants across all the exercise 
intensities may be explained by the variability in percent of maximal heart rate. However, 
the purpose of using personalised exercise thresholds was to reduce this variation. 
Repeating RAMP testing to determine an average GET would help to further reduce this 
variability (Weston and Gabbett, 2001). 
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There was no correlation between the change in blood pressure and change in ACR, which is 
expected as these are healthy participants who are normotensive and that we assume have 
normal renal autonomic control, so intraglomerular pressure should not change in response 
to a change in systemic pressure (Table 61). A limitation of these findings is that blood 
pressure and heart rate were measured directly after exercise and not during. It is therefore 
unlikely that the peak measurements were recorded.    
Our results agree with those of Viberti’s study, which showed there was no correlation in 
the change of systolic blood pressure with change in albumin excretion in both the diabetic 
group and the controls. However, my study cannot provide evidence for Viberti’s conclusion 
that it is unlikely that the change of AER after exercise is caused by an ‘abnormal’ 
cardiovascular response  (Viberti et al., 1978). This broad conclusion might not be accurate, 
as it does not consider that change in brachial pressure may not reflect changes in 
glomerular pressures. If autoregulation is failing in the patients with diabetes than 
glomerular pressures may be increasing more in patients with diabetic then in control 
participants, influencing filtration of albumin. This is explored further to explain the 
variability between subjects who demonstrate walking induced urinary albumin excretion 
(Section 6.5.6). 
A limitation of this study is the number of participants tested. The power analysis used was 
suitable to calculate the minimum required sample size to detect a difference in ACR after 
moderate exercise. However, it was not designed to detect a correlation between change in 
ACR, blood pressure and heart rate. To investigate these relationships further a new power 
analysis is required. The lack of correlation cannot therefore be taken as evidence that there 
was no relationship between the change in ACR and cardiovascular response. 
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6.5.6 Limitations and recommendations for future research 
 
These observations can’t be extrapolated to a population with diabetes, where greater 
changes are anticipated. Individuals with DM are likely to have a greater change in ACR after 
walking than was found from the healthy participants in this study (Viberti et al., 1978). This 
compromises the accuracy of random spot collections to diagnose microalbuminuria and 
investigate albumin excretion. This warrants further investigation and the challenges 
endured in this study should be considered when designing protocols in future studies.  
The importance of dipstick testing to indicate the presence of leucocytes has also been 
demonstrated in this study. The presence of leucocytes has been associated with an 
increase in AER, although the mechanism for this has not been fully investigated. It’s 
plausible that AER increases as a result of inflammation, a process common to both 
infection and exercise. A positive correlation between inflammatory biomarkers and 
albuminuria has been previously reported in  3939 participants with CKD enrolled in the 
Chronic Renal Insufficiency Cohort study between June 2003 and September 2008 (Gupta et 
al., 2012). Several mechanisms have been proposed as to how inflammation causes 
increased albuminuria, including the activation of matrix metalloproteinases (MMPs), which 
shred the glycocalyx (Kolářová et al., 2014). 
Personalised exercise thresholds were determined using a ramp test, to reduce the 
variability in ACR responses to exercise among participants. This variation was still present 
and might reflect different susceptibility to exercise, although there are several other 
factors which may contribute. Despite determining personalised exercise thresholds, the 
graphs show that the change in ACR after different intensities varies considerably between 
subjects (Figure 69, Figure 70, Figure 71 and Figure 72). They also show that the change 
increases with increasing intensity (please note the Y axis scale varies between graphs). 
It was discovered that some individuals had walked a considerable distance to and from the 
research centre on visit days. To help reduce this influence, participants should have been 
rested prior to exercise. Participants underwent heavy exercise until volitional exhaustion, 
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although verbal encouragement was given, the duration of exercise was variable, reflecting 
different levels of effort among the participants. Heavy exercise was compared to cycling up 
a steep hill, where all participants reached exhaustion after a mean (±SD) duration of 17 (±7) 
minutes. Being able to constantly monitor heart rate would provide further information on 
the effort from participants. 
Samples were also stored from this study for the later analysis of markers of proximal tubule 
function, to determine if the expected increase in albumin excretion arises from trans-
glomerular passage or reduced tubular reabsorption, as investigated in the clinical ranges in 
a previous study (Viberti et al., 1978). Biomarkers of glycocalyx shedding can also be 
measured in stored samples, which will provide more information on microvascular 
involvement in exercise/walking induced increased urinary albumin excretion.  
   
6.5.7 Impact of walking on ACR 
 
When investigating the relationship between the number of steps taken and the change in 
ACR, it is evident that some participants did not adhere to the protocol. However, this led to 
an important finding, that there are different types of responses in ACR to the number of 
steps taken. Three patterns were found; delayed change in ACR (Figure 76), immediate 
change (Figure 77) and no change (Figure 78). When investigating these patterns on 
different visit days, the pattern between ACR and steps varied between study visits for all 
participants.  No participants had the same pattern between ACR and steps taken on each 
study visit. This suggests more accurate methods of monitoring ACR and steps are required 
to investigate this finding further to determine if walking unmasks early microvascular 
dysfunction as demonstrated by increased urinary albumin excretion. 
In 2011, Koh and colleagues investigated the change in ACR, 1 and 2 hours after a one 
kilometre treadmill walking exercise in thirty-five participants with diabetes (three with 
T1DM and 32 with T2DM) and nine control subjects, those with diabetes had a range of pre 
exercise levels of albumin excretion across the full albuminuria range (Koh et al., 2011).  
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Koh et al. showed no significant change in ACR in controls in response to walking. A possible 
explanation for no change in ACR in controls in the study by Koh et al. is that they were 
unable to quantify the lowest levels of urinary albumin. In the study by Kol et al., ACR in 
females with diabetes increased above the microalbuminuria threshold at 1 hour post 
exercise on average, returning to baseline levels by 2 hours (Figure 64). Our findings support 
this in healthy subjects by indicating that ACR returns to resting levels by the next void after 
walking induced increased urinary albumin excretion. 
This incidental finding of walking induced urinary albumin excretion is reported for the first 
time in healthy normotensive individuals without diabetes in this thesis. These findings were 
only achievable by using the validated sensitive ELISA (Chapter 2), when reporting the ACR 
(Chapter 3) from samples being collected using the appropriate method (Chapter 4), which 
have been stored at -80oC (Chapter 5).  
This finding is clinically relevant as some individuals might walk to their GP surgery before 
providing a urine sample, which could result in a falsely high ACR. Previous studies have 
shown that individuals with DM have a larger increase in AER after exercise than healthy 
individuals (Viberti et al., 1978). Given that this study was carried out on healthy individuals, 
patients with DM might have an even greater rise in ACR after walking. 
The majority of participants demonstrated different response patterns across the 4 visits. 
However, participant IDL04 always had a response and IDL10 never had a response. The 
variation in responses might be the result of the method. The pedometers used were simple 
step counters, with the accumulative number of steps being manually recorded at the time 
of urine collections. Therefore, it cannot be determined when the number of steps taken 
between voids actually occurred. Participants who had a delayed response in ACR might 
have had a sudden increase in the number of steps just before providing a sample, therefore 
the ACR was only raised in the next collection. The impact of walking on the ACR was not a 
primary objective of this study, and this incidental finding warrants further investigation, 
especially on patients with DM. This could be achieved using a more robust protocol, 
utilising activity monitors which constantly record heart rate and steps taken. 
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A sample from the first morning void is the most standardised urine collection method 
among participants and an increase in ACR in the second morning void is consistent, 
although the magnitude of that increase varies (Figure 79). Figure 80 shows that after a 
threshold, around 18 steps/min, the ACR increases by over 100%. This threshold for change 
in ACR is also reflected when correlating the percentage of maximal heart rate to change in 
ACR, where change in ACR considerably increases after exercising above 70% of maximum 
heart rate (Figure 75). This confirms that ACR increases with activity.  
Walking induced increased albumin excretion might represent an early nephropathy, 
possibly caused by impaired microvascular autoregulation. The mechanisms involved and 
the clinical significance of these findings require further study, and this theory is considered 
in conjunction with results from the SUMMIT cohort in Chapter 7. 
 
6.6 Conclusion  
 
In healthy individuals heavy exercise increases ACR sufficiently enough to place 64% of 
participants into the microalbuminuria range. Thus healthy individuals should not provide a 
urine sample for ACR measurement if they have undertaken heavy exercise within the 
previous 5 hours.   
Some individuals express increased ACR in response to walking. This needs further 
investigation as patients walking to appointments could have falsely elevated ACR or it may 
indicate an increased risk of cardiovascular disease. 
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Chapter 7 Urinary Albumin Excretion and Microvascular 
Function  
 
This chapter brings the earlier validated assessments of the measurements of low levels of 
albumin excretion in urine into a relevant clinical population to explore the relationships 
between microvascular function and urinary albumin excretion and sets this in context with 
the literature. 
 
7.1 Background  
 
Microalbuminuria has been established a risk factor for diabetic kidney disease since the 
early 1980’s (Mogensen, 1987). Since then a wealth of studies have demonstrated that 
increasing urinary albumin, even within the normal range, is a risk factor for cardiovascular 
disease in subjects with and without diabetes (Hillege et al., 2002) (discussed in Chapter 1) .  
A good review by Lambers Heerspink et al. in 2011 summarises the risk of renal and 
cardiovascular morbidity with microalbuminuria across different populations from different 
studies. It is evident that microalbuminuria is a risk factor, not only in patients with DM but 
also in the general population. However, the clinical utilisation of microalbuminuria outside 
of the management of DM has not made it into common guidelines (de Zeeuw et al., 2006).  
The review by Lambers Heerspink et al. (Figure 10) demonstrates increasing risk with 
increasing urinary albumin excretion, especially when predicting cardiovascular morbidity.  
Urinary albumin excretion is a continuous risk marker with no lower limit.  Therefore small 
increases in urinary albumin excretion within the normoalbuminuria range are associated 
with an increased risk of morbidity.   
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Generalised microvascular dysfunction in diabetes, causing increased vascular permeability, 
is thought to underlie the complications of DM including DKD and CVD (Deckert et al., 1989). 
In the kidney this is expressed as increased urinary albumin excretion where as in larger 
vessels it accelerates the “permeability” of lipids into the vascular wall leading to 
atherosclerosis (Deckert et al., 1989). This is supported by evidence that urinary albumin 
excretion is associated with other microvascular complications of diabetes, such as 
retinopathy and neuropathy (Newman et al., 2005).   
It is important to investigate these relationships further because the studies which have 
investigated these relationships to date have been limited by the use of routine assays 
which can’t quantify low concentrations of urinary albumin. Thus relationships to date have 
been falsely constrained by assay limitations and it is unclear whether links between urinary 
albumin excretion and CVD and microvascular complications or dysfunction occur right 
across the spectrum of urinary albumin excretion.  
Using the validated ELISA, and applying the most accurate and reproducible method to 
collect and store samples, the lowest levels of urinary albumin excretion are examined and 
the relationship with microvascular function and microvascular complications of diabetes 
are investigated for the first time in this chapter. 
 
7.2 Introduction 
 
7.2.1 Microvasculature 
 
Microalbuminuria is a microvascular complication of diabetes. To investigate the 
relationship between urinary albumin excretion and systemic microvascular function, it is 
important to understand the human microvasculature, and how different techniques can be 
applied to assess its function. 
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Microvasculature refers to the smallest systems of blood vessels and is organised into three 
sections; arterioles, capillaries and venules, which work together with specialised cells to 
facilitate exchange between the circulatory system and tissues. Arterioles extend from 
resistance arteries and branch out into capillaries and the blood is returned to the heart via 
venules, which lead to veins. Arterioles are small vessels which are composed of endothelial 
cells surrounded by a thin layer of smooth muscles. This enables arterioles to constrict and 
dilate, controlling blood distribution and pressure, which is regulated by extrinsic (e.g. 
autonomic nervous system) and intrinsic mechanisms (e.g. local produced vasodilators and 
constrictors)  (Mader et al., 2012).  
Capillaries are the site of nutrient and gas exchange between blood and surrounding tissue. 
Capillaries are only one endothelial cell thick and are surrounded by a basement membrane. 
Capillary diameter allows a single erythrocyte to pass through at a time or in some larger 
capillaries two erythrocytes to overlap as they pass through the capillary lumen. Pericytes 
sparsely surround capillaries to provide structural support, and contractile properties 
(Mader et al., 2012). 
The traditional theory behind capillary exchange is that blood pressure gradient is higher at 
the arterial end compared to protein oncotic pressure gradient, which results in water and 
small solutes being pushed out of the capillary into the interstitium (Michel, 1997). Through 
the midsection of capillaries, oxygen, glucose and amino acids move out and are taken up by 
the surrounding cells, and metabolic waste products like carbon dioxide diffuse into the 
capillary. As the pressure difference declines across the capillary towards the venular end 
and falls below the opposing oncotic pressure, water and other waste products can diffuse 
into the capillary with blood travelling through the venule back towards the heart  (Cleaver 
and Melton, 2003).  
This traditional theory is based on the Starling’s principle , but has since been revisited by 
Adamson and colleagues in 2004 (Adamson et al., 2004). A well-received review by Levick 
and Michel proposes that across the entire capillary length, fluid is filtered into the 
interstitial space, and not just at the arteriolar end (Levick and Michel, 2010). It is thought 
that endothelial glycocalyx (Section 1.3.4.1) plays a key role in the semipermeable 
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capabilities of the membrane. In addition, reabsorption of interstitial fluid does not occur at 
venules and the ultra-filtered fluid returns to circulation via the lymphatic system (Levick 
and Michel, 2010).   
There are three types of capillaries; continuous, discontinuous and fenestrated. The type of 
capillary depends on the demands of the surrounding tissue and organ. For example; 
fenestrated capillaries enable renal glomeruli to filter blood, whereas discontinuous 
capillaries allow blood cell turnover in bone marrow, the spleen and the liver (Levick, 1991). 
Continuous capillaries have no gaps in the endothelium. Continuous capillaries are present 
in skin and muscle cells, although capillary density is much smaller in skin due to a lower 
demand in blood supply (Levick, 1991).  
 
The next section provides a superficial overview of some of the main components of 
microvasculature, followed by a review of methods which test their functionality. 
 
7.2.1.1 Endothelium 
 
The endothelium lines the interior surface of blood vessels and consists of a thin layer of 
squamous endothelial cells. In addition to contributing to the semi-selective barrier 
between blood and surrounding tissues, the endothelium plays a central role in regulating 
blood flow, blood pressure, inflammation, coagulation and angiogenesis. The functions of 
the endothelium are achieved through membrane bound receptors for a wide range of 
molecules, including lipids, proteins (e.g. growth factors, coagulants, and anti-coagulants), 
metabolites (e.g. nitric oxide and serotonin), hormones and mechanosensors (Cines et al., 
1998). 
The function of the endothelium is controlled in part by the glycocalyx, which is an 
important determinant of vascular permeability (Reitsma et al., 2007). The endothelial 
glycocalyx has also been suggested to act as a mechanotransducer, translating biochemical 
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forces from blood flow and shear stress into biomechanical signals to maintain vascular tone 
(Reitsma et al., 2007, Florian et al., 2003). 
The endothelium regulates blood flow through secretion of mediators by endothelial cells, 
which are pivotal in vasoregulation. These include vasodilators such as nitric oxide and 
prostacyclin, as well as vasoconstrictors such as endothelin-1 and platelet activating factor 
(Cines et al., 1998). Nitric oxide is a key mediator in regulating blood flow and tests that 
stimulate its production in endothelial cells can measure the blood flow response to indicate 
endothelial function (Deanfield et al., 2005).     
A study by Kwon et al which investigated NO generation in the renal microvasculature 
supports the theory that microvascular dysfunction is the common process in the 
pathophysiology of diabetic kidney disease, and cardiovascular disease, resulting in 
increased urinary albumin excretion (Kwon et al., 2009). NO generation was assessed by 
measuring urinary NO levels, nitrate and nitrite were quantified. Their findings, from a 
hundred subjects with varying degrees of acute kidney injury (AKI), indicate that diminished 
NO generation by injured endothelium could impair the vasodilatory ability of the renal 
vasculature, contributing to a reduction of GFR (Kwon et al., 2009).  
The findings of Kwon et al. highlight endothelial dysfunction’s pathophysiological 
involvement and support the Steno Hypothesis, which was the first to claim a common link 
between mechanisms involved in diabetic nephropathy and CVD. The Steno hypothesis is 
that urinary albumin excretion is a marker of overall vascular dysfunction with increased 
urinary excretion in the kidney presenting itself from increased glomerular permeability and 
also representing increased vascular permeability elsewhere increasing CV risk (de Zeeuw et 
al., 2006). However the endothelium is very heterogeneous in structure and function. 
Endothelial cells from different vascular sites have different functions and employ different 
strategies to mediate local haemostatic balance in different tissue beds and sizes / types of 
vessels (Aird, 2007). 
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7.2.1.2 Vascular smooth muscle cells 
 
Arterioles gain their contractile properties through smooth muscle cells that encompass 
them, providing arterioles the ability to intrinsically change their luminal diameter. Vascular 
smooth muscle cells respond to vasoactive substances from; endothelial cells, nerves and 
from agents in the blood. Smooth muscle cells also respond to changes in blood pressure 
(transmural pressure), known as the myogenic response (Davis and Hill, 1999). 
The myogenic mechanism is independent of neural, metabolic, and hormonal influences, 
and although it is most pronounced in arterioles, it’s occasionally demonstrated in arteries, 
venules, veins and lymphatics (Johnson, 2011).When luminal blood pressure rapidly 
increases, the stretching of the arteriole causes ion channels to open resulting in 
polarisation of the muscle, leading to vasoconstriction reducing blood flow. Diminishing 
blood pressure causes ion channels to close resulting in smooth muscle relaxation leading to 
vasodilation, increasing blood flow. (Davis and Hill, 1999). An example of arteriole 
autoregulation is in the renal glomeruli, where constant renal blood flow is maintained at 
varying arterial pressure (Aukland, 1989).  
In this chapter the relationship between urinary albumin excretion and generalised 
microvascular function is being investigated and it has been proposed that the 
microvascular function of the skin is a suitable model (Holowatz et al., 2008). The skin is 
easily accessible and there are non-invasive methods to assess its microvascular function.  
Skin microvascular function has been used as a surrogate marker for systemic vascular 
health in various diseases including hypertension (Antonios et al., 1999, Feihl et al., 2006), 
diabetes (Chang et al., 1997, Yamamoto-Suganuma and Aso, 2009, Jaap et al., 1994b, 
Sorensen et al., 2016, Strain et al., 2005a) and end stage kidney disease (Kruger et al., 2006). 
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7.1.1.3 Skin microvasculature 
 
Skin is the largest organ of the human body, protecting the internal environment from the 
external environment and playing a pivotal role in thermoregulation. Skin is separated into 
three layers; epidermis, dermis and subcutaneous tissue (also referred to as hypodermis / 
subcutis) (Figure 81).  
 
Figure 81 Architecture of skin. This illustration shows the distribution of microvessels in the 
different layers of the skin (Mulroney and Myers, 2008). The microcirculation in the dermis is 
characterised by two distinct horizontal plexuses. An upper horizontal plexus in the papillary 
layer and a lower horizontal network between the dermis and subcutaneous tissue. 
 
The epidermis is the uppermost layer and is the most biologically active layer as the 
epithelium is constantly renewing. The epidermis is avascular and densely packed with 
epithelial cells, which through an adaptive process called cornification (keratinisation) of the 
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skin forms a protective barrier against the external environment and forms the first line of 
defence against external pathogens (Shetty and Gokul, 2012).   
The epidermis is separated from the dermis layer by the basement membrane. The 
basement membrane is composed primarily of type IV collagen which provides mechanical 
stability and contains glycoproteins which promote adhesion with the epidermis (LeBleu et 
al., 2007). The dermis layer, a connective tissue matrix composed of elastin and collagen, 
provides elasticity and tensile strength to skin. The dermis contains blood and lymph 
vessels, nerves, and other structures like sweat glands and hair follicles. These structures 
have their own vascular network for example; fenestrated capillaries surround sweat glands 
and dermal papilla of hairs (Braverman, 1997). 
The microcirculation in the dermis is characterised by two distinct horizontal plexuses. An 
upper horizontal plexus in the papillary layer and a lower horizontal network between the 
dermis and subcutaneous tissue (Figure 81) (Mulroney and Myers, 2008). Arterioles and 
venules travel between the lower horizontal plexus and the upper network in the papillary 
layer, from which continuous capillary loops branch into the papillary dermis (Braverman 
and Yen, 1977). These papillary loops are the primary site for exchanging oxygen and 
nutrients to supply the epidermal cells , which also receives oxygen from outside air in 
contact with the skin (Braverman and Yen, 1977).  
Below the dermis is the adipose rich subcutaneous layer (hypodermis/subcutis) which 
connects skin to underlying fibrous tissue of bones and muscles. The subcutaneous layer 
acts as a fat reserve, through which blood vessels travel to reach the lower horizontal plexus 
at the hypodermis-dermis interface (Wong et al., 2016). 
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7.2.2 Assessing cutaneous microvascular function 
 
Optical microscopy, laser Doppler and evaluating tissue oxygenation are non-invasive 
techniques commonly used to investigate microvascular function in the skin. Laser Doppler 
techniques have been extensively used over the past few decades and are used in a range of 
methods that measure an individual’s microvascular response to various interventions 
(Roustit and Cracowski, 2012). They will be briefly reviewed here. 
 
7.2.2.1 Laser Doppler 
 
Laser Doppler fluximetry is a technique that uses the Doppler shift in a laser beam to 
continuously measure the number and velocity of moving erythrocytes in the tissue of 
interest, for example the skin microvasculature. The principle of the Doppler shift was 
proposed by Austrian physicist Christian Doppler in 1842, who stated that there is a change 
in frequency of a wavelength caused by the motion of the source (Oberg, 1990).  
When assessing the skin microvasculature, laser light is emitted at a single frequency and 
when it comes into contact with any surface the light is reflected and scattered. 
Reflected/scattered light from stationary objects will have no change in frequency, whereas 
light reflected/scattered from moving objects, erythrocytes, will have a changed frequency 
(Oberg, 1990). A photo detector collects the reflected/scattered light and by determining 
the magnitude of the shift in frequency and its occurrence, the concentration and velocity of 
erythrocytes is calculated (Roustit and Cracowski, 2012, Oberg, 1990). The laser Doppler 
output is not a direct measure of skin blood flow, but rather an index of skin perfusion or 
flux, and is reported in arbitrary perfusion units (PU) or Volts (V) (Choi and Bennett, 2003).  
The penetration depth of the laser into tissue is controlled by its wavelength. In skin, shorter 
wavelengths test superficial layers, whereas longer wavelengths penetrate deeper. 
Measurement depths vary depending on the tissue being tested. In the skin there is no 
318 
 
definite interpretation of what fraction of the laser Doppler shift is attributed to blood flow 
in capillaries, arterioles, venules and what proportion of which plexus is being assessed 
(Yvonne-Tee et al., 2006). It is suggested that laser Doppler fluximetry measurement in the 
skin represents thermoregulatory blood flow and nutritional blood flow (Knotzer and 
Hasibeder, 2007).  
 
7.2.2.2 Iontophoresis 
 
Iontophoresis is a non-invasive method of introducing vasoactive substances into skin 
microvasculature. The response in skin perfusion assessed by laser Doppler imaging 
provides a measure of microvascular function, more specifically the function of specific cell 
types (e.g. endothelial dependent or independent) depending on the vasoactive drug used.   
Iontophoresis achieves transdermal drug delivery to skin microcirculation by transferring 
charged molecules using a low intensity electrical current (Roustit and Cracowski, 2012). 
Several factors need to be considered for iontophoretic drug transfer including the pH and 
concentration of the solution, skin thickness and hair cover, and the intensity of the current 
(Kalia et al., 2004).  
Acetylcholine (ACH) and sodium nitroprusside (SNP) are vasodilators commonly used to test 
microvascular function. Although there is controversy over the exact mechanism of how 
ACH mediates vasodilation, it is established that it induces endothelium-dependent 
vasodilation (Roustit and Cracowski, 2012). The most prominent theory is that ACH binds to 
muscarinic receptors on endothelial cells, mitigating the activation of endothelial nitric 
oxide synthase and stimulating prostaglandin production (Turner et al., 2008). It is not 
certain how ACH travels to the endothelial cells; it can travel directly through the 
transepidermal route or go the appendageal route, through hair follicles and sweat glands.  
If ACH travels through the transepidermal route, ACH could enter the microvasculature 
through adventitia vessels. If ACH travels through the appendageal route, fenestrated caps 
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hair follicles and sweat glands would enable ACH to reach the microvasculature, however 
muscarinic receptors in sweat glands may influence ACH delivery (Turner et al., 2008). 
SNP does not interact with endothelial cells, once in circulation SNP breaks down to release 
nitric oxide in smooth muscle cells. The increased availability of nitric oxide in smooth 
muscle cells (from both ACH and SNP) induces a biochemical cascade that results in the 
inhibition of vasoconstriction, increasing vasodilation (Turner et al., 2008). Therefore, ACH is 
used to test endothelium-dependent vasodilation and SNP tests endothelium-independent 
vasodilation, both markers of microvascular function that don’t require neuronal input.  
Abnormal response to ACH does not prove endothelial dysfunction, unless the SNP response 
is normal. 
The response in skin perfusion is assessed by laser Doppler imaging, which needs to 
measures at a depth which corresponds to the delivery site using iontophoresis.  
 
 
7.2.2.3 Maximal hyperaemia  
 
A principal function of skin is thermoregulation, aiding heat loss or conservation by 
vasodilating or constricting respectively. Externally heating skin increases perfusion, and 
maximal blood flow or perfusion (hyperaemia) can be estimated (Sandeman et al., 1991b) 
using laser Doppler fluximetry. This vascular test indicates the microvascular capacity for 
vasodilation in response to injury, an important part of healing (Cracowski et al., 2006).  
The majority of heating protocols state that local warming to 42-43oC is sufficient to induce 
maximal vasodilation (Johnson and Kellogg, 2010) , with 44oC being reported optimal in 
healthy individuals (Saumet et al., 1998). Although the exact mechanism behind maximal 
hyperaemia after local heating are not fully understood, there are at least two independent 
phases; an initial phase which has a peak maximal hyperaemia within 10 minutes of heating, 
followed by a plateau after 20-30 minutes (Figure 82) (Minson, 2010). Therefore, skin must 
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remain heated for at least 30 minutes before estimating MBF. It has been proposed that the 
initial peak in maximal hyperaemia is predominately mediated by local sensory nerves, as 
the response can be attenuated by local anaesthesia (Arildsson et al., 2000). Whereas the 
second phase of vasodilation is largely attributed to local nitric oxide production (Minson et 
al., 2001) though the magnitude of its involvement has been disputed (Gooding et al 2006).  
 
 
 
Figure 82 Skin blood flux in response to local heating. Skin blood flux was determined using 
laser speckle contrast imaging on the forearm (Roustit and Cracowski, 2012) PU denotes 
perfusion units. 
 
Minimum vascular resistance 
 
Vascular resistance is the resistance that must be overcome to push blood through the 
circulatory system. Minimum vascular resistance (MVR) is the lowest resistance to 
overcome, which occurs during maximal vasodilation. In the microvasculature, MVR can be 
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calculated when estimating maximal hyperaemia, where vasodilation is induced by localised 
heating. MVR is calculated by a rearrangement of Darcy’s law to calculate blood flow by 
dividing mean arterial pressure by maximal hyperaemia (Jayalalitha et al., 2008).    
High minimum vascular resistance and low maximum hyperaemia are associated with 
structural alterations to microvessels (Adingupu et al., 2015, Williams and Tooke, 1992, Jaap 
et al., 1994b) 
 
7.2.2.4 Post-occlusive reactive hyperaemia 
 
Post-occlusive reactive hyperaemia (PORH) refers to the transient increase in skin blood 
flow above baseline levels following the release from arterial occlusion. Vessel beds dilate 
during occlusion due to hypoxia, upon release blood rushes down the dilated vessels 
causing a sudden increase in perfusion / pressure. It is thought that reactive hyperaemia is 
caused by; myogenic relaxation to reduce vascular resistance, an abundance of locally 
produced vasodilators (produced in response to hypoxia), and by metabolites of ischaemic 
tissues (Kilbom and Wennmalm, 1976, Nowak and Wennmalm, 1979). Sensory nerves have 
also been shown to be involved in the reactive hyperaemia response (Larkin and Williams, 
1993). This myogenic / auto regulatory response returns blood flow to normal (Cracowski et 
al., 2006).  
Following the release from occlusion tissues become oxygenated, subsequently less 
vasodilators are produced and normal vascular resistance returns. The contribution of the 
different factors in the reactive hyperaemia response are debated (Wong et al., 2003, 
Lorenzo and Minson, 2007).  
Traditionally there are three measurements that are utilised when evaluating PORH; the 
height of the peak in blood flux (peak hyperaemia), the time to reach it and the time to 
return to baseline (Figure 83).  
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Figure 83 Blood flux during post occlusive reactive hyperaemia testing. Blood flux is shown 
at a time constant of 3.0 seconds for 5 minutes resting (baseline), after which arterial 
occlusion at the ankle occurred for 4 minutes to generate a biological zero. At nine minutes 
the cuff is released followed by a rapid increase in flux which reaches a maximum height of 
peak, where the time to reach it and time to return to baseline can be calculated. 
Abbreviations: Tp, time to peak; TBL, time to baseline; AU, arbitrary unit. Adapted from 
(Adingupu, 2013). 
 
Usually only one peak is reported, however Ray et al. identified different response curves 
after the release from a two minute occlusion at the ankles when reducing the time 
constant to follow blood flux (Ray et al., 1999). This has been investigated further and three 
distinct patterns of post-occlusive flow have been described; 1) a gradual rise to peak 
response classified as ‘normal’, 2) a ‘non-dominant early peak’ with an early rise within 2 
seconds but which is lower than the subsequent ‘normal’ peak and 3) a ‘dominant early 
peak’ within 2 seconds which declines rapidly and is followed by a lesser ‘normal’ peak 
(Strain et al., 2005). 
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Figure 84 Early peak response curve morphology. Type 1: gradual controlled rise to peak 
response classified as ‘normal’, type 2: a ‘non-dominant early peak’ with an early rise within 
2 seconds but which is lower than the subsequent peak and type 3: a ‘dominant early peak’ 
that is within 2 seconds of cuff release, which declines rapidly and is followed by a less 
‘normal’ peak (Strain et al., 2005a). 
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Studies carried out by The Diabetes and Vascular Research Centre in Exeter have proposed 
that impaired myogenic vasoconstriction or its modulation via the endothelium or nerves, 
leads to a very rapid unmodulated increase in blood flow (Strain et al., 2005a). Wall stress is 
the stimulus for the myogenic response, therefore  a thickened wall structure, such as that 
occurring in diabetes or hypertension, will reduce the response at a given pressure 
(Matchkov et al., 2002) and may delay the onset of the myogenic response so that an early 
increase in flow is observed before the myogenic vasoconstriction (Strain et al., 2005a). 
Post occlusive reactive hyperaemia has been used to assess macro- and microvascular 
function in healthy individuals, diabetes,  and in disease states (Tur et al., 1991, Minson and 
Wong, 2004, Higashi et al., 2001), with impaired reactive hyperaemia associated with risk 
factors for CVD (Yamamoto-Suganuma and Aso, 2009, Morales et al., 2005, Vuilleumier et 
al., 2002) and with the presence of coronary artery disease (Shamim-Uzzaman et al., 2002). 
 
 
7.2.3 Post occlusive reactive hyperaemia and urinary albumin excretion 
 
A prominent study carried out by Strain et al. investigated the relationship between in vivo 
microvascular function with lower levels of urinary albumin excretion within the normal 
range (Strain et al., 2005a). The study was a second analysis of participants aged 40-60 years 
of African Caribbean and European descent with and without diabetes. Using a time 
constant of 0.1 seconds to trace blood flux during PORH testing, early peak morphologies 
were identified and used to group participants (Table 65) (described above in Figure 84 ). 
 
 
 
325 
 
Variable 
Group 1: 
normal peak 
Group 2: 
early non-dominant 
peak 
Group 3: 
early dominant 
peak 
P for trend 
N 137 93 41 
 
Sex (% male) 43 40 64 0.06 
Age (years) 53 ± 7.8 55 ± 7.0 55 ± 8.5 0.053 
Ethnicity (% European) 55 44 51 0.2 
Resting brachial systolic 
(mmHg) 
133 ± 20 142 ± 24 146 ± 26 0.001 
Resting brachial diastolic 
(mmHg) 
81 ± 9 84 ± 11 85 ± 11 0.01 
Weight (kg) 81 ± 15 84 ± 16 90 ± 19 <0.001 
Waist (cm) 92 ± 12 95 ± 13 99 ± 20 0.005 
Fasting glucose (mmol/L) 5.6 (4.9-6.0) 6.1 (4.9-6.8) 6.6 (4.9-10.1) 0.001 
Cholesterol (mmol/L) 5.2 ± 0.9 5.1 ± 1.1 5.1 ± 1.3 0.7 
HDL (mmol/L) 1.30 ±  0.35 1.25 ± 0.33 1.20 ± 0.35 0.08 
Fasting triglycerides 
(mmol/l) 
1.08 (0.79-1.40) 1.15 (0.72-1.52) 1.23 (0.92-1.85) 0.1 
Diabetes (%) 31 42 51 0.012 
Smoking status 
(current/ex/never) (%) 
14/37/49 24/23/53 32/37/32 0.02 
Albumin excretion rate 
(µg/min) 
3.69 (3.20-4.07) 7.22 (5.47-9.53) 12.56 (7.80-20.20) <0.001 
Table 65 Participant characteristics stratified by peak response curve morphology group. 
Data are means ± standard deviation, for skewed data the median (interquartile range) are 
reported (Strain et al., 2005a).   
 
The severity of several CVD risk factors; blood pressure, glucose concentration, obesity, 
smoking status and AER, are higher in subjects with an early dominant peak compared to 
those with a normal peak. These CVD risk factors all demonstrated a significant trend across 
the three groups (Table 65). The relationship between AER and peak morphology was also 
present when dividing the cohort by diabetes status, hypertension, and the use of 
antihypertensive therapies. Furthermore, multivariate analysis was carried out to explore 
potential confounding factors in the relationship between peak response curve morphology 
and AER. A model composed of peak morphology, age, gender, systolic blood pressure, 
weight, fasting glucose, fasting triglycerides, and smoking status to predict AER, determined 
that only peak morphology is independently associated (β-coefficient= 0.57 ± 0.11, p 
<0.001), with 29% of the overall variance of AER explained by the whole model. The study 
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by Strain et al. not only demonstrates that peak morphology is associated with AER, 
independently of traditional CVD risk factors; it also confirms that microvascular 
abnormalities are occurring within the normoalbuminuria range. However, the urinary 
albumin assay used in the study by Strain et al. has a lower limit of 0.05ug/dl (0.05mg/L), 
samples below this value were reported as 0.05mg/L (Strain et al., 2005a). This is most likely 
the limit of detection of the assay and not limit of quantification, where the assay can 
measure reproducibly with linearity.  
Using the validated ELISA, described in my thesis with a measurable range 0.78 – 40 mg/L to 
quantify urinary albumin, the associations between microvascular function and the lowest 
levels of urinary albumin excretion can be investigated for the first time. 
Microvascular dysfunction has been proposed as the common process in the 
pathophysiology of cardiovascular disease  and diabetic kidney disease,  resulting in 
increased urinary albumin excretion (Deckert et al., 1989). This is further supported by 
evidence that urinary albumin excretion is associated with other microvascular 
complications of diabetes, such as retinopathy and neuropathy (Newman et al., 2005). This 
relationship between urinary albumin excretion and other microvascular complications of 
diabetes is also investigated in the SUMMIT cohort. 
 
7.2.4 Urinary albumin excretion and other microvascular complications of 
diabetes 
 
DM is not only a disorder of carbohydrate metabolism but it is also a cause of vascular 
disease. Macrovascular complications of DM are mainly represented by atherosclerotic 
disease, whereas there are three major manifestations of microvascular disease; 
retinopathy, neuropathy and nephropathy. For the purpose of this chapter I will be 
focussing on the diabetes related microvascular complications.  
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7.2.4.1 Diabetic retinopathy 
 
The incidence of certifications of visual impairment (CVIs) due to diabetic retinopathy (DR) 
ranged from 30.8 to 77.4 per million population per year between 2010 and 2013 in North 
and Eastern Devon (Lin et al., 2017). Furthermore, DR is known as one of the leading causes 
of blindness among working aged adults (Frank 2004). More recent evidence suggests 
inherited retinal disorders are the leading cause of certifiable blindness among working age 
adults in England and Wales, overtaking diabetic retinopathy (Liew et al., 2014). This may be 
attributed to the success of nationwide diabetic retinopathy screening programmes and 
improved glycaemic control. After 20 years of diagnosis, nearly all individuals with T1DM 
and approximately 60 % of T2DM patients in the UK will have some degree of retinopathy 
(Scanlon, 2008).   
The retina is the light sensitive inner layer of the eye responsible for vision. DR is 
characterised by ischaemic changes within the retina. DR is graded from vascular 
morphological abnormalities on  retinal photographs, including, for example capillary 
microaneurysms, haemorrhages, cotton wool spots, capillary degeneration and excessive 
formation of new blood vessels (neovascularisation) (Forbes and Cooper, 2013).  Clinically, 
DR is classified into non-proliferative (NPDR) and proliferative (PDR) disease stages with the 
latter occurring at the advanced stages of DR. The early stages of DR are symptomless and it 
can progress undetected until it affects vision. Excessive fluid accumulation / oedema within 
the macular region, known as clinically significant diabetic macular oedema,  can result in 
the impairment / loss of central vision. This can occur within the NPDR stage of DR. 
However, patients with DM in the UK have a comprehensive dilated eye exam every year to 
18 months to detect early signs of DR.   
The earliest histopathological sign of DR is a loss of pericytes (Beckman and Creager, 2016).  
Pericytes are contractile cells which wrap around endothelial cells in capillaries. Pericytes 
assist in the maintenance of capillary tone, growth and resistance to damage from oxidative 
stress (Arboleda-Velasquez et al., 2015). As the disease progresses the basement membrane 
thickens which is accompanied by potential endothelial cell permeability and 
328 
 
microaneurysms (Tarr et al., 2013). In this initial stage of NPDR there is usually no loss in 
vision.  
Microaneurysms are usually the earliest signs of DR on retinal photographs and the first step 
on DR grading / screening scales. This tends to lead into haemorrhages, cotton wool spots, 
then into marked morphological changes – venous beading and intraretinal microvascular 
abnormalities and eventually into the growth of new vessels.   
Visual impairment usually occurs in the proliferative stage which is characterised by 
neovascularization and accumulation of fluid within the retina (Forbes and Cooper, 2013). 
PDR is caused by the occlusion or degeneration of retinal capillaries, ischemia followed by a 
subsequent release of angiogenic factors which stimulate neovascularisation. (Bresnick et 
al., 1975). 
 
Albuminuria and diabetic retinopathy 
 
In 2012, Chen et al. carried out a hospital based cohort study, consisting of 487 patients with 
T2DM, to compare the ability of microalbuminuria and moderately reduced eGFR to predict 
the development of DR over 6 years (Chen et al., 2012b). It was reported that patients with 
microalbuminuria and an eGFR ≥ 60 mL/min/1.73m2 had a significantly greater risk of 
developing and progressing DR (HR 3.34 [95% CI 1.04-10.70]) compared with those with 
moderate renal impairment (eGFR 30-59.9 mL/min/1.73m2) and normoalbuminuria. Chen et 
al concluded that microalbuminuria predicts DR better than eGFR predicts DR. This study 
investigated the clinical albumin excretion ranges with clinical retinopathy. In my thesis, 
using the SUMMIT cohort, subclinical background changes in DR are compared with 
subclinical urinary albumin excretion.    
There are only a few studies with a large number of participants that have investigated the 
association between urinary albumin excretion and DR in patients with T2DM. The majority 
of studies that have reported  a relationship found albumin excretion was not an 
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independent predictor for DR incidence and progression when adding it to multivariate 
regression models that included age, diabetic duration, glycaemic level and blood pressure 
(Newman et al., 2005). These studies are also limited by only investigating the clinical micro- 
and macro- albuminuria ranges. 
It is suggested that nearly all T1DM patients have retinopathy within 20 years of diagnosis 
(Scanlon, 2008). Therefore it is important to consider the influence diabetes duration may 
have on the relationship between urinary albumin excretion and DR. Other potential 
confounding factors are discussed in Section 7.2.8.   
In 2012, a prospective study of 197 patients with T2DM  reported that albumin excretion, 
within the normoalbuminuria range, was an independent risk factor for DR development  
over 4.5 years (3.7–5.1) (Chen et al., 2012a). All patients were without DR at baseline with a 
mean duration of diabetes 6.2 years ±6.0. Sixty-eight patients (22.9%) developed DR over 
the 4.5 years. A discrimination value of 10.7 mg/24hr, in the normoalbuminuria range 
(microalbuminuria range is 30-300 mg/24hr), has a relative risk ratio of developing DR of 
2.13 (95% CI: 1.58 to3.62, p<0.001). Fifty-one patients (29.0%) of the 176 subjects with 
urinary albumin excretion between 10.7 and 30 mg/24 h developed DR, while 17 patients 
(14.1%) of the 121 subjects with lower albumin excretion (<10.7 mg/24 h) developed DR 
(Chen et al., 2012a). 
The study by Chen et al. supports the theory that increasing urinary albumin excretion 
represents generalised microvascular function, and it provides further evidence that urinary 
albumin excretion is a continuous risk factor for microvascular dysfunction which 
commences within the clinically defined “normal” range. 
 
7.2.4.2 Diabetic neuropathy 
 
Diabetic neuropathy is defined as peripheral nerve dysfunction in patients with DM in whom 
other causes of peripheral nerve dysfunction, such as hypertension, have been excluded 
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(Bansal et al., 2006). Approximately half of patients with DM will develop neuropathy 
(Tesfaye and Selvarajah, 2012) with an estimated lifetime risk of 15% of having one or more 
lower extremity amputations (Forbes and Cooper, 2013). Diabetes is the most common 
cause of peripheral neuropathy, and is the most frequent cause of non-traumatic 
amputations in the U.K.(Diabetes UK, 2014). 
Diabetic neuropathy affects both the somatic and autonomic divisions of the peripheral 
nervous system and is classified according to the distribution of the affected areas; if it is on 
one side of the body (asymmetric) or both (symmetric). Distal symmetrical polyneuropathy 
(DSPN) is the most common form of diabetic neuropathy, affecting more than 90% of 
patients with diabetic neuropathy (Tesfaye et al., 2013). In DSPN, sensory impairment 
occurs in a stocking or glove distribution and is characterised by the loss of nerve fibres 
(Bansal et al., 2006). Ulcers on the feet and painful neuropathy are the main clinical 
presentations of DSPN and are linked with higher morbidity and mortality (Boulton et al., 
2004). Around 10% of patients with DM experience persistent pain, which is termed painful 
diabetic neuropathy. It is typically worse at night and is characterised by tingling, sharp and 
shooting pain (Bansal et al., 2006).  
The pathogenesis of diabetic neuropathy is not fully understood, but it is generally accepted 
that microvascular dysfunction in blood vessels supplying nerves contributes to 
development of neuropathy. This results in ischaemia and subsequent nerve damage due to 
hypoxia. Histopathological evidence for this is vascular basement membrane thickening and 
endothelial hyperplasia (Bansal et al., 2006). Nerve fibres deteriorate as the disease 
progresses ultimately leading to sensory neuronal loss (Bansal et al., 2006). Diabetic 
neuropathy is a consequence of longstanding hyperglycaemia, where peripheral nerve 
injury occurs through microvascular damage arising from an increased flux of the polyol 
pathway, enhanced advanced glycation end‐products formation, excessive release of 
cytokines, activation of protein kinase C and exaggerated oxidative stress (Yagihashi et al., 
2011).  
The progression of neuronal loss is when patients demonstrate clinically recognised altered 
sensitivities to vibrations and thermal thresholds  
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Albuminuria and diabetic neuropathy 
 
Diagnosing diabetic neuropathy is usually based on symptoms, medical history and a 
physical exam. The physical exam focuses on the feet, which are examined for lesions and 
loss of sensitivity. The formation of lesions and a loss in sensitivity occur as a result of 
neuronal degeneration and death, and there are no clinical routine tests to identify those at 
risk of diabetic neuropathy at an earlier stage. If vascular changes occur before neuronal 
degeneration and loss, then increasing urinary albumin excretion, caused by generalised 
microvascular dysfunction, could be a potential biomarker for those at risk of developing 
neuropathy at an earlier stage. 
An observational study carried out a medical record review of 78 patients with T2DM and 
demonstrated that microalbuminuria was associated with neuropathy, diagnoses using 
routine clinical assesments and sensitivity testing (Bell et al., 1992). They reported an odds 
ratio (OR) of 4.83 for having diabetic neuropathy if microalbuminuria was present (p<0.005). 
This relationship was still significant when adjusting for age, sex and duration of DM (OR of 
4.44, p=0.01).  
This finding has also been reported from a larger study of 947 T2DM patients (Savage et al., 
1996). Using chi-squared analysis they demonstrated that increasing urinary albumin 
excretion was significantly associated with the presence of neuropathy (p<0.001). 
Neuropathy was assessed by neurological symptom and disability scores, autonomic 
function testing, and quantitative sensory exams involving thermal and vibratory sensation 
(Savage et al., 1996). They reported macroalbuminuria was independently associated with 
neuropathy (OR (CI) = 1.95 (1.19, 3.18), p=0.001), although microalbuminuria was not (OR 
(CI) = 1.20 (0.85, 1.71), p=0.3) (Savage et al., 1996). This suggests that the clinically 
recognised thresholds, using inadequate assessments, only detect diabetic neuropathy 
when microvascular dysfunction/disease progression is as late as the macroalbuminuria 
stage.   
332 
 
There are only a few studies that have reported the association between diabetic 
neuropathy and urinary albumin excretion. This might be due to the nature of accurately 
diagnosing neuropathy, which clinically relies on subjective information and inadequate 
assessments. During the physical examination, the most common device to test for a loss in 
sensitivity is a Semmes-Weinstein monofilament which exerts 10 g of pressure. Another 
common method of quantitative sensory testing is vibration perception, but these methods 
are not fully objective and the results strongly depend on the cooperation of the patient and 
the operator. It is estimated that 50% of DSPN cases are asymptomatic with patients 
unaware of foot lesions (Kasznicki, 2014). 
Nerve conductivity tests that measure the conduction velocity of an electrical impulse 
through a nerve can be used to determine nerve damage. This provides more quantifiable 
data and may identify individuals with diabetic neuropathy who might be missed by the 
traditional methods. However, the use of nerve conductivity tests has not been routinely 
adopted in clinics.  
In 2010, a study evaluated the discriminative power of; examination score, monofilament 
examination, and vibration perception threshold, to diagnose diabetic neuropathy in 100 
patients with T2DM (Mythili et al., 2010). They identified 71 participants who had evidence 
of diabetic neuropathy, which was confirmed by nerve conduction studies. The examination 
score gave a sensitivity of 83% and a specificity of 79%. The sensitivity of a monofilament 
test was 98.5% with a specificity of 55%. Vibration perception thresholds yielded a 
sensitivity of 86% and a specificity of 76% (Mythili et al., 2010). They concluded that a 
simple neurological examination is as good as vibration perception to detect diabetic 
neuropathy. However, the two tests can be used together to make a diagnosis. 
The progression of neuronal loss is when patients demonstrate clinically recognised altered 
sensitivities to vibrations. By assessing this in the SUMMIT cohort, the relationship between 
diabetic neuropathy and urinary albumin excretion will be investigated. 
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7.2.5 Diabetes and microvascular function  
 
7.2.5.1 Skin microvascular response to acetylcholine and sodium nitroprusside in 
diabetes 
 
Research carried out in the Diabetes and Vascular Research Centre in Exeter, investigated 
endothelial and smooth muscle function in the skin microcirculation of patients with non-
insulin dependent diabetes (NIDDM)  (Morris et al., 1995). Hyperaemia response of the skin 
microcirculation to acetylcholine and sodium nitroprusside was carried out on 14 male 
patients with NIDDM and 14 age-paired matched controls. The mean age of the cohort was 
59 ± 2.5 years, with a mean duration of 9.1 ±1.9 years in subjects with NIDDM.  
Morris et al. reported no significant difference in basal skin flow between groups. ACH 
increased skin perfusion (p < 0.001) in all subjects, but peak response to ACH was lower in 
patients with NIDDM compared to controls (0.86 ± 0.09 vs 1.36 ± 0.14 arbitrary units (AU), 
p<0.01). Similarly, all subjects showed a significant increase in skin perfusion in response to 
SNP (p < 0.001) that was significantly lower in patients compared to controls (0.12 ± 0.05 vs 
0.45 ± 0.11 AU, respectively, p<0.01). 
The only information regarding urinary albumin excretion is that 3/14 patients with NIDDM 
had raised ACR, it is not reported if that refers to microalbuminuria or macro albuminuria. 
6/14 patients with NIDDM had background retinopathy and one had proliferative 
retinopathy. This demonstrates that this cohort has a variety of microvascular complications 
of diabetes, at different stages of severity. The mean duration of diabetes was 9.1 ±1.9 
years, and reflects the typical prevalence of microvascular complications after ten years 
(Diabetes UK, 2014). 
S Morris et al. demonstrated that endothelial and/or smooth muscle function may be 
impaired in the skin microcirculation of patients with NIDDM. In this chapter, subjects 
without clinically recognised levels of retinopathy and/or neuropathy are selected from the 
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SUMMIT cohort, and the relationship with early changes in microvascular function and low 
levels of urinary albumin excretion is investigated.  
Furthermore, studies at the Diabetes Research Centre in Exeter, have demonstrated 
maximal hyperaemia is  reduced in both the hypertensive   and normotensive  type 2 
diabetic patients when compared with control subjects (Jaap et al., 1994b). 
 
 
7.2.5.2 Post occlusive reactive hyperaemia and diabetes 
 
Response to PORH is significantly different between patients with NIDDM (n=25) and 
controls matched by sex and age (n=25) (Tur et al., 1991). Peak hyperaemia is also 
significantly lower in patients with T1DM (p<0.02), indicating impaired autoregulation in 
patients with diabetes, regardless of insulin dependency. These studies tested PORH on the 
forearm, whereas in the SUMMIT cohort the skin microvasculature on the foot is studied. 
The mean age of the NIDDM diabetic cohort in the study by Tur et al. was 64.5 ±2.0 years, 
with a mean duration of diabetes of 16.2 ±2.3. Among the patients with diabetes, 14 had 
proliferative DR and the ratio between peak hyperaemia and time to reach it, was 
significantly lower in these patients compared to controls (p<0.05). Unfortunately urinary 
albumin excretion was not reported in the study. The study by Tur et al. demonstrates 
advanced retinopathy is associated with microvascular dysfunction and impaired 
microvascular autoregulation plays a role in its aetiology. In the SUMMIT background stages 
of pre-clinical retinopathy are analysed. 
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7.2.6 Microvascular dysfunction precedes clinical complications of cardiovascular 
disease 
 
Urinary albumin excretion might be a surrogate marker for microvascular damage in other 
microvascular beds, which results in macrovascular disease (Strain et al., 2005a). This is 
supported by further work carried out in the Diabetes and Vascular Research Centre in 
Exeter that demonstrates the ability of ACR in spot samples to improve risk stratification in 
patients with transient ischemic attacks (TIA) and minor stroke (Elyas et al., 2016).  
Urinary ACR was measured on a spot sample in 150 patients attending a daily stroke clinic 
following a recent TIA or minor stroke. Patients were followed up after 7, 30, and 90 days to 
determine recurrent stroke, cardiovascular events, or death (Elyas et al., 2016). ACR was 
higher in high-risk patients (3.4 [CI: 2.2 to 5.2] vs. 1.7 [1.5 to 2.1] mg/mmol, p=0.004), 
independent of age, sex, blood pressure, diabetes, and previous stroke. An ACR greater than 
1.5 mg/mmol predicted high-risk patients (Cox proportional hazard ratio 3.5 (95% CI 1.3-9.5, 
p= 0.01) (Elyas et al., 2016). 
Although this study does not consider gender specific thresholds for ACR, it demonstrates 
the association of urinary albumin excretion with microvascular dysfunction in other 
microvascular beds and with an ACR threshold of 1.5mg /mmol, the risk of macrovascular 
disease/event commences within the normoalbuminuria range (Elyas et al., 2016). 
Microvascular dysfunction is a complication of diabetes, and precedes the development of 
atherosclerosis and is thought to occur in response to CVD risk factors (smoking, obesity, 
hypertension, and dyslipidaemia) (Shimokawa, 1999, Holowatz et al., 2008). However, the 
increased risk of CVD with microvascular dysfunction has also been demonstrated in healthy 
individuals (Anderson et al., 2011), 
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7.2.7 Microvascular function is associated with risk factors of CVD 
 
The association between microvascular dysfunction and  cardiovascular risk has been 
demonstrated in a healthy population (Vuilleumier et al., 2002). The relationship between 
PORH assessed on the forearm with cardiovascular risk determined by Framingham risk 
score was investigated in a population based cohort of 862 healthy females (mean (SD) age: 
54.6 years ±7.0). The measure from PORH testing reported in this study is peak hyperaemia , 
calculated as: ((maximal hyperaemia - baseline blood flow) / baseline blood). The 
Framingham risk score was low in the female population (CVD event risk (CI) at 10 years 
7.89 (7.49 to 8.30), however there was a correlation between PORH and the CVD risk score ( 
P<0.001) (Vuilleumier et al., 2002) suggesting that a higher peak reactive hyperaemic 
response is associated with a great CVD risk . 
A longitudinal study of 1,547 men (mean age of 49.4 years) free from CVD demonstrated 
that microvascular function predicts cardiovascular events in primary prevention (Anderson 
et al., 2011). These are the long-term results from the Firefighters and Their Endothelium 
(FATE) study. The mean follow-up period was 7.2 ±1.7 years, with 71 subjects identified as 
having 111 CVD events. Maximal hyperaemia assessed at baseline had a hazard ratio (CI) of 
0.70 (0.54 to 0.90), p=0.006) for adverse cardiovascular outcomes in a multivariable analysis 
that included Framingham risk score (Anderson et al., 2011). Anderson et al.  concluded that 
maximal hyperaemia is a novel tool that may improve CVD risk stratification of lower-risk 
healthy men (Anderson et al., 2011). 
Waist circumference is an index of abdominal adipose tissue deposition (Pouliot et al., 1994)  
and is accepted as a risk factor for CVD (Després, 2012). A study by de Jongh et al. 
demonstrated microvascular function is associated with risk factors of CVD such as waist 
and an increased risk of developing microangiopathy, hypertension, and insulin resistance 
(de Jongh et al., 2004).  
Twenty-eight healthy women (mean age, 38.9 ±6.7 years), 16 of whom were lean (BMI <24 
kg/m2) and 12 were obese (BMI >30 kg/m2), had microvascular function examined in the 
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basal state and during physiological systemic hyperinsulinemia. Skin capillary recruitment 
after arterial occlusion with capillaroscopy and skin endothelium dependent and 
independent vasodilation by iontophoresis of acetylcholine and sodium nitroprusside were 
investigated (de Jongh et al., 2004).  Obese women had higher systolic blood pressure 
(p<0.05), impaired insulin sensitivity (p<0.01), impaired capillary recruitment in the basal 
state (p<0.05) and during hyperinsulinemia (p<0.05), compared with lean women. 
ACH mediated vasodilation was impaired in obese woman in the basal state (P<0.05) and 
during hyperinsulinemia (P<0.01), however, SNP mediated vasodilation was similar in lean 
and obese women. This suggests endothelial dependent microvascular function is impaired 
in obese women and is not accompanied by smooth muscle dysfunction in contrast to the 
situation in T2DM where both endothelial cell and smooth muscle cell function are 
impaired. 
The increased risk of CVD with microvascular dysfunction has been demonstrated in 
diabetes (Sokolnicki et al., 2007), renal disease (Stewart et al., 2004) and hypertension 
(Carberry et al., 1992). This demonstrates the need to consider the influence of CVD risk 
factors on the relationship between microvascular function and urinary albumin excretion. 
 
7.2.8 CVD risk factors 
 
The prominent study carried out by Strain et al. demonstrated the relationship between 
PORH peak morphology with lower levels of albuminuria within the normal range, and with 
other CVD risk factors  (Strain et al., 2005a). Subjects with an early dominant peak had 
significantly higher blood pressure (systolic bp; p=0.001), waist (p<0.001), fasting glucose 
(p=0.001), a higher prevalence of diabetes (58%, p=0.012) and were more likely to be 
current or ex-smokers (p=0.02) compared to subjects with other early peak morphologies. 
These risk factors have also been adjusted for in other studies which have investigated 
microvascular dysfunction as a risk factor for CVD. Age, waist circumference, and blood 
pressure have been reported to be associated with skin blood flow in the Maastricht Study 
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(Muris et al., 2014). The Maastricht Study is an observational prospective population-based 
cohort study in the Netherlands. The study focuses on the aetiology, pathophysiology, 
complications, and comorbidities of T2DM and is characterized by an extensive phenotyping 
approach. 506 participants from the population based cohort, all without prior CVD event 
had blood flow measured using laser Doppler at rest, without localised heating. They 
reported that resting skin blood flow increases with age (p < 0.001) and systolic blood 
pressure (p < 0.001) and decreases with increasing waist circumference (p = 0.01).  
The identified CVD risk factors from the Strain et al. study and the Maastricht cohort are 
established to have a relationship with microvascular function, therefore their influence on 
the relationship between increasing urinary albumin excretion and microvascular 
impairment needs to be considered.  To determine if urinary albumin excretion has an 
independent relationship with measures of microvascular function, the following risk factors 
will be adjusted for in regression analysis: age, gender, smoking, HDL, systolic blood 
pressure HbA1c and waist.  
Cohorts of the Strain study and the Maastricht study are population based, and when 
comparing results and conclusions with cohorts like the SUMMIT cohort, which are research 
volunteers, consideration must be given to the differences between cohorts, as research 
volunteers tend to be more health conscious than the general public. Even population based 
studies rely on volunteers so are not truly population, but more diversity is usually tested. 
I am not aware of any longitudinal studies which have reported change in in vivo 
measurements of microvascular function. The SUMMIT cohort is a prospective study and 
the changes in microvascular function and microvascular complications are reported for the 
first time.  
Microvascular dysfunction is a very early feature in cardiovascular disease progression, 
before clinically recognised manifestations of CVD. Using the validated sensitive ELISA, the 
relationship with low levels of urinary albumin excretion can be investigated for the first 
time. To support the hypothesis that urinary albumin excretion is caused by generalised 
microvascular dysfunction, the association of urinary albumin excretion and pre-clinical 
changes in retinopathy and neuropathy are also investigated. 
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7.3 Aim 
 
To quantify urinary albumin in the SUMMIT cohort using the validated ELISA described in 
earlier chapters of my thesis and to compare the results with those determined using the 
traditional clinically routine method of assessing urinary albumin excretion. 
 
To investigate the relationship between urinary albumin excretion and microvascular 
function and with diabetes related microvascular complications in the SUMMIT cohort  
 
The hypotheses are: 
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7.3.1 Hypothesis 1 
 
Urinary albumin excretion is related to microvascular function, with higher levels of albumin 
excretion being associated with an impairment of microvascular function. The magnitude of 
change in microvascular function over three years is related to the change in albumin 
excretion. Furthermore, this relationship is present in individuals with and without diabetes, 
and changes of urinary albumin excretion within the normoalbuminuria range relate to 
changes in microvascular function. 
 
Objectives: 
 
1. To quantify urinary albumin in the SUMMIT cohort using the validated ELISA and to 
compare the results with those determined using the traditional routine method to 
confirm earlier validation work. 
 
2. To compare albumin excretion levels and microvascular function in individuals with 
T2DM (±CVD) and individuals without diabetes (±CVD) 
 
3. To determine if there is a correlation between urinary albumin excretion and 
vascular function across the full albumin excretion range, and to evaluate the impact 
diabetes and CVD has on that relationship. 
 
4. To determine if this relationship exists within the normoalbuminuria range. 
 
5. To determine if there is a correlation between the change in urinary albumin 
excretion over three years with a change in vascular function. 
 
6. To determine if a change in urinary albumin excretion over three years within the 
normoalbuminuria range correlates to a change in vascular function. 
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7.3.2 Hypothesis 2 
 
Urinary albumin excretion is not only an early marker of diabetic kidney disease but is an 
early marker of other diabetes related microvascular complications (retinopathy and 
neuropathy), with an increase in albumin excretion associated with a worsening in 
complication status in patients with diabetes. Furthermore, high levels of urinary albumin 
excretion, or an increase in albumin excretion over three years increases the likelihood of 
disease progression. 
 
Objectives: 
 
1. To investigate the relationship between urinary albumin excretion and the early 
stages of diabetic retinopathy and neuropathy. 
 
2. To investigate the relationship between urinary albumin excretion and 
progression/development of diabetic retinopathy and neuropathy.    
 
3. To determine if an increase in urinary albumin excretion over three years is related 
to a progression/development of diabetic retinopathy and neuropathy. 
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7.4 Method  
 
 
7.4.1. Participant recruitment 
 
The hypotheses of this chapter are tested using participants from the SUMMIT study 
(Surrogate markers for micro- and macro-vascular hard endpoints for innovative diabetes 
tools) cohort (Section 1.9).  
SUMMIT is a European consortium (http://www.imi-summit.eu/) which aims at identifying 
markers that predict the risk of developing diabetes related vascular complications, in 
particular DKD, CVD, and diabetic retinopathy (DR). One of the objectives of SUMMIT was to 
identify non-invasive imaging related surrogate markers for the early identification and 
monitoring of atherosclerosis and retinopathy. The University of Exeter participated in the 
SUMMIT consortium. As part of its involvement, participants (described below) were 
comprehensively characterised, with both clinical and vascular parameters measured over 
time. Four participant groups in Exeter were recruited:  
Group 1: 150 individuals with T2DM with known CVD 
Group 2: 150 individuals with T2DM without CVD 
Group 3: 75 individuals without diabetes but with CVD 
Group 4: 75 individuals without diabetes or CVD 
Participants were classified as having T2DM with an Hba1c > 47 mmol/mol and were 
diagnosed with T2DM after the age of 35 years. CVD was defined as a medical history of 
myocardial infarction, percutaneous coronary intervention, coronary arterial bypass graft, 
unstable angina, peripheral artery disease and verified cerebrovascular event (stroke and / 
or transient ischaemic attack). 
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Structural and functional measurements of the micro and macrovascular system were 
carried out on all participants, along with standard clinical assessments (e.g. blood pressure) 
including blood and urine analysis. Diabetic neuropathy was tested for by sensory testing, 
accompanied by recording their medical history.  
An additional group of 450 participants, all of whom had a previous diagnosis of T2DM, had 
DR assessed by traditional eye examination tests (two field retinal photographs) and also 
imaged by optical coherence tomography (imaging system under investigation for SUMMIT) 
(they did not have functional vascular measurements carried out).  
 
All participants were assessed on two occasions; the first visit is termed ‘baseline’ and the 
second visit ~three years later is termed ‘follow up’. The participant inclusion criteria for 
each hypothesis are summarised in Table 66.  
 
 Objectives Participant inclusion criteria 
Hypothesis 1 
 
1 ,2,3 & 4 Two overnight urine collections and microvascular 
measurements at follow up 
5 & 6 One spot ACR and microvascular measurements at baseline and 
follow up 
Hypothesis 2 
1 & 2 One spot ACR at baseline, retinal photography and neuropathy 
tests at baseline and follow up 
3 One spot ACR, retinal photography and neuropathy tests at 
baseline and follow up 
Table 66 Participant inclusion criteria for each hypothesis. Participants are selected from 
subjects assessed in Exeter as part of the SUMMIT study.  
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7.4.2 Participant screening 
 
Height was measured in metres (m) to two decimal places (d.p), weight was measured in 
kilograms (kg) to 1 d.p, waist was measured in centimetres (cm) to 1 d.p, hip was measured 
in cm to 0 d.p. These measurements were taken with the participants wearing indoor 
clothing and without shoes. Height was measured when the patient stood as tall as possible, 
with their back against the vertical scale, looking straight ahead with feet close to the wall. 
Waist (minimum circumference between rib cage and iliac crest) and hip (maximum 
circumference) were measured with the participant standing erect in a relaxed manner 
whilst breathing normally, with the measurement taken at the end of a normal expiration. 
Clothing, except underwear, was removed around waist and hips. Percentage body fat was 
determined using scales which measured electrical impedance. Blood pressure was 
measured three times in the left arm using a digital blood pressure monitor; with the mean 
of the last two measurements representing brachial blood pressure.  
Participants selected to test hypothesis one had provided a fasting blood sample, two 
overnight urine collections and a single random spot urine sample. Participants in 
hypothesis two were not fasted when they provided a blood sample and they provided a 
single random spot urine sample. A clinical research nurse collected samples, recorded 
medical history and conducted anthropometric measurements. 
 
7.4.3 Sample analysis 
 
Blood samples underwent routine analysis on the day of collection, the analytical methods 
used are summarised in Table 67. Urinary creatinine was measured using the Jaffe (rate 
blanked) method on the day of collection in overnight urine collection samples. In random 
spot samples urinary creatinine was measured from aliquots stored at -80oC. It was 
identified that urinary creatinine degrades during prolonged storage at -80oC, therefore 
urinary creatinine concentration is corrected using the following equation (Chapter 5): 
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     Corrected urinary                 =              Measured creatinine concentration        x 100 
creatinine concentration                               (100 – (0.029 x days stored *) 
 
*input 541 for samples stored more than 541 days  
  
 
Aliquots from all urine samples were stored on the day of collection at -80oC. Once the 
study was complete, urinary albumin was quantified using the Fitzgerald ELISA on an 
automated platform (Dynex DS2).  
Analyte Analyser Method 
Total Cholesterol (mmol/L) Roche Modular CHOD-PAP 
HDL (mmol/L) Roche Modular Direct enzymatic 
LDL (mmol/L) Roche Modular Enzymatic 
Triglycerides (mmol/L) Roche Modular Enzymatic (GPO/PAP) 
Glucose (mmol/L) Roche Modular Enzymatic (GOD-PAP) 
Creatinine (µmol/L) Roche Modular Jaffe, rate blanked 
HbA1c (mmol/mol) TOSOH G7 HPLC 
Table 67 Analytical methods used in routine analysis of blood samples. (HDL: high density 
lipoprotein, LDL: low density lipoprotein, CHOD-PAP: cholesterol oxidase/peroxidase 
aminophenazone, GPO/PAP:  glycerol-3-phosphate oxidase / peroxidase aminophenazone, 
GOD-PAP: glucose oxidase / peroxidase aminophenazone, HPLC: High performance liquid 
chromatography) 
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7.4.4 Microvascular tests 
 
Participants attended the clinical research facility for their microvascular assessments 
having refrained from food or drink (except water) for at least two hours before the visit, 
they also avoided smoking, drinking tea or coffee, alcohol, and strenuous exercise on the 
study day as this can impact measures of microvascular function (Noguchi et al., 2015). If 
needed, diabetic medications were altered on the study day to avoid hypoglycaemia. All 
antihypertensive medications were taken as normal. After providing a blood sample, 
participants were provided with a standardised meal (two slices of wholemeal bread with 
butter and a glass of water). To acclimatise participants before microvascular assessment, 
subjects lay in a supine position for 20 minutes in a quiet temperature controlled room (21.5 
to 22.5oC). 
 
7.4.4.1 Iontophoresis 
 
Endothelial dependent and independent microvascular responsiveness was assessed by 
measuring the skin perfusion response to iontophoretic delivered acetyl choline (ACH) and 
sodium nitroprusside (SNP), respectively. The volar aspect of the right arm was wiped gently 
with alcohol (Klercide 70/30) and then sterile water. Perspex direct electrode chambers (30 
mm total diameter x 3 mm height, inner (drug) chamber 10 mm diameter) were attached to 
forearm, using a double-sided adhesive ring, avoiding visible veins, freckles and hair. 
Chambers were filled with solutions being tested; ACH (1 % Miochol-E, Novartis, Camberly, 
UK) dissolved in mannitol and SNP (0.25 %) (25 mg/ml Nitropress, Hospira, Lake Forest, USA) 
dissolved in 0.45 % w/v saline. A glass cover slip was placed on the drug chamber to prevent 
reflection artefacts from the solution in the chamber. An indifferent electrode was attached 
to the volar aspect of the participant’s wrist and connected to the chamber terminal to 
complete the circuit.  
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A solid-state laser Doppler perfusion imager (LDPI, Moor Instruments, Axminster) was used 
to measure the flux, with the head of the LDPI positioned 50 cm above the centre of the 
Perspex chamber, the LDPI was set to scan 2.5 x 2.5cm measurement area at a penetration 
depth of 1 to 1.5 mm (Braverman, 1997). The LDPI was interfaced with a computer 
equipped withMoor LDI dedicated software (Version 5.3). A battery-powered iontophoresis 
controller (MIC 1; Moor Instruments, Axminster, UK) was used to provide the current for 
iontophoresis. 
ACH was delivered using an anodal current of five pulses of 100 micro amps for 20 seconds 
with a 60 seconds interval between each dose (total charge of 10mCoulombs). Forearm skin 
red blood cell flux was recorded before the start of current protocol, and at the start and 
end of each period of iontophoresis. SNP was delivered by cathodal current to the volar 
aspect of the forearm. A single pulse of 200 micro amps was introduced for 60 seconds 
(total charge of 12mCoulombs). Forearm skin red blood cell flux was assessed before the 
start of the current protocol, and then every 60 seconds for 6 mins after the start.  
Images obtained from the LDPI were analysed by selecting a region of interest around the 
total area of skin scanned to generate a mean perfusion response. Iontophoresis data were 
expressed in arbitrary units (AU). The peak response was defined as the highest cutaneous 
perfusion response reached during the monitoring period, referred to as ACH or SNP peak 
response in the results. To examine the total response the area under the curve (AUC) of the 
whole curve, normalised for resting flow (scan 1), was determined and referred to as ACH or 
SNP total response. 
 
7.4.4.2 Maximal blood flow and minimum vascular resistance 
 
Maximal blood flow was assessed in response to local heating. The area of the skin (foot) 
under investigation was initially warmed to 36oC using warm air. A plastic collar, into which 
a brass heater disc 0.7cm2 area was fitted, was attached onto a flat region on the dorsum of 
the left foot not overlying any large vessels, using a double-sided adhesive disc. Skin 
348 
 
temperature was maintained at ≥ 42C for 30 minutes, as assessed by a thermocouple 
underlying the heater probe. At the end of the 30 minutes heating phase, the maximum 
hyperaemic response to the thermal stimulus was assessed using a single point laser 
Doppler fluximeter (DRT4; Moor Instruments Axminster, UK), by measuring skin vessel flux 
at eight equidistant points within the heated area for 30 seconds each and averaging the 
flux. Off line analysis was carried out using the DRT4 for windows software (Version 2.0, 
Moor Instruments, Axminster, UK).  
Minimum vascular resistance (MVR) is the lowest resistance to overcome, which occurs 
during maximal vasodilation. In the microvasculature, MVR can be calculated when 
assessing maximal blood flow, where vasodilation is induced by localised heating. MVR is 
calculated by a rearrangement of Darcy’s law to calculate blood flow by dividing mean 
arterial pressure by MBF (Jayalalitha et al., 2008).    
 
 
7.4.4.3 Post-occlusive reactive hyperaemia 
 
Skin reactive hyperaemia was assessed in response to arterial occlusion. During 
acclimatisation an appropriately sized sphygmomanometer cuff with six outlets was 
carefully placed around the ankle above the medial malleolus. Peak reactive hyperaemia 
was measured using single point laser Doppler fluximetry (LDF) (DRT4; Moor Instruments 
Axminster, UK). A flathead LDF probe was placed on the dorsum of the foot, clear of any 
visible large blood vessels or tendons, arterial pulsations and bony projections. Resting skin 
basal flux was recorded for 20 minutes, as a pressure reservoir for the sphygmomanometer 
cuff was primed to 200 mmHg. Participants were advised that the cuff would instantly 
inflate and asked to remain still throughout the process. The cuff was rapidly inflated to 200 
mmHg (or suprasystolic pressure) and maintained for 4 minutes. Prior to releasing the cuff, 
participants were asked to remain still during the release and for three minutes after to 
ensure the flux tracing recorded post cuff release was clean enough to allow accurate 
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determination of peak(s) morphology. Resting/baseline flux, biological zero, height of peak, 
time to peak, time to return to baseline (using a 3 second time constant) and peak 
morphology classification (using a 0.1 second time constant, (Strain et al., 2005a)) were 
analysed on data collected on the DRT4. 
  
7.4.4.4. Reproducibility of microvascular function tests 
 
The operator carrying out microvascular vascular function tests on the SUMMIT cohort, at 
baseline and follow up, tested their reproducibility during their initial training prior to the 
study commencing. One subject was tested eight times to determine the reproducibility of 
MBF which was 19.7%, and for PORH testing time to peak was 13.5% and peak hyperaemia 
was 16.2%. To assess the reproducibility of assessing hyperaemia response to iontophoresis, 
one subject was assessed five times on different days. Total and peak endothelial 
dependent response to ACH reproducibility was 23.1% and 13.2% respectively. Total and 
peak endothelial independent response to SNP reproducibility was 27.8% and 20.0% 
respectively.  These results are comparable with the reproducibility reported by other 
studies (Klonizakis et al., 2011, Sharad et al., 2010).  
Microvascular testing was carried out by Dr Francesco Casanova at the Diabetes and 
Vascular Research Centre in Exeter. 
 
7.4.5 Retinopathy 
 
Two field retinal photography (45o nasal and macular view), obtained via the National 
Diabetes Retinal Screening Programme or in house (Canon CR-DGi retinal camera), were 
used for grading DR. Retinopathy status was based on the eye with the severest DR.  
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Criteria to classify DR status vary between countries. The SUMMIT study is a multinational 
consortium so specific criteria were developed to ensure continuity among the different 
research centres (Table 68). This criteria is very similar to the international clinical DR 
severity scale recommendations (Wilkinson et al., 2003), separating background retinopathy 
as defined by the National Grading Scheme into minimal and mild DR, enabling the early 
stages of DR to be investigated. 
 
Classification Clinical features 
No DR No abnormalities 
Minimal DR Microaneurysms only 
Mild DR More than just microaneurysms (e.g.blot 
haemorrhages, hard exudates, and / or cotton 
wool spots)  
Moderate DR Venous abnormalities (small infarcts), venous 
bleeding, venous loop, venous reduplication, 
and intraretinal microvascular abnormalities. 
Proliferative DR Neovascularisation  
Table 68 Classification of diabetic retinopathy status used in the SUMMIT study. 
 
7.4.6 Peripheral Neuropathy 
 
A 10g monofilament (Semmes Weinstein) was used to assess peripheral neuropathy. The 
monofilament was applied to the subject’s hands so the participant knew what to expect. 
When lying supine, the monofilament was applied at 90o to the skin surface at 6 points on 
the feet (Figure 85). The monofilament was applied until it buckled and was then held for 1-
2 seconds. After each application the subject was asked if they could feel a sensation arising 
at that site. Subjects were asked to look away during the test to avoid any false visually 
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associated positive results. Significant neuropathy is present if the subject is only able to feel 
the monofilament in 3 or less of the 6 sites in one or both feet. 
 
 
 
 
 
 
 
 
7.4.7 Statistical analysis 
 
All statistical analysis was carried out using STATA 14. The statistical analysis plan is 
presented in detail below. Throughout the analysis significance was defined as p<0.05. 
 
 
7.4.7.1 Agreement between the Cobas and Fitzgerald methods   
 
Passing-Bablok regression and Bland Altman analysis were used to evaluate the relationship 
between the validated ELISA and the traditional routine method to quantify urinary 
albumin. The details of these analyses are described in Chapter 2, Section 2.3.9. 
 
Figure 85 Peripheral neuropathy testing sites. Six sites were tested by a 10g monofilament 
to determine peripheral sensitivity. 
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7.4.7.2 Participant characteristics 
 
Normality of data was tested using the Shaprio-Wilk test. For non-normally distributed data 
the median and interquartile range is reported, for normally distributed data the mean and 
standard deviation is described. 
When participants’ characteristics are separated by diabetes status, the difference between 
the two groups is tested using; T-test for normally distributed data, Wilcoxon rank sum test 
for non-normally distributed data, and Chi-squared test for binary and categorical data.  
 
7.4.7.3 Correlation 
 
Correlation between AER/ACR with measures of microvascular function was carried out by 
three methods: 
Pearson’s correlation using transformed variables is the first method, where normal 
distribution was achieved by calculating either the log, the square root or one divided by 
square root of the data. The best normal distribution was determined by comparing 
histograms and using the Shaprio-Wilk test for normality. The second method also tests the 
Pearson’s correlation between the two variables, but the log of the data is being used for 
both variables. The third method used untransformed data, and due to all variables having 
non-normally distributed data, Spearman’s rank correlation was tested.  
 
Tables demonstrating the correlation between variables have symbols next to variables 
using transformed data. Caution needs to be taken when interpreting correlations, where 
data has been transformed by 1/square root, as the direction of the relationship is reversed 
when comparing the variables with untransformed data.  
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For all correlations the coefficient (r) value is reported and to measure the significance of 
the relationship the p value is reported, where p<0.05 indicates the null hypothesis can be 
rejected. 
To investigate these relationships further, the interaction of diabetes and CVD in regression 
models was used to determine if these relationships are different in individuals with and 
without diabetes and CVD. 
 
7.4.7.4 Regression analysis 
 
If any of the correlations were significant, regardless of the method used to test it, then the 
association between AER/ACR with measures of microvascular function were tested further 
using regression analysis, to determine if the association is independent of other potential 
confounding factors. 
Other possible contributing variables which are used in regression models were identified 
from previous literature (Strain et al., 2005a), and are common risk factors for CVD (Section 
7.2.8). An assumption of regression analysis is that factors entered into the model cannot be 
strongly associated with each other and where multiple measures of a related parameter 
(e.g. body composition: weight, body mass index, waist, percent body fat) were available a 
Spearman’s rank correlation was carried out to identify which had the strongest relationship 
with each vascular measure. The most prominent among the related variables was used in 
regression models. The confounding factors used in regression models are: age, gender, 
smoking, high-density lipoprotein (HDL), systolic BP, previous CVD event, diabetes and 
waist. 
A forced entry, hierarchal approach to regression modelling was adopted where 
confounding variables are accumulatively added to determine the impact on the 
relationship between AER/ACR and vascular function when accounting for them individually 
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and collectively. Therefore, only the beta coefficient and p value of AER/ACR is reported for 
each model.  
 
7.4.7.5 Regression diagnostics 
 
Each regression model is tested to ensure all assumptions for the analysis were met. In 
order to ensure that the residuals had the same variance, they were plotted so 
heteroscedasticity could be identified, and confirmed if p< 0.05 using Breush-Pagan/Cook 
Weisburg test. Residuals were plotted to visualise their distribution, with normality checked 
by the Shaprio-Wilk test. 
Multicollinearity (linear relationship between predictors) was checked using variance 
inflation factor, with a result >10 indicating a linear relationship between predictors.   
To identify outliers the residuals were standardised by dividing the residual by an estimate 
of their standard deviation (z scores). The distribution of these standardised residuals were 
plotted where 95% of the results should be within 2 standard deviations. If this was not 
true, the impact of individual results on the overall regression model was tested by 
calculating Cook’s d value. A Cook’s d value > 1 indicates the case is over-influencing the 
results from the model. The model was then re-run excluding the outlier.  
 
7.4.7.6 Relationships with categorical variables 
 
Box and whisker plots are used to visualise the distribution of AER by categorical data. For 
binary variables a Wilcoxon rank sum test was used to test for significant difference 
between the two groups. For categorical variables with more than two groups a one-way 
analysis of variance (ANOVA) was used to determine whether there is any statistical 
difference between the means of any of the groups. If there is a statistical difference and 
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the data met the homogeneity of variances assumption, post hoc analysis using Bonferroni 
test was carried out to determine between which groups there was a significant difference.    
 
7.4.7.7 Albuminuria classification 
 
The AER used in the analysis is the mean AER from two overnight urine collections. The ACR 
is from a single random spot sample. All albumin measurements were carried out using the 
Fitzgerald ELISA and all creatinine measurements made using the routine Jaffe method.  
Analysis is carried out across the whole albuminuria range and then repeated just in the 
normoalbuminuria range. The normoalbuminuria range is defined as a mean AER <20 
µg/min and as an ACR <2.5mg/mmol in men, and <3.5mg/mmol in women.  
 
 
7.4.7.8 Progression of diabetic retinopathy classification 
 
A progression of two retinopathy steps or more, as demonstrated in Table 68, across both 
eyes was classified as being clinically significant. Therefore, individuals with a worsening of 
two steps of retinopathy in one eye are classified as a progressor, as would an individual 
with a worsening of one stage in both eyes.  
Non progressors were defined as individuals who did not have a worsening of two steps of 
retinopathy in one eye or worsening of one stage in both eyes.  
Receiver operator characteristic curves (described in Chapter 3) were used to evaluate the 
performance of ACR to identify individuals who had a progression in retinopathy. 
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7.4.7.9 Progression of diabetic neuropathy classification 
Monofilament sensitivity was carried out on six sites on both feet. Significant neuropathy is 
clinically defined if the participant is only able to feel the monofilament in three or less sites 
in either foot. Therefore people who went from a score of four or above to below four, in 
either foot are classified as a neuropathy progressor.  
Non progressors were defined as individuals who did not have a monofilament score go 
from above 4 to below 4. 
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7.5 Results 
 
Participant recruitment   
 
Two-hundred and forty eight participants met the inclusion criteria to test Hypothesis One 
(Table 66). These participants provided two overnight urine collections and had 
microvascular measurements taken at follow up (Figure 86). Objectives 1, 2, 3 and 4 are 
investigated using this cohort (Table 69). Of these participants, 144 provided spot urine 
samples and microvascular measurements at baseline and follow up (Table 90). Objectives 5 
and 6 are investigated on these 144 participants. 
Three-hundred and twenty one participants diagnosed with type 2 diabetes, who had a 
urine sample from a random spot collection stored at baseline, and retinal photography and 
neuropathy tests carried out at both baseline and follow up were selected to test  
hypothesis two (Figure 87).  
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Hypothesis 1: 
 
 
Figure 86 Participant recruitment and inclusion in analysis to test Hypothesis one. Data 
was collected from 248 subjects from the SUMMIT cohort. 62 participants did not have data 
recorded for potential confounding variables which were used in regression analysis. 140 
subjects did not have a spot ACR sample stored at baseline; therefore objectives five and six 
were tested on 144 participants. 
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Hypothesis 2: 
 
Figure 87 Participant recruitment and inclusion in analysis to test Hypothesis two. 321 
participants from the SUMMIT cohort, all diagnosed with type 2 diabetes, who had a urine 
sample from a random spot collection stored at baseline, and retinal photography and 
neuropathy tests carried out at baseline were selected to test Hypothesis two. Data from 58 
subjects was not available at follow up. A spot ACR was not provided or stored for 93 
subjects at follow up, therefore 170 subjects from the SUMMIT study were tested for 
objective 3.* Attributed to participant withdrawal from the study, death or inability to collect 
data. 
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7.5.1 Hypothesis 1 
 
7.5.1.1 Participant characteristics for study 1 
 
It is an elderly cohort with a mean age of 70 (±8.2) years, 67% of whom were male. 65% of 
participants were diagnosed with diabetes, 45% had a previous CVD event, with 64% on 
antihypertensive therapy and 69% on statin therapy (Table 69). The median eGFR [IQR] was 
78.3 [66.3 to 87.0] ml/min/1.73m2, putting the majority of participants (67%) in the G2 stage 
of CKD (eGFR between 60 and 89 ml/min/1.73m2), this mild reduction in eGFR is typical for 
an elderly population (National Kidney Foundation, 2002). 
Characteristic Full Cohort Diabetes No Diabetes 
P  
(DM vs 
No DM) 
N 248 160 88   
Gender (%male) 67 73 58 0.019* 
Ethnicity (% white British) 99 100 99 0.203 
Age (years) 70.0 (±8.2) 70.8 (±7.8) 68.5 (±8.8] 0.03* 
Height (m) 
1.72 1.72 1.71 
0.22 
[1.65 to 1.77] [1.66 to 1.77] [1.63 to 1.78] 
Weight (kg) 
82.0 86.6 72.6 
<0.001* 
[73.2 to 92.5] [79.0 to 95.6] [64.5 to 82.2] 
Body fat (%) 
30.6 31.9 28.4 
0.001* 
[25.3 to 37.5] [26.2 to 39.7] [23.6 to 34.3] 
BMI (kg m-2) 
27 29 25 
<0.001* 
[25 to 31] [27 to 32] [23 to 27] 
Waist (cm) 100.8 (±14.1) 106.4 (±11.9) 91.0 (±12.1) <0.001* 
Hip (cm) 
106 110 102 
<0.001* 
[102 to 115] [104 to 117] [97.8 to 105.9] 
Waist hip ratio 0.93 (±0.09) 0.95 (±0.08) 0.89 (±0.09) <0.001* 
Systolic BP (mmHg) 131.9 (±14.3) 133.7 (±14.1) 128.8 (±14.1) 0.013* 
Diastolic BP (mmHg) 69.6 (±7.9) 69.9 (±8.1) 69.0 (±7.6) 0.678 
Total cholesterol (mmol/L) 
4.1 3.9 4.9 
<0.001* 
[3.6 to 5.2] [3.4 to 4.6] [4.0 to 5.9] 
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Characteristic Full Cohort Diabetes No Diabetes 
P  
(DM vs 
No DM) 
HDL (mmol/L) 
1.35 1.28 1.67 
<0.001* 
1.12 to 1.72] [1.06 to 1.47] [1.32 to 1.97] 
LDL (mmol/L) 
2.17 1.95 2.7 
<0.001 
[1.64 to 3.03] [1.54 to 2.63] [1.95 to 3.42] 
Fasting triglycerides (mmol/L) 
1.24 1.39 0.96 
<0.001* 
[0.84 to 1.70] [0.90 to 1.94] [0.78 to 1.27] 
Glucose (mmol/L) 
6.5 7.6 5.1 
<0.001* 
[5.3 to 8.2] [6.5 to 9.0] [4.9 to 5.5] 
HbA1c (mmol/mol) 
47 55 40 
<0.001* 
[42 to 60] [48 to 64] [37 to 43] 
Duration of diabetes (years) n/a 8 (±6) n/a  
CVD n (%) 100 (45%) 70 (44%) 41 (47%) 0.737 
Antihypertensive therapy n (%) 159 (64%) 125 (78%) 34 (39%) <0.001* 
Statin therapy n (%) 171 (69%) 126 (79%) 44 (50%) <0.001* 
Smokers (current/ex/never) (%) 4/48/48 4/49/47 5/45/50 0.883 
Renal function: 
   
Serum creatinine (µmol/L) 
83 85 81 
0.038* 
[71 to 93] [75 to 96] [69 to 90] 
eGFR (ml/min/1.73m2) 
78.3 77.0 79.0 
0.3637 
[66.3 to 87.0] [65.0 to 85.0] [66.0 to 88.0] 
CKD stage n (%): 
   
0.233 
G1 38 (18%) 20 (15%) 18 (23%) 
 
G2 142 (67%) 93 (68%) 49 (64%) 
 
G3A 23 (11%) 14 (10%) 9 (12%) 
 
G3B 6 (3%) 5 (4%) 1 (1%) 
 
G4 4 (2%) 4 (3%) 0 (0%) 
 
G5 0 (0%) 0 (0%) 0 (0%)   
Table 69 Participant characteristics for Hypothesis One (n=248). Participants were selected 
from the SUMMIT cohort if they met the inclusion criteria to test Hypothesis One (Table 66). 
Data are presented as mean (±SD) or median [IQR]. * P value < 0.05 indicates a significant 
difference in a characteristic between subjects with and without diabetes.  
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7.5.1.2 Objective 1 
 
To quantify urinary albumin in the SUMMIT cohort using the validated ELISA and to compare 
the results with those determined using the traditional routine method to confirm earlier 
validation work. 
Urinary albumin excretion in the SUMMIT cohort (n = 248) using the validated ELISA and the 
traditional routine method are compared in Table 70. The Fitzgerald was able to quantity 
urinary albumin in two overnight collections from all 248 participants. The Cobas assay 
measured albumin in 106 (43%) of participants in the first collection, and 100 (40%) in the 
second collection. The Cobas assay quantified albumin in 46% of random spot urine 
samples.  
There was no significant difference between in AER between the two overnight collections 
using the Fitzgerald assay (p=0.368). Therefore the mean of the two collections is utilised for 
the remaining analysis, as it provides the best estimate of albumin excretion. 
 
  Full Cohort Diabetes No diabetes 
P(DM vs No 
DM) 
First overnight urine collections:   
Fitzgerald ELISA 
   
  
Number of measurable samples 
n (%) 
248 (100%) 160 (100%) 88 (100%)   
Overnight AER (FITZ)  7.91 9.60 5.82 
<0.001* 
(µg/min) 
[4.75 TO 
14.09] 
[5.47 to 
18.60] 
[4.00 to 
9.17] 
COBAS assay 
      
  
Number of measurable samples 
n (%) 
106 (43%) 78 (49%) 28 (32%)   
Overnight AER (COBAS)  9.34 11.9 5.76 
<0.001* 
(µg/min) 
[5.58 to 
25.20] 
[6.57 to 
39.34] 
[2.97 to 
9.78] 
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  Full Cohort Diabetes No diabetes 
P(DM vs No 
DM) 
Second overnight urine collection:   
Fitzgerald ELISA 
   
  
Number of measurable samples 
n (%) 
248 (100%) 160 (100%) 88 (100%)   
Overnight AER (FITZ)  7.6 9.42 5.83 
<0.001* 
(µg/min) 
[4.75 to 
14.48] 
[5.11 to 
18.01] 
[4.31 to 
8.35] 
COBAS assay 
      
  
Number of measurable samples 
n (%) 
100 (40%) 79 (49%) 21 (24%)   
Overnight AER (COBAS)  9.06 10.59 6.32 
0.035* 
(µg/min) 
[4.63 to 
22.54] 
[5.48 to 
29.75] 
[4.00 to 
10.45] 
Albuminuria classification using both samples   
Fitzgerald ELISA 
   
  
Normoalbuminuria n (%) 224 (90%) 139 (87%) 85 (97%)   
Microalbuminuria n (%) 22 (9%) 19 (12%) 3 (3%)   
Macroalbuminuria n (%) 2 (1%) 2 (1%) 0 (0%)    
COBAS assay 
      
  
Normoalbuminuria n (%) 57 (73%) 44 (70%) 13 (87%)   
Microalbuminuria n (%) 19 (24%) 17 (27%) 2 (13%)   
Macroalbuminuria n (%) 2 (3%) 2 (3%) 0 (0%)   
                  
One random spot collection:   
Fitzgerald ELISA 
      
  
Number of measurable samples 
n (%) 
221 (100%) 141 (100%) 80 (100%)   
Spot ACR (mg/mmol) 
1.11 1.44 0.82 <0.001* 
[0.74 to 
2.28] 
[0.74 to 
3.56] 
[0.52 to 
1.42] 
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  Full Cohort Diabetes No diabetes 
P(DM vs No 
DM) 
COBAS assay 
      
  
Number of measurable samples 
n (%) 
123 (56%) 90 (64%) 33 (41%)   
Spot ACR (mg/mmol) 
0.92 1.25 0.62 <0.001* 
[0.51 to 2.80]  [0.54 to 4.11] [0.44 to 1.22]   
Table 70 Urinary albumin excretion determined using both the Fitzgerald and Cobas 
methods in participants with and without diabetes. Albumin excretion was assessed by two 
overnight urine collection and a single spot collection for all participants (n=278). Albumin 
excretion values are reported as medians [IQR] for each collection. P value indicates if there 
is a significant difference in a characteristic between subjects with and without diabetes (* 
denotes p<0.05). There was no significant difference in AER between the two overnight 
collections using the Fitzgerald assay (p=0.368). 
 
The Passing Bablok regression demonstrated a significant correlation between the two 
methods (p<0.001) to quantify urinary albumin (y=1.37 (1.25 to 1.49) + 2.00 (1.24 to 2.81). 
The “y intercept” value of 2.00 mg/L indicates a positive systematic difference between the 
two methods. This was confirmed by Bland Altman analysis which demonstrates that the 
Fitzgerald method has a mean positive bias of 4.24 mg/L ± 3.35 compared to the Cobas 
method (Figure 88). This supports the findings of the initial validation studies, which 
demonstrated a mean bias of 3.55mg/L (±2.13) over the Cobas method (Chapter 2, Section 
2.3.4). 
In this investigation 17 samples (6%) were identified as outliers. Future data analysis 
includes these outliers. No significant difference was found when re-analysing the data 
when excluding these outliers.  
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Figure 88 Bland Altman difference plot for Fitzgerald and COBAS methods to measure 
urinary albumin in 278 samples. The line of identity represents no difference in measuring 
urinary albumin between the two methods. The mean difference (4.24 mg/L ± 3.35) is shown 
in green, with the 95% confidence intervals in red. 17 samples (6%) were identified as 
outliers (outside red intervals). At the lowest mean albumin concentrations there is a floor 
affect, as the difference in albumin is influenced by the limit of the Cobas assay (3mg/L). 
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7.5.1.3 Objective 2 
 
To compare albumin excretion levels and microvascular function in individuals with T2DM 
(±CVD) and individuals without diabetes (±CVD). 
 
Albumin excretion and microvascular function in individuals with T2DM (±CVD) and 
individuals without diabetes (±CVD) are reported in Table 71. Endothelial dependent and 
independent microvascular response is significantly lower in patients with diabetes (p values 
<0.001). Maximal blood flow is significantly lower (p=0.002) in subjects with diabetes and 
minimum vascular resistance is significantly higher compared to no diabetes group (<0.001). 
In regards to parameters of skin reactive hyperaemia assessed in response to arterial 
occlusion; time to peak hyperaemia was significantly lower in subjects with diabetes 
(<0.001), however peak hyperaemia (p=0.078) and time to baseline (p=0.073) were not 
significantly different. Type of early peak morphology was not significantly different 
between individuals with and without T2DM (p=0.449), with the prevalence of each peak 
type similar in both groups.  
Median AER [IQR] in subjects with T2DM was 9.75 µg/min [5.53 to 18.48], this is significantly 
higher (p<.001) than in subjects without diabetes (AER: 6.02 µg/min [4.10 to 8.93]. The 
same pattern occurs when assessing urinary albumin excretion in random spot samples, 
where ACR (1.44 mg/mmol [0.74 to 3.56]) was significantly higher in the diabetes group 
(p<0.001) compared to the control group (0.82 mg/mmol [0.52 to 1.42]). The relationship 
between microvascular function and albumin excretion is investigated further in objective 3 
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Full Cohort Diabetes No diabetes 
P 
(DM vs 
No DM)  
N 248 160 88  
Two overnight collections:     
Mean overnight AER (FITZ)  
(µg/min) 
7.96 9.75 6.02 
<0.001 [4.92 to 
14.50] 
[5.53 to 
18.48] 
[4.10 to 8.93] 
One random spot collection: 
 
Spot ACR (FITZ) (mg/mmol) 
1.00 1.44 0.82 
<0.001 
[0.66 to 2.31] [0.74 to 3.56] [0.52 to 1.42] 
Vascular assessments: 
  
Maximal blood flow (AU) 
139.9 135.2 165.7 
0.002 [106.4 to 
198.5] 
[99.7 to 
179.8] 
[117.4 to 
215.6] 
Minimum vascular resistance 
(mmHg/AU) 
0.64 0.69 0.54 <0.001 
[0.45 to 0.82] [0.51 to 0.89] [0.40 to 0.75]  
ACH; total endothelial dependent 
response (AU) 
82297 77170 97257 
<0.001 [54922 to 
111461] 
[50189 to 
101786} 
[66345 to 
122599] 
ACH; peak endothelial dependent 
response (AU) 
433.6 405.5 484.0 
<0.001 [348.7 to 
535.7] 
[332.1 to  
498.0] 
[393.4 to 
564.5] 
SNP; total endothelial independent 
response (AU) 
50050 45135 60385 
<0.001 [32890 to 
68760] 
[29430 to 
64560] 
[44670 to 
73350] 
SNP; peak endothelial independent 
response (AU) 
329.5 308.0 373.5 
<0.001 [254.0 to 
408.0] 
[237.0 to 
381.0] 
[308.0 to 
443.0] 
PORH; peak hyperaemia (AU) 
72.9 72.0 73.0 
0.784 
[49.5 to 
105.0] 
[52.5 to 
104.9] 
[46.7 to 
106.3] 
368 
 
 
Full Cohort Diabetes No diabetes 
P 
(DM vs 
No DM)  
PORH; time to peak 
hyperaemia(seconds) 
14.3 12.9 16.7 
<0.001 
[10.6 to 23.2] [10.3 to 18.1] [12.3 to 32.2] 
PORH; time to baseline  
(seconds) 
149.7 146.1 157.8 
0.073 [120.6 to 
189.5] 
[111.2 to 
185.0] 
[129.7 to 
199.8] 
PORH; type of peak: n=216 n=140 n=76 0.449 
Normal 106 (49%) 67 (48%) 39 (51%) 
 
Early non-dominant 72 (33%) 45 (32%) 27 (36%) 
 
Early dominant 38 (18%) 28 (20%) 10 (13%)   
Table 71 Urinary albumin excretion and microvascular function in participants with and 
without diabetes. Albumin excretion is reported as the mean of two overnight urine 
collections and a single spot collection for all participants (n=278). Urinary albumin was 
quantified using the Fitzgerald ELISA. P value < 0.05 indicates if there is a significant 
difference in a characteristic between subjects with and without diabetes.  
369 
 
7.5.1.4 Objective 3 
 
To determine if there is a correlation between urinary albumin excretion and vascular 
function across the full albuminuria range, and to evaluate the impact diabetes has on that 
relationship. 
 
There is a significant correlation between urinary albumin excretion with all the different 
measures of microvascular function (Table 72). The association between AER/ACR with 
measures of microvascular function is not significantly different in subjects with diabetes 
compared to those without diabetes (Table 73). 
Caution needs to be taken when interpreting correlations where data has been transformed 
by 1/square root ($), as the direction of the relationship is reversed, compared to using 
untransformed. 
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AER ACR 
  
Best 
distribution 
Log  
Non 
parametric 
Best 
distribution 
Log  
Non 
parametric 
Maximal blood flow 
n 249 235 
r 0.17$ -0.19 -0.13 0.13$ -0.13 -0.12 
p 0.008* 0.003* 0.038* 0.046* 0.045* 0.063 
Minimum Vascular 
resistance 
n 236 220 
r -0.14$ 0.17 0.12 -0.13$ 0.15 0.15 
p 0.029* 0.008* 0.068 0.051 0.026* 0.031* 
Iontophoresis: n 246 234 
ACH; total 
endothelial 
dependent response  
r 0.18$ -0.18 -0.17 0.19$ -0.17 -0.20 
p 0.004* 0.005* 0.009* 0.004* 0.010* 0.003* 
ACH; peak 
endothelial 
dependent response  
r 0.17$ -0.18 -0.17 0.20$ -0.19 -0.24 
p 0.007* 0.004* 0.006* 0.002* 0.003* 0.000* 
SNP; total 
endothelial 
independent 
response  
r 0.13$ -0.16 -0.11 0.20$ -0.17 -0.21 
p 0.046* 0.012* 0.086 0.003* 0.010* 0.002* 
SNP; peak 
endothelial 
independent 
response  
r 0.13$ -0.16 -0.11 0.21$ -0.19 -0.22 
p 0.035* 0.014* 0.087 0.002* 0.003* 0.001* 
Peak Reactive 
Hyperaemia: 
n 225 208 
Peak hyperaemia  
r -0.14$ 0.09 0.08 0.06$ -0.04 -0.08 
p 0.033* 0.163 0.220 0.375 0.533 0.273 
Time to peak 
hyperaemia 
r 
n/a 
-0.02 -0.13 -0.06$ 0.09 -0.03 
p 0.766 0.046* 0.382 0.224 0.671 
Time to baseline 
r 
n/a 
-0.13 -0.22 0.07$ -0.05 -0.11 
p 0.060 0.001* 0.337 0.470 0.130 
Table 72 Correlation between urinary albumin excretion and microvascular function. 
Pearson correlation coefficient was determined between variables using; a) transformed 
data (to achieve normal data distribution) and b) log transformed data. Spearman rank 
correlation was carried out on untransformed data. $ denotes result in which data was 
transformed by 1/square-root. n/a denotes data which could not be transformed to achieve 
normal distribution.  * denotes a significant relationship where p<0.05.   
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Interaction of T2DM on 
correlation between AER 
and microvascular function 
Interaction of T2DM on 
correlation between ACR 
and microvascular function 
 β-coefficient p β-coefficient p 
Maximal blood flow -0.07$ 0.743 0.17$ 0.382 
Minimum Vascular resistance -0.17$ 0.433 -0.31$ 0.124 
Iontophoresis:     
ACH; total endothelial dependent 
response  
-0.02$ 0.917 0.03$ 0.858 
ACH; peak endothelial dependent 
response  
-0.04$ 0.840 -0.01$ 0.992 
SNP; total endothelial independent 
response  
-0.04$ 0.847 0.17$ 0.381 
SNP; peak endothelial independent 
response 
-0.09$ 0.649 0.13$ 0.507 
Peak Reactive Hyperaemia:     
Peak hyperaemia  -0.18$ 0.176 -0.11$ 0.591 
Time to peak hyperaemia -0.04$ 0.831 0.15$ 0.465 
Time to baseline 0.23
$ 0.273 0.24$ 0.262 
Table 73 Interaction of diabetes on the relationship between microvascular function and 
albumin excretion. Albumin excretion is reported as AER (from two overnight collections) 
and an ACR (from a single random spot sample). This analysis was carried out on the same 
participants included in the previous analysis (Table 72). $ denotes result in which data was 
transformed by 1/square-root. The association between AER/ACR with measures of 
microvascular function is not significantly different in subjects with diabetes compared to 
those without diabetes.   
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The association between AER/ACR with measures of microvascular function is not 
significantly different in subjects with diabetes compared to those without diabetes (Table 
73). The SUMMIT cohort has a high prevalence of CVD (43%) which may influence the 
relationship between AER/ACR with measures of microvascular function. The interaction of 
CVD on this relationship is reported in Table 74, demonstrating the relationship between 
AER/ACR and time to peak hyperaemia (PORH) is influenced by CVD. 
  
 
Interaction of CVD on 
correlation between AER 
and microvascular function 
Interaction of CVD on 
correlation between ACR 
and microvascular function 
 β-coefficient p β-coefficient p 
Maximal blood flow 0.34$ 0.069 0.19$ 0.286 
Minimum Vascular resistance -0.22$ 0.260 -0.12$ 0.519 
Iontophoresis:     
ACH; total endothelial dependent 
response  
-0.20$ 0.267 -0.20$ 0.255 
ACH; peak endothelial dependent 
response  
-0.15$ 0.407 -0.23$ 0.189 
SNP; total endothelial independent 
response  
-0.21$ 0.240 -0.16$ 0.367 
SNP; peak endothelial independent 
response 
-0.19$ 0.290 -0.16$ 0.367 
Peak Reactive Hyperaemia:     
Peak hyperaemia  -0.11$ 0.571 0.04$ 0.821 
Time to peak hyperaemia -0.64$ 0.001* -0.65$ 0.001* 
Time to peak baseline -0.12$ 0.542 0.00$ 0.994 
Table 74 Interaction of CVD on the relationship between microvascular function and 
albumin excretion. Albumin excretion is reported as AER (from two overnight collections) 
and an ACR (from a single random spot sample). $ denotes result in which data was 
transformed by 1/square-root.  
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Next regression analysis is carried out to determine if the AER has an independent 
relationship with all measures of microvascular function when accounting for other 
contributing factors (Table 76). This is then followed by an investigation into the interaction 
of CVD on relationship between AER/ACR and time to peak hyperaemia (PORH). 
 
All measures of microvascular function had a significant correlation with urinary albumin 
excretion (Table 72). If any of the correlations were significant, regardless of the method 
used to test it, then the association between AER/ACR with measures of microvascular 
function were tested further using regression analysis, to determine if the association is 
independent of other potential confounding factors. 
Complete confounding factor data for 62 participants was not available for regression 
modelling. Consequently, the correlation between AER and MBF (p=0.24), MVR (p=0.08), 
SNP; total response (p=0.18), SNP; peak response (p=0.15) and time to baseline after PORH 
testing (p=0.06) were no longer significant, and further analysis was not carried out. The 
relationship between ACR and MBF (p=0.22) and MVR (p=0.10) also lost significance and 
were not investigated further. 
Regression analysis on the remaining relationships demonstrates that AER is independently 
associated with peak response PORH when accounting for other contributing factors but not 
with the response to ACH or PORH time to peak (Table 75). ACR did not have an 
independent relationship with any of the measures of microvascular function (Table 76). 
Further analysis on the relationship between skin reactive hyperaemia, assessed in response 
to arterial occlusion, with ACR was not carried out as there was no indication of an initial 
correlation (Table 72). 
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Regression model 
ACH; total 
endothelial 
dependent 
response 
ACH; peak 
endothelial 
dependent 
response 
Peak reactive 
hyperaemia 
Time to peak 
reactive 
hyperaemia 
 
n=207 n=207 n=186 n=186 
 
beta P beta p beta p beta p 
AER unadjusted 0.16$ 0.021* 0.15$ 0.030* -0.14$ 0.051 0.15$ 0.046* 
AER adj by Age 0.14$ 0.043* 0.14$ 0.054 -0.18$ 0.012* 0.16$ 0.035* 
AER adj by Age & Gender 0.13$ 0.073 0.13$ 0.075 -0.16$ 0.032* 0.12$ 0.137 
AER adj by Age & Gender & Smoking 0.13$ 0.070 0.13$ 0.070 -0.16$ 0.033* 0.12$ 0.132 
AER adj by Age & Gender & Smoking 
& HDL 
0.12$ 0.102 0.12$ 0.119 -0.16$ 0.033* 0.10$ 0.185 
AER adj by Age & Gender & Smoking 
& HDL & Sys BP 
0.13$ 0.095 0.12$ 0.112 -0.17$ 0.028* 0.09$ 0.226 
AER adj by Age & Gender & Smoking 
& HDL & Sys BP & CVD Event 
0.09$ 0.241 0.13$ 0.078 -0.13$ 0.082 0.09$ 0.257 
AER adj by Age & Gender & Smoking 
& HDL & Sys BP & CVD Event & 
HbA1c 
0.08$ 0.305 0.09$ 0.270 -0.15$ 0.046* 0.05$ 0.515 
AER adj by Age & Gender & Smoking 
& HDL & Sys BP & CVD Event & 
HbA1c & Waist 
0.03$ 0.661 0.03$ 0.735 -0.21$ 0.008* 0.02$ 0.778 
Table 75 Regression analysis between AER and microvascular function. A forced entry 
approach to regression modelling with confounding variables accumulatively added. Beta 
coefficient and p value of the relationship of AER with microvascular function after 
adjustment is reported. * denotes a significant relationship (p<0.05) between AER and 
microvascular function. $ denotes result in which data was transformed by 1/square-root. 
Adj denotes adjusted. 
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AER has a significant relationship with peak hyperaemia response after arterial occlusion 
when accounting for other confounding variables (p=0.008). The direct correlation between 
AER and peak hyperaemia is presented in Figure 89A. The estimated relationship between 
AER and peak hyperaemia when adjusting for confounding factors is displayed in Figure 89B. 
 
 
Figure 89 Correlation between AER and peak height during post-occlusive reactive 
hyperaemia testing. A: Correlation between peak height and AER (log scale) with no 
adjustment. B: Correlation between peak height and AER (data transformed by 1/square 
root) after adjusting for all the variables used in the regression model in Table 75. 
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Regression model ACH AUC ACH Peak SNP AUC SNP Peak 
  n=194 n=194 n=190 n=190 
  beta  p beta  p beta  p beta  p 
ACR unadjusted 0.18$ 0.009* 0.22$ 0.002* 0.18$ 0.013* 0.19$ 0.008* 
ACR adj by Age 0.16$ 0.029* 0.19$ 0.007* 0.16$ 0.033* 0.18$ 0.017* 
ACR adj by Age & Gender 0.17$ 0.023* 0.20$ 0.006* 0.16$ 0.033* 0.18$ 0.018* 
ACR adj by Age & Gender & 
Smoking 
0.16$ 0.026* 0.20$ 0.007* 0.15$ 0.040* 0.17$ 0.022* 
ACR adj by Age & Gender & 
Smoking & HDL 
0.15$ 0.039* 0.18$ 0.012* 0.13$ 0.066 0.15$ 0.038* 
ACR adj by Age & Gender & 
Smoking & HDL & Sys BP 
0.15$ 0.051 0.18$ 0.014* 0.13$ 0.081 0.15$ 0.050 
ACR adj by Age & Gender & 
Smoking & HDL & Sys BP & CVD 
Event 
0.16$ 0.037* 0.20$ 0.009* 0.14$ 0.064 0.16$ 0.037* 
ACR adj by Age & Gender & 
Smoking & HDL & Sys BP & CVD 
Event  & HbA1c 
0.10$ 0.195 0.14$ 0.063 0.06$ 0.313 0.09$ 0.250 
ACR adj by Age & Gender & 
Smoking & HDL & Sys BP & CVD 
Event & HbA1c & Waist 
0.06$ 0.393 0.10$ 0.172 0.04$ 0.612 0.05$ 0.513 
Table 76 Regression analysis between ACR and microvascular function. A forced entry 
approach to regression modelling with confounding variables accumulatively added. Beta 
coefficient and p value of the relationship of ACR with microvascular function after 
adjustment is reported. * denotes a significant relationship (p<0.05) between ACR and 
microvascular function. $ denotes result in which data was transformed by 1/square-root. 
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Interaction of CVD on the relationship between AER and time to peak hyperaemia 
(PORH) 
 
There are significant correlations between AER and ACR with time to peak hyperaemia 
(PORH) in subjects with and without CVD (Table 77), positive in the CVD group compared to 
negatively associated in the non-CVD group. However, none were independent when 
accounting for other confounding risk factors of CVD (Table 78). The interaction of CVD on 
the relationship between microvascular function and urinary albumin excretion is 
investigated further in the normoalbuminuria range in Objective 4. 
 
      
Time to peak 
hyperaemia 
      
r p 
CVD 
AER 
n 104 
Best distribution 0.11 0.263 
Log 0.21 0.030* 
Non parametric 0.09 0.377 
ACR 
n 98 
Best distribution 0.17 0.09 
Log 0.34 <0.001* 
Non parametric 0.15 0.139 
No CVD 
AER 
n 119 
Best distribution -0.31 <0.001* 
Log -0.30 0.001* 
Non parametric -0.34 <0.001* 
ACR 
n 107 
Best distribution -0.24 0.016* 
Log -0.26 0.008* 
Non parametric -0.20 0.038* 
Table 77 Correlation between urinary albumin excretion and time to peak hyperaemia 
(PORH) in subjects with and without CVD.  Pearson correlation coefficient was determined 
between variables using; a) transformed data (to achieve normal data distribution) and b) 
log transformed data. Spearman rank correlation was carried out on untransformed data. * 
denotes a significant relationship where p<0.05.   
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  CVD No CVD 
Regression model AER ACR AER ACR 
 Time to peak hyperaemia 
(PORH) 
n=74 n=70 n=111 n=102 
  beta  p beta  p beta  p beta  p 
AER/ACR unadjusted -0.02
$
 0.894  -0.08
$
 0.507  -0.31
$
 0.001*  -0.19
$
  0.058 
AER/ACR adj by Age -0.03$ 0.828 -0.09$  0.481 -0.32$ 0.001* -0.20$  0.062 
AER/ACR adj by Age & 
Gender 
-0.05$ 0.723 -0.08$  0.490 -0.25$ 0.010* -0.25$ 0.014*  
AER/ACR adj by Age & 
Gender & Smoking 
-0.06
$
 0.631 -0.09
$
 0.469  -0.23
$
 0.020* -0.23
$
 0.021*  
AER/ACR adj by Age & 
Gender & Smoking & HDL 
-0.05
$
 0.689 -0.09
$
  0.465 -0.22
$
 0.030* -0.20
$
 0.052  
AER/ACR adj by Age & 
Gender & Smoking & HDL 
& Sys BP 
-0.05
$
 0.708 -0.09
$
  0.491 -0.20
$
 0.043* -0.18
$
 0.080  
AER/ACR adj by Age & 
Gender & Smoking & HDL 
& Sys BP & CVD Event  & 
HbA1c 
-0.03$ 0.803 -0.07$  0.568 -0.15$ 0.140 -0.12$ 0.257  
AER/ACR adj by Age & 
Gender & Smoking & HDL 
& Sys BP & CVD Event & 
HbA1c & Waist 
0.00$ 0.980  -0.05$ 0.722  -0.12$ 0.264  -0.11$  0.296 
Table 78 Regression analysis between AER and microvascular function in subjects with and 
without CVD. A forced entry approach to regression modelling with confounding variables 
accumulatively added. Beta coefficient and p value of the relationship of AER/ACR with 
microvascular function after adjustment is reported. * denotes a significant relationship 
(p<0.05) between AER and microvascular function. $ denotes result in which data was 
transformed by 1/square-root. Adj denotes adjusted. 
 
Post occlusive reactive hyperaemia curve morphology: 
AER was stratified by peak response curve morphology (Table 79, Figure 90). A one way 
ANOVA demonstrated there was no significant difference in AER distribution between 
groups (p=0.246).  
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Post occlusive reactive hyperaemia curve morphology: 
 
Normal Early non-dominant Early dominant 
n 107 73 38 
AER (µg/min) 
7.92 7.77 10.34 
[4.67 to 12.56] [4.73 to 14.78] [5.45 to 16.77] 
Table 79 Distribution of AER by curve morphology after post occlusive reactive hyperaemia 
testing. Median AER [inter-quartile range] is presented. There is no significant difference in 
the distribution of AER among the different peak types (p=0.246). 
 
 
Figure 90 AER distribution by curve morphology after post occlusive reactive hyperaemia 
testing. AER is presented on a log scale. The horizontal line inside the box represents the 
median, the edges of the box are the upper and lower interquartile and the whiskers 
represent the minimum and maximum values, with outlying results individually plotted. 
There is no significant difference in the distribution of AER among the different peak types 
(p=0.332). 74% of outliers across all groups were on antihypertensive therapy, and 78% on 
statins. 
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The characteristics of the participants by curve morphology are summarised in Table 80. Age 
(p=0.031), weight (p=0.013), BMI (p<0.001), waist (p=0.003), hip circumference (p=0.003), 
systolic blood pressure (p=0.046), history of CVD (p=0.038), on antihypertensive therapy 
(p=0.049) and renal decline (p=0.034) were significantly more prominent in subjects with an 
early dominant peak, demonstrating an increased risk of CVD across all groups.  
 
Peak and total endothelial dependent response to ACH was significantly reduced in subjects 
with an early dominant peak response to arterial occlusion (Total response; p=0.019, peak 
response; p=0.012) (Table 80). 
 
 
Characteristic Normal 
Early non-
dominant 
Early 
dominant 
p 
(across all 
groups) 
n 107 73 38   
Gender (%male) 75 (71%) 51 (71%) 26 (68%) 0.953 
Ethnicity (% white British) 100% 98% 100% 0.346 
Age (years) 69.0 (±7.6) 70.1 (±8.3) 72.1 (±9.1) 0.031*£  
Height (m) 
1.72 1.71 1.73 
0.311 
[1.66 to 1.78] [1.65 to 1.76] [1.67 to 1.77] 
Weight (kg) 
81.0 80.8 88.5 
0.013*& 
[71.6 to 88.7] [72.7 to 94.9] [80.7 to 102.5] 
Body fat (%) 
28.7 30.2 32.8 
0.080 
[23.9 to 36.0] [25.3 to 36.9] [27.2 to 38.5] 
BMI (kg m-2) 
27 28 30 
<0.001* 
[24 to 30] [25 to 32] [28 to 33] 
Waist (cm) 98.5 (±13.8) 101.8 (±13.5) 106.3 (±14.5) 0.003* 
Hip (cm) 
104 106 109 
0.003*$ 
[101 to 112] [101 to 113] [105 to 117] 
Waist hip ratio 0.92 (±0.08) 0.94 (±0.09) 0.95 (±0.09) 0.080 
Systolic BP (mmHg) 130.1 (±14.1) 133.1 (±13.5) 135.1 (±15.3) 0.046* 
Diastolic BP (mmHg) 70.4 (±9.0) 68.9 (±6.3) 69.6 (±8.3) 0.444 
Total cholesterol (mmol/L) 
4.1 4.3 4.3 
0.764 
[3.5 to 5.2] [3.7 to 5.5] [3.7 to 4.9] 
HDL (mmol/L) 
1.4 1.31 1.31 
0.068 
[1.15 to 1.83] [1.09 to 1.67] [1.04 to 1.71] 
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Characteristic Normal 
Early non-
dominant 
Early 
dominant 
p 
(across all 
groups) 
LDL (mmol/L) 
2.15 2.24 2.03 
0.908 
[1.61 to 2.97] [1.73 to 3.25] [1.61 to 2.66] 
Fasting triglycerides (mmol/L) 
1.00 1.26 1.32 
0.139 
[0.81 to1.50] ]0.84 to 1.94] [0.88 to 1.53] 
Glucose (mmol/L) 
6.5 6.5 6.6 
0.282 
[5.1 to 8.2] [5.5 to 7.5] [5.2 to 9] 
HbA1c (mmol/mol) 
48 47 54 
0.209$ 
[41 to 60] [43 to 54] [42 to 63] 
CVD n (%) 42 (40%) 31 (43%) 24 (63%) 0.038* 
Antihypertensive therapy n (%) 60 (57%) 48 (67%) 30 (79%) 0.049* 
Statin therapy n (%) 73 (69%) 49 (68%) 28 (74%) 0.839 
Smokers (current/ex/never) (%) (5/42/53) (1/61/38) 8/39/53) 0.072 
 
Renal function:    
Serum creatinine (µmol/L) 
83 86 87 
0.178 
[70 to 92] [74 to 97] [75 to 91] 
eGFR (ml/min/1.73m2) 
80.4 73.3 76.2 
0.034* 
[71.5 to 88.2] [62.8 to 84.9] [60.8 to 85.2] 
CKD stage n (%): 
   
0.034* 
G1 16 (18%) 9 (15%) 5 (15%) 
 
G2 65 (73%) 39 (64%) 21 (62%) 
 
G3A 6 (7%) 7 (11%) 8 (24%) 
 
G3B 2 (2%) 2 (3%) 0 
 
G4 0 4 (7%) 0 
 
G5 0 0 0   
Albuminuria: 
   
0.489 
Normoalbuminuria n (%) 91 (86%) 59 (82%) 31 (82%) 
 
Microalbuminuria n (%) 13 (12%) 13 (18%) 7 (18%) 
 
Macroalbuminuria n (%) 2 (2%) 0 0 
 
Vascular assessments:       
Maximal blood flow (AU) 
148.1 139.3 130.8 
0.129 
[112.5 to 202.0] [94.5 to 198.5] [105.6 to 181.2] 
Minimum vascular resistance 
(mmHg/AU) 
0.63 0.69 0.67 
0.165 
[0.44 to 0.82] [0.45 to 0.91] [0.51 to 0.79] 
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Characteristic Normal 
Early non-
dominant 
Early 
dominant 
p 
(across all 
groups) 
ACH; total endothelial 
dependent response (AU) 
85334 85312 65875 
0.019*@ [56351 to 
113561] 
[59706 to 
108505] 
[36041 to 
99729] 
ACH; peak endothelial 
dependent response (AU) 
447.3 439.0 375.7 
0.012*@ 
[368.9 to 546.0] [345.7 to 537.4] [287.0 to 275.2] 
SNP; total endothelial 
independent response (AU) 
51890 50680 43940 
0.436@ 
[34180 to 69200] 
[36860 to 
73020] 
[25740 to 
64560] 
SNP; peak endothelial 
independent response (AU) 
330.0 344.0 290.0 
0.446@ 
[270.0 to 403.0] [264.0 to 425.0] [235.0 to 376.0] 
PORH; peak hyperaemia (AU) 
82.3 66.3 59.0 
<0.001*& 
[57.1 to 101.5] [43.6 to 98.8] [44.1 to 91.8] 
PORH; time to peak 
hyperaemia(seconds) 
13.1 19.2 10.6 
0.995& 
[11.1 to 16.1] [13.3 to 38.1] [8.2 to 15.6] 
PORH; time to baseline  
140.9 159.4 157.2 
0.248& 
[116.4 to 171.1] [128.2 to 200.8] [118.3 to 212.8] 
Diabetes n (%) 67 (63%) 45 (63%) 28 (74%) 
0.427 
Glucose (mmol/L) 
8.0 7.4 8.9 
0.306 
[6.6 to 9.0] [6.6 to 9.0] [6.5 to 9.7] 
HbA1c (mmol/mol) 
57 51 60 
0.381 [49 to 63] [47 to 62] [53 to 66] 
Duration of diabetes (years) 6.5 (±5.6) 7.8 (±6.8) 10.6 (±6.8) 0.011*@ 
Table 80 Participant characteristics and microvascular function stratified by peak response 
curve morphology group. Data are presented as mean (±SD) or median [IQR]. * P value < 
0.05 indicates a significant difference in a characteristic between subjects with different 
peak morphology, across all three groups. The following symbols represent results obtained 
from transformed data to ensure normal distribution of residuals from regression analysis: £ 
denotes squared data, &denotes logged data, $denotes 1/square root transformation and 
@denotes data transformed by square root.  
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7.5.1.5 Objective 4 
To determine if the associations between urinary albumin excretion and microvascular 
vascular function exists within the normoalbuminuria range. 
 
The correlations between AER/ACR with measures of vascular function in the 
normoalbuminuria range are displayed in Table 81. The interaction of diabetes on these 
relationships is presented in Table 82. 
 
  
AER ACR 
    
Best 
distribution 
Log  
Non 
parametric 
Best 
distribution 
Log 
Non 
parametric 
Maximal blood flow 
n 211 184 
r 
n/a 
-0.08 -0.09 0.06
$
 -0.07 -0.08 
p 0.229 0.213 0.411 0.333 0.280 
Minimum Vascular 
resistance 
n 203 175 
r 
n/a 
0.06 0.07 -0.06
$
 0.08 0.09 
p 0.389 0.309 0.421 0.302 0.247 
Iontophoresis: n 209 183 
ACH; total endothelial 
dependent response  
r -0.12$ -0.12 -0.09 0.07$ -0.06 -0.06 
p 0.09 0.077 0.173 0.360 0.390 0.393 
ACH; peak endothelial 
dependent response  
r -0.09$ -0.1 -0.08 0.09
$
 -0.09 -0.11 
p 0.199 0.152 0.233 0.237 0.233 0.127 
SNP; total endothelial 
independent response  
r -0.04$ -0.03 -0.03 0.13
$
 -0.11 -0.12 
p 0.589 0.646 0.687 0.076 0.142 0.103 
SNP; peak endothelial 
independent response  
r -0.04$ -0.04 -0.02 0.16$ -0.15 -0.15 
p 0.589 0.594 0.756 0.038* 0.049* 0.046* 
Peak Reactive 
Hyperaemia: 
n 189 161 
Peak hyperaemia  
r 
n/a 
0.22 0.17 0.08$ -0.11 -0.09 
p 0.003* 0.023* 0.293 0.175 0.277 
Time to peak 
hyperaemia 
r 
n/a 
-0.12 -0.19 
n/a 
0.05 0.01 
p 0.101 0.009* 0.493 0.862 
Time to baseline 
r 
n/a 
-0.16 -0.22 
n/a 
-0.01 -0.09 
p 0.033* 0.002* 0.889 0.271 
Table 81 Correlation between albuminuria and microvascular function within the 
normoalbuminuria range. * denotes p<0.05.  $ denotes data transformed by 1/square-root. 
n/a denotes data which could not be transformed to achieve normal distribution.  
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Interaction of T2DM on 
correlation between AER 
and microvascular function 
Interaction of T2DM on 
correlation between ACR 
and microvascular function 
 β-coefficient p β-coefficient p 
Maximal hyperaemia -0.18$ 0.498 0.07$ 0.819 
Minimum Vascular resistance 0.17$ 0.546 -0.18$ 0.550 
Iontophoresis:     
ACH; total endothelial dependent 
response  
-0.04$ 0.884 -0.51$ 0.076 
ACH; peak endothelial dependent 
response  
-0.05$ 0.844 -0.59$ 0.038* 
SNP; total endothelial independent 
response  
-0.19$ 0.479 -0.25$ 0.389 
SNP; peak endothelial independent 
response 
-0.25$ 0.345 -0.27$ 0.354 
Peak Reactive Hyperaemia:     
Peak hyperaemia  0.02$ 0.930 -0.54$ 0.088 
Time to peak hyperaemia -0.06$ 0.837 0.54$ 0.087 
Time to baseline 0.42$ 0.119 0.33$ 0.289 
Table 82 Interaction of diabetes in the relationships between measures of microvascular 
function and albumin excretion in the normoalbuminuria range. Albumin excretion is 
reported as AER (from two overnight collections) and an ACR (from a single random spot 
sample). This analysis was carried out on the same participants included in the previous 
analysis (Table 81). $ denotes result in which data was transformed by 1/square-root. The 
association between ACR with ACH peak is significantly different in subjects with diabetes 
compared to those without diabetes.   
 
The relationship between ACR and peak endothelial independent response to SNP is 
influenced by diabetes. There is no significant correlation between peak hyperaemia and 
ACR among subjects with T2DM (RS = -0.16, p=0.057), but there is in subjects without T2DM 
(RS = -0.24, p=0.021). Both results suggest an association, and no firm hypothesis can be 
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made due to the closeness of the result in subjects with T2DM (p=0.057) to the p<0.05 
threshold for significance. The loss of significance may be influenced by subjects with CVD in 
the group without T2DM. 
The interaction of CVD on relationship between AER/ACR and microvascular function in the 
normoalbuminuria was also assessed in the SUMMIT cohort (Table 83) and shows CVD had a 
significant interaction on the relationship between AER and maximal hyperaemia and 
minimum vascular resistance, and also between ACR and total and peak endothelial 
dependent response to ACH. 
 
Interaction of CVD on 
correlation between AER 
and microvascular function 
Interaction of CVD on 
correlation between ACR 
and microvascular function 
 β-coefficient p β-coefficient p 
Maximal hyperaemia 0.61$ 0.020* 0.18$ 0.473 
Minimum Vascular resistance -0.67$ 0.014* -0.22$ 0.404 
Iontophoresis:     
ACH; total endothelial dependent 
response  
-0.14$ 0.581 -0.50$ 0.045* 
ACH; peak endothelial dependent 
response  
-0.10$ 0.693 -0.58$ 0.019* 
SNP; total endothelial independent 
response  
-0.03$ 0.921 -0.42$ 0.092 
SNP; peak endothelial independent 
response 
-0.01$ 0.972 -0.41$ 0.094 
Peak Reactive Hyperaemia:     
Peak hyperaemia  -0.16$ 0.547 -0.13$ 0.633 
Time to peak hyperaemia -0.24$ 0.394 -0.23$ 0.407 
Time to baseline -0.13$ 0.639 0.38$ 0.156 
Table 83 Interaction of CVD on the relationship between microvascular function and 
albumin excretion in the normoalbuminuria range. Albumin excretion is reported as AER 
(from two overnight collections) and an ACR (from a single random spot sample). $ denotes 
result in which data was transformed by 1/square-root.*denotes p<0.05 
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Next regression analysis was carried out to determine if AER has an independent 
relationship with all measures from PORH testing when accounting for other contributing 
factors in the normoalbuminuria range (Table 84). This is then followed by an investigation 
into the interaction of CVD on relationship between AER/ACR and microvascular function. 
Regression analysis was carried out to determine if the AER has an independent relationship 
with all measures from PORH testing when accounting for other contributing factors in the 
normoalbuminuria range (Table 84). There was also a significant correlation between ACR 
and peak response to SNP (Table 81), therefore regression analysis was carried out to 
determine if ACR has an independent association with SNP peak height (Table 85). 
 
Peak 
reactive 
hyperaemia 
Time to 
peak 
reactive 
hyperaemia 
Time to 
baseline 
Regression model n=157 n=157 n=164 
 beta  p beta  p beta  p 
AER unadjusted 0.22$ 0.006* -0.15$ 0.055 -0.13$ 0.106 
AER adj by Age 0.23$ 0.003* -0.16$ 0.052 -0.13$ 0.108 
AER adj by Age & Gender 0.21$ 0.007* -0.12$ 0.131 -0.09$ 0.284 
AER adj by Age & Gender & Smoking 0.21$ 0.007* -0.13$ 0.111 -0.09$ 0.242 
AER adj by Age & Gender & Smoking & HDL 0.21$ 0.008* -0.11$ 0.182 -0.08$ 0.325 
AER adj by Age & Gender & Smoking & HDL & Sys 
BP 
0.21$ 0.009* -0.11$ 0.176 -0.08$ 0.328 
AER adj by Age & Gender & Smoking & HDL & Sys 
BP & CVD Event 
0.18$ 0.021* -0.12$ 0.161 -0.08$ 0.313 
AER adj by Age & Gender & Smoking & HDL & Sys 
BP & CVD Event  & HbA1c 
0.20$ 0.014* -0.10$ 0.256 -0.07$ 0.366 
AER adj by Age & Gender & Smoking & HDL & Sys 
BP & CVD Event & HbA1c & Waist 
0.24$ 0.003* -0.08$ 0.372 -0.06$ 0.475 
Table 84 Regression analysis between AER and post-occlusive reactive hyperaemia in the 
normoalbuminuria range. Beta coefficient and p value of the relationship of AER with 
microvascular function after adjustment is reported. * denotes a significant relationship 
(p<0.05) between AER and post-occlusive reactive hyperaemia. $ denotes result in which 
data was transformed by 1/square-root. 
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SNP; peak endothelial 
independent response 
Regression model n=152 
  beta p 
ACR unadjusted 0.17 0.037* 
ACR adj by Age 0.15 0.063 
ACR adj by Age & Gender 0.16 0.071 
ACR adj by Age & Gender & Smoking 0.15 0.081 
ACR adj by Age & Gender & Smoking & HDL 0.14 0.111 
ACR adj by Age & Gender & Smoking & HDL & Sys 
BP 
0.14 0.114 
ACR adj by Age & Gender & Smoking & HDL & Sys 
BP & CVD Event 
0.14 0.112 
ACR adj by Age & Gender & Smoking & HDL & Sys 
BP & CVD Event  & HbA1c 
0.12 0.148 
ACR adj by Age & Gender & Smoking & HDL & Sys 
BP & CVD Event & HbA1c & Waist 
0.10 0.238 
Table 85 Regression analysis between ACR and peak endothelial independent response to 
sodium nitroprusside in the normoalbuminuria range. Beta coefficient and p value of the 
relationship of ACR with peak endothelial independent response to sodium nitroprusside 
after adjustment is reported. * denotes a significant relationship (p<0.05). ACR is not 
independently related to peak endothelial independent response to sodium nitroprusside in 
the normoalbuminuria range. 
 
AER in the normoalbuminuria range has an independent relationship with peak reactive 
hyperaemia post arterial occlusion when accounting for other confounding variables. ACR is 
not independently related to peak endothelial independent response to sodium 
nitroprusside in the normoalbuminuria range. 
The direct correlation between AER and peak height in the normoalbuminuria range is 
demonstrated in Figure 91A. The estimated relationship between AER and peak height 
when adjusting for confounding factors is displayed in Figure 91B. 
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Figure 91 Correlation between AER and peak hyperaemia from post-occlusive reactive 
hyperaemia testing in the normoalbuminuria range. A: Unadjusted correlation between 
peak hyperaemia and AER (log scale). B: Correlation between peak hyperaemia and AER 
(data log transformed) after adjusting for all the variables used in the regression model in 
Table 76. 
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Interaction of CVD on relationship between AER/ACR and microvascular function 
in the normoalbuminuria range 
 
There are significant correlations between AER and maximal blood flow and minimum 
vascular resistance in subjects with CVD (Table 86). However, due to reduced sample size 
during regression modelling the relationships between AER and MBF (p=0.068) and MVR 
(p=0.101) were no longer significant and not investigated further.   
There are significant correlations between ACR and endothelial dependent and independent 
response to ACH and SNP respectively in subjects without CVD (Table 86). The relationship 
between ACR and endothelial dependent response to ACH in subjects without CVD was 
independent of other confounding factors for CVD (Table 87). However the relationship 
between ACR and endothelial independent response to SNP was accounted by the included 
confounding factors (Table 87). 
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Maximal blood 
flow 
Minimum 
Vascular 
resistance 
ACH; total 
endothelial 
dependent 
response  
ACH; peak 
endothelial 
dependent 
response  
SNP; total 
endothelial 
independent 
response  
SNP; peak 
endothelial 
independent 
response 
      r p r p r p r p r p r p 
CVD 
AER 
n 92 87 89 91 86 88 
Best distribution 0.27
$
 0.009* -0.26
$
 0.014* 0.13
$
 0.233 0.09
$
 0.412 0.03
$
 0.754 0.05
$
 0.613 
Log -0.29 0.005* 0.29 0.006* -0.15 0.170 -0.12 0.241 -0.01 0.912 -0.05 0.672 
Non parametric -0.30 0.004* 0.30 0.005* -0.09 0.412 -0.10 0.347 -0.04 0.726 -0.05 0.648 
ACR 
n 87 82 84 86 81 83 
Best distribution 0.13$ 0.242 -0.11
$ 0.319 0.01
$ 0.923 0.01
$ 0.964 0.03
$ 0.786 0.04
$ 0.703 
Log -0.15 0.153 0.14 0.197 0.03 0.761 0.01 0.943 0.02 0.858 -0.02 0.883 
Non parametric -0.13 0.221 0.13 0.260 0.03 0.767 0.00 0.991 -0.01 0.964 -0.03 0.800 
No CVD 
AER 
n 119 116 118 118 117 117 
Best distribution -0.08
$
 0.403 0.11
$
 0.223 0.12
$
 0.202 0.10
$
 0.290 0.05
$
 0.618 0.05
$
 0.621 
Log 0.10 0.299 -0.13 0.162 -0.10 0.268 -0.08 0.404 -0.05 0.565 -0.04 0.706 
Non parametric 0.09 0.306 -0.10 0.266 -0.08 0.362 -0.07 0.450 0.00 0.985 0.01 0.946 
ACR 
n 102 100 101 101 100 100 
Best distribution 0.00$ 0.983 -0.02
$ 0.843 0.27
$ 0.007* 0.34
$ 0.001* 0.25
$ 0.012* 0.27
$ 0.006* 
Log 0.02 0.839 0.01 0.935 -0.27 0.007* -0.35 <0.001* -0.25 0.014* -0.27 0.006* 
Non parametric -0.02 0.826 0.06 0.564 -0.28 0.004* -0.37 <0.001* -0.25 0.011* -0.28 0.005* 
Table 86 Correlation between urinary albumin excretion and microvascular function in subjects with and without CVD with 
normoalbuminuria.  Pearson correlation coefficient was determined between variables using; a) transformed data (to achieve normal data 
distribution) and b) log transformed data. Spearman rank correlation was carried out on untransformed data. * denotes a significant 
relationship where p<0.05. $ denotes result in which data was transformed by 1/square-root. Grey boxes highlight significant correlations.
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  No CVD 
Regression model 
ACH; total 
endothelial 
dependent 
response  
ACH; peak 
endothelial 
dependent 
response  
SNP; total 
endothelial 
independent 
response  
SNP; peak 
endothelial 
independent 
response 
  n=96 n=96 n=95 n=95 
  beta  p beta  p beta  p beta  p 
ACR unadjusted 0.26
$
 0.012* 0.33
$
 0.001* 0.26
$
 0.009* 0.29
$
 0.005* 
ACR adj by Age 0.22
$
 0.033* 0.30
$
 0.003* 0.21
$
 0.040* 0.25
$
 0.017* 
ACR adj by Age & Gender 0.25
$
 0.023* 0.34
$
 0.002* 0.19
$
 0.076 0.23
$
 0.041* 
ACR adj by Age & Gender 
& Smoking 
0.26
$
 0.018* 0.34
$
 0.002* 0.20
$
 0.070 0.23
$
 0.038* 
ACR adj by Age & Gender 
& Smoking & HDL 
0.26$ 0.02* 0.34$ 0.003* 0.17$ 0.126 0.20$ 0.070 
ACR adj by Age & Gender 
& Smoking & HDL & Sys 
BP 
0.26
$
 0.026* 0.34
$
 0.003* 0.17
$
 0.138 0.20
$
 0.077 
ACR adj by Age & Gender 
& Smoking & HDL & Sys 
BP & HbA1c 
0.23
$
 0.049* 0.32
$
 0.007* 0.14
$
 0.204 0.17
$
 0.142 
ACR adj by Age & Gender 
& Smoking & HDL & Sys 
BP & HbA1c & Waist 
0.21$ 0.069 0.30$ 0.010* 0.12$ 0.275 0.15$ 0.194 
Table 87 Regression analysis between ACR and microvascular function in subjects without 
CVD. A forced entry approach to regression modelling with confounding variables 
accumulatively added. Beta coefficient and p value of the relationship of AER/ACR with 
microvascular function after adjustment is reported. * denotes a significant relationship 
(p<0.05) between AER and microvascular function. $ denotes result in which data was 
transformed by 1/square-root. Adj denotes adjusted. 
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Post occlusive reactive hyperaemia curve morphology: 
 
AER in the normoalbuminuria range was stratified by PORH peak response curve 
morphology (Table 88, Figure 92).  A one way ANOVA demonstrated there was no significant 
difference in AER distribution between groups (p=0.308).  
 
 
 
 
 
 
PRH; Peak type: 
 
Normal Early non-dominant Early dominant 
n 92 60 31 
AER (µg/min) 
6.71 6.86 9.02 
[4.26 to 9.90] [4.36 to 9.58] [5.25 to 12.01] 
Table 88 Distribution of AER by curve morphology after post occlusive reactive hyperaemia 
testing in the normoalbuminuria range. Median AER [inter-quartile range] is presented. 
There is no significant difference in AER distribution between groups (p=0.308). 
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Figure 92 AER distribution by curve morphology after post occlusive reactive hyperaemia 
testing in participants in the normoalbuminuria range. There is no significant difference in 
AER distribution between groups (p=0.308).  
 
 
The characteristics of the participants by curve morphology are summarised in Table 89.  
Weight (p=0.040), BMI (p0.001), waist (p=0.010), hip size (p=0.004), systolic blood pressure 
(p=0.036) and renal impairment (p=0.025) were significantly more prominent in subjects 
with an early dominant peak across all groups, demonstrating an increased risk of CVD. 
 
Peak and total endothelial dependent response to ACH was significantly reduced in subjects 
with an early dominant peak response to arterial occlusion (Total response; p=0.043, peak 
response; p=0.028). Post occlusive reactive peak hyperaemia (the second, traditional peak) 
was significantly lower in subjects with an early dominant first peak (p=0.001) (Table 89). 
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Characteristic Normal 
Early non-
dominant 
Early 
dominant 
P  
(across all 3 
groups) 
n 92 60 31   
Gender (%male) 61 (67%) 39 (65%) 19 (61%) 0.858 
Ethnicity (% white British) 100% 98% 100% 0.330 
Age (years) 68.6 (±7.7) 69.2 (±8.0) 71.5 (±9.7) 0.065£ 
Height (m) 
1.72 1.71 1.71 
0.151 
[1.66 to 1.79] [1.65 to 1.76] 
[1.64 to 
1.76] 
Weight (kg) 
80 80.1 87 
0.040*& 
[71.3 to 88.4] [71.9 to 90.9] 
[80.6 to 
97.3] 
Body fat (%) 
28.4 30.2 32.6 
0.070 
[23.6 to 35.9] [26.1 to 36.9] 
[26.7 to 
39.5] 
BMI (kg m-2) 
26.58 27.44 29.66 
0.001* 
[24.28 to 29.87] [24.67 to 31.12] 
[27.74 to 
32.67] 
Waist (cm) 97.4 (±14.0) 100.1 (±13.8) 
104.9 
(±14.2) 
0.010* 
Hip (cm) 
104 105 108 
0.004*$ 
[100 to 112] [100 to 113] [106 to 116] 
Waist hip ratio 0.92 (±0.08) 0.93 (±0.08) 0.94 (±0.09) 0.190 
Systolic BP (mmHg) 128.9 (±13.7) 132.6 (±13.4) 
134.4 
(±15.6) 
0.036* 
Diastolic BP (mmHg) 69.9 (±8.3) 68.8 (±6.0) 68.9 (±8.2) 0.442 
Total cholesterol (mmol/L) 
4.1 4.4 4.1 
0.838 
[3.5 to 5.2] [3.8 to 5.6] [3.7 to 4.7] 
HDL (mmol/L) 
1.4 1.3 1.4 
0.094 
[1.2 to 1.9] [1.1 to 1.7] [1.0 to 1.7] 
LDL (mmol/L) 
2.15 2.34 2.12 
0.966 
[1.61 to 2.97] [1.78 to 3.46] 
[1.53 to 
2.66] 
Fasting triglycerides (mmol/L) 
0.99 1.18 1.32 
0.129 
[0.82 to 1.50] [0.84 to 1.98] 
[0.87 to 
1.51] 
Glucose (mmol/L) 
6.0 6.1 6.6 
0.096 
[5.1 to 7.9] [5.4 to 7.5] [5.4 to 9.0] 
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Characteristic Normal 
Early non-
dominant 
Early 
dominant 
P  
(across all 3 
groups) 
HbA1c (mmol/mol) 
45 46 51 
0.170$ 
[40 to 57] [42 to 51] [42 to 63] 
CVD n (%) 38 (42%) 22 (37%) 18 (58%) 0.173 
Antihypertensive therapy n (%) 47 (52%) 35 (58%) 23 (74%) 0.099 
Statin therapy n (%) 61 (67%) 38 (63%) 21 (68%) 0.945 
Smokers (current/ex/never) (%) (3/43/54) (2/56/42) (10/39/52) 0.188 
Renal function: 
   
Serum creatinine (µmol/L) 
81 85 87 
0.212 
[69 to 90] [73 to 95] [70 to 90] 
eGFR (ml/min/1.73m2) 
81.4 93.3 76.2 
0.025* 
[72.9 to 88.9] [63.1 to 85.4] 
[61.5 to 
83.5] 
CKD stage n (%): n=75 n=51 n=28 0.212 
G1 15 (20%) 8 (16%) 5 (18%) 
 
G2 55 (73%) 34 (67%) 17 (61%) 
 
G3A 4 (5%) 6 (12%) 6 (21%) 
 
G3B 1 (1%) 1 (2%) 0 
 
G4 0 2 (4%) 0 
 
G5 0 0 0   
Vascular assessments:     
Maximal blood flow (AU) 
148.5 139.3 134.8 
0.365 
[112.5 to 202.0] [102.2 to 205.9] 
[118.7 to 
184.9] 
Minimum vascular resistance 
(mmHg/AU) 
0.62 0.67 0.67 
0.544 
[0.44 to 0.81] 
[0.45 to 0.91] 
[0.51 to 
0.78] 
ACH; total endothelial 
dependent response (AU) 
92500 89087 66342 
0.043*@ [58072 to 
116405] 
[63075 to 
1221473] 
[36041 to 
99729] 
ACH; peak endothelial 
dependent response (AU) 
455.7 443.9 394.3 
0.028*@ 
[372.0 to 550.1] [362.1 to 550.4] 
[302.9 to 
475.2] 
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Characteristic Normal 
Early non-
dominant 
Early 
dominant 
P  
(across all 3 
groups) 
SNP; total endothelial 
independent response (AU) 
52190 56155 45020 
0.636@ 
[34080 to 70510] 
[41050 to 
84970] 
[25740 to 
64560] 
SNP; peak endothelial 
independent response (AU) 
333.0 351.5 301.0 
0.656@ 
[262.0 to 408.0] [297.0 to 461.0] 
[242.0 to 
376.0] 
PORH; peak hyperaemia (AU) 
81.4 66.7 59.3 
0.001*& 
[57.8 to 113.4] [49.4 to 101.8] 
[44.4 to 
91.8] 
PORH; time to peak 
hyperaemia(seconds) 
13.7 19.4 10.0 
0.153& 
[11.3 to 18.1] [13.3 to 38.0] [8.1 to 13.0] 
PORH; time to baseline  
145.3 159.5 166.8 
0.525& 
[117.7 to 178.9] [129.0 to 197.9] 
[118.3 to 
212.8] 
Diabetes n (%) 43 (47%) 30 (50%) 19 (61%) 
 
Glucose (mmol/L) 
7.9 7.3 8.1 
0.153 
[6.5 to 9.0] [6.5 to 8.5] [6.5 to 9.5] 
HbA1c (mmol/mol) 
56 50.0 59 
0.370$ 
[48 to 63] [47 to 59] [49 to 68] 
Duration of diabetes (years) 6.1 (±4.8) 7.4 (±7.1) 8.6 (±5.4) 0.085@ 
Table 89 Participant characteristics and microvascular function stratified by peak response 
curve morphology group in subjects with normoalbuminuria. Data are presented as mean 
(±SD) or median [IQR]. * P value < 0.05 indicates a significant difference in a characteristic 
between subjects across all three groups. The following symbols represent results obtained 
from transformed data to ensure normal distribution of residuals from regression analysis: £ 
denotes squared data, &denotes logged data, $denotes 1/square root transformation and 
@denotes data transformed by square root.  
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7.5.1.6 Objective 5 
 
To determine if there is a correlation between the change in urinary albumin excretion over 
three years with a change in vascular function. 
 
 
One-hundred and forty four participants who had baseline and follow-up ACR and 
microvascular assessments (selection criteria from Table 66) were selected from the 
SUMMIT cohort to test this hypothesis (Table 90). At baseline the mean age was 66.3 (±8.1) 
years, 69% of whom were male. 69% of participants had been diagnosed with diabetes 
(Hba1c > 47 mmol/mol and were diagnosed with T2DM after the age of 35 years).  
50% were classified as having CVD if they had a medical history of myocardial infarction, 
percutaneous coronary intervention, coronary arterial bypass graft, unstable angina, 
peripheral artery disease and verified cerebrovascular event (stroke and / or transient 
ischaemic attack). 
At baseline 67% of subjects were on antihypertensive therapy and 73% on statin therapy. 
The median eGFR [IQR] was 79.3 [68.7 to 91.0] ml/min/1.73m2, putting the majority of 
participants (58%) in the G2 stage of CKD (eGFR between 60 and 89 ml/min/1.73m2). 
The mean follow up period was 37 (±3) months, the minimum duration was 29 months and 
the maximum was 49 months.   
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7.5.1.6.1 Participant characteristics at baseline 
 
Characteristic Full Cohort Diabetes 
No 
Diabetes 
p  
(DM vs 
no DM) 
n 144 100 44  
Sex (%male) 69 71 64 0.380 
Ethnicity (% white British) 100 100 100  
Age (years) 66.3 (±8.1) 67.1 (±8.4) 64.7 (±7.4) 0.094 
Height (m) 
1.72 1.72 1.72 
0.607 
[1.67 to 1.77] [1.67 to 1.77] [1.66 to 1.79] 
Weight (kg) 
86.0 88.8 76.9 
<0.001 
[76.2 to 95.6] [81.6 to 99.6] [68.4 to 84.0] 
Body fat (%) 
31.7 32.6 28.7 
<0.001 
[26.2 to 38.7] [26.8 to 41.1] [25.0 to 34.1] 
BMI (kg.m-2) 
29 30 26 
<0.001 
[26 to 32] [27 to 34] [23 to 27] 
Waist (cm) 102.8 (±12.8) 106.6 (±12.0) 94.0 (±10.1) <0.001 
Hip (cm) 
105.9 108.6 102.6 
<0.001 
[101.8 to 111.8] 
[104.0 to 
117.0] 
[98.1 to 
105.3] 
Waist hip ratio 0.95 (±0.08) 0.97 (±0.07) 0.91 (±0.09] <0.001 
Systolic BP (mmHg) 126.7 (±15.5) 128.6 (±15.0) 122.4 (±16.0) 0.513 
Diastolic BP (mmHg) 75.8 (±8.3) 76.3 (±8.6) 74.6 (±7.8) 0.798 
Total Cholesterol (mmol/L) 
4.2 3.8 4.9 
<0.001 
[3.4 to 5.1] [3.2 to 4.5] [4.2 to 5.8] 
HDL (mmol/L) 
1.27 1.22 1.47 
<0.001 
[1.09 to 1.56] [1.06 to 1.41] [1.18 to 1.90] 
LDL (mmol/L) 
2.07 1.84 2.78 
<0.001 
[1.57 to 2.89] [1.46 to 2.36] [2.09 to 3.31] 
Fasting triglycerides (mmol/L) 
1.28 1.30 1.17 
0.082 
[0.97 to 1.67] [1.00 to 1.78] [0.94 to 1.59] 
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Characteristic Full Cohort Diabetes 
No 
Diabetes 
p  
(DM vs 
no DM) 
Duration of diabetes (years) n/a 7.9 (±5.8) n/a  
Fasting glucose (mmol/L) 
6.8 7.8 5.2 
<0.001 
[5.4 to 8.4] [6.7 to 9.2] [4.8 to 5.5] 
HbA1c (mmol/mol) 
51 57 40 
<0.001 
[42 to 62] [50 to 67] [39 to 42] 
CVD n(%) 50 53 43 0.330 
Antihypertensive therapy n(%) 67 79 41 <0.001 
Statin therapy n(%) 73 83 50 <0.001 
Smokers (current/ex/never) 
n(%) 
4/50/45 4/51/45 5/50/45 0.985 
Renal function: 
 
     
Serum creatinine (µmol/L) 
82 82 82 
0.761 
[73 to 93] [73 to 94] [72 to 92] 
eGFR (ml/min/1.73m2) 79.3 80.1 78.7 
 
[68.7 to 91.0] [67.5 to 90.5] [73.4 to 91.8] 0.893 
CKD stage n (%): 
   
 
G1 41 (28%) 28 (28%) 13 (30%) 0.472 
G2 84 (58%) 57 (57%) 27 (61%)  
G3A 13 (9%) 9 (9%) 4 (9%)  
G3B 6 (4%) 6 (6%) 0 (0%)  
G4 0 (0%) 0 (0%) 0 (0%)  
G5 0 (0%) 0 (0%) 0 (0%)  
Table 90 Participant characteristics for participants selected to test hypothesis 2. Data are 
presented as mean (±SD) or median [IQR] for all subjects and sub-grouped by diabetes 
status. P value indicates if there is a significant difference in a characteristic between 
subjects with and without diabetes. 
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7.5.1.6.2 Change in ACR and microvascular function over three years in subjects with and 
without T2DM  
 
There is a significant increase in ACR over three years across the whole cohort (p<0.001) and 
in those with T2DM (p<0.001), but not in subjects without T2DM (p=0.299) (Table 91). 14 
participants (10%) developed microalbuminuria (all with T2DM) over the three years. The 
mean increase in ACR in subjects with diabetes was 2.36 (±6.50) mg/mmol, in subjects 
without T2DM the mean change was -0.11 (±1.2) mg/mmol (the change in ACR is 
significantly different when considering diabetes status, p=0.003). 
Across the whole cohort, there was a significant change in microvascular function (except 
for time to peak during PORH testing); however this change was not influenced by diabetes 
status. There is a significant loss in total endothelial dependent response to ACH over time, 
however there is a mean increase in percent change. This lack of agreement is caused by 
several subjects having very large increases in response, skewing the data. There were no 
reasons to exclude these data.  No differences were found in the outcomes of the future 
analysis if these outliers were excluded from the analysis.  
 
Full Cohort Diabetes 
No 
Diabetes 
p  
(DM vs 
non-
DM) 
Albuminuria:     
Baseline ACR  
(mg/mmol) 
0.79 0.89 0.63 
0.062 
[0.47 to 1.77] [0.50 to 2.06] [0.45 to 1.10] 
Follow up ACR 
(mg/mmol) 
1.15 1.53 0.81 <0.001
* [0.68 to 2.69] [0.74 to 3.63] [0.52 to 1.44] 
Significance between baseline 
and follow up (p) 
<0.001 <0.001 0.299  
Change in ACR (FITZ)     
Actual change in ACR 
(mg/mmol) 
1.60 (±5.57) 2.36 (±6.50) -0.11 (±1.2) 0.003* 
Percent change (%) 
175.4 (±466.4) 233.6 (±533.8) 43.1 (±103.6) 0.010* 
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Full Cohort Diabetes 
No 
Diabetes 
p  
(DM vs 
non-
DM) 
Change from 
normoalbuminuria to 
microalbuminuria n (%) 
14 (10%) 14 (14%) 0  
Change from 
microalbuminuria to 
normoalbuminuria n (%) 
7 (5%) 4 (4%) 3 (7%)  
Change in vascular 
assessment:  
     
Maximal blood flow (AU) -33.0 (±62.0) -26.1 (±56.2) -48.1 (±71.4) 0.087 
Significance between baseline 
and follow up (p) 
<0.001 <0.001 <0.001  
Minimum vascular resistance 
(mmHg/AU) 
0.1 (±0.3) 0.1 (±0.3) 0.2 (±0.2) 0.183 
(p) <0.001 0.032 <0.001  
ACH; total endothelial 
dependent response (AU) 
-17716.8 
(±39640.2) 
-18634.4 
(±35380.9) 
-15631.2 
(±48344.1) 
0.609 
 (p) <0.001 <0.001 0.038  
ACH; peak endothelial 
dependent response (AU) 
-88.3 (±124.9) -94.7 (±119.4) 
-73.7 
(±136.9) 
0.326 
(p) <0.001 <0.001 <0.001  
SNP; total endothelial 
independent response (AU) 
-13004.0 
(±25435.0) 
-13993.8 
(±23691.0) 
-10725.3 
(±29234.1) 
0.524 
(p) <0.001 <0.001 0.038  
SNP; peak endothelial 
independent response (AU) 
-92.5 (±117.7) -99.3 (±107.4) 
-76.9 
(±138.8) 
0.288 
(p) <0.001 <0.001 0.001  
PORH; peak hyperaemia (AU) -14.4 (±61.1) -14.7 (±60.5) -13.8 (±63.3) 0.893 
(p) 0.042 0.121 0.226  
PORH; time to peak 
hyperaemia(seconds) 
3.9 (±28.6) 2.4 (±29.8) 7.1 (±25.8) 0.462 
(p) 0.220 0.680 0.130  
PORH; time to baseline  
(seconds) 
20.2 (±122.4) 26.9 (±115.8) 5.9 (±136.2) 0.316 
(p) 0.035 0.033 0.557  
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Full Cohort Diabetes 
No 
Diabetes 
p  
(DM vs 
non-
DM) 
Percent change in vascular 
assessment:  
     
Maximal blood flow (%) -13.5 (±31.1) -10.3 (±30.4) -20.5 (±31.8) 0.122 
Minimum vascular resistance 
(%) 
25.6 (±59.1) 19.9 (±60.4) 37.4 (±55.1) 0.186 
ACH; total endothelial 
dependent response (%) 
21.8 (±411.8) 31.0 (±492.9) 0.6 (±62.8) 0.713 
ACH; peak endothelial 
dependent response (% 
-14.3 (±32.2) -16.1 (±34.3) -10.1 (±26.5) 0.273 
SNP; total endothelial 
independent response (%) 
-2.0 (±123.9) -2.3 (±144.4) -1.5 (±53.6) 0.934 
SNP; peak endothelial 
independent response (%) 
-17.7 (±30.2) -20.4 (±30.3) -11.4 (±29.2) 0.082 
PORH; peak hyperaemia (%) 6.3 (±77.1) 6.0 (±76.0) 6.9 (±80.5) 0.808 
PORH; time to peak 
hyperaemia(%) 
43.2 (±133.1) 28.2 (±107.9) 76.9 (±174.0) 0.085 
PORH; time to baseline  
(%) 
44.2 (±132.7) 56.3 (±152.5) 18.1 (±68.7) 0.109 
Change in blood pressure:     
 
-3.2 -2.5 -4.9 
 
Change in systolic blood 
pressure (mmHg) 
[-10.8 to 2.7] [-11.2 to 4.8] [-9.4 to 0.3] 0.377 
Percent change in systolic 
blood pressure (%) 
-2.4 (±8.4) -2.0 (±8.7) -3.3 (±7.9) 0.364 
Table 91 Change in ACR, blood pressure and microvascular function over 37 months (±3) in 
144 participants from the SUMMIT cohort. Data are presented as mean (±SD) or median 
[IQR] for all subjects and sub-grouped by diabetes status. P value indicates if there is a 
significant difference in a characteristic between subjects with and without diabetes. 
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7.5.1.6.3 Correlation between change in ACR over three years with change in vascular 
function  
Using Spearman’s rank correlation test, there was no significant relationship between 
change in ACR over three years with change in vascular function (Table 92). 
 
Absolute 
change in vascular 
measurement: 
 
Absolute 
change in ACR 
 
Percent 
change in vascular 
measurement: 
 
Percent 
change in 
ACR 
Maximal blood flow 
n 141  
Maximal blood flow 
n 141 
r 0.03  r 0.06 
p 0.740  p 0.483 
Minimum Vascular 
resistance 
n 131 
 
Minimum Vascular 
resistance 
n 131 
r -0.09  r -0.10 
p 0.321  p 0.236 
Iontophoresis: n 144 
 
Iontophoresis: n 144 
ACH; total endothelial 
dependent response  
r 0.06  ACH; total endothelial 
dependent response  
r 0.08 
p 0.471  p 0.322 
ACH; peak endothelial 
dependent response  
r 0.06  ACH; peak endothelial 
dependent response  
r 0.11 
p 0.468  p 0.197 
SNP; total endothelial 
independent response  
r -0.04  SNP; total endothelial 
independent response  
r -0.09 
p 0.627  p 0.297 
SNP; peak endothelial 
independent response  
r -0.04  SNP; peak endothelial 
independent response  
r -0.07 
p 0.668  p 0.435 
Peak Reactive 
Hyperaemia: 
n 126 
 Peak Reactive 
Hyperaemia: 
n 126 
Peak hyperaemia  
r -0.07  
Peak hyperaemia  
r -0.07 
p 0.457  p 0.422 
Time to peak 
hyperaemia 
r -0.01 
 
Time to peak 
hyperaemia 
r 0.01 
p 0.879  p 0.870 
Time to baseline 
r 0.15  
Time to baseline 
r 0.13 
p 0.095  p 0.152 
Table 92 Correlation between change in albuminuria with change in microvascular 
function in whole cohort across the full range of albumin excretion. A: absolute change. B: 
Percent change. Spearman rank test for correlation was used. 
A B 
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7.5.1.6.3 Objective 6 
 
To determine if a change in ACR over three years within the normoalbuminuria range 
correlates to a change in vascular function.  
 
In the normoalbuminuria range, there was a significant correlation between the change 
(absolute and percentage change) in ACR with change in maximal blood flow and with 
change in minimum vascular resistance (Table 93). To determine if this is an independent 
relationship regression analysis with potential confounding variables was carried out 
assessing actual change (Table 94) and percent change (Table 95).  
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Absolute change in 
vascular measurement:  
Absolute 
change in ACR  
Percent change in 
vascular 
measurement: 
 
Percent 
change in 
ACR 
Maximal blood flow 
n 102 
 Maximal blood 
flow 
n 102 
r 0.25 
 
r 0.26 
p 0.010* 
 
p 0.008* 
Minimum Vascular 
resistance 
n 98 
 Minimum Vascular 
resistance 
n 98 
r -0.27 
 
r -0.24 
p 0.007* 
 
p 0.018* 
Iontophoresis: n 101 
 
Iontophoresis: n 101 
ACH; total endothelial 
dependent response  
r 0.13 
 
ACH; total 
endothelial 
dependent 
response  
r 0.16 
p 0.183 
 
p 0.117 
ACH; peak 
endothelial 
dependent response  
r 0.07 
 
ACH; peak 
endothelial 
dependent 
response  
r 0.13 
p 0.483 
 
p 0.196 
SNP; total endothelial 
independent 
response  
r -0.02 
 
SNP; total 
endothelial 
independent 
response  
r -0.06 
p 0.849 
 
p 0.588 
SNP; peak endothelial 
independent 
response  
r -0.01 
 
SNP; peak 
endothelial 
independent 
response  
r -0.04 
p 0.947 
 
p 0.672 
Peak Reactive 
Hyperaemia: 
n 92 
 
Peak Reactive 
Hyperaemia: 
n 92 
Peak hyperaemia  
r -0.09 
 Peak hyperaemia  
r -0.09 
p 0.417 
 
p 0.411 
Time to peak 
hyperaemia 
r -0.03 
 
Time to peak 
hyperaemia 
r 0.01 
p 0.779 
 
p 0.953 
Time to baseline 
r -0.01 
 Time to baseline 
r 0.00 
p 0.931 
 
p 0.978 
Table 93 Correlation between change in albuminuria within the normoalbuminuria range 
with change in microvascular function. A: absolute change. B: Percent change. Spearman 
rank test for correlation was used. * denotes a significant relationship where p<0.05. 
B A 
  
406 
 
 
  
Absolute change 
in Maximal Blood 
Flow 
Absolute change in 
Minimum Vascular 
Resistance 
  n=79 n=79 
  beta  p beta  p 
Change (∆) in ACR unadjusted 0.25 0.026* -0.25 0.025* 
ACR adj by Age 0.25 0.025* -0.25 0.024* 
ACR adj by Age & Gender 0.25 0.026* -0.25 0.023* 
ACR adj by Age & Gender & Smoking 0.24 0.033* -0.24 0.031* 
ACR adj by Age & Gender & Smoking & ∆ HDL 0.24 0.044* -0.24 0.044* 
ACR adj by Age & Gender & Smoking & ∆HDL & ∆Sys BP 0.14 0.238 -0.22 0.075 
ACR adj by Age & Gender & Smoking & ∆HDL & ∆Sys BP 
& CVD Event 
0.14 0.228 -0.22 0.079 
ACR adj by Age & Gender & Smoking & ∆HDL & ∆Sys BP 
& CVD Event  & ∆HbA1c 
0.15 0.197 -0.21 0.104 
ACR adj by Age & Gender & Smoking & ∆HDL & ∆Sys BP 
& CVD Event & ∆HbA1c & ∆Waist 
0.15 0.201 -0.21 0.107 
Table 94 Regression analysis between absolute change in ACR within the 
normoalbuminuria range with change in microvascular function. A forced entry approach 
to regression modelling with confounding variables accumulatively added. Beta coefficient 
and p value of the relationship of change of ACR with change of microvascular function after 
adjustment is reported. ∆ denotes ‘change’,  Adj denotes adjusted. Change in ACR does not 
have an independent association with change in MBF and MVR in the full model. The 
regression model was repeated without change in systolic blood pressure due to potential 
collinearity with change in MVR; change in ACR was not independently associated with 
change in MVR (p>0.05) . 
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Percent change in 
Maximal Blood Flow 
Percent change in 
Minimum Vascular 
Resistance 
  n=79 n=79 
  beta  p beta  p 
Percent Change (%∆) in ACR unadjusted 0.13 0.245 -0.15 0.181 
ACR adj by Age 0.13 0.268 -0.15 0.202 
ACR adj by Age & Gender 0.13 0.261 -0.15 0.201 
ACR adj by Age & Gender & Smoking 0.15 0.188 -0.18 0.126 
ACR adj by Age & Gender & Smoking & %∆ HDL 0.15 0.185 -0.17 0.137 
ACR adj by Age & Gender & Smoking & %∆HDL & 
%∆Sys BP 
0.10 0.376 -0.16 0.182 
ACR adj by Age & Gender & Smoking & %∆HDL & %∆Sys 
BP & CVD Event 
0.10 0.370 -0.16 0.170 
ACR adj by Age & Gender & Smoking & %∆HDL & %∆Sys 
BP & CVD Event  & %∆HbA1c 
0.11 0.353 -0.16 0.185 
ACR adj by Age & Gender & Smoking & %∆HDL & %∆Sys 
BP & CVD Event & %∆HbA1c & %∆Waist 
0.11 0.362 -0.16 0.190 
Table 95 Regression analysis between percent change in ACR within the 
normoalbuminuria range with percent change in microvascular function. A forced entry 
approach to regression modelling with confounding variables accumulatively added. Beta 
coefficient and p value of the relationship of percent change of ACR with percent change of 
microvascular function after adjustment is reported. %∆ denotes ‘percent change’, Adj 
denotes adjusted. 
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7.5.2 Hypothesis 2 
 
 
Three-hundred and twenty one participants diagnosed with type 2 diabetes, who had a 
urine sample from a random spot collection stored at baseline, and retinal photography and 
neuropathy tests carried out at both baseline and follow up were selected to test this 
hypothesis (Figure 87). Participant characteristics were similar to the previous cohorts, with 
32% having had a CVD event, 74% on hypertensive therapy and 79% on statin therapy with a 
median [IQR] HbA1c of 55 [49 to 65] mmol/mol. The median ACR was 0.89 [0.45 to 1.96] 
with the majority of participants in the normoalbuminuria range (77%), 20% of participants 
had microalbuminuria and 3% with macroalbuminuria (Table 96).  
16% of participants had significant neuropathy at baseline, with 6% of the cohort developing 
significant neuropathy over the three years. Significant neuropathy is clinically defined if the 
participant is only able to feel the monofilament in three or less sites in either foot. 
Therefore people who went from a score of four or above to below four, in either foot are 
classified as a neuropathy progressor. Non progressors were defined as individuals who did 
not have a monofilament score go from above 4 to below 4. 
A progression of two retinopathy steps or more, as demonstrated in Table 68, across both 
eyes was classified as being clinically significant. Therefore, individuals with a worsening of 
two steps of retinopathy in one eye are classified as a progressor, as would an individual 
with a worsening of one stage in both eyes. Non progressors were defined as individuals 
who did not have a worsening of two steps of retinopathy in one eye or worsening of one 
stage in both eyes.  
The majority of participants had no diabetic retinopathy (DR) (55%), 29% had minimal DR, 
15% had mild DR and 2 % had moderate DR at baseline.11% had a significant progression in 
DR over the three years (Table 96). 
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7.5.2.1 Participant characteristics  
 
 
 
Characteristic: Full Cohort 
n 321 
Sex (%male) 69 
Ethnicity (% white British) 100 
Age (years) 67.4 (±9.5) 
Height (m) 
1.71 
[1.65 to 1.77] 
Weight (kg) 
87.3 
[79.0 to 101.1] 
Body fat (%) 
32.6 
[27.2 to 40.8] 
BMI (kg m-2) 
30 
[26 to 34] 
Waist (cm) 107.1 (±14.4) 
Hip (cm) 
107 
[102 to 115] 
Waist hip ratio 0.97 (±0.09) 
Systolic BP (mmHg) 146.6 (±18.1) 
Diastolic BP (mmHg) 79.8 (±9.4) 
HbA1c (mmol/mol) 
55 
[49 to 65] 
Duration of diabetes (years) 8.2 (±7.2) 
CVD event n (%) 104 (32%) 
Antihypertensive therapy n (%) 238 (74%) 
Statin therapy n (%) 252 (79%) 
Smokers (current/ex/never) (%) 23/175/123 
 
Renal function: 
  
Serum creatinine (µmol/L) 
84 
[72 to 98] 
eGFR (ml/min/1.73m2) 79 
[62 to 90] 
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CKD stage n (%):   
G1 81 (26%) 
G2 167 (54%) 
G3A 34 (11%) 
G3B 23 (7%) 
G4 5 (2%) 
G5 0 (0%) 
Albuminuria:   
Baseline ACR (mg/mmol) 
0.89 
[0.45 to 1.96] 
Normoalbuminuria n (%) 247 (77%) 
Microalbuminuria n (%) 64 (20%) 
Macroalbuminuria n (%) 10 (3%) 
 
 
Neuropathy: 
 
 
 
Lowest monofilament score  
n (%): 
Full Cohort 
Normoalbuminuria 
range 
 n=318 n=249 
0 12 (4%) 9 (4%) 
1 8 (3%) 6 (2%) 
2 4 (1%) 1 (1%) 
3 26 (8%) 17 (7%) 
4 31 (10%) 25 (10%) 
5 50 (16%) 33 (13%) 
6 187 (59%) 158 (63%) 
Progression from non-clinical 
to significant neuropathy  
n (%): 
19/318 (6%) 14/187 (7%) 
Baseline retinopathy 
status n (%): 
Full cohort 
Normoalbuminuria 
range 
 n=321 n=247 
1 (No DR) 176 (55%) 143 (58%) 
2 Minimal DR 92 (29%) 69 (28%) 
3 Mild DR 47 (15%) 31 (13%) 
4 Moderate DR 6 (2%) 4 (2%) 
5 Proliferative DR 0 0 
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Progressors (two step increase 
across both eyes) n (%): 
29/263 (11%) 6/109 (6%) 
DR prevalence at initial 
examination n (%) 
145 (45%) 104 (42%) 
Developed proliferative DR 
over three years n (%) 
2 (0.87%) 0 
Table 96 Baseline participant characteristics for the individuals with type 2 diabetes 
selected to test Hypothesis 3 (n=321). Participants were recruited from the SUMMIT cohort, 
and included in this investigation if they met the inclusion criteria to test Hypothesis Two 
(Table 66). Data are presented as mean (±SD) or median [IQR] for all subjects and sub-
grouped by diabetes status. DR = Diabetic retinopathy. 
 
 
7.5.2.2 Objective 1 
 
To investigate the relationship between urinary albumin excretion and the early stages of 
diabetic retinopathy and neuropathy. 
 
One way ANOVA demonstrates there is a significant difference (p=0.016) in the distribution 
in ACR among groups; no DR, minimal DR and mild DR (moderate DR was excluded to 
investigate the relationship of ACR with background retinopathy (minimal and mild DR)) 
(Figure 93). Post hoc analysis using Bonferroni multiple comparison test indicated that ACR 
was signicantly higher in the mild DR group compared to the  no DR group (p=0.012).  
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Figure 93 Distribution of ACR at different stages of diabetic retinopathy. Post hoc analysis 
using Bonferroni multiple comparison test indicates a signifcant difference in ACR between 
mild DR and no DR (p=0.012). Moderate DR was excluded from statistical analysis to 
investigate the relationship of ACR with background retinopathy (minimal and mild DR). 
 
One way ANOVA demonstrates there is no significant difference (p=0.199) in the 
distribution in ACR among the scores for clinically non significant neuropathy (monofilament 
score four to six) (Figure 94) 
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Figure 94 Distribution of ACR at different monofilament scores. One way ANOVA 
demonstrates there is no significant difference (p=0.199) in the distribution in ACR amoung 
the scores for clinically non significant neuropathy (four to six). 
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7.5.2.3 Objective 2 
 
To investigate the relationship between urinary albumin excretion and progression / 
development of diabetic retinopathy and neuropathy.    
Diabetic retinopathy: 
 
A progression of two retinopathy steps or more across both eyes (Table 68) was classified as 
being clinically significant and identified as a progressor. Non DR progressors were defined 
as individuals who did not have a worsening of two steps of retinopathy in one eye or 
worsening of one stage in both eyes.  
Median [IQR] ACR was 0.84 [0.42 to 1.55] mg/mmol in non DR progressors (Figure 95), 
compared to 1.24 [0.62 to 7.66] mg/mmol in DR progressors (p=0.0498) (Table 97). Clinical 
characteristics of DR progressors are compared to those with no clinically meaningful 
progression in Table 98. 
 
 
Figure 95 Distribution of ACR among individuals who had a clinically meaningful 
progression in retinopathy and those who did not. ACR is significantly (p=0.0498) higher in 
DR progressors (n=29) compared to those without DR progression. 
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Number of 
participants 
(%males) 
Mean (±SD) 
ACR 
(mg/mmol) 
Median [IQR] 
ACR  
(mg/mmol) 
Wilcoxon 
rank sum test 
(p) 
No retinopathy 
progression 
234 (68%) 3.17 (±8.13 ) 
0.84 
0.0498* 
[0.42 to 1.55] 
Retinopathy 
progression 
29 (85%) 4.54 (±7.61) 
1.24 
[0.62 to 7.66] 
Table 97 Difference in ACR between individuals who had a meaningful progression in 
retinopathy and those who did not. ACR is significantly (p=0.0498) higher in DR progressors. 
 
 
Due to the low numbers of individuals with a progression in retinopathy, it is not suitable to 
carry out logistic regression to determine in ACR is indecently associated. However, the 
clinical characteristics between individuals who had a meaningful progression in DR and 
those who did not are compared in Table 98. Duration of diabetes was significantly higher in 
subjects who had a meaningful progression in DR (p=0.033) 
 
 
Baseline Characteristics: No DR progression DR Progression p 
N 234 29   
Sex n (%male) 160 (68%) 22 (75%) 0.410 
Age (years) 67 (±9) 70 (±9) 0.065 
Weight (kg) 
87.2 86.7 
0.584 
[78.1 to 101.5] [79.0 to 92.7] 
Body fat (%) 
33.0 30.1 
0.157 
[27.6 to 40.9] [25.1 to 40.3] 
BMI (kg m-2) 
30 29 
0.475 
[27 to 34] [26 to 33] 
Waist (cm) 106.9 (±14.6) 105.9 (±14.1) 0.935 
Systolic BP (mmHg) 136 (±15) 143 (±24) 0.295 
HbA1c (mmol/mol) 
53 58 
0.117 
[49 to 63] [49 to 70] 
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Baseline Characteristics: No DR progression DR Progression p 
Duration of diabetes (years)  7.5(±7.2)  9.6(±6.5) 0.033* 
CVD event n (%) 77 (33%) 7 (24%) 0.339 
Antihypertensive therapy n (%) 173 (74%) 20 (69%) 0.568 
Statin therapy n (%) 181 (77%) 23 (79%) 0.811 
Renal function:       
Serum creatinine (µmol/L) 
84 88 
0.408 
[72 to 98] [72 to 106] 
eGFR (ml/min/1.73m2) 
79.6 77.5 
0.329 
[63.6 to 90.1] [55.9 to 86.7] 
CKD stage n (%): 
  
0.124 
G1 59 (26%) 5 (19%) 
 
G2 126 (55%) 14 (54%) 
 
G3A 22 (10%) 4 (15%) 
 
G3B 19 (8%) 1 (3%) 
 
G4 2 (1%) 2 (8%) 
 
G5 0 0   
Table 98 Participant characteristics for subjects who had a progression in retinopathy and 
those who did not. P value indicates if there is a significant difference in a characteristic 
between the two groups.* denotes a significant difference where p< 0.05. Duration of 
diabetes was significantly higher in subjects who had a meaningful progression in DR 
(p=0.033) 
 
The diagnostic accuracy of ACR at baseline to identify individuals who had a meaningful 
progression in retinopathy was carried out using ROC curve analysis (Figure 96). Due to the 
impact of gender on ACR, only men were analysed as the majority of subjects who had a 
progression in DR were male (n=22) (75%).the ROC area under the curve (CI) was 0.60 (0.47 
to 0.73). 
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Figure 96 Diagnostic accuracy of ACR to identify men with type 2 diabetes who had a 
meaningful progression in retinopathy (n=22). ROC area under the curve (CI) = 0.60 (0.47 to 
0.73). The solid diagonal line represents the line of identify, where the test is neither specific 
nor sensitive. 
 
7.5.2.3.1 Characteristics of subjects with no DR progression with and without 
clinical levels of albumin excretion. 
 
Contrary to the hypothesis, 51 subjects who had no progression in DR had an ACR in the 
microalbuminuria range or above (Figure 95). To investigate this group further their 
characteristics are explored and compared with subjects who had no progression with an 
ACR in the normoalbuminuria range (n=183) in (Table 99). 
Subjects with albumin excretion in the clinical ranges were at a higher risk of CVD than the 
subjects with albumin excretion in the normal range. The group with an ACR in the clinical 
ranges had a significantly higher; systolic blood pressure (p=0.014), HbA1c (p=0.022), 
0
.0
0
 
0
.2
5
 
0
.5
0
 
0
.7
5
 
1
.0
0
 
S
e
n
s
it
iv
it
y
 
0.00 0.25 0.50 0.75 1.00 
1 - Specificity 
  
418 
duration of diabetes (p=0.001), with 88% on anti-hypertensive medication compared to 70% 
in the normoalbuminuria group (p=0.009) (Table 99).  
 
Baseline Characteristics: 
No DR progression 
with 
normoalbuminuria 
No DR progression 
& elevated albumin 
excretion in the 
clinical range 
P 
N 183 51  
Sex n (%male) 120 (66%) 40 (78%) 0.081 
Age (years) 66 (±10) 68 (±7) 0.198 
Weight (kg) 
87 88.2 
0.348 
[78.0 to 101.1] [80.6 to 107.5] 
Body fat (%) 
33.8 32.3 
0.109 
[27.6 to 41.2] [27.0 to 36.1] 
BMI (kg m-2) 
30 30 
0.435 
[26 to 33] [27 to 34] 
Waist cm) 106.3 (±14.3) 109.5 (±15.6) 0.221 
Systolic BP (mmHg) 127 (±13) 138 (±12) 0.014* 
Diastolic BP (mmHg) 77 (±9) 78 (±9) 0.349 
HbA1c (mmol/mol) 
52 55 
0.022* 
[48 to 62] [50 to 69] 
Duration of diabetes 
(years) 
6.7 (±6.8) 11.8 (±8.6) 0.001* 
CVD event n (%) 58 (32%) 19 (37%) 0.455 
Antihypertensive 
therapy n (%) 
128 (70%) 45 (88%) 0.009* 
Statin therapy n (%) 137 (75%) 44 (86%) 0.085 
Smokers 
(current/ex/never) (%) 
43/52/5 37/53/10 0.380 
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Renal function: 
 
 
 
Serum creatinine 
(µmol/L) 
83 84 
0.091 
[72 to 95] [75 to 109] 
eGFR (ml/min/1.73m2) 
79.6 80.1 
0.178 
[65.4 to 91.3] [60.1to 89.3] 
CKD stage n (%):  
 
 
G1 48 (27%) 11 (22%) 0.421 
G2 100 (56%) 26 (52%)  
G3A 17 (10%) 5 (10%)  
G3B 12 (7%) 7 (14%)  
G4 1 (1%) 1 (2%)  
G5 0 0  
ACR (mg/mmol) 0.75 6.47 <0.001* 
 
[0.45 to 1.19] [3.75 to 13.84]  
Normoalbuminuria n (%) 183 (100%) -  
Microalbuminuria n (%) - 43 (84%)  
Macroalbuminuria n (%) - 8 (16%)  
Table 99 Clinical characteristics of individuals who had no progression in retinopathy who 
had either an ACR in the normoalbuminuria range or higher. 51 participants had an ACR in 
the clinically abnormal albumin excretion ranges. These subjects have a significantly higher; 
systolic blood pressure (p=0.014), HbA1c (p=0.022), duration of diabetes (p=0.001), with a 
larger proportion on anti-hypertensive medication (p=0.009), compared to those with 
normoalbuminuria. P value indicates if there is a significant difference in a characteristic 
between subjects with and without higher levels of albumin excretions. 
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Diabetic neuropathy: 
 
 
Monofilament sensitivity was carried out on six sites on both feet. Significant neuropathy is 
clinically defined if the participant is only able to feel the monofilament in three or less sites 
in either or both feet. Therefore people who went from a score of four or above to below 
four, in either foot are classified as a neuropathy progressor. Non progressors were defined 
as individuals who did not have a monofilament score go from above 4 to below 4. 
Median [IQR] ACR was 0.80 [0.43 to 1.47] mg/mmol in non-neuropathy progressors (Figure 
97), compared to 0.73 [0.48 to 1.44] mg/mmol in progressors (p=0.683) (Table 100). 
 
 
Figure 97 The distribution of ACR among individuals who had a meaningful progression in 
neuropathy and those who did not. ACR is not significantly (p=0.683) different in 
progressors (n=19) compared to those without progression in neuropathy. 
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Number of 
participants 
Mean (±SD) 
ACR 
(mg/mmol) 
Median [IQR] 
ACR  
(mg/mmol) 
Wilcoxon rank 
sum test (p) 
No neuropathy 
progression 
301 2.46 (±6.03) 
0.80 
0.683 
[0.43 to 1.47] 
Neuropathy 
progression 
19 3.39 (±10.69) 
0.73 
[0.48 to 1.44] 
Table 100 Difference in ACR between individuals who had a meaningful progression in 
neuropathy and those who did not. ACR is not significantly (p=0.683) different in 
progressors (n=19) compared to those without progression in neuropathy. 
 
There was no relationship between ACR at baseline and the progression of diabetic 
neuropathy, therefore only the relationship with the progression of diabetic retinopathy is 
investigated further. 
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7.5.2.4 Objective 3 
 
To determine if an increase in urinary albumin excretion over three years is related to a 
progression/development of diabetic retinopathy and neuropathy. 
 
321 participants from the SUMMIT cohort, all diagnosed with type 2 diabetes, who had a 
urine sample from a random spot collection stored at baseline, and retinal photography and 
neuropathy tests carried out at baseline were selected to test Hypothesis two (Figure 87). 
Out of 321 participants, only 263 subjects had data available for follow up assessments to 
test Objective 2. Out of those 263, only 170 subjects had a spot ACR store at follow up as 
well, these subjects  were used  to test objective three.  
 
 
7.5.2.4.1 Participant characteristics 
 
Characteristics Full cohort 
n 170 
Sex (%male) 69 
Ethnicity (% white British) 100 
Age (years) 67.8 (±9.0) 
Height (m) 
1.71 
[1.65 to 1.77] 
Weight (kg) 
87.3 
[78.1 to 102.5] 
Body fat (%) 32.6 
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Characteristics Full cohort 
[27.2 to 40.8] 
BMI (kg m-2) 
30 
[27 to 33] 
Waist (cm) 106.3 (±14.3) 
Hip (cm) 
107 
[102 to 116] 
Waist hip ratio 0.96 (±0.11) 
Systolic BP (mmHg) 140.7 (±16.2) 
Diastolic BP (mmHg) 77.6 (±8.6) 
HbA1c (mmol/mol) 
55 
[49 to 65] 
CVD event n (%) 66 (39%) 
Antihypertensive therapy n (%) 130 (76) 
Statin therapy n (%) 131 (77) 
Smokers (current/ex/never) (%) 3/55/42 
Renal function: 
 
Creatinine (µmol/L) 
85 
[74 to 101] 
eGFR (ml/min/1.73m2) 
77.5 
[61.5 to 89.2] 
CKD stage n (%): 
 
G1 34 (20%) 
G2 96 (58%) 
G3A 20 (12%) 
G3B 14 (8%) 
G4 2(1%) 
G5 - 
Mean change in eGFR -4.8 (±8.0) 
Mean percent change in eGFR (%) -7.0 (±12.8) 
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Characteristics Full cohort 
Retinopathy: 
 
Baseline Retinopathy n (%): 
 
1 (No DR) 92 (54%) 
2 Minimal DR 47 (28%) 
3 Mild DR 29 (17%) 
4 Moderate DR 2 (1%) 
Progressors n (%): 16/170 (9%) 
Urinary Albumin Status: 
 
Baseline ACR (mg/mmol) 
0.85 
[0.42 to 2.23] 
Normoalbuminuria n (%) 141 (83%) 
Microalbuminuria n (%) 24 (14%) 
Macroalbuminuria n (%) 5 (3%) 
  
 
Mean change in ACR (mg/mmol) 2.47 (±12.98) 
Mean percent change in ACR (%) 237 (±738) 
Table 101 Baseline participant characteristics for the individuals with type 2 diabetes 
selected to test Objective 3. Participants were recruited from the SUMMIT cohort, and 
included in this investigation if met the inclusion criteria to test Hypothesis Two (Table 66). 
Data are presented as mean (±SD) or median [IQR] for all subjects. DR = Diabetic 
retinopathy.  
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7.5.2.4.2 To determine if change in ACR over three years is different between individuals 
who have had a meaningful progression in retinopathy and those who have not. 
 
A progression of two retinopathy steps or more across both eyes (Table 68) was classified as 
being clinically significant and identified as a progressor. Non DR progressors were defined 
as individuals who did not have a worsening of two steps of retinopathy in one eye or 
worsening of one stage in both eyes.  
 
Median [IQR] absolute change in ACR was 0.40 [0.05 to 1.43] mg/mmol in non DR 
progressors (Figure 98), compared to 0.12 [-0.62 to 3.70] mg/mmol in DR progressors 
(p=0.612) (Table 102). Clinical characteristics of DR progressors are compared to those with 
no progression in Table 98. 
Median [IQR] percent change in ACR was 53.5% [4.8 to 201.7] in non DR progressors (Figure 
99), compared to 22.1% [-43.1 to 134.8] in DR progressors (p=0.156) (Table 103).  
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Figure 98 Distribution of the change in ACR between individuals who had a progression in 
retinopathy and those who did not. The change in ACR is not significantly (p=0.612) higher 
in DR progressors (n=16) compared to those without meaningful DR progression (n=154). 
 
 
 
Number of 
participants 
Mean (±SD) 
absolute change 
in ACR  
(mg/mmol) 
Median [IQR] 
absolute change 
in ACR 
(mg/mmol) 
Wilcoxon rank 
sum test (p) 
No retinopathy 
progression 
154 2.54 (±13.05) 
0.40 
0.612 
[0.05 to 1.43] 
Retinopathy 
progression 
16 1.85 (±12.64) 
0.12 
[-1.22 to 3.70] 
Table 102 Change in ACR between individuals who had a progression in retinopathy and 
those who did not. The change in ACR is not significantly (p=0.612) higher in DR progressors 
(n=16) compared to those without DR progression (n=154). 
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Figure 99 Distribution of the percent change in ACR between individuals who had a 
progression in retinopathy and those who did not. The percent change in ACR is not 
significantly (p=0.156) higher in DR progressors (n=16) compared to those without DR 
progression (n=154). 
 
 
Number of 
participants 
Mean (±SD) 
percent change 
in ACR  
(%) 
Median [IQR] 
percent change 
in ACR 
(%) 
Wilcoxon rank 
sum test (p) 
No retinopathy 
progression 
154 249.2 (±769.3) 
53.5 
0.1556 
[4.8 to 201.7] 
Retinopathy 
progression 
16 122.2 (±288.5 
22.1 
[-43.1 to 134.8] 
Table 103 Percent change in ACR between individuals who had a progression in 
retinopathy and those who did not. The percent change in ACR is not significantly (p=0.156) 
higher in DR progressors (n=16) compared to those without DR progression (n=154). 
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7.5.2.5 Matched pairs analysis 
 
 
There are a large proportion of participants who have had a large increase in ACR with no 
DR progression (Figure 98 and Figure 99). This could be attributed to the diverse cohort 
being tested, where nearly 40% of participants have already had a CVD event. To accurately 
test the difference in change in ACR between individuals who had a progression in 
retinopathy status and those who did not, I undertook an analysis of matched cases to 
controls. Two controls were matched to each individual who had a meaningful progression 
in retinopathy. Controls were matched exactly by gender, previous CVD event (not by type 
of event but by a positive history of any event) and ACE inhibitor treatment. Controls were 
further matched as close as possible by alpha-2 receptor blocker treatment, baseline ACR, 
age (±8 years), duration of diabetes (± 5 years), waist and HbA1c. All matching was carried 
out whilst blinded to the change in ACR. The characteristics of the DR progressors and 
match controls are summarised in Table 104. 
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Characteristic 
Retinopathy 
progression 
No retinopathy  
progression 
p 
n 16 32 
 
Matched Characteristics: 
   
Sex n (%male) 11 (69%) 22 (69%) 1 
Ethnicity (% white British) 100 100 1 
CVD event n (%) 6 (38%) 12 (38%) 1 
ACE inhibitors 8 (50%) 16 (50%) 1 
Alpha-1 Blockers 2(13%) 2 (6%) 0.460 
ACR (mg/mmol) 
2.32 1.36 
0.685 
[0.68 to 8.78] [0.73 to 3.65] 
Age (years) 70 (±9) 69 (±7) 0.181 
Duration of diabetes (years) 8 (±6) 9 (±7) 0.887 
Waist (cm) 103.2 (±16.3) 105.7 (±13.7) 0.548 
HbA1c (mmol/mol) 
58 57 
0.753 
[50 to 71] [49 to 70] 
Unmatched Characteristics: 
   
Height (m) 
1.71 1.71 
0.785 
[1.65 to 1.75] [1.64 to 1.77] 
Weight (kg) 
80.7 87.2 
0.3526 
[76.7 to 90.7] [79.0 to 94.6] 
Body fat (%) 
29.9 30.1 
0.811 
[24.7 to 40.7] [25.1 to 40.3] 
BMI (kg m-2) 
28 29 
0.323 
[26 to 31] [28 to 32] 
Systolic BP (mmHg) 141 (±27) 136 (±12) 0.907 
Statin therapy n (%) 13 (81%) 27 (84%) 0.784 
Smokers (current/ex/never) (%) 2/10/4 2/20/10   
 
Renal function:    
Creatinine (µmol/L) 
85 88 
0.489 
[71 to 104] [75 to 109] 
eGFR (ml/min/1.73m2) 
78.0 66.6 
0.752 
[55.9 to 89.2] [59.2 to 89.3] 
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Characteristic 
Retinopathy 
progression 
No retinopathy  
progression 
p 
CKD stage n (%): 
  
0.556 
G1 3 (20%) 5 (16%) 
 
G2 8 (53%) 18 (58%) 
 
G3A 2 (13%) 3 (10%) 
 
G3B 1 (7%) 5 (16%) 
 
G4 1(7%) 0 
 
G5 0 0 
 
Mean change in eGFR (ml/min/1.73m2) -5.8 (±10.6) -2.5 (±8.0) 0.437 
Mean percent change in eGFR (%) -9.7 (±18.7) -3.3 (±11.7) 0.378 
Retinopathy: 
  
  
Baseline Retinopathy n (%): 
  
0.554 
1 (No DR) 10 (63%) 18 (56%) 
 
2 Minimal DR 5 (31%) 8 (25%) 
 
3 Mild DR 1 (6%) 6 (18%) 
 
4 Moderate DR 0 0   
Table 104 Participant characteristics at baseline for subjects with a progression in 
retinopathy and their matched controls. Participants were selected from the SUMMIT 
cohort, and included in this investigation if they met the inclusion criteria to test Hypothesis 
Two (Table 66). Data are presented as mean (±SD) or median [IQR] for all subjects. P value 
indicates if there is a significant difference in a characteristic between subjects with and 
without retinopathy progression. There are no significant differences between groups, 
demonstrating their suitability for matched pair analysis. 
 
Median [IQR] absolute change in ACR was 1.00 [0.18 to 2.08] mg/mmol in non DR 
progressors (Figure 100), compared to 0.12 [-1.22 to 3.70] mg/mmol in DR progressors 
(p=0.431) (Table 105).  
Median [IQR] percent change in ACR was 43% [7 to 144] in non DR progressors (Figure 101), 
compared to 22% [-43 to 134] in DR progressors (p=0.284) (Table 106).  
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Figure 100 Distribution in the change of ACR between individuals who had a progression in 
retinopathy and matched controls. The change in ACR is not significantly (p=0.431) higher in 
DR progressors (n=16) compared to those without DR progression (n=32). 
 
 
 
Number of 
participants 
Mean (±SD) 
absolute change 
in ACR  
(mg/mmol) 
Median [IQR] 
absolute change 
in ACR 
(mg/mmol) 
Wilcoxon rank 
sum test (p) 
No retinopathy 
progression 
32 2.68 (±6.75) 
1.00 
0.431 
[0.18 to 2.08] 
Retinopathy 
progression 
16 1.85 (±12.64) 
0.12 
[-1.22 to 3.70] 
Table 105 Difference in the change in ACR between individuals who had a progression in 
retinopathy and matched controls. The change in ACR is not significantly (p=0.431) higher in 
DR progressors (n=16) compared to those without DR progression (n=32). 
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Figure 101 Distribution in the percent change of ACR between individuals who had a 
progression in retinopathy and matched controls. The percent change in ACR is not 
significantly (p=0.284) higher in DR progressors (n=16) compared to those without DR 
progression (n=32). 
 
Number of 
participants 
Mean (±SD) 
percent change 
in ACR  
(%) 
Median [IQR] 
percent change 
in ACR 
(%) 
Wilcoxon rank 
sum test (p) 
No retinopathy 
progression 
32 189 (±429) 
43 
0.284 
[7 to 144] 
Retinopathy 
progression 
16 122 (±289) 
22 
[-43 to 134] 
Table 106 Difference in the percent change in ACR between individuals who had a 
progression in retinopathy and matched controls. The percent change in ACR is not 
significantly (p=0.284) higher in DR progressors (n=16) compared to those without DR 
progression (n=32). 
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7.6 Discussion  
 
In this discussion an overview of participant recruitment to test each hypothesis is carried 
out. Results are discussed individually for each objective, with a summary of the findings for 
each hypothesis at the end. Future investigations to progress the findings of this chapter are 
also discussed, followed by an overall conclusion. 
 
7.6.1 Participant recruitment 
 
Two-hundred and forty eight participants met the inclusion criteria to test Hypothesis One 
(Table 66). Sixty-two of these participants did not have data recorded for various 
confounding factors used in regression models (Objectives 3 & 4) and were therefore 
excluded from the regression analysis. The majority of missing data are from not having 
routine blood tests carried out as the participant was unable to provide a blood sample 
(Figure 86). 
One-hundred and forty four participants from the SUMMIT cohort where selected to 
investigate the relationship between change in urinary albumin excretion and change in 
microvascular function for the first in objectives 5 and 6 (Table 90). The cause for this loss in 
participants is due to an inconsistency between laboratory staff to store urine samples at 
baseline (104 samples not stored). 
Three-hundred and twenty one participants diagnosed with type 2 diabetes, who had a 
urine sample from a random spot collection stored at baseline, and retinal photography and 
neuropathy tests carried out at both baseline and follow up were selected to test  
hypothesis two (Figure 87). Fifty eight participants did not have retinal photography and 
neuropathy data available at follow up (Objective 2), and a further 93 participants had no 
spot ACR sample provided at follow up (Objective 3).  
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The target duration between visits was 36 months. The actual mean follow up period was 37 
months (±3), demonstrating a good adherence to the SUMMIT study protocol by the 
research nurse who made the appointments and carried out screening visits. 
Across the whole SUMMIT cohort recruited in Exeter; 298 (36%) of participants did not 
return after three years for a follow up visit. The most common reason was subjects unable 
/ unwilling to return to the research centre, in which case a medical questionnaire was 
carried out over the phone if possible. In several cases participants had moved away from 
the area, some had developed serious illness, others had deceased. 
Before officially entering the study, participants’ consented for researchers to access their 
medical records, so their clinical information could be collected over a long period of time 
for research purposes. 
 
 
Hypothesis 1: 
 
Urinary albumin excretion is related to microvascular function, with higher levels of albumin 
excretion being associated with an impairment of microvascular function. The magnitude of 
change in microvascular function over three years is related to the change in albumin 
excretion. Furthermore, this relationship is present in individuals with and without diabetes, 
and changes of urinary albumin excretion within the normoalbuminuria range relate to 
changes in microvascular function. 
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7.6.1.1 Participant characteristics 
 
It is an elderly cohort with a mean age of 70 (±8.2) years, 67% of whom were male. 65% of 
participants were diagnosed with diabetes. When comparing participant characteristics by 
diabetes status, attributes of diabetic milieu and risk factors for CVD arise as expected; 
where subjects with diabetes are significantly heavier (p=0.03), have a higher proportion of 
body fat (p=0.001), higher BMI (p<0.001), higher triglycerides (p<0.001), higher fasting 
glucose (p<0.001) and HbA1c (p<0.001).  
Our results are in accordance with the Maastricht study, and many other studies, which also 
reported larger waist, higher systolic blood pressure, triglycerides, HbA1c, fasting glucose, in 
their subjects with T2DM (n= 609) compared to non-diabetic group (n=1269) (Sorensen et 
al., 2016). The Maastricht study has the largest cohort with microvascular assessments in 
subjects with and without diabetes, therefore their characteristics are compared to the 
SUMMIT cohort to enable comparisons to be drawn between the studies in later analyses. 
Diabetic cohorts of the Maastricht and SUMMIT studies have a very similar mean age. In the 
Maastricht study mean age was 62.8 ±7.6 years, compared to 68.5 ±8.8 years in the 
SUMMIT study. Duration of diabetes is very similar in both studies, 8.2 ±7.0 years in the 
Maastricht cohort compared to 8 ±6 years in the SUMMIT study. The most notable 
difference between the cohorts is glycaemic control when assessed by glycated 
haemoglobin. In the Maastricht study mean HbA1c was 51.7 ±11.4 mmol/mol, compared to 
a median HbA1c in the SUMMIT cohort of 40 [37 to 43] mmol/mol. 
 
7.6.1.2 Number of measurable samples using two assays 
 
Urinary albumin excretion in the SUMMIT cohort was quantified using the validated 
Fitzgerald ELISA and the routine Cobas method. The Fitzgerald ELISA was able to quantity 
urinary albumin in two overnight collections from all 248 participants. The Cobas assay 
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could only quantify albumin in 106 (43%) of participant samples from the first collection, 
and 100 (40%) in the second collection. The portion of measurable samples using the Cobas 
assay reduced further in subjects without diabetes, to only 32% in the first collection and 
24% in the second. This reflects the importance of using an assay with a lower quantification 
limit when investigating urinary albumin excretion in subjects without diabetes. 
The Cobas assay could measure albumin in 56% of random spot urine collections.  This is 
most likely because albumin excretion is higher during the day than overnight and so more 
of the values fall within the detection range of the Cobas assay when a spot urine sample is 
collected. Similar findings were observed during the urine collection studies in Chapter 4.  
 
7.6.1.3 Agreement between the two methods of quantifying urinary albumin 
 
From previous validation studies it was determined the Fitzgerald assay has mean bias of 
3.55mg/L (±2.13) over the Cobas method (Chapter 2, Section 2.3.4). These findings were 
confirmed in the SUMMIT investigation. The previous validation work determined that the 
analytical range for the Fitzgerald assay was 0.78 to 40mg/L, therefore samples which had 
an albumin concentration >40mg/L were diluted into this range.  
The Passing Bablok regression demonstrated a significant correlation between the two 
methods (p<0.001) to quantify urinary albumin (y=1.37 (1.25 to 1.49) + 2.00 (1.24 to 2.81). 
The “y intercept” value of 2.00 mg/L indicates a positive systematic difference between the 
two methods. This was confirmed by Bland Altman analysis which demonstrates that the 
Fitzgerald method has a mean positive bias of 4.24 mg/L ± 3.35 compared to the Cobas 
method (Figure 88). This supports the findings of the initial validation studies, which 
demonstrated a mean bias of 3.55mg/L (±2.13) over the Cobas method (Chapter 2, Section 
2.3.4). All subsequent analysis has been carried out using urinary albumin measurements 
determined using the Fitzgerald assay.  
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7.6.1.4 Prevalence of microalbuminuria in the SUMMIT cohort 
 
In the SUMMIT cohort, 3% of subjects (n=3) without diabetes were identified as having 
microalbuminuria based on two overnight urine collections, compared to 12% (n=19) in 
subjects with T2DM, when urinary albumin is measured using the Fitzgerald assay.  
In the Maastricht cohort 4% of subjects without diabetes were in the microalbuminuria 
range, compared to 17.4% in subjects with T2DM (Sorensen et al., 2016). The prevalence of 
microalbuminuria in the two studies is very similar, and the higher incidence of 
microalbuminuria in the Maastricht study may be attributed to the difference in urine 
collection methods. Albumin excretion was assessed by two 24 hour urine collections in the 
Maastricht cohort.  Twenty-four hour urine collections are influenced by activity throughout 
the day, elevating albumin excretion (Chapters 4 and 6).  
Diabetic cohorts of the Maastricht and SUMMIT cohorts are of similar age and duration of 
diabetes. Therefore it is expected that microalbuminuria prevalence would be similar in 
both cohorts. In addition to different collection methods, an alternative explanation for 
increased prevalence of microalbuminuria in the Maastricht study is that it is a population 
based cohort with poorer glycaemic control, a known contributor to diabetes related 
complications. 
In 2014, 3.9 million people in the U.K. had been diagnosed with diabetes and it is estimated 
that over 25% will develop diabetic kidney disease, usually ten years after diabetes 
diagnoses (Diabetes UK, 2014). Prevalence of microalbuminuria in the SUMMIT cohort is 
12%. This might reflect the short duration of diabetes in the cohort (8 (±6) years) or it may 
reflect their good glycaemic control (median HbA1c [IQR]: 40 [37 to 43] mmol/mol).  
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7.6.1.5 Urinary albumin excretion in subjects with and without type 2 diabetes 
 
Median [IQR] AER was 9.75 [5.53 to 18.48] µg/min in subjects with diabetes, compared to 
6.02 [4.10 to 8.93] µg/min in subjects without T2DM (p<0.001). ACR was also significantly 
higher in subjects with T2DM (p<0.001) as is expected and reflected in many studies (Hillege 
et al., 2001). However, using the sensitive ELISA to quantify urinary albumin, this is the first 
study to accurately report the full normoalbuminuria range, and report the differences in 
diabetes and microvascular function. 
Studies like those from the Maastricht cohort use routine clinical assays to measure urinary 
albumin and are unable to quantify the lowest levels of albumin concentration. It is 
probable that these studies report the LOQ of their albumin assay in undetectable samples, 
if they intended to investigate relationships with albumin excretion. It is common that only 
microalbuminuria and macroalbuminuria prevalence are reported to describe a cohort. 
 
7.6.1.6 Microvascular function in the SUMMIT cohort 
 
Endothelial dependent and independent microvascular response to iontophoretic delivery 
of acetyl choline (ACH) and sodium nitroprusside (SNP) is significantly lower in subjects with 
diabetes (p<0.001) (Table 71).  
Maximal hyperaemia response to localised heating (p=0.002) and minimum vascular 
resistance (<0.001) are also significantly lower in subjects with diabetes. 
Results were mixed for skin reactive hyperaemia in response to arterial occlusion. Time to 
peak hyperaemia was significantly lower in subjects with T2DM (<0.001), however peak 
hyperaemia (p=0.078), time to baseline (p=0.073), and the type of early peak (p=0.449) 
were not significantly different.  
These relationships are explored further in the following sections. 
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7.6.1.7 Maximal hyperaemia in the SUMMIT cohort 
 
Maximal hyperaemia, or maximal blood flow/flux, in response to localised heating is one of 
the most common non-invasive tests used to represent generalised microvascular function. 
Maximal hyperaemia is an indicator of the maximal capacity of the vessels to vasodilate, and 
is significantly lower in subjects with T2DM (p=0.002) in the SUMMIT cohort. The 
attenuation of maximal hyperaemia in diabetes has been previously reported. (Sandeman et 
al., 1991a, Jaap et al., 1994a, Jaap et al., 1994b, Colberg et al., 2003, Schmiedel et al., 2007) 
. 
A study by Jaap et al. was carried out at the Diabetes and Vascular Research Centre in 
Exeter, with very similar protocols used in their methods to those used in the SUMMIT 
investigation. Jaap et al. reported significantly lower hyperaemic response to local heating in 
the feet of 9 normotensive subjects with T2DM compared to  9 age- and sex-matched 
control subjects (p<0.001) (Jaap et al., 1994b). Subjects with T2DM in the study by Jaap et 
al. have a similar duration of diabetes (mean (range) of 7 years (4 to 19), and similar 
glycaemic control  compared n to those in the SUMMIT cohort (Jaap et al., 1994b). 
Participants from the Jaap study were recruited from a diabetic clinic in Exeter (U.K.); the 
majority of participants were European, similar to the SUMMIT cohort (99% white British). 
Previous studies have demonstrated attenuated maximal hyperaemia in subjects with T2DM 
in both European and African Caribbean cohorts (Strain et al., 2005b). 
In the T2DM-enriched population-based Maastricht study cohort; 2,214 participants (51% 
men, aged 59.7±8.2 years) had heat-induced skin hyperaemia measured by laser-Doppler 
flowmeter (Sorensen et al., 2016). The percent increase in maximal hyperaemia when 
heating was reported in the Maastricht study, whereas maximal hyperaemia in response to 
localised heating (maximal blood flow) is reported in the SUMMIT study. Participants with 
normal glucose metabolism had a mean percent increase in hyperaemia of 1235% (±810%), 
compared to 1109 % (±748%) and 937% (±683%) in prediabetes and in T2DM respectively (p 
<0.001). In the SUMMIT cohort, there is also a significant loss in maximal hyperaemia in 
subjects with diabetes (135.2 AU [99.7 to 179.8] compared to subjects without diabetes 
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(165.7 AU [117.4 to 215.6] (p=0.002) (Table 71). Percent increase in maximal hyperaemia 
was not calculated in the SUMMIT cohort, however the data is available to do so. 
In the Maastricht study, flicker light induced retinal arteriolar dilation was also measured 
and they concluded that prediabetes, T2DM, and measures of hyperglycaemia are 
independently associated with impaired microvascular function in the retina and skin 
(Sorensen et al., 2016). To determine if low levels of urinary albumin excretion are a marker 
of early generalised impaired microvascular function, then it may correlate to early changes 
in the retina, this is investigated in Hypothesis two. 
 
7.6.1.8 Endothelial dependent and independent microvascular response in the 
SUMMIT cohort 
 
The findings from the SUMMIT cohort are in accordance with previous studies that have 
demonstrated endothelial dependent and independent microvascular response to 
iontophoretic delivery of acetyl choline (ACH) and sodium nitroprusside (SNP) is impaired in 
subjects with diabetes (Beer et al., 2008, Morris et al., 1995, Caballero et al., 1999, Lim et 
al., 1999, McVeigh et al., 1992).  
A study by Morris et al. (1995) was conducted in the Diabetes and Vascular Research Centre 
in Exeter, using similar methods to those used in the SUMMIT cohort. The finding from the 
SUMMIT investigation, that the function of the endothelium and/or smooth muscle may be 
attenuated in diabetes, extend the results of the study by Morris et al. into a larger, more 
diverse cohort. The Morris et al. paper was published in 1995 and there have been changes 
in glycaemic targets and medication regimens in this time but that even with these changes 
microvascular impairments are still occurring.  
In the study by Morris et al. the only information regarding urinary albumin excretion is that 
3/14 patients with T2DM had raised ACR, it is not reported if that refers to micro- and/or 
macro-albuminuria. There are, to my knowledge, no previous studies which have 
investigated the relationship between urinary albumin excretion and endothelial dependent 
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and independent microvascular response to ACH and SNP. One study has demonstrated that 
endothelial dysfunction is evident in subjects with T2DM with normoalbuminuria, 
suggesting the pathogenic process of vasculopathy in T2DM  occurs before the development 
of microalbuminuria (Lim et al., 1999). 
 
7.6.1.9 Post occlusive reactive hyperaemia in the SUMMIT cohort 
 
In the SUMMIT cohort, time to peak reactive hyperaemia was significantly lower in subjects 
with T2DM; however peak hyperaemia, time to baseline and the type of early peak not 
significantly different. These findings contradict those from a study by Strain et al. which 
demonstrated attenuated peak hyperaemia in 51 European and 66 African Caribbean 
subjects with diabetes, aged between 40 and 65 years, recruited from the general 
population (Strain et al., 2005b). A further analysis of the European and African Caribbean 
cohort by Strain et al. demonstrated early peak morphology was influence by diabetes 
status (Strain et al., 2005a). This was identified in the SUMMIT cohort. 
A possible explanation for these differences between these studies is the different 
populations were tested. Approximately half of the participants in the Strain et al. study 
were African Caribbean, the remaining were from European descent. African Caribbean’s 
have an increased risk of CVD (Chaturvedi, 2003), with the risk of stroke 1.5–2.5 times 
greater than the general population (Wild and McKeigue, 1997). Although the SUMMIT 
cohort might be a lower risk factor group as the subjects are all from European descent 
(99% are white British), they are much older and 45% have a history of CVD.  
In the SUMMIT cohort peak hyperaemia and early peak morphology were comparable 
between patients with and without diabetes.  A study by Yamamoto et al. demonstrated 
comparable peak hyperaemia in patients with diabetes and controls, but reported 
significant differences in dominant peak morphology, supporting the work described by 
Strain et al. (Yamamoto-Suganuma and Aso, 2009). 
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Time to baseline was not reported in the study by Yamamoto, however PORH index, defined 
as the ratio of the post-AUC 1 min relative to the pre-AUC 1 min, was significantly lower in 
patients with diabetes than in control subjects (Yamamoto-Suganuma and Aso, 2009). 
Yamato et al. propose that among all measures of PORH, the area under the curve (AUC) 
over the duration of prolonged hyperaemia would be associated more strongly with CVD 
than the traditionally reported peak hyperaemia and time to peak hyperaemia, or 
morphological analysis. PORH index was not reported in the SUMMIT cohort in this analysis, 
but data is available to calculate it.  
 
Measuring microvascular function and albumin excretion in the SUMMIT cohort has 
confirmed that albumin excretion is higher and vascular function is impaired in subjects with 
diabetes. However, being able to quantify the lowest levels of albumin excretion, the 
relationship with microvascular function can be fully investigated for the first time across 
every individual in the cohort rather than assigning individuals below the detection limit of 
the assay, the value equal to this lower limit. 
 
 
7.6.1.10 Correlation between albumin excretion and microvascular function and 
the interaction of T2DM and CVD. 
 
There is a significant correlation between urinary albumin excretion and all measures of 
microvascular function (Table 72). The association between AER/ACR with measures of 
microvascular function is not significantly different in subjects with diabetes compared to 
those without diabetes (Table 73). This is the first study to report the association with the 
urinary albumin excretion across the full range with microvascular function. 
Microvascular dysfunction precedes the development of atherosclerosis and is thought to 
occur in response to CVD risk factors (smoking, obesity, hypertension, and dyslipidaemia) 
(Shimokawa, 1999, Holowatz et al., 2008). The findings from the SUMMIT cohort support 
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previous findings that increased risk of CVD is associated with biomarkers of microvascular 
dysfunction in healthy individuals (Anderson et al., 2011). 
The results from the SUMMIT cohort support a review by Lambers Heerspink which 
demonstrated that urinary albumin excretion is a predictor of all-cause mortality in diabetes 
and the general population (Lambers Heerspink et al., 2011). A focal point of their review 
was a prominent study by Hillege et al. from the PREVEND study (Hillege et al., 2002). 
Hillege et al. demonstrated that a higher urinary albumin concentration increased the risk of 
CVD and non CVD death in 40,548 subjects after adjustment for other well established risk 
factors for CVD over a median follow up period of 961 days in the general population.  
In the SUMMIT cohorts the direction of the relationship between AER/ACR and 
microvascular function are as expected, although the increase in AER with increased peak 
hyperaemia during PORH testing needs cautious interpreting.  
In the SUMMIT cohort only the relationship between AER and ACR with time to peak 
hyperaemia were significantly different in subjects with and without CVD. This 
demonstrates that the relationship between AER/ACR with microvascular function is 
present in all individuals, not just those with established CVD. There are significant 
correlations between AER and ACR with time to peak hyperaemia (PORH) in subjects with 
and without CVD (Table 77). However, none were independent when accounting for other 
confounding risk factors of CVD (Table 78). The interaction of CVD on the relationship 
between microvascular function and urinary albumin excretion was investigated further in 
the normoalbuminuria range. 
 
7.6.1.11 Microvascular function and urinary albumin excretion assessed by 
overnight collection and spot samples 
 
The discrepancies in the relationships identified between overnight AER or spot ACR and 
microvascular function may be attributed to the accuracy and variability of the different 
urine collection methods. AER obtained from two overnight collections provides the most 
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accurate assessment of albumin excretion however random spot samples are more 
frequently used in routine practice. Previous chapters have explored the limitations of 
random spot samples which have demonstrated poor reproducibility and they are 
influenced by exercise.  
From the results derived from the SUMMIT study, an alternative hypothesis to explain the 
differences between the relationships between AER or ACR with microvascular function can 
be proposed. 
The discrepancies in the relationships identified between AER or ACR with microvascular 
function may be attributed to overnight collections (AER) assessing resting albumin 
excretion whereas ACR from a random spot sample is a marker of a stress test. 
In Chapter 6, it was demonstrated that there are different types of responses in ACR to 
walking. Three patterns were found; delayed change in ACR, immediate change and no 
change. Perhaps the reason for the correlation between microvascular function and ACR 
from random spot samples is because individuals with poor microvascular function 
(impaired autoregulation) have a high ACR after walking, whereas overnight they would 
have a low albumin excretion, hence there is no correlation with overnight AER. The role of 
random spot samples as a stress test to identify exercise induced increased urinary albumin 
needs further investigating, and its clinical application as a risk factor evaluated. 
Walking induced increased urinary albumin excretion is supported by the findings of Koh 
and colleagues, who in 2011 investigated the change in ACR one and two hours after one 
kilometre walking on a treadmill (Koh et al., 2011). Their study involved thirty-five 
participants with diabetes, with a range of pre walking levels of albumin excretion, and nine 
control subjects. They demonstrated that in females with diabetes, on average ACR 
increased above the microalbuminuria threshold at 1 hour post walking returning to 
baseline levels by 2 hours. This data indicates that female patients with diabetes and 
normoalbuminuria have walking induced increased albumin excretion, which might 
represent an early sign of nephropathy. Koh et al. demonstrated no increase in ACR in 
control subjects after walking.  
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It has been demonstrated that subjects with diabetes have a greater increase in ACR in 
response to exercise than subjects without diabetes, although exercise induced ACR is 
variable among individuals (Viberti et al., 1978). This increased susceptibility in diabetes 
might help explain why controls in the study by Koh et al. did not show increased ACR after 
walking, although it does not explain why male subjects with diabetes did not have 
increased ACR. In our exercise study, healthy men and women demonstrated walking 
induced albumin excretion. Other studies might not be able to deter walking induced 
urinary albumin excretion if using inadequate assay which are unable to measure small 
changes in ACR in the normoalbuminuria range. 
To my knowledge, apart from my study and the study by Koh et al., there are no other 
studies which have investigated the impact of walking on an ACR. Walking induced 
increased urinary albumin excretion might help identify individuals at risk of CVD, and the 
clinical implications of this is that samples collected from a first morning void, may not 
identify these individuals. The Hillege study reported urinary albumin concentration from 
early morning voids and demonstrated the risk of CVD mortality (Hillege et al., 2002). The 
risk of CVD mortality might be more prominent if urinary albumin excretion was assessed in 
random spot samples. 
The function of a random spot ACR as a stress test is a novel theory. Previous studies have 
reported exercise induced albuminuria, but they investigated the clinical ranges after very 
high intensity of exercise (Mogensen, 1976, Mogensen and Vittinghus, 1975, Viberti et al., 
1978). In Chapter 6, the sensitive ELISA enabled small changes in ACR to be examined, and 
due to participant discordance with the protocol, the relationship with number of steps 
taken throughout the day was investigated. This is the first study to report the association of 
ACR with walking, which has clinical implications when considering patients walking to GP 
surgeries. This theory is revisited and supported by the findings in the normoalbuminuria 
range. 
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7.6.1.12 The relationship between albumin excretion and post occlusion peak 
reactive hyperaemia.  
 
In the SUMMIT cohort; an increase in albumin excretion is independently associated with an 
increase in post occlusive peak reactive hyperaemia after adjusting for age, gender, smoking 
status, HDL, systolic blood pressure, history of CVD, HbA1c and waist (p=0.008) (Table 75). 
This was the only independent relationship between albumin excretion and measures of 
microvascular function. 
This result is contradictory to other studies which suggest that low peak hyperaemia is 
associated with poor health, with higher peak hyperaemia associated with individuals with 
better health without any known CVD or known risk of CVD (Stewart et al., 2004, Tur et al., 
1991). There are considerable discrepancies between these studies and ours, where 
different cohorts are being tested and methodological differences may explain the 
inconsistent findings.   
Stewart et al. reported lower peak height in individuals with end stage renal disease [ESRD] 
(n=63) compared to healthy individuals, in comparison the SUMMIT cohort did not contain 
any individuals with ESRD (Stewart et al., 2004). This difference in the patient characteristics 
might explain the differences in findings. Tur et al reported that peak height was 
significantly lower in patients with diabetes (p<0.02) compared to  non-diabetic controls 
(Tur et al., 1991). In the SUMMIT cohort there is no significant difference in peak reactive 
hyperaemia (p=0.784) between subjects with and without T2DM (Table 69). However, the 
studies by Stewart et al. and Tur et al. tested PORH on the forearm whereas in the SUMMIT 
cohort it was tested on the feet, which might reflect the heterogeneity of microvascular 
cells in different vascular beds. This is discussed further in Section 7.6.1.4.8.   
Although it initially appears the positive correlation between AER and peak hyperaemia is 
contradictory to other studies, in fact it is logical that impaired autoregulation at the 
glomerulus results in increased albumin excretion, just as impaired autoregulation in skin 
microvasculature results in increased peak hyperaemia after PORH testing. 
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In the SUMMIT cohort, the relationship between AER/ACR was only investigated with 
individual parameters (e.g. peak hyperaemia) of post occlusive reactive hyperaemia. A study 
by Yamamoto and Asp reported that PORH index correlated negatively with urinary 
albumin, (Yamamoto-Suganuma and Aso, 2009). This demonstrates that the overall 
response in PORH is reduced with increasing urinary albumin excretion. Perhaps the 
increase in peak hyperaemia with urinary albumin excretion identified in the SUMMIT 
cohort is the result of early impaired autoregulation and as CVD progresses the overall 
PORH response declines as urinary albumin excretion continues to rise. The PORH index 
needs to be calculated in the SUMMIT to investigate these findings further. 
The study by Yamamoto and Aso demonstrates that urinary albumin excretion is association 
with PORH index and that PORH index is related to peroneal motor nerve conduction 
velocity (Yamamoto-Suganuma and Aso, 2009) . This supports the hypothesis that urinary 
albumin excretion is linked to generalised microvascular dysfunction (de Zeeuw et al., 2006) 
In the SUMMIT cohort, urinary albumin excretion correlates to time to peak reactive 
hyperaemia and time to return to baseline, but these relationships are not independent of 
traditional risk factors for CVD and are not influenced by diabetes. Visualising the regression 
between albumin excretion and post occlusive peak reactive hyperaemia demonstrates the 
variability in these biological measurements (Figure 89A). When adjusting this relationship 
for all the confounding variables, the relationship is evident, but there is still a lot of 
variation in the regression. (Figure 89B). This relationship is explored further in the 
normoalbuminuria range in Section 7.6.1.5. 
 
7.6.1.13 CVD risk factors 
 
Regression analysis was carried out not only to determine if the relationship between 
albumin excretion and microvascular function was independent, but also to investigate the 
influence of confounding factors on those relationships. 
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Accumulatively adding variables to regression models, it is evident that waist circumference 
has the largest influence on the regression coefficient factor of the relationships between 
albumin excretion and microvascular function (Table 75, Table 76). Waist circumference is 
an index of abdominal adipose tissue deposition (Pouliot et al., 1994)  and is accepted as a 
risk factor for CVD (Després, 2012). This indicates that the majority of relationships between 
albumin excretion and microvascular function can be explained by abdominal fat. This is an 
accordance with the results of Jongh et al. who demonstrated impaired microvascular 
function in obesity (de Jongh et al., 2004)  
There is a wealth of evidence demonstrating the risk of CVD with obesity, but the molecular 
mechanisms are unclear. In diabetes, it has been proposed that adipocytokines, which are 
produced by the adipose tissue, can directly influence the pro-atherogenic and pro-
inflammatory environment of the vascular walls (Cha et al., 2012). Leptin and adiponectin 
are the two most abundant adipocytokines, and have previously been linked with vascular 
complications in patients with T2DM, including subjects with nephropathy (Hanai et al., 
2010). These observations are supported by a systematic review and meta-analysis of 
controlled cross sectional studies which suggests leptin and adiponectin levels are higher in 
T2DM patients with microvascular complications (Rodríguez et al., 2016).  
Age and gender can also explain a large proportion of the relationships. Age, gender and 
abdominal fat are well established CVD risk markers (Jousilahti et al., 1999), and 
demonstrate a limited use for AER being included in risk predication models, except for 
estimating peak reactive hyperaemia after arterial occlusion.  
 
7.6.1.14 Albumin excretion and post occlusion response early peak morphology 
 
There was no significant difference in AER distribution between groups (p=0.243) when 
stratifying by peak response curve morphology in this cohort (Table 79, Figure 90). This does 
not support the relationship found by Strain et al. who demonstrated that AER was 
significantly higher with an early dominant peak response (Strain et al., 2005a). 
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The mean age of the participants in the Strain study was approximately 55 years old, of 
whom approximately 50% were African Caribbean, whereas the SUMMIT cohort are 99% 
white British and much older (mean age of 77 years,). The SUMMIT cohort also has a much 
lower prevalence of current smokers (4%) compared to 22% in the Strain study, which 
reported that individuals with an early dominant peak were more likely to be smokers 
(p=0.02).  The study by Yamamoto also reported comparable urinary albumin excretion 
among the three different peak morphologies, and they found no significant difference in 
the prevalence of CVD (Yamamoto-Suganuma and Aso, 2009).  
Visualising AER distribution by peak morphology (Figure 90) and comparing medians suggest 
that AER is higher in subjects with an early dominant peak, although it is not statistically 
significant (p=0.243). This lack of statistical significance may be influenced by individuals 
with a high AER with normal peak curve morphology. 74% of these abnormal results were 
from subjects on antihypertensive therapy and 78% on statins.  
To explore the risk of CVD by different early peak morphology and to understand why the 
results from the Strain study were not reflected in the SUMMIT cohort, the characteristics of 
each group were summarised by peak morphology (discussed in the next section). 
 
7.6.1.15 CVD risk factors and post occlusion reactive early peak morphology 
 
In the SUMMIT cohort, age, weight, BMI, waist, hip size, systolic blood pressure, history of 
CVD, on antihypertensive therapy and renal decline were significantly more prominent in 
subjects with an early dominant peak, demonstrating an increased risk of CVD. This confirms 
the findings from the Strain study (Strain et al., 2005a). The study by Yamamoto reported no 
significant difference in the prevalence of CVD, but did not investigate CVD risk factors in 
the different early peak morphology groups (Yamamoto-Suganuma and Aso, 2009). 
 
Although subjects with normal peak morphology have the lowest prevalence of CVD (40%) it 
is still very high and helps explain the increased albumin excretion in this group, of whom 
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57% are on antihypertensive therapy and 69% on statins. These outliers (subjects with high 
AER) provide a bias in the normal peak morphology group, influencing the analysis.  
 
This relationship between albumin excretion and post occlusion reactive early peak 
morphology is examined further by studying the relationship in subjects with 
normoalbuminuria. Therefore subjects with high AER in the microalbuminuria range or 
above are excluded to determine if the same relationships exists without their influence. 
 
Peak and total endothelial dependent response to ACH was significantly reduced in subjects 
with an early dominant peak response to arterial occlusion (Total response; p=0.019, peak 
response; p=0.012). Endothelial independent response to SNP was not significantly different 
in subjects with dominant early peak morphology (Table 80). This suggests that early 
dominant curve morphology may be related to impaired endothelial function, and warrants 
further investigation. 
 
 
7.6.1.16 Urinary albumin excretion and endothelial dependent and independent 
hyperaemia  
 
Urinary albumin excretion had a significant correlation with endothelial dependent and 
independent response to the iontophoretic delivery of ACH and SNP. This relationship was 
not independent when adjusting for age and gender. To my knowledge, this is the first study 
to report the association of urinary albumin excretion and in vivo measures of microvascular 
endothelial function. Endothelial dysfunction is a precursor to CVD, occurring at the earliest 
stages. The relationship of endothelial dysfunction with small changes in albumin excretion 
within the normoalbuminuria is discussed in Section 7.6.1.5.   
Results from the SUMMIT cohort indicate AER has an independent relationship with peak 
hyperaemia, suggesting impaired autoregulation could be driving generalised microvascular 
dysfunction, resulting in increasing AER. 
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Our findings might support the ‘Steno hypothesis’, which was the first to claim a common 
link between mechanisms involved in diabetic nephropathy and CVD. The Steno hypothesis 
is that urinary albumin excretion is a marker of overall vascular dysfunction with increased 
urinary excretion in the kidney presenting itself from increased glomerular permeability and 
also representing increased vascular permeability elsewhere increasing CV risk (de Zeeuw et 
al., 2006). This is tested further in the SUMMIT cohort, by assessing if urinary albumin 
excretion is also associated with other microvascular complications of diabetes (Hypothesis 
2). 
 
7.6.1.17 Limitations 
 
When assessing the relationship between measures of biological function; urinary albumin 
excretion and microvascular function, it is important to consider the overall variability of 
those measures. The biological variation of the different urine collection methods to assess 
urinary albumin excretion needs to be considered in conjunction with assay variability to 
quantity albumin (and creatinine if reporting ACR). When assessing in vivo measurements of 
microvascular function; intra-individual biological variation of the different tests needs to be 
considered in conjunction with the reproducibility of the method, and the operator 
conducting the test (reported in Section 7.4.4.4). This overall variability becomes more 
influential when investigating the relationship between these variables over time (Objective 
5). 
In the SUMMIT cohort, microvascular assessments are being carried out on the skin of the 
arm (for iontophoretic delivery of ACH and SNP) and of the feet (PORH and maximal 
hyperaemia in response to localised heating). Endothelial cells at these sites are 
heterogeneous, and their function is largely influenced by thermoregulation. The measures 
of microvascular function test different response pathways for example; endothelial 
dependent response (ACH), endothelial independent response (SNP) and vascular 
autoregulation (PORH). If there is no association between urinary albumin excretion and 
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endothelial dependent response to ACH, this does not necessarily mean that the same 
results will be found when testing on the foot. The foot is more susceptible to neuropathy 
due to the distance of cell bodies from the synapses and the basement membrane 
thickening is substantially greater in the foot compared to the eye.  These and other factors 
might contribute to differences between the foot and the arm response.   
 
7.6.1.18 Correlation between albumin excretion and microvascular function and 
the interaction of T2DM in the normoalbuminuria range. 
 
The initial results from Objective 3 demonstrated significant correlations between all 
measures of microvascular function with urinary albumin excretion. In the 
normoalbuminuria range the relationships with maximal blood flow, minimum vascular 
resistance and endothelial dependent response to ACH were no longer significant (Table 
81). This indicates that either these relationships are driven by subjects with clinically 
recognised levels of urinary albumin excretion, or a reduction in sample size results in a loss 
of power to get the correlation coefficient needed. 
In the normoalbuminuria range there were significant correlations between all the 
measures from PORH with AER, and a correlation between ACR and peak endothelial 
independent response after delivery of SNP (Table 81). When accounting for other 
confounding factors, only AER has an independent relationship with peak hyperaemia from 
PORH testing (p=0.003). This reinforces the relationship found in Objective 3, demonstrating 
that an increase in peak hyperaemia is associated with an increase in AER, and this 
relationship occurs within the normoalbuminuria range (Figure 91). This is the first time that 
this association has been shown, as the full normoalbuminuria range can be investigated.  
Small increases in urinary albumin excretion within the normoalbuminuria range are 
associated with an increased risk of CVD morbidity, in subjects with and without diabetes 
(Hillege et al., 2002). The results from the SUMMIT cohort, demonstrate that impaired 
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autoregulation could be an underlying mechanism associated with increased risk of CVD and 
increasing urinary albumin excretion at subclinical levels. 
The distribution of AER did not significantly differ by peak response curve morphology 
(Table 88, Figure 92), which does not support the hypothesis proposed by Strain et al. that a 
rapid peak flow response is associated with an elevated AER, which they demonstrated 
within the normoalbuminuria range (Strain et al., 2005a). 
 
7.6.1.19 Interaction of CVD on the relationship between AER/ACR with 
microvascular function in the normoalbuminuria range 
 
There is a significant interaction of CVD on the relationship between AER/ACR with 
microvascular function in the normoalbuminuria range. There are significant correlations 
between AER and maximal blood flow (MBF) and minimum vascular resistance (MVR) in 
subjects with CVD (Table 86) but not in those with no CVD with or without diabetes. There 
are significant correlations between ACR and endothelial dependent and independent 
response to ACH and SNP respectively in subjects without CVD, but not in those with CVD. 
A possible reason for the association of ACR with endothelial dependent and independent 
response to ACH and SNP, and not with AER is because ACR can identify stress induced 
urinary albumin excretion whereas overnight AER assesses resting conditions. Stress 
induced urinary albumin excretion may be an early marker of microvascular dysfunction, 
and may be associated with endothelial function, but these early changes are only 
detectable by using an ACR.  
This is supported by the observation that the association of ACR with endothelial dependent 
and independent response to ACH and SNP has been demonstrated in young subjects 
without CVD with normoalbuminuria, demonstrating this is very early microvascular 
impairment, and not detectable using overnight AER / resting conditions. 
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Only in subjects already with CVD was AER associated with MBF and MVR, there is no 
association with spot ACR. MBF and MVR may occur later in the progression of 
microvascular dysfunction, hence why this association is only found in subjects who already 
have CVD.   
Due to reduced sample size during regression modelling the relationships between AER and 
MBF (p=0.068) and MVR (p=0.101) were no longer significant and not investigated further.   
The relationship between ACR and endothelial independent response to SNP was not 
independent (Table 87). However, the relationship between ACR and endothelial dependent 
response to ACH in subjects without CVD was independent of other confounding factors for 
CVD (Table 87), demonstrating that an increase in ACR is associated with endothelial 
dysfunction in subjects without CVD with and without diabetes. 
 
7.6.1.20 Random spot ACR to identify subject with walking induced urinary 
albumin excretion  
 
The earliest impaired microvascular dysfunction might only be detected when putting the 
subject under activity / stress, for example by using walking as a stress test and using 
random spot samples to assess change in ACR. The findings from Chapter 4 demonstrated 
that FMV is the best surrogate of overnight urine collection, ‘the gold standard’ to identify 
subjects with microalbuminuria. However, overnight collections might not identify people 
with walking induced albumin excretion, which may occur at an early stage in the 
progression of microvascular dysfunction, before microalbuminuria is detectable.  
The clinical significance of this could be that stress testing identifies those who are 
susceptible to induced urinary albumin excretion as they may be at risk of CVD compared to 
those who are not. 
To investigate this further in the SUMMIT cohort, the difference in ACR from the overnight 
collections and random spot collections can be investigated. Microvascular function in 
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subjects with a meaningful increase in ACR may have impaired microvascular function, 
supporting the hypothesis that walking induced urinary albumin excretion is an early marker 
of microvascular dysfunction.  The mechanism common to walking induced urinary albumin 
excretion and generalised microvascular dysfunction could be impaired autoregulation. This 
is supported by the post-occlusive reactive hyperaemia testing where peak hyperaemia is 
independently associated with increasing urinary albumin from a random spot collection, 
within the normoalbuminuria range. 
This hypothesis supports the role of microvascular function in pathogenesis of increasing 
urinary albumin which is a precursor to DKD. It does not support the albumin retrieval 
hypothesis which proposes a defective proximal tubule retrieval system is an alternative 
hypothesis for albuminuria arising during the early stages of DKD (Russo et al., 2007, 
Comper, 2008). This theory is based on observations in rats that suggests the glomerular 
barrier is intact and normally filters nephrotic levels of protein which is bound and retrieved 
by the proximal tubule cells, and only the dysfunction of this retrieval pathway leads to 
albuminuria (Russo et al., 2007, Russo et al., 2009). Additional samples have been stored in 
the optimal conditions from the SUMMIT cohort, and markers of tubular function such as β-
2 macroglobulin can be measured to investigate this further (Zeng et al., 2014). 
 
7.6.1.21 Post occlusive reactive hyperaemia and urinary albumin excretion in the 
normoalbuminuria range 
 
PORH is an indicator of autoregulation function (Cracowski et al., 2006) and refers to the 
transient increase in skin blood flow above baseline levels following the release from arterial 
occlusion. Reactive hyperaemia is a homeostatic mechanism of vessels to increase the 
delivery of blood to tissues following a brief period of ischaemia. I have demonstrated that 
there is an independent positive relationship between peak hyperaemia and urinary 
albumin excretion, which is present across the full urinary albumin excretion range and 
within the normoalbuminuria range, regardless of diabetes status.  
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This finding is contrary to other studies which suggest that high peak hyperaemia indicates a 
healthy response, whereas a low height is associated with disease (Tur et al., 1991). 
However, increased urinary albumin excretion, especially within the normoalbuminuria 
range, is a very early indicator of renal disease/CVD (Lambers Heerspink et al., 2011). In the 
earliest stages of diabetic kidney disease, hyper-filtration can occur which increases GFR, 
whilst urinary albumin excretion remains in the normoalbuminuria range. Impaired 
autoregulation has been proposed as a pathogenic mechanism in the hyper filtration 
process (Helal et al., 2012).  
Perhaps the same is occurring in the skin microvessels, in the earliest stages of CVD, there is 
impaired autoregulation which is causing an increase in peak hyperaemia, at the same time 
as AER increases. As the process of CVD progresses peak height might decline, much like 
GFR in DKD.  
Hyperfiltration caused by increased intra-glomerular pressure, is the result of vascular 
abnormalities. Hyperfiltration can be caused by afferent arteriolar vasodilation, as seen in 
patients with diabetes, and/or by efferent arteriolar vasoconstriction. These vascular 
changes stimulate the renin– angiotensin–aldosterone system, leading to glomerular 
hypertension (Bank, 1991, O'Bryan and Hostetter, 1997) 
Due to challenges of assessing intra-glomerular pressure the majority of studies are limited 
to animal models (Levine, 2008). To further investigate if autoregulation is the cause of 
increasing urinary albumin excretion and hyperfiltration, improved estimates of GFR would 
be required. An alternative is to measure, as opposed to estimate, GFR however doing so 
has its limitations (Chapter 1. Section 1.2.2). 
The results of this objective support the theory that impaired autoregulation could be the 
mechanism behind increased urinary albumin levels, in the early pathological stages. This is 
the first study to demonstrate the relationship between low levels of urinary albumin 
excretion with generalised impaired autoregulation.  
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7.6.1.22 Change in ACR over three years  
 
There is a significant increase in ACR over three years across the whole cohort (p<0.001) and 
in those with T2DM (p<0.001), but not in subjects without T2DM (p=0.299) (Table 91). 14 
participants (10%) developed microalbuminuria (all with T2DM) over the three years. The 
mean increase in ACR in subjects with diabetes was 2.36 (±6.50) mg/mmol, in subjects 
without T2DM the mean change was -0.11 (±1.2) mg/mmol (the change in ACR is 
significantly different when considering diabetes status, p=0.003). The standard deviation of 
the mean change (2.36 ±6.50 mg/mmol) demonstrates a large variability among subjects.  
A limitation of the method to test this hypothesis is that change in albumin excretion was 
determined by using a single ACR at baseline and a single ACR three years later. Random 
spot samples have poor reproducibility, and a diagnosis of microalbuminuria requires 
confirmation in at least two spot samples. Thus it is possible that the number of patients 
who increased albumin excretion or entered the microalbuminuria range was 
underestimated in my study even though significant changes in albumin excretion were 
observed. 
In 2014, 3.9 million people in the U.K. had been diagnosed with diabetes and it is estimated 
that over 25% will develop diabetic kidney disease (Diabetes UK, 2014). 14% (n=14) of the 
diabetic cohort progressed to develop microalbuminuria over the three year period. The 
SUMMIT cohort have a short duration of diabetes (8 (±6) years) and have good glycaemic 
control (median HbA1c [IQR]: 40 [37 to 43] mmol/mol, Table 69). This might explain the 
slightly low incidence of microalbuminuria (10%).  
Longitudinal studies following urinary albumin excretion over time are required. A further 
analysis of the SUMMIT cohort could be carried out, by selecting a control group of “healthy 
individuals” (no diabetes, CVD or any other disease), to determine what a “normal” change 
in ACR is over three years. 
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7.6.1.23 Change in microvascular function over three years and relationship with 
ACR 
 
Across the whole cohort, there was a significant change in microvascular function (except 
for time to peak during PORH testing); however this change was not influenced by diabetes 
status. There is a significant loss in total endothelial dependent response to ACH over time, 
however there is a mean increase in percent change. This lack of agreement is caused by 
several subjects having very large increases in response, skewing the data. This 
disagreement between actual change and percent change also occurs for peak hyperaemia 
during PORH testing. The actual and percent changes in vascular function are highly variable 
between individuals, represented by very large standard deviations in the results (Table 91).   
There are, to my knowledge, no longitudinal studies which have reported change in 
microvascular measurements over time, which use the same methods to assess reactive 
hyperaemia to compare my results to. Studies reporting change in microvascular function in 
different age groups would broaden our understanding microvascular biological variation, 
which could help inform clinical decision thresholds. 
There were no significant correlations between the change in ACR and change in any 
measure of microvascular function across the full albuminuria range. This most likely 
reflects the limitations of using a single random sample as the indicator of albumin excretion 
and its change over time. As discussed in the urine collection and exercise studies, ACR from 
a single random samples is affected by mild changes in activity, urinary tract disorders and 
fever (Lillehoj and Poulik, 1986).  
In the SUMMIT cohort, significant changes in microvascular function were detected, which 
demonstrates that the reproducibility of these in vivo measures does not restrict their 
analysis overtime. The clinical benefit of monitoring change in microvascular function over 
time was demonstrated in a study by Jaap et al. in twelve patients with T2DM (Jaap et al., 
1995). They reported that maximal hyperaemia increased in response to improved 
glycaemic control over a year, demonstrating that the early microvascular abnormalities 
demonstrated in Type 2 diabetes are potentially reversible. 
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In the SUMMIT cohort, when investigating the relationship between urinary albumin 
excretion and microvascular function, it was shown that blood pressure had a significant 
contribution. Changes in blood pressure may explain changes in microvascular function over 
time. If blood pressure increases over three years then it would be expected that maximal 
hyperaemia would increase, and if there was impaired autoregulation in the glomerular 
capillaries, then urinary albumin excretion might increase. However, in the SUMMIT cohort 
67% of subjects receive antihypertensive therapy and is reflected by an average reduction in 
blood pressure over three years.  
In the normoalbuminuria range there was a significant correlation between the change 
(absolute and percentage change) in ACR with change in maximal hyperaemia and with 
change in minimum vascular resistance. However, these relationships were not independent 
when considering all other confounding variables in regression. When investigating the 
relationship between actual change (not percent change), the majority of the variability in 
the relationship between change in ACR and change in MBF and MVR could be explained by 
change in systolic blood pressure. Data regarding the change in blood pressure is available in 
the SUMMIT cohort and warrants further analysis. 
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Hypothesis 2 
 
Urinary albumin excretion is not only an early marker of diabetic kidney disease but is an 
early marker of other diabetes related microvascular complications (retinopathy and 
neuropathy), with an increase in albumin excretion associated with a worsening in 
complication status in patients with diabetes. Furthermore, high levels of urinary albumin 
excretion, or an increase in albumin excretion over three years increases the likelihood of 
disease progression. 
 
7.6.2.1 Participant characteristics 
 
Three-hundred and twenty one participants, all diagnosed with type 2 diabetes, who had a 
urine sample from a random spot collection stored at baseline, and retinal photography and 
neuropathy tests carried out at both baseline and follow up were selected to test this 
hypothesis (Table 96). Participant characteristics were similar to the previous cohorts, with 
32% having had a CVD event, 74% on hypertensive therapy and 79% on statin therapy with a 
median [IQR] HbA1c of 55 [49 to 65] mmol/mol. 
The median ACR was 0.89 [0.45 to 1.96] mg/mmol with the majority of participants in the 
normoalbuminuria range (77%), 20% of participants had microalbuminuria and 3% with 
macroalbuminuria. 16% of participants had significant neuropathy at baseline, with 6% of 
the cohort developing significant neuropathy over the three years. 
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7.6.2.2 Retinopathy prevalence and progression 
 
The majority of participants had no diabetic retinopathy (DR) (55%), 29% had minimal DR, 
15% had mild DR and 2 % had moderate DR at baseline. 11% had a significant progression in 
DR over the three years (Table 96). 
The incidence of certifications of visual impairment (CVIs) due to diabetic retinopathy (DR) 
ranged from 30.8 to 77.4 per million population per year between 2010 and 2013 in North 
and Eastern Devon (Lin et al. 2017). In a diabetic population, Lin et al. estimated CVI due to 
DR was 0.47 to 1.21 per 1000 patients per year with diabetes for 2010–2013 (Lin et al. 
2017). This low prevalence was reflected in the SUMMIT cohort tested in Hypothesis two, 
where zero participants (of 321 subjects) had visual impairment, defined as proliferative 
retinopathy. 
In this cohort the presence of venous abnormalities (small infarcts, venous bleeding, venous 
loop, venous reduplication, and intraretinal microvascular abnormalities) are used to classify 
moderate DR, a precursor to visual impairment (Table 68). The incidence of moderate DR in 
this T2DM diabetes population was 20 per 1000 patients (Table 96). Although Lin et al. 
didn’t report the incidence of moderate DR, the incidence reported from the SUMMIT 
cohort study are typical , given a CVI incidence range of 0.47 to 1.21 per 1000 patients. 
The United Kingdom Diabetic Retinopathy Electronic Medical Record Users Group produced 
a report of using baseline retinopathy and clinical features to predict progression of diabetic 
retinopathy (Lee et al., 2017).  They reported a prevalence of DR in a hospital eye clinic–
based study population as 72.4% at initial examination. In the SUMMIT cohort DR 
prevalence was 46% at initial examination. This reduced incidence can be explained by the 
SUMMIT investigation design, where the cohort are research volunteers purposely recruited 
to investigate the early changes in DR, who were not recruited from hospital clinics. 
Seventy-four percent of the SUMMIT cohort receives antihypertensive therapy, which 
should reduce DR prevalence. 
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The Lee et al report also analysed data from 32,553 patients with diabetes and concluded 
that approximately 44%–56% of patients with severe or very severe non-proliferative 
diabetic retinopathy progress  to proliferative diabetic retinopathy (PDR) or vitreous 
haemorrhage in less than 3 years (Lee et al., 2017). 
In the SUMMIT cohort study, only two participants (2/231, 0.87%) developed proliferative 
DR over three years (one with Mild DR, the other with Moderate DR at baseline). This 
reflects having so few patients with severe non-proliferative DR at baseline, and the high 
prevalence of subjects on antihypertensive therapy (74%) and also the relative short 
duration of diabetes in this cohort of 8 years (±7). 
The higher occurrence of proliferative DR progression in the Lee et al. report may be 
attributed to the inclusion of patients with T1DM. The difference in PDR progression rates 
between the two studies may reflect the differences in DR pathophysiology by type of 
diabetes.  
Previous epidemiology studies have also reported varying rates of progression to 
proliferative DR. The Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) 
reported 9% over 4 years (Klein et al., 1989). A UK cohort of 20,686 patients between 1990 
and 2006 showed an 11% progression to PDR over 10 years (Jones et al., 2012b). The 
relatively low progression rate in the SUMMIT cohort (0.87%) may also be attributed to the 
nature of using research participants. Research participants do not represent the general 
population, as they tend to be more health conscious and are often from the same 
socioeconomic group. Epidemiological studies sample a much more diverse population. 
In 2014, 3.9 million people in the UK had been diagnosed with diabetes and it is estimated 
that over 25% will develop microalbuminuria (Diabetes UK, 2014). This SUMMIT cohort has 
a slightly lower prevalence of 20% (Table 96). This slight reduction in incidence might be 
attributed again to test research participants, who in this cohort demonstrate relatively 
good glycaemic control (HbA1c: 55 [49 to65] mmol/mol) (Table 96) 
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7.6.2.3 The relationship between urinary albumin excretion and the early stages 
of diabetic retinopathy and neuropathy 
 
One way ANOVA demonstrates there is a significant difference (p=0.016) in the distribution 
in ACR across diabetic retinopathy groups; no DR, minimal DR and mild DR (moderate DR 
was excluded to investigate the relationship of ACR with background retinopathy (minimal 
and mild DR) (Table 96).  
 
Post hoc analysis using Bonferroni multiple comparison test indicated a significant 
difference in ACR between mild DR and no DR (p=0.012), supporting  the hypothesis that 
urinary albumin excretion is related to other microvascular complications of diabetes, and 
that the risk is continuous occuring in the earliest stages of retinopathy. This is the first 
study able to demonstrate this as low levels of urinary albumin were accurately measured, 
and background retinoapthy was divided into different stages. However, it is not an 
exclusive relationship as there are lots of individuals who have a very high ACR with no 
diabetic retinopathy (Figure 93).  These subjects may reflect the prevalence of CVD in the 
cohort (n=104, 32%) and/or renal failure  (Table 96). However, only five subjects (2%) have 
an eGFR < 60 ml/min/1.73m2, which does not account for all the subjects with high ACR and 
no DR. 
 
One way ANOVA demonstrates there is no significant difference (p=0.199) in the 
distribution in ACR across the scores for non clinically significant neuropathy (four to six) 
(Figure 94). Furthermore, when examining distribution of ACR across all neuropathy scores, 
there is no association. Other studies have demonstrated that microalbuminuria is 
associated with significant neuropathy (Bell et al., 1992, Savage et al., 1996), but none have 
investigated the relationship between the early/preclinical stages of neuropathy with low 
levels of albuminuria.  
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The diagnosis of neuropathy in this study relies on subjective information and assessments 
using monofilament sensitivity tests. Although these assessments have been shown to be 
equal to vibration testing in the clinical assessment of neuropathy (Mythili et al., 2010), it is 
likely that both tests are only capable of detecting clinically relevant levels of change in 
nerve function rather than more subtle changes which might more accurately be related to 
the subtle changes in urinary albumin excretion being assessed in this study.  It is likely that 
nerve conductivity tests, which provide quantifiable data, would be beneficial to test the 
hypothesis that urinary albumin excretion across the normoalbuminuria range is associated 
with early changes in neuropathy. However this was not assessed in the SUMMIT study. 
 
7.6.2.4 The relationship between urinary albumin excretion and progression / 
development of diabetic retinopathy    
 
Twenty-nine individuals had a meaningful progression in retinopathy who had a median 
[IQR] ACR of 1.24 [0.62 to 7.66] mg/mmol, which was significantly higher (p=0.0498) than 
those who did not have a progression in DR (ACR; 0.84 [0.42 to 1.55] mg/mmol) (Figure 95, 
Table 97). The only significant difference (apart from ACR) in participant characteristics was 
duration of diabetes (p = 0.033). The mean duration of diabetes was 7.5(±7.2) years in 
subjects with no DR progression compared to 9.6(±6.5) years among those who had a 
progression in DR (Table 98). 
ROC analysis was carried out to determine the overall diagnostic accuracy of ACR to identify 
men who had a meaningful progression in retinopathy, the area under the curve (CI) was 
0.60 (0.47 to 0.73) (Figure 96). The low area under the curve (especially with a lower 
confidence interval <0.5) indicates that ACR could not be used as a clinical test alone to 
identify individuals who were going to have a progression in DR over three years. However, 
it does support the hypothesis that there is a relationship between ACR and a progression in 
DR status. Larger studies would be required to assess if the addition of ACR has the potential 
to strengthen risk models to predict DR.    
  
465 
7.6.2.4.1 Characteristics of subjects with no DR progression with and without clinical 
levels of urinary albumin excretion. 
 
Contrary to the hypothesis, 51 subjects had no progression in DR and had an ACR in the 
microalbuminuria range or above, impacting the diagnostic specificity of ACR to identify DR 
progressors (Figure 95). Subjects who had no progression in DR and an ACR in the 
microalbuminuria range or above had significantly higher blood pressure (p=0.014), HbA1c 
(p=0.022), duration of diabetes (p=0.001), and a larger proportion receiving 
antihypertensive therapy (p=0.009) Table 99). 
88% of these individuals were already receiving antihypertensive therapy, and 85% receiving 
statin therapy. Therefore, their risk of kidney disease and CVD was already known at 
baseline and treatment was underway, impeding the progression of diabetic complications 
or non-diabetes related chronic kidney disease.  
In 2012, Chen et al. carried out a hospital based cohort study, consisting of 487 patients with 
T2DM, and demonstrated that microalbuminuria was an independent risk factor for DR 
development (Chen et al., 2012a). Our results suggest that ACR would not be an 
independent predictor of DR progression within the earliest stages of DR, supporting the 
findings of other studies (Newman et al., 2005). However there are considerable differences 
in the cohorts tested and methods applied between studies including; duration of diabetes, 
follow up duration and retinopathy classification. The majority of studies have focussed on 
the prediction of severe levels of DR with clinical levels of albumin excretion. The study from 
the SUMMIT cohort is the first to explore the lowest levels of urinary albumin excretion with 
small changes in background retinopathy, which occur in the earliest stages of retinopathy. 
To classify the severity of retinopathy we used criteria similar to the international 
guidelines, which enable small changes in the earliest stages of retinopathy to be classified. 
Retinal photography is the traditional method of assessing eye disease, however newer 
technologies are available such as optical coherence tomography (OCT). This is a non-
invasive imaging test which takes cross-sectional images and measurements of the retina.  
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OCT measures macular thickness and is used clinically to detect macular oedema and 
generalised thickening of the retina, which may reflect increased permeability of these 
vessels that could link more with albumin excretion. These changes occur before the 
clinically recognised manifestations detected by traditional photography and the association 
with low levels of urinary albumin warrants investigation. Previously our group has shown 
that increases in retina thickness are linked to increases in capillary pressure, the final 
outcome of changes in microvascular function (Gooding et al., 2010) 
 
7.6.2.5 The relationship between urinary albumin excretion and progression / 
development of diabetic neuropathy 
 
Nineteen subjects progressed from subclinical to significant neuropathy, assessed by 
monofilament. There was no significant difference (p=0.683) in the distribution of ACR 
between individuals who had a progression in neuropathy and those who did not (Table 
100). This is contrary to the hypothesis and may be the result of using monofilament testing 
that is inadequate to diagnose significant neuropathy alone. Furthermore, the median ACR 
among subjects who progressed to significant neuropathy was lower (0.73 [0.48 to 1.44] 
mg/mmol) than those who had no progression (0.80 [0.43 to 1.47] mg/mmol), indicating 
there is no relationship between albuminuria and neuropathy progression which is 
supported by the large numbers of participants with a high ACR with no progression (Figure 
97).  
Other studies have demonstrated that microalbuminuria is associated with significant 
neuropathy (Bell et al., 1992, Savage et al., 1996), but none have investigated the 
relationship between the early/preclinical stages of neuropathy with low levels of urinary 
albumin excretion.  
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7.6.2.6 Relationship between urinary albumin excretion over three years and 
progression/development of diabetic retinopathy and neuropathy 
 
One hundred and seventy participants with diabetes, who had a from a random spot urine 
sample stored and retinal photography available at baseline and follow up were selected to 
test this hypothesis. The cohort was very similar to the previous cohort in Objective three 
with the majority of participants (54%) having no retinopathy at baseline, and 16 (9%)  of 
subjects having a meaningful progression in retinopathy over three years.  
A progression of two retinopathy steps or more (Table 68) across both eyes was classified as 
being clinically significant. Non progressors were defined as individuals who did not have a 
worsening of two steps of retinopathy in one eye or worsening of one stage in both eyes.  
The mean change in ACR over three years was 2.47 (±12.98) mg/mmol with a mean percent 
change of 237 (±738) % (Table 101). This large variation in the change in ACR over three 
years was also identified in Hypothesis One, and can most likely be attributed to the 
limitations of using a single random spot sample. 
There was no significant difference in actual change (0.612) and percent change (p=0.156) in 
ACR between subjects who had a progression in retinopathy and those who did not (Figure 
98, Table 102, Figure 99, Table 103). This was influenced by the large number of participants 
who had a big change in ACR who had no progression in retinopathy. This limitation was 
discussed in Section 7.5.2.3.2. It was shown previously (Table 99) that the risk of kidney 
disease and CVD was already known at baseline and treatment was underway, impeding the 
progression of diabetic complications or they might have had non-diabetes related chronic 
kidney disease. One study demonstrates that the lack of retinopathy in the presence of CKD 
could imply that the CKD is not diabetes related in subjects with a short duration of diabetes 
(< 5 years) (Dong et al., 2016) 
In addition to the limitation of using a single ACR from a random spot sample to measure 
change in urinary excretion, the biological variation of ACR over three years due to normal 
physiological changes has not been investigated. The average increase in ACR might be a 
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normal physiological response and longitudinal studies following urinary albumin excretion 
over time are required. A further analysis of the SUMMIT cohort could be carried out, by 
selecting a control group of “healthy individuals” (no diabetes, CVD or any other disease). 
The analysis on change in ACR does not consider the urinary albumin excretion levels of an 
individual at baseline. For example; a change in ACR of 5 mg/mmol in subjects with clinically 
significant macroalbuminuria is a small change compared to the change in subjects with 
normoalbuminuria. These highly variable measurements of change in ACR are then being 
compared by change in DR status, which have big categorical differences, almost rendering 
the data unsuitable for analysis by this method. Therefore matched pair analysis was carried 
out to reduce the influence of high ACR in subjects without DR progression. 
 
7.6.2.6.1 Matched pair analysis 
 
The aim of conducting the matched paired analysis was to remove outlying results which 
were influencing the relationship between change in ACR and DR progression.    
Controls were closely matched to subjects who had DR progression. There were no 
significant differences in characteristics between the two groups (Table 104). In this 
matched analysis there was no significant difference in actual change (p=0.431) and percent 
change (p=0.284) in ACR (Figure 100, Table 105, Figure 101, Table 106). This reinforces the 
limitations of using a single random spot sample, the severities of which are amplified when 
measuring change in ACR over time when compared with big changes in DR status.  
 
7.6.2.7 Limitations: 
 
When investigating the change in measures of biological function over time, the 
reproducibility of the measures is an important factor to consider. To reduce the impact of 
  
469 
the variability between visits the same protocol was applied at both visits whilst ensuring 
subjects were tested at the same time of day, the same standardised meal was consumed 
prior to testing, with microvascular testing carried out in the same room set at the same 
temperature by the same operator.  
The variability of biological markers over time is an important consideration when 
comparing the change of two biological markers. Increased variability over time demands a 
higher sample size to increase the confidence in the results, however a considerable number 
of subjects did not attended the second visit or data/samples were not available for both 
visits, resulting in a decreased number of subjects. 
If a correlation between change in ACR and change in microvascular function was identified 
it would require further investigation. The change in both biological measures could be 
attributed to ageing, much like the normal decline in eGFR with age. To account for this a 
control group needs to be established containing healthy subjects to determine the 
“normal” change in ACR and microvascular function over time, enabling individuals who 
have had a meaningful/pathological change to be identified. 
Progression in retinopathy and neuropathy status was determined over a three year period, 
which is a relatively short time period to see significant changes. In this study the incidence 
of disease progression was low compared to regional data. The main reason for this is that 
subjects with minimal complications were recruited to investigate early pathological 
changes. The majority of the cohort were receiving statins and antihypertensive therapies, 
and had a good control of their diabetes (HbA1c of 55 [49 to 65] mmol/mol) which would 
reduce progression in retinopathy and neuropathy. 
Novel techniques which provide sensitive measurements of retinopathy and neuropathy are 
required to fully investigate the relationship between the lowest levels of albumin excretion 
and microvascular complications of diabetes, at their earliest stages. OCT and nerve 
conductions tests provide quantifiable data, enabling small changes over a small time period 
to be detected. However the biological variation of the tests must be known first to enable 
meaningful/pathological changes to be identified.  
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7.7 Conclusion  
 
Using the validated ELISA, and applying the most accurate and reproducible method to 
collect and store samples, the lowest levels of albumin excretion were examined and the 
relationship with microvascular function investigated for the first time. 
The Fitzgerald assay measured urinary albumin in all samples from the SUMMIT cohort, and 
had a strong agreement with the Cobas method. This supports the findings of the initial 
validation studies (Chapter 2, Section 2.3.4). 
Albumin excretion is higher and vascular function is impaired in subjects with diabetes. The 
independent relationship between urinary albumin excretion and peak reactive hyperaemia 
following arterial occlusion suggests that altered autoregulation in the microvasculature 
plays a role during the earliest stages of increasing albumin excretion. This relationship is 
present within the normoalbuminuria range supporting work demonstrating the risk of CVD 
at sub clinical levels of urinary albumin excretion.  
This supports the work from Strain et al. who propose impaired myogenic vasoconstriction 
or its modulation via the endothelium or nerves, leads to a very rapid unmodulated increase 
in blood flow (Strain et al., 2005a).      
Wall stress is the stimulus for the myogenic response, therefore  a thickened wall structure, 
such as that occurring in diabetes or hypertension, will reduce the response at a given 
pressure (Matchkov et al., 2002) and may delay the onset of the myogenic response so that 
an early increase in flow is observed before the myogenic vasoconstriction (Strain et al., 
2005a). 
The discrepancies in the relationships identified between AER and ACR with microvascular 
function may be attributed to overnight collections (AER) assessing resting albumin 
excretion whereas ACR from a random spot sample is a marker of a stress test. 
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This is supported by the independent relationship between peak endothelial dependent 
response to ACH and ACR from a random spot sample and not with AER in young subjects 
without CVD with normoalbuminuria. This demonstrates that this is very early microvascular 
impairment, and not detectable using overnight AER / resting conditions. 
There is a relationship between ACR and early stages of diabetic retinopathy. There was no 
association between ACR and neuropathy, although the study was limited by the use of 
assessments unable to detect sensitive preclinical changes. 
There were no independent relationships between change in ACR and change in 
microvascular function or progression on diabetic retinopathy/neuropathy. When 
investigating the change in measures of biological function, the reproducibility of the 
measures is an important factor to consider. Single random spot samples are not suitable to 
monitor change in ACR over time.  In addition, progression in retinopathy and neuropathy 
status was determined over a three year period, which is a short time period to see 
significant changes. This has been reflected in studies such as DIRECT Protect 2 that had to 
extend the duration of their studies as there was little progression in DR in their placebo 
group (Sjolie et al., 2008). A further follow up of the SUMMIT cohort who had retinopathy 
assessed is being performed but is not available for this thesis. 
This chapter provides novel evidence that increasing urinary albumin excretion, including 
within the normal range, is linked to generalised microvascular dysfunction. Furthermore, 
impaired microvascular autoregulation may play a role in the pathogenesis and is not 
influenced by diabetes. This is also supported by the association of urinary albumin 
excretion with background (early) changes in diabetic retinopathy. 
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Chapter 8 Overall discussion, new findings, conclusions 
and area for future work 
 
This thesis provides novel evidence that increasing urinary albumin excretion, including 
within the normal range, reflects generalised microvascular dysfunction. Furthermore, 
impaired microvascular autoregulation plays a role in the pathogenesis and this is not 
influenced by diabetes. This is also supported by the association of urinary albumin 
excretion with background (early) changes in diabetic retinopathy. 
This thesis describes a procedure for assessing low levels of albumin excretion and 
characterises its association with microvascular function. As a direct result of this work, new 
procedures for the collection, processing and storage of urine samples have been 
implemented within the Diabetes and Vascular Research Centre in Exeter. There is a 
validated sensitive assay to quantify urinary albumin on an automated platform available in 
pathology at the Royal Devon and Exeter NHS Foundation Trust and also a correction factor 
to correct for the loss of urinary creatinine during prolonged storage is being published.  
This chapter provides an overview of the main findings of this thesis, the conclusions, 
limitations, impact of the findings and potential areas of future research. 
 
8.1 Background 
 
Microvascular dysfunction has been proposed as the common process in the 
pathophysiology of cardiovascular disease and diabetic kidney disease, resulting in 
increased urinary albumin excretion (Deckert et al., 1989). This is further supported by 
evidence that urinary albumin excretion is associated with other microvascular 
complications of diabetes, such as retinopathy and neuropathy (Newman et al., 2005).   
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It is important to investigate these relationships further because it could improve our ability 
to identify those at risk of CVD and microvascular complications of diabetes at an earlier 
stage. Studies which have investigated these relationships are limited by the use of routine 
assays which can’t quantify low concentrations of urinary albumin. 
 
8.2 Quantifying urinary albumin and creatinine 
 
The ability of immunoassays to measure total urinary albumin content has been questioned 
(Comper et al., 2004a). However, three routine immunoassays have shown good overall 
agreement to the candidate reference (LC-MS/MS) method (Seegmiller et al., 2009b). From 
the three selected ELISAs to undergo validation in my thesis, only the Fitzgerald assay met 
performance requirements suitable for the investigative work conducted throughout this 
thesis. The routine assay could only measure albumin in 46% of participants in the SUMMIT 
study at baseline (who were recruited in Exeter), therefore a sensitive assay is required to 
investigate the lower levels of urinary albumin excretion.  
The Fitzgerald assay ELISA is suitable for batch testing samples but it cannot be adopted for 
routine use. The adaptation of immunoassays to quantify low concentrations of urinary 
albumin on high throughput analysers would be required if it was considered important to 
explore the clinical application of low levels of urinary albumin excretion further.  
The enzymatic assay to quantify urinary creatinine had a modestly lower CV%, and had a 
small proportional bias (0.52 ± 3.08 %) compared to the Jaffe method. This is the first study 
to compare the two assays to measure urinary creatinine. They reflect the findings from 
studies testing serum samples (Myers et al., 2006a). Overall, there is little improvement 
when using the more expensive enzymatic assay over the routinely used Jaffe method and 
therefore the Jaffe method was used throughout the thesis.  
 
 
  
474 
8.3 Adjusting urinary albumin for urinary concentration in spot 
samples. 
 
The albumin to creatinine ratio (ACR) is routinely reported in spot samples to account for 
the variation in urinary concentration. However, creatinine excretion is highly variable 
between individuals, which impacts on the ability of ACR to normalise albumin 
concentration in untimed samples. Three equations that estimate albumin excretion were 
validated in the SUMMIT cohort. The results showed a high correlation with measured AER, 
which is in accordance to other validation studies (Fotheringham et al., 2014, Abdelmalek et 
al., 2014). This was investigated further and it was demonstrated that there is no 
improvement in diagnostic accuracy compared to reporting ACR alone. An alternative 
measure of urinary concentration is urine specific gravity. The USG-α refractometer 
validated in this theses is highly reproducible and has a strong agreement with urinary 
creatinine, however it offers no clinical advantages over reporting the well-established 
creatinine measurement.  
 
8.4 Urinary albumin and creatinine stability during prolonged storage 
 
Previous studies have demonstrated significant losses in urinary albumin during prolonged 
storage at -20 oC and shown it is stable at -80 oC in the clinically relevant ranges (Brinkman et 
al., 2007a). The results of this thesis support this and demonstrate the same occurs at the 
lowest albumin concentrations.  
The loss of urinary albumin has been attributed to sample pH (Brinkman et al., 2007a, 
Townsend, 1986a) and bacterial contamination (Kania et al., 2010).This is not supported by 
the results of this thesis, no additives or low protein binding tubes prevented urinary 
albumin loss in samples stored at -20 oC. The decline in urinary albumin concentration 
appears to stabilise by six months with around 36% of the original quantity lost. This is 
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similar to previous findings which have shown UAC to stabilise at around 30% loss after 8 
months storage at -20oC (Brinkman et al., 2005).  
ACR is most commonly reported in stored spot urine samples and our study is the first to 
investigate the impact of prolonged storage on urinary creatinine. Urinary creatinine 
degrades in samples stored at -80oC at a rate of 0.024% / day for 541 days and then 
stabilises. Creatinine degradation is an important finding as many epidemiological studies 
store samples for many years prior to analysis, and will need to account for creatinine 
degradation when using it to account for variation in urinary concentration. The rate of 
urinary creatinine degradation was accounted for in samples stored from the SUMMIT 
cohort. 
 
8.5 Collecting samples and reporting urinary albumin excretion 
 
The results from this study indicate that, to assess albumin excretion in the normal range, a 
first morning void (FMV) is the most appropriate surrogate for an overnight urine collection, 
and that ACR should be reported, as they have the lowest median intra-individual 
reproducibility (CV = 15.9%) and the highest correlation with overnight AER (Rs = 0.88). This 
agrees with the findings of other studies in the clinical albuminuria ranges, including those 
from the PREVEND cohort, who reported an intra-reproducibility of 19.0% for a FMV sample 
reporting the ACR (Witte et al., 2009).  
Using the validated ELISA, the biological variation of albumin excretion in healthy individuals 
was investigated for the first time. Albumin excretion is significantly lower overnight than 
during the day (p=0.0005). Random spot samples have the highest variability which may be 
influenced by exercise/walking induced urinary albumin excretion.  
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8.6 Influence of exercise, and clinical implications when collecting 
random spot samples. 
 
In healthy individuals heavy exercise increases ACR sufficiently enough to place 64% of 
participants into the microalbuminuria range. Thus healthy individuals should not provide a 
urine sample for ACR measurement if they have undertaken heavy exercise within the 
previous five hours. These results are in accordance with another study who also exercised 
healthy subjects to exhaustion to reach microalbuminuria levels (Heathcote et al., 2009).  
By measuring low concentrations of urinary albumin our study is the first to demonstrate 
the relationship between walking and ACR. These results suggest there are different types of 
responses in ACR to walking; delayed change in ACR, immediate change and no change. This 
needs further investigation as patients walking to appointments could have falsely elevated 
ACR and it may indicate an increased risk of cardiovascular disease. It has been proposed in 
this thesis that random spot samples are capable of identifying subjects with walking/ stress 
increased urinary albumin excretion, compared to overnight AER or a FMV, which measure 
albumin excretion during a state of rest. This is discussed further and supported by 
microvascular measurements in Section 8.9. 
 
8.7 Urinary albumin excretion and microvascular function in diabetes 
 
Median [IQR] AER was 9.75 [5.53 to 18.48] µg/min in subjects with diabetes who had good 
glycaemic control, clinically appropriate treatment for their blood pressure and lipids and 
who had no or background retinopathy and minimal neuropathy, compared to 6.02 [4.10 to 
8.93] µg/min in subjects without T2DM (p<0.001). ACR was also significantly higher in 
subjects with T2DM (p<0.001) as is expected and reflected in many studies (Hillege et al., 
2001). 
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Endothelial dependent and independent microvascular response to iontophoretic delivery 
of acetyl choline (ACH) and sodium nitroprusside (SNP) is significantly lower in subjects with 
diabetes (p<0.001). This reaffirms previous findings from small scale studies that suggest the 
function of the endothelium and/or smooth muscle may be abnormal in T2DM (Morris et 
al., 1995). 
Maximal hyperaemia response to localised heating is significantly lower in diabetes 
(p=0.002), supporting the findings from previous small studies in newly diagnosed patients 
with diabetes and after one year of treatment (Jaap et al., 1994b) and studies from the 
Maastricht cohort which were reported since the commencement of this thesis, and have a 
cohort with similar age and duration of diabetes as the SUMMIT cohort  (Sorensen et al., 
2016). 
 
8.8 Relationship between microvascular function and urinary 
albumin excretion 
 
There is a significant correlation between urinary albumin excretion and all measures of 
microvascular function, across the full urinary albumin excretion range. The association 
between AER/ACR with measures of microvascular function is not significantly different in 
subjects with diabetes compared to those without diabetes. This extends the findings of 
Hillege et al. who also demonstrated, using a traditional albumin assessment, that the risk of 
CVD with increasing urinary albumin concentration is not limited to diabetes and occurs in 
the non-diabetic population (Hillege et al., 2002). Although not detailed in the paper, the 
evidence from my study would suggest that up to 40% of the participants in the Hillege 
study would fall below the limit of detection for the albumin assay and would have been 
excluded from the analysis or assigned values at the detection limit of the assay as is often 
practise.    
In the SUMMIT cohort; an increase in albumin excretion is independently associated with an 
increase in post occlusive peak reactive hyperaemia after adjusting for age, gender, smoking 
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status, HDL, systolic blood pressure, history of CVD, HbA1c and waist across the full urinary 
albumin excretion range (p=0.008) and within the normoalbuminuria range (p=0.003), 
regardless of diabetes status. This is the first study to demonstrate the relationship between 
low levels of urinary albumin excretion with generalised impaired autoregulation.  
The findings from the SUMMIT cohort do not support the albumin retrieval hypothesis 
which proposes a defective proximal tubule retrieval system is an alternative hypothesis for 
rising urinary albumin excretion during the early stages of DKD (Russo et al., 2007, Comper, 
2008). It is most likely that tubular dysfunction arises after microvascular dysfunction, but it 
does contribute to the progression of renal disease. Urine samples have been stored from 
the SUMMIT cohort so markers of tubular function such as α-2 and  β-2 microglobulin (Zeng 
et al., 2014) can be measured and the function of proximal tubules with low levels of urinary 
albumin excretion can be investigated together. 
Urinary albumin excretion had a significant correlation with endothelial dependent response 
to the iontophoretic delivery of ACH; however this was not an independent relationship 
when adjusting for age and gender. Our findings do not support or disprove the ‘Steno 
hypothesis’, which proposes a disturbance in vascular permeability,  is a common process 
causing increased urinary albumin excretion and generalised endothelial dysfunction 
(Satchell and Tooke, 2008). A disturbance in endothelial glycocalyx disrupts endothelial 
function and vascular tone, especially if driven by chronic hyperglycaemia (Sandoo et al., 
2010). Samples are stored for the analysis of glycocalyx markers to investigate this 
hypothesis further.  
There was no significant difference in AER distribution between groups (p=0.243) when 
stratifying by peak response curve morphology in this cohort. This does not support the 
relationship found by Strain et al. who demonstrated that AER was significantly higher with 
an early dominant peak response (Strain et al., 2005a). In the SUMMIT cohort, the results 
were influenced by individuals with a high AER with normal peak curve morphology. 74% of 
these abnormal results were from subjects on antihypertensive therapy and 78% were on 
statins. However, when excluding these subjects when investigating normoalbuminuria, 
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there was still no significant distribution of AER among the groups, although AER does 
appear to be higher in subjects with an early dominant peak. 
 
8.9 Change in albumin excretion and microvascular function over 
three years. 
 
Using the developed method to investigate low levels of urinary albumin excretion, it was 
possible to study, for the first time, change in ACR over three years in subjects with and 
without diabetes. The mean increase in ACR in subjects with diabetes was 2.36 (±6.50) 
mg/mmol, in subjects without T2DM the mean change was -0.11 (±1.2) mg/mmol (the 
change in ACR is significantly different when considering diabetes status, p=0.003). The large 
standard deviation of mean change demonstrates a large variability among subjects.  
A limitation of the method to test this hypothesis is that change in albumin excretion was 
determined by using a single ACR at baseline and a single ACR three years later. These were 
the only samples available in the cohort. Random spot samples have poor reproducibility, 
reflected by the need to confirm microalbuminuria in at least two spot samples to make a 
diagnosis.  
Across the whole cohort there was a significant change in microvascular function over three 
years, except for time to peak hyperaemia during PORH testing. The change in 
microvascular function was not influenced by diabetes. This is the first time the change in 
microvascular function has been reported when assessed by in vivo measurements. The 
actual and percent changes in vascular function are highly variable between individuals. 
These are in-vivo measures of microvascular function and they have high biological 
variability, which suggests that large sample sizes are required to compare change in 
microvascular function over time in different groups. 
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There were no significant correlations between the change in ACR and change in any 
measure of microvascular function. This most likely reflects the limitations of assessing 
change in ACR using a single random spot sample.  
 
8.10 Interaction of CVD on the relationship between AER/ACR with 
microvascular function in the normoalbuminuria range 
 
This is the first study to demonstrate that the relationship between AER/ACR in the 
normoalbuminuria range and microvascular function, which differed in patients with and 
without cardiovascular disease. There are significant correlations between AER and maximal 
hyperaemia and minimum vascular resistance (MVR) in subjects with CVD but not in those 
without CVD. In contrast there are significant correlations between ACR and endothelial 
dependent and independent response to ACH and SNP respectively in subjects without CVD 
but not in those with CVD. 
A possible reason for the association of ACR, but not AER, with endothelial dependent and 
independent response to ACH and SNP, is because ACR can identify walking induced 
albumin excretion.  This has been demonstrated in subjects without CVD with 
normoalbuminuria, suggesting this is very early microvascular impairment, and not 
detectable using overnight AER. Furthermore the relationship between ACR and endothelial 
dependent response to ACH in subjects without CVD was independent of other confounding 
factors for CVD. 
 
8.11 Random spot samples to detect walking induced urinary albumin 
excretion 
 
The evidence from this thesis enables a new hypothesis to be formed that can explain the 
discrepancies in the relationships between AER and ACR with microvascular function.  
  
481 
Overnight urine collections assess resting albumin excretion whereas an ACR from a random 
spot samples is a marker of a stress / activity test. 
The earliest impaired microvascular dysfunction might only be detected by using walking as 
a stress test and using random spot samples to assess change in ACR. The findings from 
Chapter 4 demonstrated that FMV is the best surrogate of overnight urine collection, ‘the 
gold standard’ to identify subjects with microalbuminuria. However, overnight collections 
might not identify people with walking induced albumin excretion, which may occur at an 
early stage in the progression of microvascular dysfunction, before microalbuminuria is 
detectable.  
The clinical significance of this could be that stress testing identifies those who are 
susceptible to induced urinary albumin excretion as they may be at risk of CVD compared 
those who are not. It is important to investigate these relationships further as it could 
improve our ability to identify those at risk of CVD, and complications of diabetes at an 
earlier stage. This would result in significant improvement in the quality of lives of diabetic 
patients and save the health service resources in dealing with the complications of diabetes.  
 
8.12 Albumin excretion and microvascular complications of diabetes 
 
This thesis supports the hypothesis that microvascular dysfunction is the common process in 
the pathophysiology of diabetic kidney disease, and cardiovascular disease, resulting in 
increased urinary albumin excretion (Deckert et al., 1989). This hypothesis is further 
supported by evidence that urinary albumin excretion is associated with diabetic 
retinopathy, reinforcing previous findings (Newman et al., 2005).   
The results from the SUMMIT cohort demonstrate that low levels of urinary albumin are 
associated with subclinical changes in diabetic retinopathy. However, it is not an exclusive 
relationship as there are lots of individuals with established CVD in the cohort who have a 
very high ACR with no diabetic retinopathy. There was no association between ACR and 
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neuropathy, although the study was limited by the use of crude clinical assessments of 
neuropathy. 
 
There was no relationship between change in ACR and change in microvascular function or 
progression on diabetic retinopathy/neuropathy. When investigating the change in 
measures of biological function, the reproducibility of the measures is an important factor 
to consider. Single random spot samples are not suitable to monitor change in ACR over 
time.  In addition, progression in retinopathy and neuropathy status was determined over a 
three year period, which is a short time period to see significant changes, especially in these 
early stages.   
 
8.13 Future work 
 
1) An assay which can quantify low concentrations of urinary albumin and can be 
applied to high throughput analysers needs to be developed which meets clinical 
requirements. 
 
2) The creatinine degradation equation needs to be validated.  
 
3) The relationship between walking induced urinary albumin excretion and risk of 
developing CVD and the influence of diabetes needs to be fully investigated. A 
matched-case control study is required to assess microvascular function, a CVD risk 
factor, in subjects with walking induced urinary albumin excretion.  
 
4) Further biomarker analysis in samples from the SUMMIT cohort is required. This is 
one of the main focuses of the SUMMIT study and biomarker analysis is underway. 
SUMMIT (Surrogate markers for micro- and macro-vascular hard endpoints for 
innovative diabetes tools) is a European consortium which aims at identifying 
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markers that predict the risk of developing diabetes related vascular complications, 
in particular DKD, CVD, and diabetic retinopathy.  
 
5) The relationship with low levels of urinary albumin excretion and sensitive measures 
of early retinopathy changes needs to be investigated. This data is available from the 
SUMMIT cohort as subjects who had retinopathy assessed by retinal photography 
also underwent OCT imaging for the measurement of macular thickness. 
 
6) The diagnostic ability of low levels of urinary albumin excretion to identify subjects 
who have background progression in retinopathy and neuropathy needs to be 
investigated. The SUMMIT cohort who had retinopathy/neuropathy assessed, are 
being followed up again 4.5 years from their initial assessment. Sensitive nerve fibre 
conduction tests to examine neuropathy are being carried out and the relationship 
with low levels of albumin excretion can be investigated for the first time.  
 
 
8.14 Overall conclusion 
 
This thesis provides novel evidence that increasing urinary albumin excretion, including 
within the normal range, results from generalised microvascular dysfunction. Furthermore, 
impaired microvascular autoregulation plays a role in the pathogenesis that is not 
influenced by diabetes. This is also supported by the association of urinary albumin 
excretion with background (early) changes in diabetic retinopathy. 
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Appendix 1: Genway ELISA kit information 
 (Genway Biotech Inc. San Diego, CA, USA) 
 
Kit Contents: (enough for ten 96-well plates)  
Coating Antibody     (Catalog # 15-288-10067F)  
Affinity purified Chicken IgY against Human Serum Albumin  
Concentration: 2.7 mg/mL  
Volume: 75 μL  
Working concentration: 1.8 μg/mL  
Lot: 130520A-10067F  
 
Protein Calibrator     (Catalog # 10-288-10067F)  
Purified Human HSA Antigen  
Concentration: 30 μg/mL  
Working concentration: 3,000-4 ηg/mL  
Volume: 1 mL  
Lot: 130520C-10067F  
 
Detection Antibody     (Catalog # 27-288-10067F)  
Affinity purified Chicken IgY against Human HSA – Horseradish Peroxidase (HRP) Conjugate  
Concentration: 0.44 mg/ml  
Working concentration: 200 ηg/mL  
Volume: 50 μL  
Lot: 130520D-10067F  
Notes:  
1. Range of Detection: 3,000 – 4 ηg/ml.  
2. Shelf life: One year from date of receipt.  
 
3. Storage: -20°C.  
 
4. Assay Condition:  
The kit performance has been optimized for the stated protocol using the materials listed and 
standard dilutions from 3,000-4 ηg/ml of HSA. For alternative assay conditions, the operator must 
determine appropriate dilutions of reagents. ELISA assay reactivity is sensitive to any variation in 
operator, pipetting and washing techniques, incubation time and temperature, composition of 
reagents, and kit age. Adjustments may be required to position the standard curve and/or samples in 
the desired detection range.  
4. Country of Origin: United States of America.  
5. Assay Use: For in vitro laboratory use only. Not for any clinical, therapeutic, or diagnostic use or 
consumption in human or animals. GenWay Biotech, Inc. HSA ELISA Kit Manual  
______________________________________________________________________________
___ For research use only; not for diagnostic or therapeutic use. Page 3  
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HSA Quantitative ELISA Protocol  
Materials  
 
1. TMB Peroxidase Substrate System. KPL, Cat. # 50-76-00.  
2. Costar 96 well EIA/RIA high binding plate (Corning, Inc. Cat #. 3590)  
3. Sodium Bicarbonate. MW 84.01, Sigma-Aldrich, Cat. # S6014-5kg.  
4. Tris Hydroxvmethy Aminomethano Hydrochloride. MW 157.6, Fisher. Cat. # BP153-1.  
5. Tris Crystallized free base. MW 121.14, Fisher. Cat. # BP 152-5.  
6. NaCl, MW 58.44, Fisher. Cat. # BP 358-10.  
7. Tween 20, Sigma. Cat. # P-1379.  
8. BSA, Sigma. Cat. # A3059-100G.  
9. Sulfuric Acid, 4.0N. Labchem Inc., Cat. # LC 25830-2.  
 
Buffer Preparation  
1. Coating Buffer: 0.05 M Carbonate-Bicarbonate, pH 9.6  
2. Wash Solution: 0.05% Tween 20 in PBS, pH 7.4  
3. Blocking Solution: 50 mM Tris, 0.14 M NaCl, 1% BSA, pH 8.0  
4. Sample/Conjugate Diluents: 50 mM Tris, 0.14 M NaCl, 1% BSA, 0.05% Tween 20, pH  
 
8.0  
Step-by-Step Method (Perform all steps at room temperature)  
1. Coat with Capture Antibody  
1) Determine the number of single wells needed. Standards, samples, blanks and/or controls should 
be analyzed in triplicates.  
2) Dilute capture antibody with Coating Buffer to 1.8 ug/ml. Transfer 100 μl to each well.  
3) Incubate coated plate for 60 minutes at room temperature/37 °C or overnight at 4 °C.  
4) After incubation, aspirate the Capture Antibody solution from each well.  
5) Wash each well with Wash Solution as follows:  
a. Fill each well with Wash Solution  
b. Remove Wash Solution by aspiration  
c. Repeat for a total of 3 washes.  
2. Blocking  
1) Add 200 μl of Blocking Solution to each well.  
2) Incubate 60 minutes at room temperature.  
3) After incubation, remove the Blocking Solution and wash each well three times as in Step 1.5.  
3. Standards and Samples  
1) Dilute the standards (calibrator) in Sample Diluent to a concentration of 3000 ηg/ml, then do a 1/3 
serial dilutions down to 4.11 ηg/ml  
2) Dilute the samples, based on the expected concentration of the analyte, to fall within the 
concentration range of the standards.  
3) Transfer 100 μl of standard or sample to assigned wells.  
4) Incubate plate 60 minutes at room temperature.  
5) After incubation, remove samples and standards and wash each well 5 times as in Step 1.5.  
GenWay Biotech, Inc. HSA ELISA Kit Manual  
______________________________________________________________________________
___ For research use only; not for diagnostic or therapeutic use. Page 4  
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4. HRP Detection Antibody  
1) Dilute the HRP conjugate in dilution buffer to a concentration of 200 ηg/ml. (Note: Adjustments in 
dilution may be needed depending on substrate used, incubation time, and age of kit).  
2) Transfer 100 μl to each well.  
3) Incubate 60 minutes at room temperature.  
4) After incubation, remove HRP Conjugate and wash each well 5 times as in Step 1.5.  
 
5. Enzyme Substrate Reaction  
 
1) Prepare the substrate solution according to the manufacturer’s recommendation.  
2) Transfer 100 μl of substrate solution to each well.  
3) Incubate plate for 5-15 minutes.  
4) To stop the TMB reaction, apply 100 μl of 2.0N Sulfuric Acid to each well. If using another 
substrate, use the stop solution recommended by manufacturer.  
 
6. Plate Reading  
Using a microtiter plate reader, read the plate at the wavelength that is appropriate for the substrate 
used (450 nm for TMB).  
Calculation of Results  
1. Average the readings from each standard, control, and sample.  
2. Subtract the zero reading from each averaged value above.  
3. Create a standard curve by reducing the data using computer software capable of generating a four 
parameter logistic (4-PL) curve-fit. Other curve fits may also be used.  
4. A standard curve should be generated for each set of samples. See example below:  
GenWay Biotech, Inc. HSA ELISA Kit Manual  
______________________________________________________________________________
___ For research use only; not for diagnostic or therapeutic use. Page 5  
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Appendix 2: Bethyl E88-129 ELISA kit information  
(Bethyl Laboratories Inc. Montgomery, TX, USA)  
Albumin Kit 
Cat. No. E88-129 
 
Components Supplied 
 Human Albumin Pre-Coated 96-well Strip Plate, 1 each 
 Human Albumin Standard, 500 ng/vial, 2 each 
 Human Albumin Detection Antibody, 12 ml 
 20X Dilution Buffer C, 25 ml 
 HRP Solution A, 12 ml 
 TMB Substrate, 12 ml 
 Stop Solution, 12 ml 
 20X Wash Buffer, 50 ml 
 Sealing Tape, 6 sheets 
 
 
Shelf Life: 6 months from date of sale. 
For In vitro laboratory use only. Not for any clinical, therapeutic, or diagnostic 
use in humans or animals. Not for animal or human consumption. 
Bethyl Laboratories, Inc., www.bethyl.com 
Telephone: 800-338-9579 • Fax: 866-597-6105 
 
Introduction 
This enzyme linked immunosorbent assay (ELISA) is for the detection of Human 
Albumin in serum, plasma, cerebrospinal fluid, milk, and urine. This kit contains 
sufficient components to quantitate Human albumin in up to 40 samples, tested in 
duplicate. 
 
Background 
Albumin is the most abundant human protein in plasma. It constitutes about 60% of 
human plasma protein. Albumin is produced in the liver and serves as a carrier for 
molecules of low water solubility. Albumin is also important for regulating blood 
volume by monitoring the colloid osmotic pressure of the blood compartment. 
Albumin concentration in normal human serum ranges from 25 mg/ml to 50 mg/ml. 
Low albumin (hypoalbuminaemia) concentrations may be caused by liver 
disease, nephrotic syndrome, burns, malabsorption, malnutrition, late pregnancy, 
genetic variations and malignancy. High albumin is almost always caused by 
dehydration. Therefore, an accurate quantitation of albumin in plasma or serum is 
important for medical diagnostics, as well as for monitoring the efficacy of treatment 
regimens. 
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Principle of the Assay 
This kit is based on a sandwich ELISA. Human albumin present in the test 
sample is captured by anti-human albumin antibody that has been pre-adsorbed 
on the surface of microtiter wells. After sample binding, unbound proteins and 
molecules are washed off, and a biotinylated detection antibody is added to the 
wells to bind to the captured albumin. A strepavidin-conjugated horseradish 
peroxidase (SA-HRP) is then added to catalyze a colorimetric reaction with the 
chromogenic substrate TMB (3,3’,5,5’-tetramethylbenzidine). The colorimetric 
reaction produces a blue product, which turns yellow when the reaction is 
terminated by addition of dilute sulfuric acid. The absorbance of the yellow 
product at 450 nm is proportional to the amount of albumin analyte present in 
the sample and a four-parameter standard curve can be generated. The albumin 
concentrations in the test samples can then be quantified by interpolating their 
absorbance from the standard curve generated in parallel with the samples. After 
factoring sample dilutions, the albumin concentrations in the original sample can 
finally be calculated. 
 
Procedure Overview 
1. Add 100 l of standard or sample to designated wells. 
Note: Run each standard or sample in duplicate. 
2. Cover the plate and incubate at room temperature (20-25 C) for 1 hour. 
3. Wash the plate FOUR times. 
4. Add 100 l of anti-albumin Detection Antibody to each well. 
5. Cover the plate and incubate at room temperature for 1 hour. 
6. Wash the plate FOUR times. 
7. Add 100 l of HRP Solution A to each well. 
8. Cover the plate and incubate at room temperature for 30 minutes. 
9. Wash the plate FOUR times. 
10. Add 100 l of TMB Substrate Solution to each well. 
11. Incubate the plate in the dark at room temperature for 30 minutes. 
12. Stop the reaction by adding 100 l of Stop Solution to each well. 
13. Measure absorbance on a plate reader at 450 nm. 
 
 
Additional Materials Required 
 Ultrapure water 
 Precision pipettors, with disposable plastic tips 
 Polypropylene or polyethylene tubes to prepare standard and samples 
Do not use polystyrene, polycarbonate or glass tubes. 
 A container to prepare 1X Dilution Buffer C 
 A container to prepare 1X Wash Buffer 
 A 96-well plate washer or a wash bottle 
An autoclavable plate washer is recommended, if available. 
 Disposable reagent reservoirs 
 A standard microtiter plate reader for measuring absorbance at 450 nm for 
end-point ELISA. 
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Precautions 
 Store all reagents at 2-8ºC. Do not freeze reagents. 
 All reagents must be at room temperature (20-25 C) before use. 
 Vigorous plate washing is essential. 
 Use new disposable pipette tips for each transfer to avoid crosscontamination. 
 Use a new adhesive plate cover for each incubation step. 
 Minimize lag time between wash steps to ensure the plate does not become 
completely dry during the assay. 
 Avoid microbial contamination of reagents and equipment. Automated plate 
washers can easily become contaminated and result in erroneous data. 
 Do not contaminate the TMB Solution. Do not expose TMB Substrate 
solution to glass, foil, or metal. If the solution is blue before use, DO NOT 
USE IT. 
 Individual components may contain preservatives. Wear gloves while 
performing the assay and follow proper disposal procedures. 
 
 
 
Handling and Preparation of Reagents, Standards, and Samples 
Preparation of 1X Dilution Buffer C 
 Prepare 1X Dilution Buffer C by diluting 25 ml of 20X Dilution Buffer C 
into 475 ml of ultra pure water. Mix well. Store reconstituted 1X Dilution 
Buffer C at 2-8ºC for up to six (6) months. Do not use 1X Dilution Buffer C 
if it becomes visibly contaminated during storage. 
 
Preparation of Standard Solutions 
 Standard solutions should be treated as a biological material and universal 
precautions should be followed. 
1. Reconstitute the 500-ng hAlbumin standard vial with 1.0 ml of 1X Dilution 
Buffer C to achieve a final concentration of 500 ng/ml. Mix well. 
2. Label seven (7) tubes, one for each standard curve point: 167, 55.6, 18.5, 
6.17, 2.06, 0.69, and 0 ng/ml. The original vial of re-suspended standard 
solution represents the top standard at 500 ng/ml. 
3. Add 300 μl of 1X Dilution Buffer C into each of the seven tubes. 
4. Serially dilute 1:3 by adding 150 l of the 500 ng/ml standard into the first 
tube containing 300 l of 1X Dilution Buffer C. Mix well. Continue the 
dilution by adding 150 μl of the previous standard into 300 μl of 1X 
Dilution Buffer C in the next tube until the sixth tube (0.69 ng/ml). 
5. The seventh tube containing 300 l of 1X Dilution Buffer C serves as the 
zero standard value or blank. 
 Using this dilution scheme, only 350 l of the re-suspended standard 
solution should be used. The remaining standard solution can be used for 
another assay within the same day. Otherwise, use the second vial of 
lyophilized standard. 
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Sample Handling 
 This ELISA assay can be used for human serum, plasma, cerebrospinal 
fluid, urine, and milk samples. 
 All blood components and biological materials should be handled as 
potentially hazardous. Follow universal precautions when handling and 
disposing of infectious agents. 
 
 
 
 100 l of sample or standard is required per well. 
 Samples must be assayed in duplicate each time the assay is performed. 
 Store samples to be assayed within 24 hours at 2-8ºC. For long-term 
storage, aliquot and freeze samples at -70 C. Avoid repeated freeze-thaw 
cycles when storing samples. 
 If particulates are present in samples, centrifuge prior to analysis. 
 If blood samples are clotted, grossly hemolyzed, lipemic, or the integrity of 
the sample is of concern, make a note on the Plate Template and interpret 
results with caution. 
 
Sample Preparation 
 The dilution schemes indicated below are only suggestions. Dilutions 
should be based on the expected concentration of the unknown sample such 
that the diluted sample falls within the dynamic range of the standard curve. 
Prepare one or more dilutions of the sample in 1X Dilution Buffer C using 
the same serial dilution technique described below until the desired 
concentration is obtained. 
 Serum and plasma – Recommended starting dilution is 1:5,000,000. With 
this large dilution one must strive for accurate pipetting. A typical dilution 
scheme starts by adding 10 l of plasma into 990 l of 1X Dilution Buffer 
C to give a 1:100 dilution. This is repeated by adding 10 l of the 1:100 
diluted sample to 990 l of 1X Dilution Buffer C to give 1:10,000 dilution. 
This is again repeated by adding 10 l of the 1:10,000 diluted sample to 990 
l of 1X Dilution Buffer C to give 1:1,000,000 dilution. Finally, 100 l of 
the 1:1,000,000 diluted sample is added to 400 l of 1X Dilution Buffer C 
to result in a 1:5,000,000 dilution. It is important to mix thoroughly at each 
dilution step. 
 Cerebrospinal fluid and milk - Recommended starting dilution is 1:5,000. 
 Urine - Recommended starting dilution is 1:100. 
 Milk – Recommended starting dilution is 1:1000. 
 
Preparation of 1X Wash Buffer 
 Prepare 1X Wash Buffer diluting 20X Wash Buffer in ultrapure water. For 
example, if preparing 1 L of 1X Wash Buffer, dilute 50 ml of 20X Wash 
Buffer into 950 ml of ultrapure water. Mix well. Store reconstituted 1X 
Wash Buffer at 2-8ºC for up to six (6) months. Do not use 1X Wash Buffer 
if it becomes visibly contaminated during storage. 
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Assay Procedure 
Sample Incubation 
 Determine the number of strips required. Leave these strips in the plate 
frame. Place unused strips in the foil pouch with desiccant and seal tightly. 
Store unused strips at 2-8 C. After completing assay, keep the plate frame 
for additional assays. 
 Use a Plate Template to record the locations of the standards and unknown 
samples within the wells. 
1. Add 100 l of appropriately diluted standards or samples to each well. Run 
each standard, sample, or blank in duplicate. 
Note: Serum, plasma, cerebral fluid, milk, and urine samples must be 
diluted prior to testing (see Sample Preparation section above). 
2. Carefully cover the wells with a new adhesive plate cover and incubate for 
one (1) hour at room temperature, 20-25 C. 
3. Carefully remove the adhesive plate cover and wash FOUR times with 1X 
Wash Buffer, as described in the Plate Washing section below. 
Plate Washing 
 Using a manual or automated plate washer 
1. Rinse the tips of the plate washer by dispensing the 1X Wash Buffer into 
the wash trough and aspirating the solution. Repeat this step five times. For 
automated plate washers, program the rinse step accordingly. 
Note: This initial rinse step is necessary especially if the plate washer has 
been idle for several days or longer. Automated plate washers are 
susceptible to microbial growth in the fluid lines and cavities. 
2. Aspirate the solutions from the wells. Fill the wells to about 90% full with 
1X Wash Buffer and then aspirate the wash solution. Repeat this wash step 
three more times. For automated plate washers, program 4 washes at 300 l 
per wash, according to the manufacturer’s instructions. 
 Using a squirt bottle 
1. Gently squeeze the long sides of plate frame before washing to ensure all 
strips remain securely in the frame. 
Bethyl Laboratories, Inc., www.bethyl.com 
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2. Empty the plate contents by quickly dumping the contents of the wells into 
the sink using a quick, flipping motion. 
3. Use a squirt wash bottle to fill each well completely with 1X Wash Buffer, 
and then empty the plate contents. Repeat procedure three more times for a 
total of FOUR washes. Blot the plate onto paper towels or other absorbent 
material. 
Incubation with Detection Antibody 
 Only remove the required amount of Detection Antibody reagent for the 
number of strips being used. 
1. Add 100 l of Detection Antibody to each well containing standard, sample 
or blank. Mix well by gently tapping the plate several times. 
2. Carefully attach a new adhesive plate cover and incubate the plate for one 
hour at room temperature, 20-25 C. 
3. Carefully remove the adhesive plate cover, discard plate contents and wash 
FOUR times with 1X Wash Buffer (see Plate Washing section above). 
Incubation with HRP Solution A 
 Remove only the required amount of HRP Solution A for the number of 
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strips being used. 
1. Add 100 l of HRP Solution A to each well containing standard, sample or 
blank. 
2. Carefully attach a new adhesive plate cover and incubate plate for 30 
minutes at room temperature, 20-25°C. 
3. Carefully remove the adhesive plate cover, discard plate contents and wash 
FOUR times with 1X Wash Buffer (see Plate Washing section). Blot off 
any residual liquid at the bottom of the wells that might interfere later with 
the absorbance readings. 
Incubation with TMB Substrate and Stopping the Reaction 
 Remove only the required amount of TMB Substrate Solution and Stop 
Solution for the number of strips being used. 
 Do NOT use glass pipette to measure the TMB Substrate Solution. Do NOT 
cover the plate with aluminum foil or metalized mylar. Do NOT return 
leftover TMB Substrate to bottle. Do NOT contaminate the unused TMB 
Substrate Solution. If the solution is blue before use, DO NOT USE IT! 
1. Add 100 l of TMB Substrate Solution into each well and allow the 
enzymatic reaction to develop a blue color at room temperature (20-25ºC) 
in the dark for 30 minutes. Do NOT cover plate with a plate sealer. 
2. Stop the reaction by adding 100 l of Stop Solution to each well. Tap plate 
gently to mix. The solution in the wells should immediately change in color 
from blue to yellow. 
Absorbance Measurement 
Note: Wipe the underside of the wells with a lint-free tissue. 
1. For end-point ELISA, measure the absorbance on an ELISA plate reader set 
at 450 nm within 30 minutes after the addition of the Stop Solution. 
Calculation of Results 
 Duplicate absorbance values should be within 10% of each other. Care 
should be taken when interpreting data with differences in absorbance 
values greater than 10%. 
1. Prepare a standard curve to determine the amount of albumin in an 
unknown sample. Plot the average absorbance obtained for each standard 
concentration on the vertical (Y) axis versus the corresponding albumin 
concentration on the horizontal (X) axis using curve-fitting software. 
2. Calculate the albumin concentration in unknown samples using the prepared 
standard curve. Determine the amount of albumin in each unknown sample 
by noting the albumin concentration (X axis) that correlates with the 
absorbance value (Y axis) obtained for the unknown sample. 
3. If the sample was diluted, multiply the observed albumin concentration by 
the dilution factor to determine the concentration of albumin in the original, 
undiluted sample. 
Note: Most plate readers come with appropriate templates and curve-fitting 
software. The standard curve of this assay can be fitted into a 4-parameter 
curve fitting equation that can be programmed to calculate and display a 
table (or tables) consisting of the raw absorbance readings, net absorbance 
readings, the analyte concentration in the assay solution, dilution factors, 
and analyte concentration in the original unknown sample. 
Performance Characteristics 
Typical Standard Curve 
 This typical standard curve was generated using the Human Albumin 
ELISA Kit Protocol. This standard curve is for demonstration only. A 
standard curve must be generated for each assay. 
Assay Range: 0.69 – 500 ng/ml 
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 Suggested standard curve points are 500 ng/ml, 167 ng/ml, 55.6 ng/ml, 18.5 
ng/ml, 6.17 ng/ml, 2.06 ng/ml, 0.69 ng/ml, and 0 ng/ml. 
 Expected OD value for 500 ng albumin standard is 1.8 – 2.2. OD value for 
low standard should be higher than background. 
Specificity 
 By immunoelectrophoresis and ELISA the antibodies in this set react 
specifically with human albumin, not with human immunoglobulins or 
other human serum proteins. Cross-reactivity with other species has not 
been tested. 
Representative Data 
 Serum, plasma, cerebrospinal fluid, milk, and urine samples were collected 
from apparently healthy individuals and evaluated in this assay. The levels 
of Human Albumin detected were as follows: 
Human Urine (n=2): avg. = 2.19 g/ml 
Human cerebral serum fluid (n=4): avg. = 347 g/ml 
Human Milk (n=1): 188 g/ml 
Warranty 
Products are warranted by Bethyl Laboratories, Inc. to meet stated product 
specifications and to conform to label descriptions when used, handled and 
stored according to instructions. Unless otherwise stated, this warranty is limited 
to six months from date of sale. Bethyl Laboratories sole liability for the product 
is limited to replacement of the product or refund of the purchase price. Bethyl 
Laboratories products are supplied for research applications. They are not 
intended for medicinal, diagnostic or therapeutic use. The products may not be 
resold, modified for resale or used to manufacture commercial products without 
prior written approval from Bethyl Laboratories, Inc. 
Background References 
1. Anderson NL and Anderson NG (1977). Proceeding of the National 
Academy of Sciences 74: 5421–5425. 
2. Adkins JN et al. (2002). Molecular and Cellular Proteomics 1: 947–955. 
3. Jacobs JM et al. (2005).. Journal of Proteome Research 4: 1073–1085. 
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Appendix 3: Fitzgerald ELISA information  
(Fitzgerald Industries International, North Acton, MA, USA) 
 
 55R-ORG5MA  
MicroAlbumin ELISA kit  
Immunometric Enzyme Immunoassay for the determination of Micro-Albumin in urine  
Fitzgerald Industries International www.fitzgerald-fii.com/55R-ORG5MA 
 
1.NAME AND INTENDED USE: 
 
Micro-Albumin is a competitive solid phase enzyme immunoassay (ELISA) for the measurement of 
human albumin in urine. The assay is intended for research use only as an aid in the investigation of 
microalbuminuria.  
2.SUMMARY AND EXPLANATION OF THE TEST: 
 
Proteins passing the glomerular basal membrane of the kidney undergo differentiated filtering. The 
permeability is inversely proportional to the molecular weight (albumin about 0.6 %, myoglobulin 
about 75 %). Nevertheless, only minimal quantities of protein are detectable in urine, because big 
quantities of protein are reabsorbed by the tubuli. Elevated glomerular protein permeability and 
high tubular plasma protein elimination can be differentiated by measuring the molecular weight 
distribution of the eliminated proteins.  
Albumin has a relative molecular mass of 66 kDa. It is contained in urine at very low concentrations. 
In case of a very active glomerular filtering process the albumin secretion can arise without an 
underlying kidney disease. This situation is called "microalbuminuria". The detection of these small 
secretion quantities (30 to 150 ug/min or ml) requires very sensitive test systems , i.e. 
immunological techniques. Physical stress can also induce elevated albumin secretion, without the 
occurrence of a kidney disease.  
3.PRINCIPLE OF THE TEST: 
 
Highly purified human albumin is bound to microwells. Calibrators, controls and undiluted unknown 
samples are pipetted together with anti-human-albumin-peroxidase conjugate in the wells. 
Microalbumin, if present in diluted urine, will compete with coated albumin for binding of the anti-
albumin-conjugate. Washing of the microwells removes unspecific components.  
An enzyme substrate in the presence of bound conjugate hydrolyzes to form a blue color. The 
addition of an acid stops the reaction forming a yellow end-product. The intensity of this yellow 
color is measured photometrically at 450 nm. The amount of color is inversely proportional to the 
concentration of albumin present in the original sample.  
4.WARNINGS AND PRECAUTIONS: 
 
1.All reagents of this kit are strictly intended for research use only. 
 
2.Do not interchange kit components from different lots. 
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3.Components containing human serum were tested and found negative for HBsAg, HCV, HIV1and 
HIV2 by FDA approved methods. No test can guarantee the absence of HBsAg, HCV,HIV1 or HIV2, 
and so all human serum based reagents in this kit must be handled as thoughcapable of transmitting 
infection.  
 
4.Avoid contact with the TMB (3,3´,5,5´-Tetramethyl-benzidine). If TMB comes into contactwith skin, 
wash thoroughly with water and soap. 
 
5.Avoid contact with the Stop Solution which is acid. If it comes into contact with skin, 
 
wash thoroughly with water and seek medical attention. 
6.Some kit components (i.e. Controls, Sample buffer and Buffered Wash Solution) containSodium 
Azide as preservative. Sodium Azide (NaN3) is highly toxic and reactive in pure form.At the product 
concentrations (0.09%), though not hazardous. Despite the classification asnon-hazardous, we 
strongly recommend using prudent laboratory 
 
practices. 
7.Some kit components contain Proclin 300 as preservative. When disposing reagentscontaining 
Proclin 300, flush drains with copious amounts of water to dilute the componentsbelow active 
levels. 
 
8.Wear disposable gloves while handling specimens or kit reagents and wash handsthoroughly 
afterwards. 
 
9.Do not pipette by mouth. 
 
10.Do not eat, drink, smoke or apply makeup in areas where specimens or kit reagents arehandled. 
 
11.Avoid contact between the buffered peroxide solution and easily oxidized materials;extreme 
temperature may initiate spontaneous combustion. 
 
12.Observe the guidelines for performing quality control by assaying controls and/or pooledsera. 
During handling of all kit reagents, controls and serum samples observe the existingregulations.  
 
5.CONTENTS OF THE KIT: 
 
- Package Size: 96 determ.  
 
- Divisible microplate consisting of 12 modules of 8 wells each, coated with highly purified Lysozyme. 
Ready to use.  
 
- 6 vials, 1.5 ml each Micro-Albumin-Calibrators (A-F) in a PBS/BSA matrix (NaN3 <0.1%  
 
(w/w)) containing micro-albumin: 0.15; 1.5; 6; 25; 100 and 400 ug/ml. Ready to use.  
- 2 vials, 0.5 ml each Micro-Albumin Controls in a PBS/BSA matrix (NaN3 <0.1% (w/w))  
 
positive (1) and negative (2), for the respective concentrations see the en-closed package insert. 
Ready to use.  
- 1 vial, 10 ml Sample buffer (Tris, NaN3 <0.1% (w/w)), yellow. Ready to use.  
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- 1 vial, 15 ml Enzyme conjugate solution (PBS, Proclin 300 <0.5% (v/v)), (light red) containing 
polyclonal rabbit anti-human albumin; labeled with horseradish peroxidase. Ready to use.  
 
- 1 vial, 15 ml TMB substrate solution. Ready to use.  
 
- 1 vial, 15 ml Stop solution (contains acid). Ready to use.  
 
- 1 vial, 20 ml Wash solution (PBS, NaN3 <0.1% (w/w)), concentrate (50x).  
 
6.ADDITIONAL MATERIALS REQUIRED: 
 
- Microplate reader capable of endpoint measurements at 450 nm  
- Multi-Channel Dispenser or repeatable pipette for 100 μl  
- Vortex mixer  
- Pipettes for 10 μl, 100 μl and 1000 μl  
- Laboratory timing device  
- Data reduction software  
 
Preparation of Reagents:  
- Distilled or deionised water  
- Graduated cylinder for 100 and 1000 ml  
- Plastic container for storage of the wash solution  
 
7.STORAGE AND STABILITY: 
 
- Store the kit at 2-8 °C.  
- Keep microplate wells sealed in a dry bag with desiccants.  
- The reagents are stable until expiration of the kit.  
- Do not expose test reagents to heat, sun or strong light during storage and usage.  
- Diluted sample buffer and wash buffer are stable for at least 30 days when stored at 2-8 °C.  
 
8.COLLECTION, STORAGE AND HANDLING OF UNKNOWNS: 
 
1.Collect morning urine. 
 
2.Samples may be refrigerated at 2-8 °C for up to five days or stored at -20 °C up to sixmonths. 
 
3.Avoid repetitive freezing and thawing of urine samples. This may result in variable loss ofalbumin 
activity. 
 
4.Murine samples need not to be diluted. If higher concentrations are expected, samplesshould be 
diluted with sample buffer and dilutions considered during calculation. 
 
9.PROCEDURAL NOTES: 
 
1.Do not use kit components beyond their expiration dates. 
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2.Do not interchange kit components from different lots. 
3.All materials must be at room temperature (20-28 °C). 
4.Have all reagents and samples ready before start of the assay. Once started, the test mustbe 
performed without interruption to get the most reliable and consistent results. 
5.Perform the assay steps only in the order indicated. 
6.Always use fresh sample dilutions. 
7.Pipette all reagents and samples into the bottom of the wells. 
8.To avoid carryover contamination, change the tip between samples and different kitcontrols. 
9.It is important to wash microwells thoroughly and remove the last droplets of wash buffer 
toachieve best results. 
10.All incubation steps must be accurately timed. 
11.Control sera or pools should routinely be assayed as unknowns to check performance of 
thereagents and the assay. 
12.Do not re-use microplate wells. 
 
For all controls, the respective concentrations are provided on the labels of each vial. Using these 
concentrations a calibration curve may be calculated to read.  
 
10.PREPARATION OF REAGENTS: 
 
Preparation of wash solution  
Dilute the contents of each vial of the buffered wash solution concentrate (50x) with distilled or 
deionised water to a final volume of 1000 ml prior to use. Store refrigerated: stable at 2-8 °C for at 
least 30 days after preparation or until the expiration date printed on the label.  
11.TEST PROCEDURE: 
 
1.Prepare a sufficient number of microplate modules to accommodate calibrators, controlsand 
unknowns in duplicate. 
 
2.Pipette 20 μl of calibrators, controls and unknowns into the wells. 
3.Add 100 μl of enzyme conjugate solution into each well. 
4.Incubate for 30 minutes at room temperature (20-28 °C) 
5.Discard the contents of the microwells and wash 3 times with 300 μl of wash solution. 
6.Dispense 100 μl of TMB substrate solution into each well. 
7.Incubate for 15 minutes at room temperature. 
8.Add 100 μl of stop solution to each well of the modules and leave untouched for 5 minutes. 
9.Read the optical density at 450 nm and calculate the results. Bi-chromatic measurementwith a 
reference at 600-690 nm is recommended. 
10.The developed color is stable for at least 30 minutes. Read optical densities during this time. 
 
Automation:  
The Micro-Albumin ELISA is suitable for use on open automated ELISA processors. The test 
procedure detailed above is appropriate for use with or without automation.  
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12.RESULTS: 
 
Quality Control  
This test is only valid if the optical density at 450 nm for Positive Control (1) and Negative Control (2) 
as well as for the Calibrator A and F complies with the respective range indicated on the Quality 
Control Certificate enclosed to each test kit! If any of these criteria is not fulfilled, the results are 
invalid and the test should be repeated.  
For the Micro-Albumin test a 4-Parameter-Fit with lin-log coordinates for optical density and 
concentration is recommended.  
Manual Data Reduction: Recommended Lin-Log Plot  
First calculate the averaged optical densities for each calibrator well. Use lin-log graph paper and 
plot the averaged optical density of each calibrator versus the concentration. Draw the best fitting 
curve approximating the path of all calibrator points. The calibrator points may also be connected 
with straight line segments. The concentration of unknowns may then be estimated from the 
calibration curve by interpolation. The dilution of urine samples has to be considered.  
13.PERFORMANCE CHARACTERISTICS: 
 
Parallelism  
In dilution experiments urine samples with high Albumin concentrations were diluted with sample 
buffer and assayed in the Micro- Albumin kit. The assay showed linearity over the full measuring 
range.  
Precision (Reproducibility)  
Statistics were calculated for each of three samples from the results of 24 determinations in a single 
run for Intra-Assay precision. Run-to-run precision was calculated from the results of 5 different runs 
with 6 determinations each:  
Sensitivity: The lower detection limit for Micro-Albumin has been determined at 0.5 μg/ml.  
Specificity: The antisera (polyclonal, rabbit) labeled with horseradish peroxidase is highly specific for 
human Albumin.  
14.LIMITATIONS OF PROCEDURE: 
 
The Micro-Albumin ELISA is intended for research use only – not for use in diagnostic procedures.  
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Appendix 4: Patient information sheet for urine collection 
study.  
         
 
 
Patient Information Sheet 
Version 2.0 / 28th January 2014 
What is the best collection method to measure albumin in urine? 
 
Principal Investigator: Dr Kim Gooding  
Chief Investigator: Professor Angela Shore 
 
     
We would like to invite you to take part in a research study. 
 
Before you decide, it is important for you to understand why the research is being 
done and what it will involve. Please take the time to read the following information 
and to discuss it with other people, including the researchers, your friends, relatives 
and your healthcare team if you wish. Ask us if there is anything that is not clear or if 
you would like more information or the opportunity to discuss the study further. Take 
time to decide whether you wish to take part in this study.  
 
Thank you for taking the time to read this information. 
 
What is the purpose of this study? 
 
Albumin is a protein produced by the liver. It then circulates in the blood stream. The 
kidneys filter the blood to remove waste products which then leave the body in urine. 
Albumin is normally retained in the blood but sometimes the kidney blood vessels 
are not working properly, which results in albumin leaking out of the vessels and 
passing out the body in urine along with other waste products. When high levels of 
albumin are found in the urine it is known as albuminuria, which indicates kidney 
damage known as diabetic nephropathy.  
 
Small amounts of albumin in urine is termed microalbuminuria and is an early marker 
of kidney damage, and may also suggest more widespread damage in the body. 
Early identification of microalbuminuria is important so patients’ can take medication 
to prevent the kidney damage getting worse. Hospital laboratories measure the 
concentration of albumin in urine to identify if microalbuminuria is present. Currently, 
microalbuminuria is clinically defined within a range and measurements below this 
range are considered ‘normal’ suggesting no risk of developing kidney damage. 
However, recent evidence suggests that even a small amount of albumin in urine, 
within the normal range, may be an early marker of damage to the blood vessels. 
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Hospital laboratories are unable to measure such small amounts of albumin but this 
study will use a different type of test which is able to measure albumin at these low 
concentrations. This type of test will be used in future studies to assess the link with 
early blood vessel damage. 
 
However, before we can do this we must establish the best, most reproducible, way 
of collecting the urine samples to be used with this test taking into account changes 
over the day and reliability / ease of sample collection. There are several ways of 
collecting the urine samples. The most comprehensive collection method to 
determine the level of albumin in urine is to collect all the passed urine over a timed 
period, this accounts for differences in the amount of albumin being passed at 
different times. However, this can be cumbersome and inaccurate. An alternative 
collection method includes obtaining on the spot untimed (random) samples from 
patients at various points throughout the day. However, one of the main weaknesses 
of these spot tests are that people drink different amounts of water so the 
concentration of albumin in the urine may be very high if an individual drinks very 
little or the concentration might be very low if they drink a lot. To account for this 
variation we compare the albumin concentration to the concentration of a waste 
product in the urine called creatinine. Creatinine is passed out of the body at a 
constant rate and this comparison is known as the albumin-to-creatinine ratio (ACR). 
The ACR can therefore be used in these spot samples to determine if 
microalbuminuria is present. There are several tests available to measure creatinine. 
This study will use two, the routine test used by hospital laboratories and a more 
modern test. The difference in results will be examined to determine if a more 
modern test provides a more accurate and reliable ACR. 
 
For this study, participants will collect urine samples over a 36 hour period in 
different containers on 3 separate occasions. By measuring the albumin and 
creatinine levels in these samples using the new tests we will determine the most 
reproducible way of collecting the urine and expressing the results for future studies 
examining the relationship between low levels of albumin and blood vessel health.  
 
 
Why have I been invited? 
 
To perform the study we are looking for 17 healthy individuals and we believe you fit 
the requirement we are looking for. 
 
 
Who is organising the study? 
 
The organisers of the study are Professor Angela Shore, Dr Kim Gooding and Daniel 
Chapman from the University of Exeter Medical School.  
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What would I have to do? 
 
Firstly, you would come to a screening visit at the Diabetes and Vascular Research 
Centre (DVRC) in the Royal Devon & Exeter Hospital (Wonford) site. Here you will 
get the chance to ask questions about the study and, if you wish to do so, give your 
consent to participate in this study. During this visit we would also ask you to provide 
us with a small urine sample. We would also discuss a suitable timeframe for you to 
complete the 3 collection periods, so please bring your diary with you.  
 
High albumin concentrations have been seen after heavy exercise or any out of the 
ordinary strenuous activity, sexual intercourse and during menstruation. As a result 
of this we would like to organise convenient times with you to try and avoid these 
factors.  
  
Following the screening visit you will be contacted to confirm the date of the first 
collection and to arrange giving you the urine collection containers. You will also 
receive a urine collection sheet which gives instructions on how to collect the urine 
and to be used to record all the times of the various collections. 
  
Throughout the collection period continue with your normal fluid intake. 
 
 
Once your collection period is complete you will need to get the samples to the 
DVRC by 16:45 the same day. During your screening visit we discuss the logistics of 
this and go through the options available to you. When the collection samples are 
received we will give you new containers for your next collection period.  
 
 
What happens during each collection period? 
 
Each collection period will require you to pass urine into different containers at 
different points throughout the day. Below is information on which containers to use 
and when. 
 
Container 1 (Spot): After waking up in the morning, pass the first morning urination 
into this container. Please record the time of collection on the container and 
collection sheet.  
 
Container 2 (Timed Day): Straight after the first morning urination record the start 
time on this container and collection sheet.  Please collect all urine in this container 
throughout the day until going to sleep. When preparing to go to bed pass the final 
urination into this container and record the end time on the container and collection 
sheet.   
 
Container 3 (Timed Night): Please record the start time on the container and 
collection sheet which begins as soon as you go to bed. If you awake during the 
night then collect the urine in this container. After waking up in the morning collect 
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the first morning urination in this container and then this collection is complete. 
Please record the end time of collection on the container and collection sheet. 
 
Container 4 (Spot): Only collect the next urination in this container and record the 
time on the container and collection sheet. 
 
Container 5 (Spot): Collect a single urination in this container any time after the 
second morning urination on the same day before 16:30. Once done please record 
the time of collection on the container and collection sheet.  
 
Once complete please hand in all the samples to the Diabetes and Vascular 
Research Centre on the same day before 16:45. 
 
Please store the containers whilst filling or once completed filling in a cool place (e.g. 
in a garage) or ideally in a refrigerator until handing in. Please could you record the 
storage conditions on the collection sheet. 
 
Please see appendix 1 for a flow chart which summarises the collection process with 
example collection times. 
 
Do I have to take part? 
 
Please remember that participation is entirely voluntary and if you decide to take part 
you are free to leave the study at any time without having to give a reason as to why 
you wish to do so. If you do decide to take part, you will be asked to sign a consent 
form and you will be given a signed copy of the consent form and an information 
sheet to keep for your own records.  
 
If you decide not to take part, this will in no way affect your future medical care. It is 
up to you to decide whether or not to take part. 
 
What will happen to my urine samples? 
 
All the samples will be sent to the hospital laboratory so that we can measure 
albumin and creatinine. With your consent we will also store some of your samples 
within the University of Exeter Clinical Research Facility. All samples will only be 
used for research purposes. By storing your samples we will have the opportunity to 
assess alternative ways to investigate albuminuria in the future. All stored samples 
will be anonymised; therefore your samples will not be identifiable to anyone out of 
the immediate research team in Exeter. 
 
What are the potential risks or benefits of taking part? 
 
Risks 
 
Providing a urine sample is a very non-invasive procedure and minimal risks are 
associated with it. However, there is the burden of carrying out the collection 
procedure. 
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Benefits 
 
Though participating in this study may not be of any clinical benefit to you, the 
information we will obtain from this study will help us determine if providing spot 
urine samples can be used instead of timed collections, making it easier for future 
patients. We hope that through this research we will be able to get a better 
representation of albuminuria, and thus enable us to identify the individuals at risk for 
developing kidney damage and other vascular diseases.  
 
What happens if we identify a health concern?  
 
This study is being performed for research purposes only, however, during your 
participation we may identify an elevated albumin result. If this occurs, we will inform 
you, and with your consent we will pass the information and a copy of the results on 
to your own GP. We will advise you to make an appointment with your GP, who will 
then arrange any appropriate medical care.  
 
 
What if I have a complaint?  
 
Should you have reason to complain about the way you have been treated at any 
stage during the study you can access the NHS patient advisory liaison service 
(PALS) who will be able to advise and help you (pals@rdeft.nhs.uk or 01392 
402093).  
Alternatively, you can make your complaint directly to Dr Kim Gooding, a senior 
investigators involved in this study (contact details at the end) or Dr Gill Baker, the 
Manager of the Exeter National Institute of Health Clinical Research Facility 
(G.C.Baker@exeter.ac.uk or 01392 406813), who will discuss the matter with you 
and take appropriate action.  
 
 
What about travel expenses? 
 
We will reimburse reasonable travel expenses. A travel expenses claim form will be 
made available at each visit.    
 
 
 
Are my results confidential? 
 
If you consent to take part in the study you have a right to privacy. Information from 
this study will be linked only to a unique study number and your name will not go 
outside the research team. With your permission investigators from the National 
Institute for Health Research (NIHR) at the Exeter Clinical Research Facility (CRF) 
will have access to your medical records as it is a requirement that your involvement 
in this study is noted in your medical records. Occasionally our studies are 
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monitored/audited by regulatory organisations such as the ethics committee and thus 
they may access your study data for this purpose.  
 
With your consent, your GP will be informed that you are taking part in this study.  As 
you know, your GP will also keep this information confidential. 
 
 
Who is funding this research? 
 
The study is supported by the Exeter National Institute of Health Clinical Research 
Facility.  
None of the researchers will receive any financial incentive from this study.  
 
What will happen to the results of the research study?  
 
We aim to publish the findings in medical journals and talk about the results at 
meetings and conferences. Your data will always remain anonymous and your name 
will not appear on any of the results.  
 
Who has reviewed this study? 
 
All research in the NHS is looked at by an independent group of people, called a 
Research Ethics Committee, to protect your interests. This study has been reviewed 
and given favourable opinion by the South West - Exeter Research Ethics 
Committee.  
 
Contacts for further information 
 
If you would like more information, or if you have any further questions about the 
study please contact the investigators. The numbers to call are below: 
 
 
Daniel Chapman   Tel: 01392 403059  
              D.Chapman@exeter.ac.uk 
 
Dr Kim Gooding   Tel: 01392 403081 
      K.M.Gooding@exeter.ac.uk 
 
 
 
Thank you for reading the Information Sheet and considering taking part in 
this study.  
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Appendix 1: Flow chart of collection procedure with example collection times.  
 
 
PLEASE NOTE: Women will be provided with a collecting bowl so they can 
easily pour the urine into to appropriate containers. 
 
 
 
Container 1 
• First Morning Urination 
• e.g 07:30 
Container 2 
• Timed day  
• e.g 07:31 – 23:30 
• (include final Urination before bed) 
Container 3 
• Timed overnight 
• e.g 23:31 – 07:31 
• (include first morning Urination) 
Container 4 
• Second morning Urination 
• e.g 09:50 
Container 5  
• Random Urination 
• e.g 14:07 
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Appendix 5: Patient information sheet for exercise study  
 
 
 
The Impact of Exercise on Albuminuria  
 
 
INFORMATION SHEET FOR PARTICIPANTS  
VERSION NUMBER: 2.0        DATE: 01/10/15 
 
 
Thank you for showing an interest in this project.  Please read this information sheet 
carefully before deciding whether or not to participate.  If you decide to participate 
we thank you.  If you decide not to take part we thank you for considering our 
request.   
 
 
What is the aim of the project? 
 
The aim of this study is to examine the change in urinary albumin excretion over 24 
hours after an individual has undertaken various intensities of exercise.  
 
Albumin is a protein routinely measured in urine samples. When elevated levels are 
found it indicates that damage maybe occurring in the kidneys, this is known as 
albuminuria. However, before a urine sample is collected, there are several factors 
which can influence how much albumin is excreted. This study focuses on the impact 
of exercise, investigating how albumin excretion is altered by different intensities of 
exercise and importantly how long it takes to go back to normal.  
 
This project is being undertaken as part of a PhD degree programme and will help 
improve our ability to correctly identify individuals with albuminuria. 
 
 
Description of participants required 
 
We are investigating very low levels of albumin, within the normal range, to achieve 
this we are recruiting healthy individuals (aged 18-50) who are unlikely to have any 
damage occurring to their kidneys. 
 
People who are in one or more of the categories listed below will not be able to 
participate in the project because they are not suitable for this particular study:  
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o Diabetes 
o Cardiovascular disease 
o Hypertension or on antihypertensive medication 
o Kidney disease 
o Any other medical condition which may make cycling exercise difficult, 
limited or uncomfortable.  
o Current participation in a clinical intervention study 
o Taking creatine supplements 
 
 
What will participants be asked to do? 
 
Should you agree to take part in this project, you will be asked to attend a screening 
visit at the University of Exeter NIHR Clinical Research Facility in the Royal Devon & 
Exeter Hospital (Wonford) site. Here you will get the chance to ask questions about 
the study and, if you wish to do so, give your consent to participate in this study. 
During the screening visit a standard medical history and clinical examination will be 
carried out. This will include, for example, height, weight, and questions about your 
medical history. During this visit we will take a blood sample and would also ask you 
to provide us with a small urine sample to look at your kidney function. 
 
During this visit you will need to continuously cycle on an exercise bike for 
approximately 15 minutes. The resistance will progressively increase and you will be 
required to wear a mask so we can measure your oxygen intake and carbon dioxide 
output, enabling us to determine your level of fitness. We will use this to calculate 
your personalised exercise intensities (mild, moderate and strenuous), which are 
exerted in the later visits. We would also discuss a suitable timeframe for you to 
complete the 4 visits within several weeks, so please bring your diary with you.  
 
High albumin concentrations have been seen after vigorous exercise, out of the 
ordinary strenuous activity, sexual intercourse and during menstruation. Therefore, 
when arranging your 4 visits we would like to find convenient times for you, whilst 
avoiding these factors.  
 
Following the screening visit you will be contacted to confirm the date of the first visit 
and to arrange giving you the urine collection containers and a pedometer. You will 
also receive a urine collection sheet which gives instructions on how to collect the 
urine samples. This sheet is also used to record all the times of the collections and 
the value on the pedometer at those times. 
 
On each visit day, as soon as you wake up, put on the pedometer. Then every time 
you pass urine you will be required to collect a small sample of it, using a new 
container each time. Please record the time when each sample is collected and the 
pedometer reading at that time. After each time you pass urine, we ask that you 
gradually drink a small bottle (330ml) of water until the next time you pass urine and 
to continue doing this throughout the day. This is to ensure you remain hydrated 
throughout the day and to reduce the impact of dehydration on the results. You can 
eat and drink throughout the day as you would do normally.  
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At approximately 11am you will collect a urine sample just before cycling on an 
exercise bike. The exercise will go on for a maximum of 30 minutes or until you are 
exhausted. Your blood pressure and heart rate will be monitored and recorded. You 
will need to collect another urine sample within 30 minutes of completing the 
exercise. You will then continue to collect a urine sample every time you pass urine 
up to and including the second pass of urine on the following day.  
 
On each visit day you will undergo a different exercise regime. When no exercise is 
to be carried out you will still need to collect urine samples as before but rest instead 
of cycle. Once all the samples are collected you will need to get the samples to the 
research centre by 14:00 the same day. During your screening visit we will discuss 
the logistics of this and go through the options available to you. When the samples 
are received we will give you new containers for your next visit. 
 
As you will be cycling during each visit we recommend that you wear clothes that 
you will be comfortable in. 
 
Please see appendix 1 and 2 which summarises this process with example collection 
times. 
 
 
What about travel expenses? 
 
We will reimburse reasonable travel expenses in line with the University of Exeter 
expenses polices. A travel expenses claim form will be made available at each visit.    
 
 
Time commitment  
 
The screening visit will last approximately 40 minutes. The 4 subsequent visits will 
last no longer than an hour at the research centre; however you will be collecting 
urine samples before and after this. 
 
Can participants change their mind and withdraw from the Project? 
 
You may withdraw from participation in the project at any time without any 
disadvantage to yourself of any kind. 
 
 
What data or information will be collected and what use will be made of it? 
 
All samples will be sent to the hospital laboratory so that we can use standard tests 
to examine your kidney function. With your consent we will also store some of your 
urine samples indefinitely within the University of Exeter Clinical Research Facility. 
All samples will only be used for research purposes. By storing your urine samples 
we will have the opportunity to assess alternative ways to investigate albuminuria in 
the future. All stored samples will be anonymised; therefore your samples will not be 
identifiable to anyone out of the immediate research team in Exeter. 
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The information gained from the standard medical history and clinical examination 
during the screening visit is used to characterise participants, and all data collected 
will be securely stored indefinitely in such a way that only those mentioned below will 
be able to gain access to it. 
 
Results of this project may be published but any data included will not be individually 
identifiable.   
 
Participants in this project will be sent a letter summarising the results of the study. 
 
What happens if we identify a health concern?  
 
This study is being performed for research purposes only, however, during your 
participation we measure your blood pressure and the function of your kidneys. If 
anything of concern is found, we will inform you, and with your consent we will pass 
the information and a copy of the results on to your own GP. We will advise you to 
make an appointment with your GP, who will then arrange any appropriate medical 
care.  
 
 
Why me? 
 
We are asking you because we are looking for healthy individuals, aged 18-50, who 
will meet the study criteria. 
 
 
What if participants have any questions? 
 
If you have any questions about our project, either now or in the future, please feel 
free to contact either:- 
 
Daniel Chapman    or  Kim Gooding  
Diabetes and Vascular Research.    Diabetes and Vascular 
Research 
01392 403090      01392 403088 
 
Complaints 
 
If you have any complaints about the way in which this study has been carried out 
please contact the Chair of the University of Exeter Medical School Research Ethics 
Committee:- 
 
Peta Foxall, PhD 
Chair, UEMS Research Ethics Committee 
Email : P.J.D.Foxall@exeter.ac.uk 
This project has been reviewed and approved by the 
University of Exeter Medical School Research Ethics Committee 
UEMS REC REFERENCE NUMBER:  15/09/078 
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APPENDIX 1. Study Outline 
 
 
 
NOTE: These are example times and the intensity of exercise will randomised 
for each visit. All visits (including screening) need to be complete within 5 
weeks. 
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Appendix 6: Walking increased urinary albumin excretion 
plots 
Walking and ACR after no exercise: 
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Walking and ACR after moderate exercise for 30 minutes:   
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Walking and ACR after moderate exercise for 15 minutes: 
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Walking and ACR after heavy exercise: 
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